
<html lang="en"     class="pb-page"  data-request-id="0679eb5c-77e3-48b5-b286-11c042a076ad"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-24;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.0c01362;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Recent Advances in the Development of PD-L1 Modulators: Degraders, Downregulators, and Covalent Inhibitors" /></meta><meta name="dc.Creator" content="Binbin  Cheng" /></meta><meta name="dc.Creator" content="Yao  Xiao" /></meta><meta name="dc.Creator" content="Mingming  Xue" /></meta><meta name="dc.Creator" content="Hao  Cao" /></meta><meta name="dc.Creator" content="Jianjun  Chen" /></meta><meta name="dc.Description" content="Therapeutic interference of the programmed cell death protein 1(PD-1)/immunosuppressive programmed cell death ligand 1 (PD-L1) signaling pathway by monoclonal antibodies has achieved spectacular su..." /></meta><meta name="Description" content="Therapeutic interference of the programmed cell death protein 1(PD-1)/immunosuppressive programmed cell death ligand 1 (PD-L1) signaling pathway by monoclonal antibodies has achieved spectacular su..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 4, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01362" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01362" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01362" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01362" /></link>
        
    
    

<title>Recent Advances in the Development of PD-L1 Modulators: Degraders, Downregulators, and Covalent Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01362" /></meta><meta property="og:title" content="Recent Advances in the Development of PD-L1 Modulators: Degraders, Downregulators, and Covalent Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0014.jpeg" /></meta><meta property="og:description" content="Therapeutic interference of the programmed cell death protein 1(PD-1)/immunosuppressive programmed cell death ligand 1 (PD-L1) signaling pathway by monoclonal antibodies has achieved spectacular success for treating various tumors. However, the development of small molecule inhibitors of PD-1/PD-L1 has lagged far behind due to the challenge of targeting the highly hydrophobic and relatively flat binding interface, despite the benefits small molecule can bring over therapeutic antibodies. This technical challenge provokes the adoption of different strategies in searching for small, medium-sized, and large molecule modulators (e.g., degraders, downregulators, and covalent inhibitors) of the PD-1/PD-L1 protein–protein interaction. In this review article, we discuss latest advances in the development of PD-L1 modulators, with a focus on degraders, downregulators, and covalent inhibitors." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01362"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01362">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01362&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01362&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01362&amp;href=/doi/10.1021/acs.jmedchem.0c01362" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 24</span><span class="cit-fg-pageRange">, 15389-15398</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/24" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01348" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c01378" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Recent Advances in the Development of PD-L1 Modulators: Degraders, Downregulators, and Covalent Inhibitors</span></h1><h2 class="article_header-subtitle"><span class="hlFld-SubTitle">Miniperspective</span></h2><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Binbin Cheng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Binbin Cheng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Design and Discovery Research Innovation Community, School of Pharmaceutical Sciences, Southern Medical University, Baiyun District, Guangzhou 510515, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Binbin++Cheng">Binbin Cheng</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yao Xiao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yao Xiao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Wuchang Hospital Affiliated to Wuhan University of Science and Technology, Wuhan Wuchang Hospital, Wuchang 430063, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yao++Xiao">Yao Xiao</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mingming Xue</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mingming Xue</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tianjin Tiancheng Chemical Co., Ltd., Chemical Street, Binhai New District, Tianjin 300480, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mingming++Xue">Mingming Xue</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hao Cao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hao Cao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Design and Discovery Research Innovation Community, School of Pharmaceutical Sciences, Southern Medical University, Baiyun District, Guangzhou 510515, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hao++Cao">Hao Cao</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Jianjun Chen</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jianjun Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Design and Discovery Research Innovation Community, School of Pharmaceutical Sciences, Southern Medical University, Baiyun District, Guangzhou 510515, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#bed4ddd6dbd08c8ffecdd3cb90dbdacb90ddd0"><span class="__cf_email__" data-cfemail="167c757e7378242756657b6338737263387578">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jianjun++Chen">Jianjun Chen</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5668-6572" title="Orcid link">http://orcid.org/0000-0001-5668-6572</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01362&amp;href=/doi/10.1021%2Facs.jmedchem.0c01362" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 24</span><span class="cit-pageRange">, 15389–15398</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 4, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>4 August 2020</li><li><span class="item_label"><b>Published</b> online</span>4 December 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 December 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01362" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01362</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D15389%26pageCount%3D10%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DBinbin%2BCheng%252C%2BYao%2BXiao%252C%2BMingming%2BXue%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D24%26contentID%3Dacs.jmedchem.0c01362%26title%3DRecent%2BAdvances%2Bin%2Bthe%2BDevelopment%2Bof%2BPD-L1%2BModulators%253A%2BDegraders%252C%2BDownregulators%252C%2Band%2BCovalent%2BInhibitors%26numPages%3D10%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D15398%26publicationDate%3DDecember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01362"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2639</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">3</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01362" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Recent Advances in the Development of PD-L1 Modulators: Degraders, Downregulators, and Covalent Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Binbin&quot;,&quot;last_name&quot;:&quot;Cheng&quot;},{&quot;first_name&quot;:&quot;Yao&quot;,&quot;last_name&quot;:&quot;Xiao&quot;},{&quot;first_name&quot;:&quot;Mingming&quot;,&quot;last_name&quot;:&quot;Xue&quot;},{&quot;first_name&quot;:&quot;Hao&quot;,&quot;last_name&quot;:&quot;Cao&quot;},{&quot;first_name&quot;:&quot;Jianjun&quot;,&quot;last_name&quot;:&quot;Chen&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;04&quot;,&quot;issue&quot;:&quot;24&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;15389-15398&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01362&quot;},&quot;abstract&quot;:&quot;Therapeutic interference of the programmed cell death protein 1(PD-1)/immunosuppressive programmed cell death ligand 1 (PD-L1) signaling pathway by monoclonal antibodies has achieved spectacular success for treating various tumors. However, the development of small molecule inhibitors of PD-1/PD-L1 has lagged far behind due to the challenge of targeting the highly hydrophobic and relatively flat binding interface, despite the benefits small molecule can bring over therapeutic antibodies. This technical challenge provokes the adoption of different strategies in searching for small, medium-sized, and large molecule modulators (e.g., degraders, downregulators, and covalent inhibitors) of the PD-1/PD-L1 protein–protein interaction. In this review article, we discuss latest advances in the development of PD-L1 modulators, with a focus on degraders, downregulators, and covalent inhibitors.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01362&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01362" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01362&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01362" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01362&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01362" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01362&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01362&amp;href=/doi/10.1021/acs.jmedchem.0c01362" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01362" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01362" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01362%26sid%3Dliteratum%253Aachs%26pmid%3D33272018%26genre%3Darticle%26aulast%3DCheng%26date%3D2020%26atitle%3DRecent%2BAdvances%2Bin%2Bthe%2BDevelopment%2Bof%2BPD-L1%2BModulators%253A%2BDegraders%252C%2BDownregulators%252C%2Band%2BCovalent%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D24%26spage%3D15389%26epage%3D15398%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291909" title="Immunology">Immunology</a>,</li><li><a href="/action/doSearch?ConceptID=291781" title="Degradation">Degradation</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292276" title="Small molecules">Small molecules</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/24" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/jmcmar.2020.63.issue-24/20201224/jmcmar.2020.63.issue-24.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/medium/jm0c01362_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01362&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Therapeutic interference of the programmed cell death protein 1(PD-1)/immunosuppressive programmed cell death ligand 1 (PD-L1) signaling pathway by monoclonal antibodies has achieved spectacular success for treating various tumors. However, the development of small molecule inhibitors of PD-1/PD-L1 has lagged far behind due to the challenge of targeting the highly hydrophobic and relatively flat binding interface, despite the benefits small molecule can bring over therapeutic antibodies. This technical challenge provokes the adoption of different strategies in searching for small, medium-sized, and large molecule modulators (e.g., degraders, downregulators, and covalent inhibitors) of the PD-1/PD-L1 protein–protein interaction. In this review article, we discuss latest advances in the development of PD-L1 modulators, with a focus on degraders, downregulators, and covalent inhibitors.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47770" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47770" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The PD-1/PD-L1 signaling pathway is one of the most actively pursued targets in tumor immunotherapy. PD-1 and PD-L1 interact with each other via the A′GFCC′ β-sheets of their extracellular Ig variable domains, as do the extracellular Ig variable domains of monoclonal antibodies and T cell antigen receptors.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> It is traditionally believed that overexpression of PD-L1, an important immunoinhibitory molecule that contributes to tumor immune escape and tumor progression, can transmit negative modulatory signals that cause the exhaustion of T cells (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref2 ref3 ref4 ref5 ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4 ref5 ref6 ref7 ref8">(2−8)</a> Thus far, the FDA has approved a number of monoclonal antibodies (mAbs) targeting the PD-1/PD-L1 axis for treating various tumors such as malignant melanoma,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> including PD-L1 mAbs (e.g., atezolizumab, duvalumab, atezolizumab, avelumab) and PD-1 mAbs (e.g., nivolumab, pembrolizumab).<a onclick="showRef(event, 'ref10 ref11 ref12 ref13 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12 ref13 ref14 ref15 ref16">(10−16)</a> However, mAbs have several disadvantages including but not limited to the lack of oral bioavailability, high production cost, long circulating half-life, high percentages of unresponsive patients, and immune-related adverse events,<a onclick="showRef(event, 'ref17 ref18 ref19 ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19 ref20 ref21 ref22">(17−22)</a> which has prompted the search for small, medium-sized, and large molecule modulators of PD-1/PD-L1 as alternatives to monoclonal antibodies.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/medium/jm0c01362_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic diagram of the mechanism for the inhibition of human PD-1/PD-L1 pathway in cancer immunotherapy. Activating signals (e.g., IFN-γ) can enable the upregulation of PD-L1 by cancer cells, and PD-1 (expressed in activated tumor-specific T cells) binding to PD-L1 results in immune escape and tumor growth, while inhibitory molecules (e.g., PD-1 or PD-L1 inhibitory mAbs) are able to interfere with the binding interactions of PD-L1 and PD-1, consequently enhancing antitumor immune effects.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01362&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Small Molecule PD-1/PD-L1 Binders</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10311" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10311" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Small molecule inhibitors of PD-1/PD-L1 possess certain advantages over monoclonal antibodies with regard to pharmacokinetics (e.g., oral bioavailability).<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23,24)</a> However, the design of small molecule PD-1/PD-L1 inhibitors remains a challenge because of the hydrophobic and flat binding interface between PD-1 and PD-L1 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a><b>)</b>.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25,26)</a> The hydrophobic nature of the binding interface might also result in the generation of “false positive” hits during screening processes.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/medium/jm0c01362_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Views of the human PD-1 and human PD-L1 interface. (A) Human PD-1 and human PD-L1 are colored in blue and pink, respectively. (B) Important amino acid residues for the hPD-1/PD-L1 binding interaction are highlighted as sticks: PD-1 (LEU128, Val64, ILE126, ILE134, THR76, GLN75) and PD-L1 (ILE54, TYR56, MET115, TYR123, ARG125).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01362&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Over the past decade, several groups have been actively searching for small molecule PD-1/PD-L1 modulators and discovered dozens of novel molecules (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref27 ref28 ref29 ref30 ref31 ref32 ref33 ref34 ref35 ref36 ref37 ref38 ref39 ref40 ref41 ref42 ref43 ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29 ref30 ref31 ref32 ref33 ref34 ref35 ref36 ref37 ref38 ref39 ref40 ref41 ref42 ref43 ref44 ref45">(27−45)</a> For instance, Bristol-Myers Squibb (BMS) company reported a series of resorcinol dibenzyl ether-based PD-L1 inhibitors [e.g., compound <b>1</b> (BMS-37), compound <b>2</b> (BMS-202), compound <b>3</b> (BMS-1536), compound <b>4</b> (BMS-1598), and compound <b>5</b> (BMS-1166)]. Homogenous time-resolved fluorescence (HTRF) binding assay demonstrated that BMS-series compounds exhibited excellent <i>in vitro</i> activity for disrupting the binding interaction of the soluble, extracellular domain of human PD-1 with the soluble, extracellular domain of human PD-L1, with IC<sub>50</sub> in the range of 1–300 nM. However, no <i>in vivo</i> animal studies have been performed for these potent inhibitors until recently;<a onclick="showRef(event, 'ref46 ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref46 ref47 ref48">(46−48)</a> Chen’s group extended the structure–activity relationships of the BMS-series compounds with different molecular scaffolds (e.g., flavones, chalcones) and demonstrated potent <i>in vivo</i> antitumor efficacy of these small molecule PD-L1 inhibitors [e.g., compound <b>6</b> (NP19)].<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/medium/jm0c01362_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical structures of small molecule PD-1/PD-L1 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01362&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Current small molecule inhibitors of PD-1/PD-L1 (e.g., compound <b>2</b>, MW = 419.52, log <i>P</i> = 4.4, IC<sub>50</sub> = 18 nM) (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) are generally hydrophobic, which may lead to problems like off-target toxicity and poor pharmacokinetics (e.g., low solubility, high protein binding, and low drug efficiency) during downstream development processes.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Therefore, adopting different strategies in the design of small, medium-sized, and large molecule modulators of PD-1/PD-L1 could be critical, for example, to degrade or downregulate PD-L1 protein levels by various technologies such as PROTACs and LYTACs, which may provide a novel expansion to the field of drug discovery targeting PD-1/PD-L1 axis.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/medium/jm0c01362_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Crystal structure of human PD-L1 in complex with compound <b>2</b>.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25,26)</a> (A) Compound <b>2</b> induced the formation of PD-L1 homodimer, as indicated by blue and pink space-filling models. (B) Detailed interactions of ligand (compound <b>2</b>) with the binding cleft of human PD-L1 homodimer. Compound <b>2</b> binds to the hydrophobic binding interface formed at the interface of PD-L1 dimer. All important amino acid residues for the compound <b>2</b>/hPD-L1 interaction are highlighted as sticks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01362&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Recent research has demonstrated the degradation of PD-L1 protein through either the lysosomal pathway or ubiquitin/proteasome system,<a onclick="showRef(event, 'ref51 ref52 ref53 ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref51 ref52 ref53 ref54 ref55">(51−55)</a> and a variety of downregulators, degraders, and covalent inhibitors of PD-L1 have been disclosed.<a onclick="showRef(event, 'ref56 ref57 ref58 ref59 ref60 ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref56 ref57 ref58 ref59 ref60 ref61 ref62">(56−62)</a> Thus, it is possible to develop PD-L1 modulators (downregulators, covalent inhibitors, degraders) based on small molecules, PROTAC-mimics, LYTACs, or other types of technologies as detailed below.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">3.  PROTAC-like and Bifunctional Degraders/Downregulators of PD-L1</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26235" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26235" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In 2020, Cheng et al. reported a series of PROTAC-like/bifunctional small molecules based on a BMS compound (e.g., BMS-8) and pomalidomide as dual degraders and inhibitors of PD-L1 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). The newly synthesized molecules displayed outstanding inhibitory activities against human PD-1/PD-L1 interaction with IC<sub>50</sub> ranging from 25 nM to 190 nM. Compound <b>7</b> (P22) (see <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> for structure) was identified as one of the most active compounds (IC<sub>50</sub> = 39.2 nM for inhibiting hPD-1/hPD-L1). In addition, compound <b>7</b> markedly restored immunosuppression in a coculture standard model of T cells (CD3 T cells) and tumor cells (Hep3B/OS-8/hPD-L1). Moreover, compound <b>7</b> exhibited moderate potency in reducing PD-L1 levels in a lysosome-dependent manner. Ubiquitin–proteasome system (UPS) and lysosomal pathway are the two major ways for protein degradation. Immunoblotting data showed that compound-<b>7</b>-induced degradation of PD-L1 in MDA-MB-231 cells was restored by bafilomycin (a lysosomal inhibitor) but not MG132 (a proteasome inhibitor). The results suggest that the compound-<b>7</b>-induced degradation of PD-L1 may be mediated through the lysosomal pathway, although it was originally designed as a PROTAC molecule to degrade intracellular PD-L1 (recycled to the cell or before it matures from the cell after ribosome synthesis) through the proteasomal pathway.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/medium/jm0c01362_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Rationale for the design of PD-L1 degraders based on pomalidomide and BMS-8. The PROTAC-like molecule consists of a PD-L1 inhibitor (e.g., BMS-8, BMS1233, BMS1198) and a ligand of pomalidomide. Adapted with permission from   <cite><i>European
Journal of Medicinal Chemistry</i></cite> (<a href="https://www.sciencedirect.com/journal/european-journal-of-medicinal-chemistry" class="extLink">https://www.sciencedirect.com/journal/european-journal-of-medicinal-chemistry</a>) <span class="NLM_year">2020</span>, <em>199</em>, 112377;<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Copyright 2020 Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01362&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Breast cancer susceptibility protein 1 (BRCA1) and BRCA2 deficient cancer cells are susceptible to inhibitors of poly ADP ribose polymerase (PARP) by the mechanism of synthetic lethality.<a onclick="showRef(event, 'ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref64 ref65">(64,65)</a> In 2014, Lynparza (olaparib) was approved by U.S. FDA as PARP inhibitor for treating germline mutated BRCA advanced ovarian cancer.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> In 2018, Stewart et al. reported that combination treatment of PARP inhibitors with anti-PD-L1 mAb provides enhanced antitumor response.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> In 2019, Ofori et al.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> designed a series of novel bifunctional/dual-acting PARP/PD-L1 hybrid inhibitors by merging the pharmacophores of BMS-001 (compound <b>8</b>, a PD-L1 inhibitor) and olaparib (compound <b>9</b>, a PARP inhibitor) (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>); these compounds (<b>10</b>, <b>11</b>, <b>12</b>) could significantly downregulate the levels of PD-L1 protein. Of note, PARP inhibition by olaparib (<b>9</b>) led to upregulation of cell surface PD-L1, while the bifunctional/dual-acting PARP/PD-L1 inhibitors (<b>10</b>, <b>11</b>, <b>12</b>) or PD-L1 inhibitor BMS-001 (<b>8</b>) could downregulate PD-L1. However, the exact mode of action has not been completely elucidated yet. Nevertheless, these hybrid and bifunctional molecules may be used as chemical probes to explore the downregulation/degradation of PD-L1 and the cross-talk between PARP and PD-L1 pathways.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/medium/jm0c01362_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Design of bifunctional/dual-acting small-molecule PARP1/PD-L1 inhibitors. PARP inhibitors were combined with PD-L1 inhibitors to provide enhanced antitumor activities.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01362&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">4.  HIP1R-Mimic (PD-LYSO) to Degrade PD-L1 through Lysosomal Pathway</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50635" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50635" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Wang et al. identified huntingtin-interacting protein 1-related (HIP1R) as a regulator for the lysosome-dependent degradation of PD-L1, providing insights into PD-L1 homeostasis.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Their study indicated that the signaling molecule HIP1R regulates PD-L1 protein levels via a two-step process: first interacting with PD-L1 protein and then transporting it to the lysosome for degradation. (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) Also, they found that the C-terminal domain of HIP1R binds to PD-L1 followed by lysosome-dependent degradation through an intrinsic sorting signal. Furthermore, PD-LYSO, a chimeric peptide consisting of a PD-L1 binding peptide fragment (DKEMAATSAAIEDAVRRIEDMMNQ) and a lysosomal binding region (MDFSGLSLIKLKKQ), is to mimic the function of HIP1R and thus to induce PD-L1 degradation. PD-LYSO represents a novel approach for degrading membrane proteins by manipulating the proteolytic system of lysosomes. The study suggests that HIP1R-mediated PD-L1 degradation in lysosomes may offer a potential new way for depleting extracellular or membrane proteins such as PD-L1 in cancer immunotherapies.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/medium/jm0c01362_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. HIP1R and the rationalized design of chimeric PD-LYSO peptide targeting PD-L1 for degradation in lysosomes. In the left diagram, the degradation route of PD-L1 is shown, wherein HIP1R targets PD-L1 for lysosomal degradation. PD-L1 distribution in subcellular compartments is also shown. The diagram on the right is a magnified view that shows the molecular roles of PD-LYSO. Briefly, PD-LYSO binds to the intracellular region of PD-L1 by its C-terminal domain, and then the intrinsic sorting signal of lysosomal degradation of PD-L1 was activated by adaptor protein (AP) complexes. Finally, PD-L1 can be internalized to the lysosome by interacting with the ALIX and ESCRT machinery. Adapted with permission from   <cite><i>Nature
Chemical Biology</i></cite> <span class="NLM_year">2019</span>, <em>15</em>, 42–50;<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Copyright 2019 Springer Nature Limited.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01362&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">5.  Small Molecule Degraders and Downregulators of PD-L1</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68542" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68542" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The PD-L1 protein is encoded by the B7-H1 (synonym: CD274) gene, and increased tumor CD274 gene copy number directly causes PD-L1 mRNA upregulation, which will eventually promote immune evasion. In addition, the expression of PD-L1 is also regulated by epigenetics, for instance, micro-RNAs (miRNAs) could decrease or suppress PD-L1 expression by repressing STAT3. At the transcription level, many transcription factors (TFs) have been found to control the expression of PD-L1, for example, activator protein 1 (AP-1), NF-κB, Myc, STATs, and hypoxia inducible factor 1α (HIF1-α), which were reported to transactivate and boost the expression of PD-L1. At the post-translational modification level, PD-L1 can be phosphorylated, glycosylated, ubiquitinated, acetylated, and biotinylated, which play significant roles in regulating PD-L1 expression or stability.<a onclick="showRef(event, 'ref70 ref71 ref72'); return false;" href="javascript:void(0);" class="ref ref70 ref71 ref72">(70−72)</a> In light of the PD-L1 signaling pathway and its regulatory mechanisms, scientists have identified several small molecule compounds that can degrade or downregulate PD-L1 expression as described below.</div><div class="NLM_p">In 2019, Zhang et al. discovered a novel aloperine-based small molecule, compound <b>13</b> (SA-49), which induced microphthalmia transcription factor (MITF)-dependent lysosomal degradation of human PD-L1 in NSCLC cells and significantly boosted the cytotoxic effects of cocultured T cells and natural killer (NK) cells against cancer cells (A549 and H460). Compound <b>13</b> also exhibited excellent <i>in vivo</i> anti-NSCLC efficacy in a xenograft mouse model bearing Lewis tumors (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). Their research indicated that compound <b>13</b> functions as a specific PD-L1 degrader but does not directly bind to PD-L1, and treatment with compound <b>13</b> can activate protein kinase Cα (PKCα) and subsequently inactivates glycogen synthase kinase 3β (for short GSK3β), which can lead to the nuclear translocation of MITF, boost the biogenesis of lysosome, and enhance PD-L1 translocation to lysosome for proteolysis.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/medium/jm0c01362_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Proposed mechanism for compound <b>13</b> (SA-49)-mediated degradation of PD-L1 by modulating the PKCα-GSK3β cascade to boost lysosomal function. Adapted with permission from   <cite><i>EBioMedicine</i></cite> (<a href="https://www.sciencedirect.com/journal/ebiomedicine" class="extLink">https://www.sciencedirect.com/journal/ebiomedicine</a>) <span class="NLM_year">2019</span>, <em>40</em>, 151–162,<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> published by Elsevier B.V. under license CC BY-NC-ND 4.0 (<a href="http://creativecommons.org/licenses/by-nc-nd/4.0/" class="extLink">http://creativecommons.org/licenses/by-nc-nd/4.0/</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01362&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2016, Zhu et al.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> found that compound <b>14</b> [(+)-JQ-1], a BET inhibitor, could dramatically promote anticancer immunity by downregulating PD-L1 expression (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). A subsequent mechanistic study indicated that compound <b>14</b> decreases the expression of PD-L1 mRNA in a time- and dose-dependent manner. These findings suggest that BET inhibitors like compound <b>14</b> represent a novel approach for downregulating PD-L1 expression.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/medium/jm0c01362_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Mode of action for compound <b>14</b> [(+)-JQ-1]-mediated downregulation of PD-L1. By binding to BRD4, compound <b>14</b> affects the acetylation of CD274 gene and ultimately reduces the PD-L1 expression in cancer cells. Adapted with permission from   <cite><i>Cell Reports</i></cite> <span class="NLM_year">2016</span>, <em>16</em>, 2829–2837,<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> published under license CC BY-NC-ND 4.0 (<a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="extLink">https://creativecommons.org/licenses/by-nc-nd/4.0/</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01362&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The discovery of small molecule compounds that can efficiently reduce the expression of PD-L1 as mentioned above is very encouraging and represents an attractive strategy for targeting the PD-1/PD-L1 pathway. In recent years, a number of compounds have been shown to effectively impact the PD-L1 signaling pathway and its regulatory mechanisms, thus reducing the expression of PD-L1 (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). For instance, compound <b>15</b> (10058-F4) is a potent small molecule c-Myc inhibitor that is able to efficiently decrease PD-L1 expression in cancer cells. In 2020, Liang et al.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> reported that there was a conspicuous correlation between c-Myc and PD-L1 levels, and the PD-L1 expression can be regulated by c-Myc inhibition, deletion, and overexpression in ESCC cells. In 2019, Lin et al.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> described a novel small molecule modulator of human CXCR2, compound <b>16</b> (reparixin), which could effectively decrease PD-L1 expression and strengthen the effect of cancer immunotherapy. In 2018, Maher et al.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> discovered that compound <b>17</b> (IPAG), a selective σ1 inhibitor, could induce autophagic degradation of abnormal PD-L1 in cancer cells. Additionally, TPFS compounds (<b>18</b> and <b>19</b>), two novel amide analogues of brefelamide, were found to downregulate both the mRNA and protein levels of PD-L1.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Furthermore, compound <b>20</b> (synonym: S3I-201), a selective STAT3 inhibitor with an IC<sub>50</sub> of 86 μM, was demonstrated to downregulate the expression of PD-L1 effectively in the CAL27 cell line.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Moreover, compound <b>21</b> (verteporfin), a photosensitizer for photodynamic therapy, displayed potent activity in the suppression of IFN-induced and basal PD-L1 expression through transcriptional and posttranslational mechanisms.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Overall, these newly discovered small molecule compounds may provide novel strategies for downregulating/degrading PD-L1 in cancer immunotherapy.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/medium/jm0c01362_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Representative small molecule downregulators/degraders of PD-L1 that can reduce PD-L1 expression through affecting the PD-L1 pathway as well as regulatory mechanisms.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01362&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">6.  Kinase Inhibitor-Based Downregulators of PD-L1</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25080" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25080" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Kinases are among the most intensively pursued medicinal targets of the past 2 decades.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> A number of kinase inhibitors were reported to reduce PD-L1 expression. These include EGFR inhibitors (e.g., gefitinib and erlotinib),<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> CDK5 inhibitors like roscovitine,<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> and ALK inhibitors such as crizotinib.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a></div><div class="NLM_p">In 2019, Xie et al.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> reported a novel and robust method to screen kinase inhibitors for downregulating PD-L1 in cancer cells based on the on/in-cell Odyssey Western blot (O/ICW) technology. Using this original O/ICW platform, they identified 14 kinase inhibitors that could drastically inhibit PD-L1 expression. Representative structures of these compounds (<b>22</b>–<b>28</b>) are shown in <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>. These findings offer new clues for the use of kinase inhibitors as potential tumor immunotherapies by downregulating PD-L1 expression.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/medium/jm0c01362_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Representative kinase inhibitor-based downregulators of PD-L1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01362&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">7.  LYTACs for the Degradation of PD-L1</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05604" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05604" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Lysosome targeting chimeras (LYTACs) are bifunctional molecules composed of an antibody that is fused to a glycopeptide agonist/ligand. The antibody (e.g., PD-L1 antibody) has affinity for an extracellular/membrane protein of interest (POI), while the glycopeptide ligand can bind to the receptor CI-M6PR (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>). LYTACs act by binding to a POI (extracellular or membrane) first, followed by the recognition of the glycopeptide ligand by M6PR to form a complex, which undergoes endocytosis and subsequent lysosomal degradation. This is the first proof-of-concept study that demonstrates the degradation of PD-L1 by LYTACs. Recently, Bertozzi’s group revealed that both larger peptides and small molecules can be used as warheads in LYTACS for degradation of membrane proteins such as PD-L1, which paves the way for the design of small molecule/peptide-based PD-L1 degraders in cancer immunotherapy.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Nevertheless, a key challenge remaining for further therapeutic applications of LYTACs is the modulation of the pharmacokinetic properties in order to minimize off-target side effects for a given LYTAC. Therefore, more in-depth research is necessary to assess the therapeutic potential of LYTACs.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/medium/jm0c01362_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Mechanism of extracellular and membrane protein degradation by LYTACs. LYTACs act by inducing clathrin-dependent endocytosis via the M6PR (also called IGF2R) and subsequent degradation of the target proteins in lysosomes. CI-M6PR is a cation-independent mannose 6-phosphate receptor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01362&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">8.  Covalent Inhibitors of PD-1/PD-L1</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26370" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26370" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Covalent inhibitors have unique pharmacodynamic properties (e.g., high binding affinity and the potential to overcome drug resistance) and therefore possess certain advantages over noncovalent drugs. Due to the rapidly increasing prevalence of drug resistance for current antitumor drugs, the development of covalent inhibitors has attracted tremendous attention from academia and the pharmaceutical industry. Among the numerous proteins/receptors targeted by covalent inhibitors, PD-L1 is gaining interest from researchers due to the difficulty in the design of noncovalent inhibitors targeting the hydrophobic, flat, and extended binding interface of PD-L1. For example, in 2020, Li et al.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> designed and synthesized a covalent PD-L1 inhibitor, FSY-PD-1, by incorporating a latent bioreactive amino acid [unnatural amino acid (Uaa)] fluorosulfate-<span class="smallcaps smallerCapital">l</span>-tyrosine into human PD-1, which enabled the covalent and irreversible binding of FSY-PD-1 to PD-L1 through the proximity-enabled reactive therapeutics (PERx) strategy (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>). The results showed that FSY-PD-1 can enhance T cell activation under <i>in vitro</i> conditions. Importantly, FSY-PD-1 inhibited cancer growth in two <i>in vivo</i> animal models: a xenograft Hu-Mice (immune-humanized) model and a xenograft mouse model reconstituted with human PBMCs. Therefore, covalent inhibition of PD-L1 may open a new paradigm in targeting the PD-1/PD-L1 interaction for tumor immunotherapy.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/medium/jm0c01362_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. PERx strategy to develop covalent protein drugs of PD-1. First, PD-1 protein drugs are modified with a latent bioreactive unnatural amino acid (Uaa, e.g., fluorosulfate-<span class="smallcaps smallerCapital">l</span>-tyrosine). Then, the electrophilic fluorosulfate-<span class="smallcaps smallerCapital">l</span>-tyrosine selectively reacts with a nucleophilic residue (e.g., histidine) in the PD-L1 target. The result is a covalent linkage between the modified PD-1 protein and the target residue. SuFEx, sulfur(VI)-fluoride exchange reaction; PBMCs, peripheral blood mononuclear cells. Adapted with permission from   <cite><i>Cell</i></cite> (<a href="https://www.sciencedirect.com/journal/cell" class="extLink">https://www.sciencedirect.com/journal/cell</a>) <span class="NLM_year">2020</span>, <em>182</em>, 85–97,<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Copyright 2020 Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01362&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">9.  Conclusions and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54566" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54566" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In comparison to mAbs, the development of small and medium-sized molecules targeting the PD-1/PD-L1 pathway has been lagging far behind. Small molecule PD-1/PD-L1 inhibitors are advantageous over mAbs in terms of pharmacokinetic properties (e.g., oral bioavailability), but it remains a challenge to discover high-affinity small molecule modulators of PD-L1 because the binding interface of PD-1/PD-L1 is hydrophobic, extended, and flat (∼1.700 Å). Therefore, adopting different strategies in the design and discovery of small, medium-sized, and large molecule modulators of PD-1/PD-L1 is crucial, for example, to degrade or downregulate PD-L1 protein by various technologies such as LYTACs and HIP1R-mimics, as well as to design covalent modulators of PD-L1 in order to markedly improve the binding affinity and to potentially overcome drug resistance associated with noncovalent inhibitors. Protein degraders are “event-driven” and thus have inherent advantages over the conventional “occupancy driven” inhibitors. Therefore, developing PD-L1 degraders/downregulators could complement existing mAbs and small molecules targeting the PD-L1 axis, as PD-L1 degraders might be able to overcome the drawbacks (e.g., drug resistance or poor pharmacokinetics) of mAbs and small molecule PD-L1 inhibitors. PROTACs have been extensively utilized for degrading intracellular proteins via the ubiquitin–proteasome system. Theoretically, membrane proteins such as PD-L1 can be degraded by PROTACs when the protein is recycled to the cell or before it matures from the cell after ribosome synthesis. LYTACs are a useful approach targeting extracellular proteins for degradation through the lysosomal pathway. Nevertheless, degrading/downregulating extracellular or membrane proteins (e.g., PD-L1) is still challenging due to the lack of effective means of degradation/downregulation but is a promising field owing to the large number of extracellular or membrane-bound pathogenic proteins. Covalent inhibitors of PD-L1 represent a novel strategy to improve the potency of and potentially overcome drug resistance associated with noncovalent PD-L1 inhibitors. Current degraders/downregulators of PD-L1 include small molecule degraders [e.g., SA-49, (+)-JQ-1], dual kinase inhibitors and PD-L1 downregulators (kinase inhibitor-based PD-L1 downregulators), PROTAC-mimics, HIP1R, and LYTACs. However, degradation/downregulation of PD-L1 by the above-mentioned technologies is still in the early explorative stage. The exact mechanism of degradation/downregulation, the ADMET (absorption, distribution, metabolism, excretion, and toxicology) properties, the safety profiles, the <i>in vivo</i> relevance, and the potential therapeutic applications remain to be elucidated. Also due to the limited number of currently available small molecule PD-L1 modulators, the design of structurally diversified PD-L1 degraders (e.g., PROTAC-like) has been hampered. As for covalent PD-L1 inhibitors, it remains challenging to identify small-molecule-based covalent inhibitors of PD-L1 owing to the lack of available and readily conjugatable residues such as cysteines in the PD-1/PD-L1 binding interface. A future direction of small-molecule-based covalent inhibitors of PD-L1 might be to utilize non-cycteine residues (e.g., lysine, serine) in the binding site of PD-1/PD-L1 for covalent conjugation. Nevertheless, the development of PD-L1 modulators (degraders, downregulators, and covalent inhibitors) is a promising area deserving further investigation.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01362" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58001" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58001" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianjun Chen</span> - <span class="hlFld-Affiliation affiliation">Drug
Design and Discovery Research Innovation Community, School of Pharmaceutical
Sciences, Southern Medical University, Baiyun District, Guangzhou 510515, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5668-6572" title="Orcid link">http://orcid.org/0000-0001-5668-6572</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#dcb6bfb4b9b2eeed9cafb1a9f2b9b8a9f2bfb2"><span class="__cf_email__" data-cfemail="e08a8388858ed2d1a0938d95ce858495ce838e">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Binbin Cheng</span> - <span class="hlFld-Affiliation affiliation">Drug
Design and Discovery Research Innovation Community, School of Pharmaceutical
Sciences, Southern Medical University, Baiyun District, Guangzhou 510515, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yao Xiao</span> - <span class="hlFld-Affiliation affiliation">Wuchang
Hospital Affiliated to Wuhan University of Science and Technology, Wuhan
Wuchang Hospital, Wuchang 430063, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mingming Xue</span> - <span class="hlFld-Affiliation affiliation">Tianjin
Tiancheng Chemical Co., Ltd., Chemical Street, Binhai New District, Tianjin 300480, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hao Cao</span> - <span class="hlFld-Affiliation affiliation">Drug
Design and Discovery Research Innovation Community, School of Pharmaceutical
Sciences, Southern Medical University, Baiyun District, Guangzhou 510515, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>B.C., Y.X., and M.X. contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37877" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37877" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Binbin Cheng</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01362&amp;id=BIO-d7e857-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Binbin Cheng</b> is a Ph.D. candidate at the School of Pharmaceutical Sciences, Southern Medical University, China. He is interested in medicinal chemistry.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Yao Xiao</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01362&amp;id=BIO-d7e862-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Yao Xiao</b> is a pharmacist at Wuchang Hospital Affiliated to Wuhan University of Science and Technology, Wuhan Wuchang Hospital, China. She is interested in clinical pharmacy.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Mingming Xue</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01362&amp;id=BIO-d7e867-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Mingming Xue</b> is an organic chemist at Tianjin Tiancheng Chemical Co., Ltd., Tianjin, China. He is interested in organic synthesis.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Hao Cao</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01362&amp;id=BIO-d7e872-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Hao Cao</b> is a Master student at the School of Pharmaceutical Sciences, Southern Medical University, China. He is interested in medicinal chemistry.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Jianjun Chen</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01362&amp;id=BIO-d7e877-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jianjun Chen</b> is a Professor at the School of Pharmaceutical Sciences, Southern Medical University, China. He received his Ph.D. from the University of Tennessee Health Science Center (Memphis, USA) in 2011 and has been an Assistant and Associate Professor at Chicago State University College of Pharmacy. His research mainly focuses on design, synthesis, and biological study of novel small molecules (e.g., PD-1/PD-L1 inhibitors) as anticancer agents.</p></figure></div><div class="ack" id="ACK-d7e890-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57645" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57645" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the following grants: Thousand Youth Talents Program from the Organization Department of the CPC Central Committee, China (Grant C1080092); Scientific Research Project of High Level Talents in Southern Medical University of China (Grant C1051008).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">AP</td><td class="NLM_def"><p class="first last">adaptor protein</p></td></tr><tr><td class="NLM_term">AP-1</td><td class="NLM_def"><p class="first last">activator protein 1</p></td></tr><tr><td class="NLM_term">CI-M6PR</td><td class="NLM_def"><p class="first last">cation-independent mannose 6-phosphate receptor</p></td></tr><tr><td class="NLM_term">ESCRT</td><td class="NLM_def"><p class="first last">endosomal sorting complexes required for transport</p></td></tr><tr><td class="NLM_term">FSY</td><td class="NLM_def"><p class="first last">fluorosulfate-<span class="smallcaps smallerCapital">l</span>-tyrosine</p></td></tr><tr><td class="NLM_term">GSK3β</td><td class="NLM_def"><p class="first last">glycogen synthase kinase 3β</p></td></tr><tr><td class="NLM_term">HTRF</td><td class="NLM_def"><p class="first last">homogeneous time-resolved fluorescence</p></td></tr><tr><td class="NLM_term">HIP1R</td><td class="NLM_def"><p class="first last">Huntingtin-interacting protein 1-related</p></td></tr><tr><td class="NLM_term">HIF1-α</td><td class="NLM_def"><p class="first last">hypoxia inducible factor 1α</p></td></tr><tr><td class="NLM_term">PBMC</td><td class="NLM_def"><p class="first last">human peripheral blood mononuclear cell</p></td></tr><tr><td class="NLM_term">LYTAC</td><td class="NLM_def"><p class="first last">lysosome targeting chimera</p></td></tr><tr><td class="NLM_term">mAbs</td><td class="NLM_def"><p class="first last">monoclonal antibodies</p></td></tr><tr><td class="NLM_term">MHC</td><td class="NLM_def"><p class="first last">major histocompatibility complex</p></td></tr><tr><td class="NLM_term">MITF</td><td class="NLM_def"><p class="first last">microphthalmia transcription factor</p></td></tr><tr><td class="NLM_term">O/ICW</td><td class="NLM_def"><p class="first last">on/in-cell Odyssey Western blot</p></td></tr><tr><td class="NLM_term">PD-1</td><td class="NLM_def"><p class="first last">programmed cell death 1</p></td></tr><tr><td class="NLM_term">PD-L1</td><td class="NLM_def"><p class="first last">programmed cell death-ligand 1</p></td></tr><tr><td class="NLM_term">PARP</td><td class="NLM_def"><p class="first last">poly ADP ribose polymerase</p></td></tr><tr><td class="NLM_term">PKCα</td><td class="NLM_def"><p class="first last">Protein kinase Cα</p></td></tr><tr><td class="NLM_term">POI</td><td class="NLM_def"><p class="first last">protein of interest</p></td></tr><tr><td class="NLM_term">PERx</td><td class="NLM_def"><p class="first last">proximity-enabled reactive therapeutics</p></td></tr><tr><td class="NLM_term">STAT3</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription 3</p></td></tr><tr><td class="NLM_term">TCR</td><td class="NLM_def"><p class="first last">T cell receptor</p></td></tr><tr><td class="NLM_term">TF</td><td class="NLM_def"><p class="first last">transcription factor</p></td></tr><tr><td class="NLM_term">UPS</td><td class="NLM_def"><p class="first last">ubiquitin–proteasome system</p></td></tr><tr><td class="NLM_term">SuFEx</td><td class="NLM_def"><p class="first last">sulfur(VI)-fluoride exchange reaction</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82280" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82280" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 84 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gittis, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikami, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garboczi, D. N.</span></span> <span> </span><span class="NLM_article-title">The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">3011</span>– <span class="NLM_lpage">3016</span>, <span class="refDoi"> DOI: 10.1073/pnas.0712278105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1073%2Fpnas.0712278105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=18287011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtVSitr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=3011-3016&author=D.+Y.+Linauthor=Y.+Tanakaauthor=M.+Iwasakiauthor=A.+G.+Gittisauthor=H.+P.+Suauthor=B.+Mikamiauthor=T.+Okazakiauthor=T.+Honjoauthor=N.+Minatoauthor=D.+N.+Garboczi&title=The+PD-1%2FPD-L1+complex+resembles+the+antigen-binding+Fv+domains+of+antibodies+and+T+cell+receptors&doi=10.1073%2Fpnas.0712278105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors</span></div><div class="casAuthors">Lin, David Yin-Wei; Tanaka, Yoshimasa; Iwasaki, Masashi; Gittis, Apostolos G.; Su, Hua-Poo; Mikami, Bunzo; Okazaki, Taku; Honjo, Tasuku; Minato, Nagahiro; Garboczi, David N.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3011-3016</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Signaling via the programmed death 1 (PD-1) inhibitory receptor upon binding its ligand, PD-L1, suppresses immune responses against autoantigens and tumors and plays an important role in the maintenance of peripheral immune tolerance.  Release from PD-1 inhibitory signaling revives "exhausted" virus-specific T cells in chronic viral infections.  Here the authors present the crystal structure of murine PD-1 in complex with human PD-L1.  PD-1 and PD-L1 interact through the conserved front and side of their Ig variable (IgV) domains, as do the IgV domains of antibodies and T cell receptors.  This places the loops at the ends of the IgV domains on the same side of the PD-1/PD-L1 complex, forming a surface that is similar to the antigen-binding surface of antibodies and T cell receptors.  Mapping conserved residues allowed the identification of residues that are important in forming the PD-1/PD-L1 interface.  Based on the structure, the authors show that some reported loss-of-binding mutations involve the PD-1/PD-L1 interaction but that others compromise protein folding.  The PD-1/PD-L1 interaction described here may be blocked by antibodies or by designed small-mol. drugs to lower inhibitory signaling that results in a stronger immune response.  The immune receptor-like loops offer a new surface for further study and potentially the design of mols. that would affect PD-1/PD-L1 complex formation and thereby modulate the immune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqbP0BPGxxELVg90H21EOLACvtfcHk0lgINfJ_b21pLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtVSitr4%253D&md5=5ea708a1fdb0b926d109ec515c9b81cc</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0712278105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0712278105%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DD.%2BY.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DIwasaki%26aufirst%3DM.%26aulast%3DGittis%26aufirst%3DA.%2BG.%26aulast%3DSu%26aufirst%3DH.%2BP.%26aulast%3DMikami%26aufirst%3DB.%26aulast%3DOkazaki%26aufirst%3DT.%26aulast%3DHonjo%26aufirst%3DT.%26aulast%3DMinato%26aufirst%3DN.%26aulast%3DGarboczi%26aufirst%3DD.%2BN.%26atitle%3DThe%2520PD-1%252FPD-L1%2520complex%2520resembles%2520the%2520antigen-binding%2520Fv%2520domains%2520of%2520antibodies%2520and%2520T%2520cell%2520receptors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D3011%26epage%3D3016%26doi%3D10.1073%2Fpnas.0712278105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, Y.</span></span> <span> </span><span class="NLM_article-title">The IFN-gamma/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy</span>. <i>J. Neuroinflammation</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">290</span>, <span class="refDoi"> DOI: 10.1186/s12974-018-1330-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1186%2Fs12974-018-1330-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=30333036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFaisLbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=290&author=J.+Qianauthor=C.+Wangauthor=B.+Wangauthor=J.+Yangauthor=Y.+Wangauthor=F.+Luoauthor=J.+Xuauthor=C.+Zhaoauthor=R.+Liuauthor=Y.+Chu&title=The+IFN-gamma%2FPD-L1+axis+between+T+cells+and+tumor+microenvironment%3A+hints+for+glioma+anti-PD-1%2FPD-L1+therapy&doi=10.1186%2Fs12974-018-1330-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy</span></div><div class="casAuthors">Qian, Jiawen; Wang, Chen; Wang, Bo; Yang, Jiao; Wang, Yuedi; Luo, Feifei; Xu, Junying; Zhao, Chujun; Liu, Ronghua; Chu, Yiwei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroinflammation</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">290</span>CODEN:
                <span class="NLM_cas:coden">JNOEB3</span>;
        ISSN:<span class="NLM_cas:issn">1742-2094</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">PD-L1 is an immune inhibitory receptor ligand that leads to T cell dysfunction and apoptosis by binding to its receptor PD-1, which works in braking inflammatory response and conspiring tumor immune evasion.  However, in gliomas, the cause of PD-L1 expression in the tumor microenvironment is not yet clear.  Besides, auxiliary biomarkers are urgently needed for screening possible responsive glioma patients for anti-PD-1/PD-L1 therapies.  The distribution of tumor-infiltrating T cells and PD-L1 expression was analyzed via immunofluorescence in orthotopic murine glioma model.  The expression of PD-L1 in immune cell populations was detected by flow cytometry.  Data excavated from TCGA LGG/GBM datasets and the Ivy Glioblastoma Atlas Project was used for in silico anal. of the correlation among genes and survival.  The distribution of tumor-infiltrating T cells and PD-L1 expression, which parallels in murine orthotopic glioma model and human glioma microdissections, was interrelated.  The IFN-γ level was pos. correlated with PD-L1 expression in murine glioma.  Further, IFN-γ induces PD-L1 expression on primary cultured microglia, bone marrow-derived macrophages, and GL261 glioma cells in vitro.  Seven IFN-γ-induced genes, namely GBP5, ICAM1, CAMK2D, IRF1, SOCS3, CD44, and CCL2, were selected to calc. as substitute indicator for IFN-γ level.  By combining the relative expression of the listed IFN-γ-induced genes, IFN-γ score was pos. correlated with PD-L1 expression in different anat. structures of human glioma and in glioma of different malignancies.  Our study identified the distribution of tumor-infiltrating T cells and PD-L1 expression in murine glioma model and human glioma samples.  And we found that IFN-γ is an important cause of PD-L1 expression in the glioma microenvironment.  Further, we proposed IFN-γ score aggregated from the expressions of the listed IFN-γ-induced genes as a complementary prognostic indicator for anti-PD-1/PD-L1 therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8rUADz5qf7rVg90H21EOLACvtfcHk0lgINfJ_b21pLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFaisLbI&md5=1585ebade3417a6f95360f6e4d001cea</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1186%2Fs12974-018-1330-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12974-018-1330-2%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DChu%26aufirst%3DY.%26atitle%3DThe%2520IFN-gamma%252FPD-L1%2520axis%2520between%2520T%2520cells%2520and%2520tumor%2520microenvironment%253A%2520hints%2520for%2520glioma%2520anti-PD-1%252FPD-L1%2520therapy%26jtitle%3DJ.%2520Neuroinflammation%26date%3D2018%26volume%3D15%26spage%3D290%26doi%3D10.1186%2Fs12974-018-1330-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horner, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troncoso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zebala, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DePinho, R. A.</span></span> <span> </span><span class="NLM_article-title">Effective combinatorial immunotherapy for castration-resistant prostate cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>543</i></span>,  <span class="NLM_fpage">728</span>– <span class="NLM_lpage">732</span>, <span class="refDoi"> DOI: 10.1038/nature21676</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1038%2Fnature21676" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=28321130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltVWntbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=543&publication_year=2017&pages=728-732&author=X.+Luauthor=J.+W.+Hornerauthor=E.+Paulauthor=X.+Shangauthor=P.+Troncosoauthor=P.+Dengauthor=S.+Jiangauthor=Q.+Changauthor=D.+J.+Springauthor=P.+Sharmaauthor=J.+A.+Zebalaauthor=D.+Y.+Maedaauthor=Y.+A.+Wangauthor=R.+A.+DePinho&title=Effective+combinatorial+immunotherapy+for+castration-resistant+prostate+cancer&doi=10.1038%2Fnature21676"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Effective combinatorial immunotherapy for castration-resistant prostate cancer</span></div><div class="casAuthors">Lu, Xin; Horner, James W.; Paul, Erin; Shang, Xiaoying; Troncoso, Patricia; Deng, Pingna; Jiang, Shan; Chang, Qing; Spring, Denise J.; Sharma, Padmanee; Zebala, John A.; Maeda, Dean Y.; Wang, Y. Alan; DePinho, Ronald A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">543</span>
        (<span class="NLM_cas:issue">7647</span>),
    <span class="NLM_cas:pages">728-732</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A significant fraction of patients with advanced prostate cancer treated with androgen deprivation therapy experience relapse with relentless progression to lethal metastatic castration-resistant prostate cancer (mCRPC).  Immune checkpoint blockade using antibodies against cytotoxic-T-lymphocyte-assocd. protein 4 (CTLA4) or programmed cell death 1/programmed cell death 1 ligand 1 (PD1/PD-L1) generates durable therapeutic responses in a significant subset of patients across a variety of cancer types.  However, mCRPC showed overwhelming de novo resistance to immune checkpoint blockade, motivating a search for targeted therapies that overcome this resistance.  Myeloid-derived suppressor cells (MDSCs) are known to play important roles in tumor immune evasion.  The abundance of circulating MDSCs correlates with prostate-specific antigen levels and metastasis in patients with prostate cancer.  Mouse models of prostate cancer show that MDSCs (CD11b+Gr1+) promote tumor initiation and progression.  These observations prompted the authors to hypothesize that robust immunotherapy responses in mCRPC may be elicited by the combined actions of immune checkpoint blockade agents together with targeted agents that neutralize MDSCs yet preserve T-cell function.  Here the authors develop a novel chimeric mouse model of mCRPC to efficiently test combination therapies in an autochthonous setting.  Combination of anti-CTLA4 and anti-PD1 engendered only modest efficacy.  Targeted therapy against mCRPC-infiltrating MDSCs, using multi-kinase inhibitors such as cabozantinib and BEZ235, also showed minimal anti-tumor activities.  Strikingly, primary and metastatic CRPC showed robust synergistic responses when immune checkpoint blockade was combined with MDSC-targeted therapy.  Mechanistically, combination therapy efficacy stemmed from the up-regulation of interleukin-1 receptor antagonist and suppression of MDSC-promoting cytokines secreted by prostate cancer cells.  These observations illuminate a clin. path hypothesis for combining immune checkpoint blockade with MDSC-targeted therapies in the treatment of mCRPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh7-q_yEgcWrVg90H21EOLACvtfcHk0li-kXCepK6Isg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltVWntbg%253D&md5=66daee4919d9beaeb083b73a7e686fe7</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnature21676&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature21676%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DHorner%26aufirst%3DJ.%2BW.%26aulast%3DPaul%26aufirst%3DE.%26aulast%3DShang%26aufirst%3DX.%26aulast%3DTroncoso%26aufirst%3DP.%26aulast%3DDeng%26aufirst%3DP.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DQ.%26aulast%3DSpring%26aufirst%3DD.%2BJ.%26aulast%3DSharma%26aufirst%3DP.%26aulast%3DZebala%26aufirst%3DJ.%2BA.%26aulast%3DMaeda%26aufirst%3DD.%2BY.%26aulast%3DWang%26aufirst%3DY.%2BA.%26aulast%3DDePinho%26aufirst%3DR.%2BA.%26atitle%3DEffective%2520combinatorial%2520immunotherapy%2520for%2520castration-resistant%2520prostate%2520cancer%26jtitle%3DNature%26date%3D2017%26volume%3D543%26spage%3D728%26epage%3D732%26doi%3D10.1038%2Fnature21676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, J.</span></span> <span> </span><span class="NLM_article-title">The systemic activation of programmed death 1-PD-L1 axis protects systemic lupus erythematosus model from nephritis</span>. <i>Am. J. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">379</span>, <span class="refDoi"> DOI: 10.1159/000480641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1159%2F000480641" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=29069649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvV2gsbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2017&pages=371-379&author=W.+Liaoauthor=H.+Zhengauthor=S.+Wuauthor=Y.+Zhangauthor=W.+Wangauthor=Z.+Zhangauthor=C.+Zhouauthor=H.+Wuauthor=J.+Min&title=The+systemic+activation+of+programmed+death+1-PD-L1+axis+protects+systemic+lupus+erythematosus+model+from+nephritis&doi=10.1159%2F000480641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The Systemic Activation of Programmed Death 1-PD-L1 Axis Protects Systemic Lupus Erythematosus Model from Nephritis</span></div><div class="casAuthors">Liao, Wenjun; Zheng, Hua; Wu, Sha; Zhang, Yanmei; Wang, Wei; Zhang, Zili; Zhou, Chenfei; Wu, Hongjun; Min, Jie</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Nephrology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">371-379</span>CODEN:
                <span class="NLM_cas:coden">AJNED9</span>;
        ISSN:<span class="NLM_cas:issn">0250-8095</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Background: Systemic lupus erythematosus (SLE) is characterized by abnormal activated T cells, autoreactive B cells, and massive cytokines.  The CD4+ T cells detd. B-cells differentiation and cytokines prodn.  The programmed death 1 (PD-1) is the checkpoint immunoinhibitory receptor of activated T cells, and its engagement could exhaust T cells.  In this study, we investigated the role of PD-1 systemic engagement with PD-L1-Ig in lupus-like nephritis in SLE mice.  Methods: The murine PD-L1-Ig was injected into SLE-prone mice.  The proteinuria and survival ratio were monitored.  The prodn. of anti-dsDNA autoantibodies and cytokines in serum were measured by ELISA.  The cytokine-producing T cells (interferon-γ, IFN-γ and IL-17α) in kidney and spleen were detected with flowcytometry.  The pathol. evaluation of the Ig deposition in the glomeruliand was detd. with immunofluorescence.  Lymphocytes in 24-h urine were detected with flowcytometry.  Results: The systemic administration of PD-L1-Ig activated PD-1-PD-L1 axis of CD4+ T lymphocytes, suppressed Th17 formation in many organs, including the spleen and the kidney, demolished abnormal prodn. of cytokines (IFN-γ, IL-17, and IL-10) and anti-dsDNA autoantibodies in serum, inhibited IgG deposition in the glomeruli with the decrease of proteinuria, and activated T cells in urine.  Accordingly, the systemic conjugation of PD-L1-PD-1 impaired renal autoimmune injure and prolonged survival time.  Conclusion: Our research demonstrated that the protective function of systemic activation of PD-1-PD-L1 axis with PD-L1-Ig attenuates the nephritis in SLE-prone mice, which facilitates us to understand the suppressive function of PD-1-PD-L1 axis in the pathogenesis and progress of the lupus nephritis, and to explore a possible effective therapeutic strategy to SLE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow--p2nB5yobVg90H21EOLACvtfcHk0li-kXCepK6Isg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvV2gsbvO&md5=c555ef6c1df4bfdf86d582877e357d98</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1159%2F000480641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000480641%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DW.%26aulast%3DZheng%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DMin%26aufirst%3DJ.%26atitle%3DThe%2520systemic%2520activation%2520of%2520programmed%2520death%25201-PD-L1%2520axis%2520protects%2520systemic%2520lupus%2520erythematosus%2520model%2520from%2520nephritis%26jtitle%3DAm.%2520J.%2520Nephrol.%26date%3D2017%26volume%3D46%26spage%3D371%26epage%3D379%26doi%3D10.1159%2F000480641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, H.</span></span> <span> </span><span class="NLM_article-title">Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy</span>. <i>J. Drug Targeting</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">244</span>, <span class="refDoi"> DOI: 10.1080/1061186X.2018.1440400</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1080%2F1061186X.2018.1440400" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=29448849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtVagsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=244&author=K.+Liauthor=H.+Tian&title=Development+of+small-molecule+immune+checkpoint+inhibitors+of+PD-1%2FPD-L1+as+a+new+therapeutic+strategy+for+tumour+immunotherapy&doi=10.1080%2F1061186X.2018.1440400"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy</span></div><div class="casAuthors">Li, Kui; Tian, Hongqi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Drug Targeting</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">244-256</span>CODEN:
                <span class="NLM_cas:coden">JDTAEH</span>;
        ISSN:<span class="NLM_cas:issn">1026-7158</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Cancer immunotherapy has been increasingly utilized to treat advanced malignancies.  The signalling network of immune checkpoints has attracted considerable attention.  Immune checkpoint inhibitors are revolutionising the treatment options and expectations for patients with cancer.  The reported clin. success of targeting the T-cell immune checkpoint receptors PD-1/PD-L1 has demonstrated the importance of immune modulation.  Indeed, antibodies binding to PD-1 or PD-L1 have shown remarkable efficacy.  However, antibody drugs have many disadvantages, such as their prodn. cost, stability, and immunogenicity and, therefore, small-mol. inhibitors of PD-1 and its ligand PD-L1 are being introduced.  Small-mol. inhibitors could offer inherent advantages in terms of pharmacokinetics and druggability, thereby providing addnl. methods for cancer treatment and achieving better therapeutic effects.  In this review, we first discuss how PD-1/PD-L1-targeting inhibitors modulate the relationship between immune cells and tumor cells in tumor immunotherapy.  Second, we discuss how the immunomodulatory potential of these inhibitors can be exploited via rational combinations with immunotherapy and targeted therapy.  Third, this review is the first to summarise the current clin. and preclin. evidence regarding small-mol. inhibitors of the PD-1/PD-L1 immune checkpoint, considering features and responses related to the tumors and to the host immune system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFV2nDZO10ObVg90H21EOLACvtfcHk0li-kXCepK6Isg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtVagsLs%253D&md5=faee5edc1f4cc14203c023066e802384</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1080%2F1061186X.2018.1440400&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1061186X.2018.1440400%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DK.%26aulast%3DTian%26aufirst%3DH.%26atitle%3DDevelopment%2520of%2520small-molecule%2520immune%2520checkpoint%2520inhibitors%2520of%2520PD-1%252FPD-L1%2520as%2520a%2520new%2520therapeutic%2520strategy%2520for%2520tumour%2520immunotherapy%26jtitle%3DJ.%2520Drug%2520Targeting%26date%3D2019%26volume%3D27%26spage%3D244%26doi%3D10.1080%2F1061186X.2018.1440400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keir, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butte, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, A. H.</span></span> <span> </span><span class="NLM_article-title">PD-1 and its ligands in tolerance and immunity</span>. <i>Annu. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">677</span>– <span class="NLM_lpage">704</span>, <span class="refDoi"> DOI: 10.1146/annurev.immunol.26.021607.090331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1146%2Fannurev.immunol.26.021607.090331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=18173375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltlWktrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=677-704&author=M.+E.+Keirauthor=M.+J.+Butteauthor=G.+J.+Freemanauthor=A.+H.+Sharpe&title=PD-1+and+its+ligands+in+tolerance+and+immunity&doi=10.1146%2Fannurev.immunol.26.021607.090331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">PD-1 and its ligands in tolerance and immunity</span></div><div class="casAuthors">Keir, Mary E.; Butte, Manish J.; Freeman, Gordon J.; Sharpe, Arlene H.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">677-704</span>CODEN:
                <span class="NLM_cas:coden">ARIMDU</span>;
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Programmed death 1 (PD-1) and its ligands, PD-L1 and PD-L2, deliver inhibitory signals that regulate the balance between T cell activation, tolerance, and immunopathol.  Immune responses to foreign and self-antigens require specific and balanced responses to clear pathogens and tumors and yet maintain tolerance.  Induction and maintenance of T cell tolerance requires PD-1, and its ligand PD-L1 on nonhematopoietic cells can limit effector T cell responses and protect tissues from immune-mediated tissue damage.  The PD-1:PD-L pathway also has been usurped by microorganisms and tumors to attenuate antimicrobial or tumor immunity and facilitate chronic infection and tumor survival.  The identification of B7-1 as an addnl. binding partner for PD-L1, together with the discovery of an inhibitory bidirectional interaction between PD-L1 and B7-1, reveals new ways the B7:CD28 family regulates T cell activation and tolerance.  In this review, we discuss current understanding of the immunoregulatory functions of PD-1 and its ligands and their therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTbTIs2Ruos7Vg90H21EOLACvtfcHk0ljLHSX2SFLw2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltlWktrY%253D&md5=4b9b36a8716b8b1b47b7953f134448cf</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1146%2Fannurev.immunol.26.021607.090331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.immunol.26.021607.090331%26sid%3Dliteratum%253Aachs%26aulast%3DKeir%26aufirst%3DM.%2BE.%26aulast%3DButte%26aufirst%3DM.%2BJ.%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26atitle%3DPD-1%2520and%2520its%2520ligands%2520in%2520tolerance%2520and%2520immunity%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D2008%26volume%3D26%26spage%3D677%26epage%3D704%26doi%3D10.1146%2Fannurev.immunol.26.021607.090331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoos, A.</span></span> <span> </span><span class="NLM_article-title">Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.1038/nrd.2015.35</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1038%2Fnrd.2015.35" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=26965203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVCgsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=235-247&author=A.+Hoos&title=Development+of+immuno-oncology+drugs+-+from+CTLA4+to+PD1+to+the+next+generations&doi=10.1038%2Fnrd.2015.35"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations</span></div><div class="casAuthors">Hoos, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">235-247</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Since the regulatory approval of ipilimumab in 2011, the field of cancer immunotherapy has been experiencing a renaissance.  This success is based on progress in both preclin. and clin. science, including the development of new methods of investigation.  Immuno-oncol. has become a sub-specialty within oncol. owing to its unique science and its potential for substantial and long-term clin. benefit.  Immunotherapy agents do not directly attack the tumor but instead mobilize the immune system - this can be achieved through various approaches that utilize adaptive or innate immunity.  Therefore, immuno-oncol. drug development encompasses a broad range of agents, including antibodies, peptides, proteins, small mols., adjuvants, cytokines, oncolytic viruses, bi-specific mols. and cellular therapies.  This Perspective summarizes the recent history of cancer immunotherapy, including the factors that led to its success, provides an overview of novel drug-development considerations, summarizes three generations of immunotherapies that have been developed since 2011 and, thus, illustrates the breadth of opportunities these new generations of immunotherapies represent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8GBkFRW-5VLVg90H21EOLACvtfcHk0ljLHSX2SFLw2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVCgsLo%253D&md5=547a5ef71cf6e494ea3abeb8b2c2e463</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2015.35&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2015.35%26sid%3Dliteratum%253Aachs%26aulast%3DHoos%26aufirst%3DA.%26atitle%3DDevelopment%2520of%2520immuno-oncology%2520drugs%2520-%2520from%2520CTLA4%2520to%2520PD1%2520to%2520the%2520next%2520generations%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26spage%3D235%26epage%3D247%26doi%3D10.1038%2Fnrd.2015.35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Callahan, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postow, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span> <span> </span><span class="NLM_article-title">Targeting T cell co-receptors for cancer therapy</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">1069</span>– <span class="NLM_lpage">1078</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2016.04.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1016%2Fj.immuni.2016.04.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=27192570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC28XotFarsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=1069-1078&author=M.+K.+Callahanauthor=M.+A.+Postowauthor=J.+D.+Wolchok&title=Targeting+T+cell+co-receptors+for+cancer+therapy&doi=10.1016%2Fj.immuni.2016.04.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting T Cell Co-receptors for Cancer Therapy</span></div><div class="casAuthors">Callahan, Margaret K.; Postow, Michael A.; Wolchok, Jedd D.</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1069-1078</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Checkpoint-blocking antibodies can generate potent anti-tumor responses by encouraging the immune system to seek and destroy cancer cells.  At this time, the United States Food and Drug Administration has approved three checkpoint-blocking antibodies in three disease indications, and addnl. approvals are expected to broaden the clin. scope of immunotherapy.  Herein, we review the clin. development of CTLA-4-, PD-1-, and PD-L1-blocking antibodies across tumor types and briefly discuss areas of active investigation of potential biomarkers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9tM_RjJV5G7Vg90H21EOLACvtfcHk0ljLHSX2SFLw2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XotFarsLs%253D&md5=e5e3e3df43520118b3670b514b94e466</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2016.04.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2016.04.023%26sid%3Dliteratum%253Aachs%26aulast%3DCallahan%26aufirst%3DM.%2BK.%26aulast%3DPostow%26aufirst%3DM.%2BA.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26atitle%3DTargeting%2520T%2520cell%2520co-receptors%2520for%2520cancer%2520therapy%26jtitle%3DImmunity%26date%3D2016%26volume%3D44%26spage%3D1069%26epage%3D1078%26doi%3D10.1016%2Fj.immuni.2016.04.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span> <span> </span><span class="NLM_article-title">Immunotherapy: anti-PD-1 therapies-a new first-line option in advanced melanoma</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">625</span>– <span class="NLM_lpage">626</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2015.170</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1038%2Fnrclinonc.2015.170" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=26416151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A280%3ADC%252BC283ms1Wmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=625-626&author=R.+J.+Sullivanauthor=K.+T.+Flaherty&title=Immunotherapy%3A+anti-PD-1+therapies-a+new+first-line+option+in+advanced+melanoma&doi=10.1038%2Fnrclinonc.2015.170"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Immunotherapy: Anti-PD-1 therapies-a new first-line option in advanced melanoma</span></div><div class="casAuthors">Sullivan Ryan J; Flaherty Keith T</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Clinical oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">625-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQkbwjUIJOh8YUSrryheKE6fW6udTcc2eZdULtPX-mzA7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283ms1Wmsg%253D%253D&md5=015a1194cf584003c341b1315faa8669</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2015.170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2015.170%26sid%3Dliteratum%253Aachs%26aulast%3DSullivan%26aufirst%3DR.%2BJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26atitle%3DImmunotherapy%253A%2520anti-PD-1%2520therapies-a%2520new%2520first-line%2520option%2520in%2520advanced%2520melanoma%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D12%26spage%3D625%26epage%3D626%26doi%3D10.1038%2Fnrclinonc.2015.170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimeno, A.</span></span> <span> </span><span class="NLM_article-title">Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1358/dot.2015.51.1.2250387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1358%2Fdot.2015.51.1.2250387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A280%3ADC%252BC2MrmsVyntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=7-20&author=J.+McDermottauthor=A.+Jimeno&title=Pembrolizumab%3A+PD-1+inhibition+as+a+therapeutic+strategy+in+cancer&doi=10.1358%2Fdot.2015.51.1.2250387"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer</span></div><div class="casAuthors">McDermott J; Jimeno A</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-20</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Programmed cell death protein 1 (PD-1) and its ligands, programmed cell death 1 ligand 1 (PD-L1) and 2 (PD-L2) play an important role in regulating immune response through various mechanisms.  This inhibitory action is thought to assist in immune evasion by cancer cells as PD-1, PD-L1 and PD-L2 have been found to be abnormally expressed by tumor cells and lymphocytes in the tumor microenvironment.  Preclinical studies described PD-1 blockade resulting in tumor growth suppression and even decreased metastasis.  This has led to the development of pembrolizumab (MK-3475), a highly selective, humanized monoclonal IgG4-kappa isotype antibody against PD-1.  Early clinical trials have shown high tumor response rates and long duration of effect in previously treated advanced melanoma resulting in accelerated FDA approval for the drug in this situation.  Pembrolizumab has also had success in non-small cell lung cancer and is being tested in multiple other tumor types.  This review will discuss the development, preclinical data, pharmacokinetics and clinical efficacy to date of pembrolizumab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTBBryFJmsYVMuCWE5mhx1RfW6udTcc2eZdULtPX-mzA7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MrmsVyntQ%253D%253D&md5=27520a64818c171071d2dd5b6dfae53d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1358%2Fdot.2015.51.1.2250387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2015.51.1.2250387%26sid%3Dliteratum%253Aachs%26aulast%3DMcDermott%26aufirst%3DJ.%26aulast%3DJimeno%26aufirst%3DA.%26atitle%3DPembrolizumab%253A%2520PD-1%2520inhibition%2520as%2520a%2520therapeutic%2520strategy%2520in%2520cancer%26jtitle%3DDrugs%2520Today%26date%3D2015%26volume%3D51%26spage%3D7%26epage%3D20%26doi%3D10.1358%2Fdot.2015.51.1.2250387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Atezolizumab: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1227</span>– <span class="NLM_lpage">1232</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0618-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1007%2Fs40265-016-0618-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=27412122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOlsbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=1227-1232&author=A.+Markham&title=Atezolizumab%3A+first+global+approval&doi=10.1007%2Fs40265-016-0618-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Atezolizumab: First Global Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1227-1232</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Atezolizumab (Tecentriq)-a monoclonal antibody targeting programmed death ligand 1 (PD-L1 or CD274 antigen)-is being developed by Genentech as treatment for a variety of haematol. malignancies and solid tumors.  It been approved in the US as a second-line therapy for urothelial carcinoma and is awaiting approval as a second-line therapy for non-small cell lung cancer.  This article summarizes the milestones in the development of atezolizumab leading to this first approval for urothelial carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3WAd7EcBi37Vg90H21EOLACvtfcHk0ljTFNA2ZfxDtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOlsbnI&md5=e9c8e579945779e24c9fc74fab967843</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0618-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0618-8%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DAtezolizumab%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D1227%26epage%3D1232%26doi%3D10.1007%2Fs40265-016-0618-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zobniw, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trinh, V. A.</span></span> <span> </span><span class="NLM_article-title">Avelumab: a review of its application in metastatic merkel cell carcinoma</span>. <i>Ann. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">928</span>– <span class="NLM_lpage">935</span>, <span class="refDoi"> DOI: 10.1177/1060028018768809</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1177%2F1060028018768809" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=29616562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVClsL7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2018&pages=928-935&author=J.+Josephauthor=C.+Zobniwauthor=J.+Davisauthor=J.+Andersonauthor=V.+A.+Trinh&title=Avelumab%3A+a+review+of+its+application+in+metastatic+merkel+cell+carcinoma&doi=10.1177%2F1060028018768809"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Avelumab: A Review of Its Application in Metastatic Merkel Cell Carcinoma</span></div><div class="casAuthors">Joseph, Jocelyn; Zobniw, Chrystia; Davis, Jennifer; Anderson, Jaime; Trinh, Van Anh</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Pharmacotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">928-935</span>CODEN:
                <span class="NLM_cas:coden">APHRER</span>;
        ISSN:<span class="NLM_cas:issn">1542-6270</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Objective: To summarize the clin. development of avelumab and its clin. relevance in metastatic Merkel cell carcinoma (MCC).  Data Sources: An English-language literature search using PubMed was performed using the terms avelumab, anti-PD-1, anti-PD-L1, and MCC from Jan. of 1950 to March 2018.  Data were also obtained from package inserts, meeting abstrs., and clin. registries.  Study Selection/Data Extn.: All relevant published articles of avelumab were reviewed.  Clin. trial registries and meeting abstrs. were used for information about ongoing trials.  Data Synthesis: Avelumab is a fully human monoclonal antibody that inhibits programmed death ligand-1, which reverses T-cell exhaustion and induces antitumor responses.  Avelumab is safe and effective in previously treated metastatic MCC based on a phase II trial of previously treated patients with objective response rates in 28 of 88 patients, including 10 complete responses and 19 partial responses.  Median overall survival (OS) was 12.9 mo, and 1-yr progression-free survival and OS were 30% and 52%, resp.  Grade 3 treatment-related side effects included lymphopenia (2 patients), serum creatine phosphokinase increase (1 patient), aminotransferase elevation (1 patient), and serum cholesterol increase (1 patient).  Relevance to Patient Care and Clin. Practice: This review outlines the pharmacol. and clin. trial data for avelumab in metastatic MCC and guides clinicians on avelumab's place in therapy.  Conclusions: Avelumab is the first Food and Drug Administration-approved medication for metastatic MCC and provides an advantage of durable responses and possibly improved tolerability compared with traditional platinum-based chemotherapy.  Clin. trials are under way to expand its utility into the adjuvant and frontline settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokwvc4wyjOSrVg90H21EOLACvtfcHk0ljTFNA2ZfxDtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVClsL7O&md5=9ffbd68f67e2b4c77c8b440ee4c2a6b4</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1177%2F1060028018768809&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1060028018768809%26sid%3Dliteratum%253Aachs%26aulast%3DJoseph%26aufirst%3DJ.%26aulast%3DZobniw%26aufirst%3DC.%26aulast%3DDavis%26aufirst%3DJ.%26aulast%3DAnderson%26aufirst%3DJ.%26aulast%3DTrinh%26aufirst%3DV.%2BA.%26atitle%3DAvelumab%253A%2520a%2520review%2520of%2520its%2520application%2520in%2520metastatic%2520merkel%2520cell%2520carcinoma%26jtitle%3DAnn.%2520Pharmacother.%26date%3D2018%26volume%3D52%26spage%3D928%26epage%3D935%26doi%3D10.1177%2F1060028018768809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Camacho, L. H.</span></span> <span> </span><span class="NLM_article-title">CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations</span>. <i>Cancer Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">661</span>– <span class="NLM_lpage">672</span>, <span class="refDoi"> DOI: 10.1002/cam4.371</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1002%2Fcam4.371" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=25619164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlCitL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=661-672&author=L.+H.+Camacho&title=CTLA-4+blockade+with+ipilimumab%3A+biology%2C+safety%2C+efficacy%2C+and+future+considerations&doi=10.1002%2Fcam4.371"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations</span></div><div class="casAuthors">Camacho, Luis H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">661-672</span>CODEN:
                <span class="NLM_cas:coden">CMAEDL</span>;
        ISSN:<span class="NLM_cas:issn">2045-7634</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  Melanoma remains a crit. public health problem worldwide.  Patients with stage IV disease have very poor prognosis and their 1-yr survival rate is only 25%.  Until recently, systemic treatments with a pos. impact on overall survival (OS) had remained elusive.  In recent years, the United States Food and Drug Administration (FDA) - approved several novel agents targeting the RAS/RAF/MEK/ERK pathway (vemurafenib, dabrafenib, and trametinib) - crit. in cell division and proliferation of melanoma, and an immune checkpoint inhibitor (ipilimumab) directed against the cytotoxic T lymphocyte Antigen - (CTLA-4).  Moreover, recent reports of clin. trials studying other immune checkpoint modulating agents will most likely result in their FDA approval within the next months.  This review focuses on ipilimumab, its safety and efficacy, and future considerations.  Ipilimumab has demonstrated a pos. OS impact after a several-year follow-up.  It is also recognized that due to its mechanism of action, the response patterns to ipilimumab can differ from those obsd. in patients following treatment with conventional cytotoxic agents and even the most recently approved BRAF inhibitors.  Most patients (84.8%) experience drug-related adverse events (AEs) of any grade; most of these are mild to moderate and immune mediated.  However, a minority of patients may also experience severe and life-threatening AEs.  In clin. studies, AEs were managed according to guidelines that emphasized close clin. monitoring and early use of corticosteroids when appropriate.  Preliminary results have taught us the potential greater toxicity when in combination with vemurafenib, and the greater antitumor efficacy when combined with nivolumab, a monoclonal antibody directed against programmed death receptor-1 (PD-1), another immune checkpoint inhibitor.  Future challenges include the optimization of dosing and toxicities when used as a single agent, and studying the safety and efficacy of combinations with targeted small mols. and other monoclonal antibodies to treat patients with melanoma and other malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqgKhI5zDfRrVg90H21EOLACvtfcHk0ljTFNA2ZfxDtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlCitL8%253D&md5=c228a867827d6778907e3ee39f4db25c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fcam4.371&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcam4.371%26sid%3Dliteratum%253Aachs%26aulast%3DCamacho%26aufirst%3DL.%2BH.%26atitle%3DCTLA-4%2520blockade%2520with%2520ipilimumab%253A%2520biology%252C%2520safety%252C%2520efficacy%252C%2520and%2520future%2520considerations%26jtitle%3DCancer%2520Med.%26date%3D2015%26volume%3D4%26spage%3D661%26epage%3D672%26doi%3D10.1002%2Fcam4.371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellmann, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoRusso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emens, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodi, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieu, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eder, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleary, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jelovac, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuhako, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrissey, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahrus, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirzkall, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, L. S.</span></span> <span> </span><span class="NLM_article-title">A Phase 1b dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-1 (atezolizumab) in patients with locally advanced or metastatic solid tumors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.35.15_suppl.105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1200%2FJCO.2017.35.15_suppl.105" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=105-105&author=H.+A.+Burrisauthor=M.+Gordonauthor=M.+D.+Hellmannauthor=P.+LoRussoauthor=L.+A.+Emensauthor=F.+S.+Hodiauthor=H.+C.+Lieuauthor=J.+R.+Infanteauthor=Y.+F.+Tsaiauthor=J.+P.+Ederauthor=J.+M.+Clearyauthor=D.+Jelovacauthor=A.+L.+Tsuhakoauthor=L.+Muellerauthor=R.+Linauthor=K.+Morrisseyauthor=S.+Mahrusauthor=R.+Morleyauthor=A.+Pirzkallauthor=L.+S.+Davis&title=A+Phase+1b+dose+escalation+study+of+combined+inhibition+of+IDO1+%28GDC-0919%29+and+PD-1+%28atezolizumab%29+in+patients+with+locally+advanced+or+metastatic+solid+tumors&doi=10.1200%2FJCO.2017.35.15_suppl.105"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.35.15_suppl.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.35.15_suppl.105%26sid%3Dliteratum%253Aachs%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DGordon%26aufirst%3DM.%26aulast%3DHellmann%26aufirst%3DM.%2BD.%26aulast%3DLoRusso%26aufirst%3DP.%26aulast%3DEmens%26aufirst%3DL.%2BA.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26aulast%3DLieu%26aufirst%3DH.%2BC.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DTsai%26aufirst%3DY.%2BF.%26aulast%3DEder%26aufirst%3DJ.%2BP.%26aulast%3DCleary%26aufirst%3DJ.%2BM.%26aulast%3DJelovac%26aufirst%3DD.%26aulast%3DTsuhako%26aufirst%3DA.%2BL.%26aulast%3DMueller%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DR.%26aulast%3DMorrissey%26aufirst%3DK.%26aulast%3DMahrus%26aufirst%3DS.%26aulast%3DMorley%26aufirst%3DR.%26aulast%3DPirzkall%26aufirst%3DA.%26aulast%3DDavis%26aufirst%3DL.%2BS.%26atitle%3DA%2520Phase%25201b%2520dose%2520escalation%2520study%2520of%2520combined%2520inhibition%2520of%2520IDO1%2520%2528GDC-0919%2529%2520and%2520PD-1%2520%2528atezolizumab%2529%2520in%2520patients%2520with%2520locally%2520advanced%2520or%2520metastatic%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26spage%3D105%26epage%3D105%26doi%3D10.1200%2FJCO.2017.35.15_suppl.105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brahmer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammers, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipson, E. J.</span></span> <span> </span><span class="NLM_article-title">Nivolumab: targeting PD-1 to bolster antitumor immunity</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1307</span>– <span class="NLM_lpage">1326</span>, <span class="refDoi"> DOI: 10.2217/fon.15.52</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.2217%2Ffon.15.52" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=25798726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotFait7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=1307-1326&author=J.+R.+Brahmerauthor=H.+Hammersauthor=E.+J.+Lipson&title=Nivolumab%3A+targeting+PD-1+to+bolster+antitumor+immunity&doi=10.2217%2Ffon.15.52"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Nivolumab: targeting PD-1 to bolster antitumor immunity</span></div><div class="casAuthors">Brahmer, Julie R.; Hammers, Hans; Lipson, Evan J.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1307-1326</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">Nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, blocks PD-1 and can restore anticancer immune responses by abrogating PD-1 pathway-mediated T-cell inhibition.  Nivolumab is approved in Japan and the USA for the treatment of patients with advanced melanoma.  A Phase I trial reported overall objective response rates of 17, 32 and 29% in patients with advanced non-small-cell lung cancer, melanoma and renal cell carcinoma, resp., which included many heavily pretreated patients. 1-/2-yr overall survival rates were 42%/24%, 63%/48% and 70%/50% for non-small-cell lung cancer, melanoma and renal cell carcinoma, resp.  Nivolumab significantly improved survival vs. dacarbazine in previously untreated patients with metastatic melanoma in a Phase III trial.  Nivolumab is assocd. with a manageable adverse event profile.  Numerous clin. trials are investigating nivolumab alone or in combination with other therapies in multiple cancer settings.  This article summarizes the development of nivolumab as of Nov. 2014.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxyOwDIZFMy7Vg90H21EOLACvtfcHk0ljApkyAY5KAyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotFait7g%253D&md5=674728e6f32246799ce0c8738405ace6</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.2217%2Ffon.15.52&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.15.52%26sid%3Dliteratum%253Aachs%26aulast%3DBrahmer%26aufirst%3DJ.%2BR.%26aulast%3DHammers%26aufirst%3DH.%26aulast%3DLipson%26aufirst%3DE.%2BJ.%26atitle%3DNivolumab%253A%2520targeting%2520PD-1%2520to%2520bolster%2520antitumor%2520immunity%26jtitle%3DFuture%2520Oncol.%26date%3D2015%26volume%3D11%26spage%3D1307%26epage%3D1326%26doi%3D10.2217%2Ffon.15.52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonia, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villegas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicente, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiappori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Wit, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourhaba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quantin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mekhail, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karapetis, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiret, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostoros, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubota, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz-Ares, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Castro Carpeno, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadsworth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melillo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozguroglu, M.</span></span> <span> </span><span class="NLM_article-title">Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">1919</span>– <span class="NLM_lpage">1929</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1709937</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1056%2FNEJMoa1709937" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=28885881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktVOr" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=1919-1929&author=S.+J.+Antoniaauthor=A.+Villegasauthor=D.+Danielauthor=D.+Vicenteauthor=S.+Murakamiauthor=R.+Huiauthor=T.+Yokoiauthor=A.+Chiapporiauthor=K.+H.+Leeauthor=M.+de+Witauthor=B.+C.+Choauthor=M.+Bourhabaauthor=X.+Quantinauthor=T.+Tokitoauthor=T.+Mekhailauthor=D.+Planchardauthor=Y.+C.+Kimauthor=C.+S.+Karapetisauthor=S.+Hiretauthor=G.+Ostorosauthor=K.+Kubotaauthor=J.+E.+Grayauthor=L.+Paz-Aresauthor=J.+de+Castro+Carpenoauthor=C.+Wadsworthauthor=G.+Melilloauthor=H.+Jiangauthor=Y.+Huangauthor=P.+A.+Dennisauthor=M.+Ozguroglu&title=Durvalumab+after+chemoradiotherapy+in+stage+III+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa1709937"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer</span></div><div class="casAuthors">Antonia, S. J.; Villegas, A.; Daniel, D.; Vicente, D.; Murakami, S.; Hui, R.; Yokoi, T.; Chiappori, A.; Lee, K. H.; de Wit, M.; Cho, B. C.; Bourhaba, M.; Quantin, X.; Tokito, T.; Mekhail, T.; Planchard, D.; Kim, Y.-C.; Karapetis, C. S.; Hiret, S.; Ostoros, G.; Kubota, K.; Gray, J. E.; Paz-Ares, L.; de Castro Carpeno, J.; Wadsworth, C.; Melillo, G.; Jiang, H.; Huang, Y.; Dennis, P. A.; Ozguroglu, M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1919-1929</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Most patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy).  This phase 3 study compared the anti-programmed death ligand 1 antibody durvalumab as consolidation therapy with placebo in patients with stage III NSCLC who did not have disease progression after two or more cycles of platinum-based chemoradiotherapy.  Methods: We randomly assigned patients, in a 2:1 ratio, to receive durvalumab (at a dose of 10 mg per kg of body wt. i.v.) or placebo every 2 wk for up to 12 mo.  The study drug was administered 1 to 42 days after the patients had received chemoradiotherapy.  The coprimary end points were progression-free survival (as assessed by means of blinded independent central review) and overall survival (unplanned for the interim anal.).  Secondary end points included 12-mo and 18-mo progression-free survival rates, the objective response rate, the duration of response, the time to death or distant metastasis, and safety.  Results: Of 713 patients who underwent randomization, 709 received consolidation therapy (473 received durvalumab and 236 received placebo).  The median progression-free survival from randomization was 16.8 mo (95% confidence interval [CI], 13.0 to 18.1) with durvalumab vs. 5.6 mo (95% CI, 4.6 to 7.8) with placebo (stratified hazard ratio for disease progression or death, 0.52; 95% CI, 0.42 to 0.65; P<0.001); the 12-mo progression-free survival rate was 55.9% vs. 35.3%, and the 18-mo progression-free survival rate was 44.2% vs. 27.0%.  The response rate was higher with durvalumab than with placebo (28.4% vs. 16.0%; P<0.001), and the median duration of response was longer (72.8% vs. 46.8% of the patients had an ongoing response at 18 mo).  The median time to death or distant metastasis was longer with durvalumab than with placebo (23.2 mo vs. 14.6 mo; P<0.001).  Grade 3 or 4 adverse events occurred in 29.9% of the patients who received durvalumab and 26.1% of those who received placebo; the most common adverse event of grade 3 or 4 was pneumonia (4.4% and 3.8%, resp.).  A total of 15.4% of patients in the durvalumab group and 9.8% of those in the placebo group discontinued the study drug because of adverse events.  Conclusions: Progression-free survival was significantly longer with durvalumab than with placebo.  The secondary end points also favored durvalumab, and safety was similar between the groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLr5-R3gHtVbVg90H21EOLACvtfcHk0lgXGOlxCtHZ7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktVOr&md5=95be11a1c165acdc826c4ee049a5f010</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1709937&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1709937%26sid%3Dliteratum%253Aachs%26aulast%3DAntonia%26aufirst%3DS.%2BJ.%26aulast%3DVillegas%26aufirst%3DA.%26aulast%3DDaniel%26aufirst%3DD.%26aulast%3DVicente%26aufirst%3DD.%26aulast%3DMurakami%26aufirst%3DS.%26aulast%3DHui%26aufirst%3DR.%26aulast%3DYokoi%26aufirst%3DT.%26aulast%3DChiappori%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3Dde%2BWit%26aufirst%3DM.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DBourhaba%26aufirst%3DM.%26aulast%3DQuantin%26aufirst%3DX.%26aulast%3DTokito%26aufirst%3DT.%26aulast%3DMekhail%26aufirst%3DT.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DY.%2BC.%26aulast%3DKarapetis%26aufirst%3DC.%2BS.%26aulast%3DHiret%26aufirst%3DS.%26aulast%3DOstoros%26aufirst%3DG.%26aulast%3DKubota%26aufirst%3DK.%26aulast%3DGray%26aufirst%3DJ.%2BE.%26aulast%3DPaz-Ares%26aufirst%3DL.%26aulast%3Dde%2BCastro%2BCarpeno%26aufirst%3DJ.%26aulast%3DWadsworth%26aufirst%3DC.%26aulast%3DMelillo%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DDennis%26aufirst%3DP.%2BA.%26aulast%3DOzguroglu%26aufirst%3DM.%26atitle%3DDurvalumab%2520after%2520chemoradiotherapy%2520in%2520stage%2520III%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26spage%3D1919%26epage%3D1929%26doi%3D10.1056%2FNEJMoa1709937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wargo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuben, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, R. J.</span></span> <span> </span><span class="NLM_article-title">Immune effects of chemotherapy, radiation, and targeted therapy and opportunities for combination with immunotherapy</span>. <i>Semin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">601</span>– <span class="NLM_lpage">616</span>, <span class="refDoi"> DOI: 10.1053/j.seminoncol.2015.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1053%2Fj.seminoncol.2015.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=26320064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2mur3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2015&pages=601-616&author=J.+A.+Wargoauthor=A.+Reubenauthor=Z.+A.+Cooperauthor=K.+S.+Ohauthor=R.+J.+Sullivan&title=Immune+effects+of+chemotherapy%2C+radiation%2C+and+targeted+therapy+and+opportunities+for+combination+with+immunotherapy&doi=10.1053%2Fj.seminoncol.2015.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy</span></div><div class="casAuthors">Wargo, Jennifer A.; Reuben, Alexandre; Cooper, Zachary A.; Oh, Kevin S.; Sullivan, Ryan J.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">601-616</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">There have been significant advances in cancer treatment over the past several years through the use of chemotherapy, radiation therapy, molecularly targeted therapy, and immunotherapy.  Despite these advances, treatments such as monotherapy or monomodality have significant limitations.  There is increasing interest in using these strategies in combination; however, it is not completely clear how best to incorporate molecularly targeted and immune-targeted therapies into combination regimens.  This is particularly pertinent when considering combinations with immunotherapy, as other types of therapy may have significant impact on host immunity, the tumor microenvironment, or both.  Thus, the influence of chemotherapy, radiation therapy, and molecularly targeted therapy on the host anti-tumor immune response and the host anti-host response (ie, autoimmune toxicity) must be taken into consideration when designing immunotherapy-based combination regimens.  We present data related to many of these combination approaches in the context of investigations in patients with melanoma and discuss their potential relationship to management of patients with other tumor types.  Importantly, we also highlight challenges of these approaches and emphasize the need for continued translational research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeTH_CMJTqsLVg90H21EOLACvtfcHk0lgXGOlxCtHZ7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2mur3K&md5=5c1e42a15655f8d796e35d54b7412c5f</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1053%2Fj.seminoncol.2015.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.seminoncol.2015.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DWargo%26aufirst%3DJ.%2BA.%26aulast%3DReuben%26aufirst%3DA.%26aulast%3DCooper%26aufirst%3DZ.%2BA.%26aulast%3DOh%26aufirst%3DK.%2BS.%26aulast%3DSullivan%26aufirst%3DR.%2BJ.%26atitle%3DImmune%2520effects%2520of%2520chemotherapy%252C%2520radiation%252C%2520and%2520targeted%2520therapy%2520and%2520opportunities%2520for%2520combination%2520with%2520immunotherapy%26jtitle%3DSemin.%2520Oncol.%26date%3D2015%26volume%3D42%26spage%3D601%26epage%3D616%26doi%3D10.1053%2Fj.seminoncol.2015.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vladimer, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snijder, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krall, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigenzahn, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, K. V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lardeau, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanjiv, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berglund, U. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Fuente, O. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knobl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubicek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helleday, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jager, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Superti-Furga, G.</span></span> <span> </span><span class="NLM_article-title">Global survey of the immunomodulatory potential of common drugs</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">681</span>– <span class="NLM_lpage">690</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1038%2Fnchembio.2360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=28437395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvVCltbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=681-690&author=G.+I.+Vladimerauthor=B.+Snijderauthor=N.+Krallauthor=J.+W.+Bigenzahnauthor=K.+V.+M.+Huberauthor=C.+H.+Lardeauauthor=K.+Sanjivauthor=A.+Ringlerauthor=U.+W.+Berglundauthor=M.+Sablerauthor=O.+L.+de+la+Fuenteauthor=P.+Knoblauthor=S.+Kubicekauthor=T.+Helledayauthor=U.+Jagerauthor=G.+Superti-Furga&title=Global+survey+of+the+immunomodulatory+potential+of+common+drugs&doi=10.1038%2Fnchembio.2360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Global survey of the immunomodulatory potential of common drugs</span></div><div class="casAuthors">Vladimer, Gregory I.; Snijder, Berend; Krall, Nikolaus; Bigenzahn, Johannes W.; Huber, Kilian V. M.; Lardeau, Charles-Hugues; Sanjiv, Kumar; Ringler, Anna; Berglund, Ulrika Warpman; Sabler, Monika; de la Fuente, Oscar Lopez; Knoebl, Paul; Kubicek, Stefan; Helleday, Thomas; Jaeger, Ulrich; Superti-Furga, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">681-690</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. drugs may complement antibody-based therapies in an immune-oncol. setting, yet systematic methods for the identification and characterization of the immunomodulatory properties of these entities are lacking.  We surveyed the immumomodulatory potential of 1,402 small chem. mols., as defined by their ability to alter the cell-cell interactions among peripheral mononuclear leukocytes ex vivo, using automated microscopy and population-wide single-cell image anal.  Unexpectedly, ∼10% of the agents tested affected these cell-cell interactions differentially.  The results accurately recapitulated known immunomodulatory drug classes and revealed several clin. approved drugs that unexpectedly harbor the ability to modulate the immune system, which could potentially contribute to their physiol. mechanism of action.  For instance, the kinase inhibitor crizotinib promoted T cell interactions with monocytes, as well as with cancer cells, through inhibition of the receptor tyrosine kinase MSTR1 and subsequent upregulation of the expression of major histocompatibility complex mols.  The approach offers an attractive platform for the personalized identification and characterization of immunomodulatory therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXf0_7KFGbY7Vg90H21EOLACvtfcHk0lgtySSjb8PHdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvVCltbg%253D&md5=c177974d4daf99d7a40b5c2a73c6504a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2360%26sid%3Dliteratum%253Aachs%26aulast%3DVladimer%26aufirst%3DG.%2BI.%26aulast%3DSnijder%26aufirst%3DB.%26aulast%3DKrall%26aufirst%3DN.%26aulast%3DBigenzahn%26aufirst%3DJ.%2BW.%26aulast%3DHuber%26aufirst%3DK.%2BV.%2BM.%26aulast%3DLardeau%26aufirst%3DC.%2BH.%26aulast%3DSanjiv%26aufirst%3DK.%26aulast%3DRingler%26aufirst%3DA.%26aulast%3DBerglund%26aufirst%3DU.%2BW.%26aulast%3DSabler%26aufirst%3DM.%26aulast%3Dde%2Bla%2BFuente%26aufirst%3DO.%2BL.%26aulast%3DKnobl%26aufirst%3DP.%26aulast%3DKubicek%26aufirst%3DS.%26aulast%3DHelleday%26aufirst%3DT.%26aulast%3DJager%26aufirst%3DU.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26atitle%3DGlobal%2520survey%2520of%2520the%2520immunomodulatory%2520potential%2520of%2520common%2520drugs%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D13%26spage%3D681%26epage%3D690%26doi%3D10.1038%2Fnchembio.2360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span> <span> </span><span class="NLM_article-title">Cancer immunotherapy using checkpoint blockade</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>359</i></span>,  <span class="NLM_fpage">1350</span>– <span class="NLM_lpage">1355</span>, <span class="refDoi"> DOI: 10.1126/science.aar4060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1126%2Fscience.aar4060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=29567705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltFehtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=2018&pages=1350-1355&author=A.+Ribasauthor=J.+D.+Wolchok&title=Cancer+immunotherapy+using+checkpoint+blockade&doi=10.1126%2Fscience.aar4060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer immunotherapy using checkpoint blockade</span></div><div class="casAuthors">Ribas, Antoni; Wolchok, Jedd D.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">359</span>
        (<span class="NLM_cas:issue">6382</span>),
    <span class="NLM_cas:pages">1350-1355</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  The release of neg. regulators of immune activation (immune checkpoints) that limit antitumor responses has resulted in unprecedented rates of long-lasting tumor responses in patients with a variety of cancers.  This can be achieved by antibodies blocking the cytotoxic T lymphocyte-assocd. protein 4 (CTLA-4) or the programmed cell death 1 (PD-1) pathway, either alone or in combination.  The main premise for inducing an immune response is the preexistence of antitumor T cells that were limited by specific immune checkpoints.  Most patients who have tumor responses maintain long-lasting disease control, yet one-third of patients relapse.  Mechanisms of acquired resistance are currently poorly understood, but evidence points to alterations that converge on the antigen presentation and interferon-γ signaling pathways.  New-generation combinatorial therapies may overcome resistance mechanisms to immune checkpoint therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHaFGKqeFnWLVg90H21EOLACvtfcHk0lgtySSjb8PHdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltFehtb8%253D&md5=65120662af8a2c63425212b07e423939</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1126%2Fscience.aar4060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aar4060%26sid%3Dliteratum%253Aachs%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26atitle%3DCancer%2520immunotherapy%2520using%2520checkpoint%2520blockade%26jtitle%3DScience%26date%3D2018%26volume%3D359%26spage%3D1350%26epage%3D1355%26doi%3D10.1126%2Fscience.aar4060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patchett, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darby, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tovar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, G. M.</span></span> <span> </span><span class="NLM_article-title">The immunomodulatory small molecule imiquimod induces apoptosis in devil facial tumour cell lines</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e0168068</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0168068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1371%2Fjournal.pone.0168068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=27936237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktFaju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0168068&author=A.+L.+Patchettauthor=J.+M.+Darbyauthor=C.+Tovarauthor=A.+B.+Lyonsauthor=G.+M.+Woods&title=The+immunomodulatory+small+molecule+imiquimod+induces+apoptosis+in+devil+facial+tumour+cell+lines&doi=10.1371%2Fjournal.pone.0168068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The immunomodulatory small molecule imiquimod induces apoptosis in devil facial tumour cell lines</span></div><div class="casAuthors">Patchett, Amanda L.; Darby, Jocelyn M.; Tovar, Cesar; Lyons, A. Bruce; Woods, Gregory M.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e0168068/1-e0168068/17</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The survival of the Tasmanian devil (Sarcophilus harrisii) is threatened by devil facial tumor disease (DFTD).  This transmissible cancer is usually fatal, and no successful treatments have been developed.  In human studies, the small immunomodulatory mol. imiquimod is a successful immunotherapy, activating anti-tumor immunity via stimulation of toll-like receptor-7 (TLR7) signaling pathways.  In addn., imiquimod is a potent inducer of apoptosis in human tumor cell lines via TLR7 independent mechanisms.  Here we investigate the potential of imiquimod as a DFTD therapy through anal. of treated DFTD cell lines and Tasmanian devil fibroblasts.  WST-8 proliferation assays and annexin V apoptosis assays were performed to monitor apoptosis, and changes to the expression of pro- and anti-apoptotic genes were analyzed using qRT-PCR.  Our results show that DFTD cell lines, but not Tasmanian devil fibroblasts, are sensitive to imiquimod-induced apoptosis in a time and concn. dependent manner.  Induction of apoptosis was accompanied by down-regulation of the anti-apoptotic BCL2 and BCLXL genes, and up-regulation of the pro-apoptotic BIM gene.  Continuous imiquimod treatment was required for these effects to occur.  These results demonstrate that imiquimod can deregulate DFTD cell growth and survival in direct and targeted manner.  In vivo, this may increase DFTD vulnerability to imiquimod-induced TLR7-mediated immune responses.  Our findings have improved the current knowledge of imiquimod action in tumor cells for application to both DFTD and human cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh6ZLveszvALVg90H21EOLACvtfcHk0lgtySSjb8PHdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktFaju7g%253D&md5=7b8680a2ae9eb801ac44b73e874eb218</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0168068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0168068%26sid%3Dliteratum%253Aachs%26aulast%3DPatchett%26aufirst%3DA.%2BL.%26aulast%3DDarby%26aufirst%3DJ.%2BM.%26aulast%3DTovar%26aufirst%3DC.%26aulast%3DLyons%26aufirst%3DA.%2BB.%26aulast%3DWoods%26aufirst%3DG.%2BM.%26atitle%3DThe%2520immunomodulatory%2520small%2520molecule%2520imiquimod%2520induces%2520apoptosis%2520in%2520devil%2520facial%2520tumour%2520cell%2520lines%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0168068%26doi%3D10.1371%2Fjournal.pone.0168068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ni, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassady, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, D.</span></span> <span> </span><span class="NLM_article-title">PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">1960</span>– <span class="NLM_lpage">1977</span>, <span class="refDoi"> DOI: 10.1172/JCI91138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1172%2FJCI91138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=28414296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A280%3ADC%252BC1cvotlShtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2017&pages=1960-1977&author=X.+Niauthor=Q.+Songauthor=K.+Cassadyauthor=R.+Dengauthor=H.+Jinauthor=M.+Zhangauthor=H.+Dongauthor=S.+Formanauthor=P.+J.+Martinauthor=Y.+Z.+Chenauthor=J.+Wangauthor=D.+Zeng&title=PD-L1+interacts+with+CD80+to+regulate+graft-versus-leukemia+activity+of+donor+CD8%2B+T+cells&doi=10.1172%2FJCI91138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells</span></div><div class="casAuthors">Ni Xiong; Song Qingxiao; Cassady Kaniel; Deng Ruishu; Jin Hua; Zhang Mingfeng; Dong Haidong; Forman Stephen; Martin Paul J; Chen Yuan-Zhong; Wang Jianmin; Zeng Defu</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1960-1977</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Programmed death ligand-1 (PD-L1) interacts with programmed death-1 (PD-1) and the immunostimulatory molecule CD80 and functions as a checkpoint to regulate immune responses.  The interaction of PD-L1 with CD80 alone has been shown to exacerbate the severity of graft-versus-host disease (GVHD), whereas costimulation of CD80 and PD-1 ameliorates GVHD.  Here we have demonstrated that temporary depletion of donor CD4+ T cells early after hematopoietic cell transplantation effectively prevents GVHD while preserving strong graft-versus-leukemia (GVL) effects in allogeneic and xenogeneic murine GVHD models.  Depletion of donor CD4+ T cells increased serum IFN-γ but reduced IL-2 concentrations, leading to upregulation of PD-L1 expression by recipient tissues and donor CD8+ T cells.  In GVHD target tissues, the interactions of PD-L1 with PD-1 on donor CD8+ T cells cause anergy, exhaustion, and apoptosis, thereby preventing GVHD.  In lymphoid tissues, the interactions of PD-L1 with CD80 augment CD8+ T cell expansion without increasing anergy, exhaustion, or apoptosis, resulting in strong GVL effects.  These results indicate that the outcome of PD-L1-mediated signaling in CD8+ T cells depends on the presence or absence of CD4+ T cells, the nature of the interacting receptor expressed by CD8+ T cells, and the tissue environment in which the signaling occurs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRj4Yk771GSWjDnmmyUf5qOfW6udTcc2ebcYcMdadwpr7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvotlShtQ%253D%253D&md5=39c5a3f1375dafd766a0ad4952f27dca</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1172%2FJCI91138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI91138%26sid%3Dliteratum%253Aachs%26aulast%3DNi%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DQ.%26aulast%3DCassady%26aufirst%3DK.%26aulast%3DDeng%26aufirst%3DR.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DForman%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DP.%2BJ.%26aulast%3DChen%26aufirst%3DY.%2BZ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DD.%26atitle%3DPD-L1%2520interacts%2520with%2520CD80%2520to%2520regulate%2520graft-versus-leukemia%2520activity%2520of%2520donor%2520CD8%252B%2520T%2520cells%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2017%26volume%3D127%26spage%3D1960%26epage%3D1977%26doi%3D10.1172%2FJCI91138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krupka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kufer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kischel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zugmaier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtenegger, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohnke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vick, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeremias, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metzeler, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiegl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiekermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauerle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiddemann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riethmuller, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subklewe, M.</span></span> <span> </span><span class="NLM_article-title">Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">484</span>– <span class="NLM_lpage">491</span>, <span class="refDoi"> DOI: 10.1038/leu.2015.214</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1038%2Fleu.2015.214" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=26239198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVWgtr%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=484-491&author=C.+Krupkaauthor=P.+Kuferauthor=R.+Kischelauthor=G.+Zugmaierauthor=F.+S.+Lichteneggerauthor=T.+Kohnkeauthor=B.+Vickauthor=I.+Jeremiasauthor=K.+H.+Metzelerauthor=T.+Altmannauthor=S.+Schneiderauthor=M.+Fieglauthor=K.+Spiekermannauthor=P.+A.+Bauerleauthor=W.+Hiddemannauthor=G.+Riethmullerauthor=M.+Subklewe&title=Blockade+of+the+PD-1%2FPD-L1+axis+augments+lysis+of+AML+cells+by+the+CD33%2FCD3+BiTE+antibody+construct+AMG+330%3A+reversing+a+T-cell-induced+immune+escape+mechanism&doi=10.1038%2Fleu.2015.214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism</span></div><div class="casAuthors">Krupka, C.; Kufer, P.; Kischel, R.; Zugmaier, G.; Lichtenegger, F. S.; Koehnke, T.; Vick, B.; Jeremias, I.; Metzeler, K. H.; Altmann, T.; Schneider, S.; Fiegl, M.; Spiekermann, K.; Bauerle, P. A.; Hiddemann, W.; Riethmueller, G.; Subklewe, M.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">484-491</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bispecific T-cell engagers (BiTEs) are very effective in recruiting and activating T cells.  We tested the cytotoxicity of the CD33/CD3 BiTE antibody construct AMG 330 on primary acute myeloid leukemia (AML) cells ex vivo and characterized parameters contributing to antileukemic cytolytic activity.  The E:T ratio and the CD33 expression level significantly influenced lysis kinetics in long-term cultures of primary AML cells (n=38).  AMG 330 induced T-cell-mediated proinflammatory conditions, favoring the upregulation of immune checkpoints on target and effector cells.  Although not constitutively expressed at the time of primary diagnosis (n=123), PD-L1 was strongly upregulated on primary AML cells upon AMG 330 addn. to ex vivo cultures (n=27, P<0.0001).  This phenomenon was cytokine-driven as the sole addn. of interferon (IFN)-γ and tumor necrosis factor-α also induced expression.  Through blockade of the PD-1/PD-L1 interaction, AMG 330-mediated lysis (n=9, P=0.03), T-cell proliferation (n=9, P=0.01) and IFN-γ secretion (n=8, P=0.008) were significantly enhanced.  The combinatorial approach was most beneficial in settings of protracted AML cell lysis.  Taken together, we have characterized a crit. resistance mechanism employed by primary AML cells under AMG 330-mediated proinflammatory conditions.  Our results support the evaluation of checkpoint mols. in upcoming clin. trials with AMG 330 to enhance BiTE antibody construct-mediated cytotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY6o4l8H8hXbVg90H21EOLACvtfcHk0ljaENxzj_SM1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVWgtr%252FF&md5=c7cdddb37f2e034cdfde250a0aaf6ed0</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fleu.2015.214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2015.214%26sid%3Dliteratum%253Aachs%26aulast%3DKrupka%26aufirst%3DC.%26aulast%3DKufer%26aufirst%3DP.%26aulast%3DKischel%26aufirst%3DR.%26aulast%3DZugmaier%26aufirst%3DG.%26aulast%3DLichtenegger%26aufirst%3DF.%2BS.%26aulast%3DKohnke%26aufirst%3DT.%26aulast%3DVick%26aufirst%3DB.%26aulast%3DJeremias%26aufirst%3DI.%26aulast%3DMetzeler%26aufirst%3DK.%2BH.%26aulast%3DAltmann%26aufirst%3DT.%26aulast%3DSchneider%26aufirst%3DS.%26aulast%3DFiegl%26aufirst%3DM.%26aulast%3DSpiekermann%26aufirst%3DK.%26aulast%3DBauerle%26aufirst%3DP.%2BA.%26aulast%3DHiddemann%26aufirst%3DW.%26aulast%3DRiethmuller%26aufirst%3DG.%26aulast%3DSubklewe%26aufirst%3DM.%26atitle%3DBlockade%2520of%2520the%2520PD-1%252FPD-L1%2520axis%2520augments%2520lysis%2520of%2520AML%2520cells%2520by%2520the%2520CD33%252FCD3%2520BiTE%2520antibody%2520construct%2520AMG%2520330%253A%2520reversing%2520a%2520T-cell-induced%2520immune%2520escape%2520mechanism%26jtitle%3DLeukemia%26date%3D2016%26volume%3D30%26spage%3D484%26epage%3D491%26doi%3D10.1038%2Fleu.2015.214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span> <span> </span><span class="NLM_article-title">Small-molecule targets in tumor immunotherapy</span>. <i>Nat. Prod. Bioprospect.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">297</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1007/s13659-018-0177-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1007%2Fs13659-018-0177-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=29974338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht12lsrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=297-301&author=H.+F.+Zhuauthor=Y.+Li&title=Small-molecule+targets+in+tumor+immunotherapy&doi=10.1007%2Fs13659-018-0177-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Targets in Tumor Immunotherapy</span></div><div class="casAuthors">Zhu, Hui-Fang; Li, Yan</div><div class="citationInfo"><span class="NLM_cas:title">Natural Products and Bioprospecting</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">297-301</span>CODEN:
                <span class="NLM_cas:coden">NPBAAH</span>;
        ISSN:<span class="NLM_cas:issn">2192-2209</span>.
    
            (<span class="NLM_cas:orgname">Kunming Institute of Botany, Chinese Academy of Sciences</span>)
        </div><div class="casAbstract">A review.  Cancer immunotherapy has been widely recognized as a powerful approach to fight cancers.  To date, over 50 phase III trials in cancer immunotherapy are in progress.  Among the many immunotherapy approaches, immune checkpoint therapy has attracted considerable attention.  The reported clin. success of targeting the T cell immune checkpoint receptors PD-1 or CTLA4 by antibodies blockade in advanced stages of cancers has demonstrated the importance of immune modulation.  But antibodies-based immunotherapy confronted with some disadvantages, such as immunogenicity, stability, membrane permeability, and prodn. cost.  Therefore, alternative approaches including small-mol.-regulated immune response are being introduced.  In this review, we focused on some of the key intracellular pathways where small-mol. therapeutic is potential and attractive, which highlights the great potential of natural products in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrit8YB3mZAwLVg90H21EOLACvtfcHk0ljaENxzj_SM1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht12lsrvI&md5=1ce40d184a3dea755c98c949e851e929</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1007%2Fs13659-018-0177-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13659-018-0177-7%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DH.%2BF.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DSmall-molecule%2520targets%2520in%2520tumor%2520immunotherapy%26jtitle%3DNat.%2520Prod.%2520Bioprospect.%26date%3D2018%26volume%3D8%26spage%3D297%26epage%3D301%26doi%3D10.1007%2Fs13659-018-0177-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leishman, A. J.</span></span> <span> </span><span class="NLM_article-title">Further advances in cancer immunotherapy: going beyond checkpoint blockade</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1082</span>– <span class="NLM_lpage">1086</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2018.01082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.3389%2Ffimmu.2018.01082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=29910800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1KrsrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1082-1086&author=R.+W.+Wilkinsonauthor=A.+J.+Leishman&title=Further+advances+in+cancer+immunotherapy%3A+going+beyond+checkpoint+blockade&doi=10.3389%2Ffimmu.2018.01082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Further advances in cancer immunotherapy: going beyond checkpoint blockade</span></div><div class="casAuthors">Wilkinson, Robert W.; Leishman, Andrew J.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1082/1-1082/4</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Significant advances have been made to identify effective therapies that either restore or generate de novo a patient's immune response to cancer, so-called immunotherapy or immuno-oncol. (IO) therapies.  Some tumors overcome immune surveillance by promoting mechanisms to evade or suppress the immune system.  This conference report highlights the clin. promise and current challenges of IO therapy, including the use of immune-checkpoint antagonist monoclonal antibodies.  Furthermore, this report investigates advances in preclin. modeling of cancer immunobiol. and how this is helping our understanding of which patients will receive clin. benefits from current immune-checkpoint treatment.  Looking to the future, the report looks at emerging IO approaches, which aim to specifically target the tumor microenvironment.  This includes the use of toll-like receptors (TLRs) agonists that link the activation of innate immune, cells to the priming of T cells and an adaptive memory anti-tumor immune response through to the reversal of local immunosuppression using adenosinergic and indoleamine 2,3-dioxygenase (IDO) inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxni7uIIb3obVg90H21EOLACvtfcHk0lhZXU5YGVupjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1KrsrvJ&md5=c245216e13c7f402e4a4eb438aefb512</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2018.01082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2018.01082%26sid%3Dliteratum%253Aachs%26aulast%3DWilkinson%26aufirst%3DR.%2BW.%26aulast%3DLeishman%26aufirst%3DA.%2BJ.%26atitle%3DFurther%2520advances%2520in%2520cancer%2520immunotherapy%253A%2520going%2520beyond%2520checkpoint%2520blockade%26jtitle%3DFront.%2520Immunol.%26date%3D2018%26volume%3D9%26spage%3D1082%26epage%3D1086%26doi%3D10.3389%2Ffimmu.2018.01082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zak, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grudnik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzik, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zieba, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span> <span> </span><span class="NLM_article-title">Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">30323</span>– <span class="NLM_lpage">30335</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.8730</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.18632%2Foncotarget.8730" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=27083005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A280%3ADC%252BC28bgt1egtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=30323-30335&author=K.+M.+Zakauthor=P.+Grudnikauthor=K.+Guzikauthor=B.+J.+Ziebaauthor=B.+Musielakauthor=A.+Domlingauthor=G.+Dubinauthor=T.+A.+Holak&title=Structural+basis+for+small+molecule+targeting+of+the+programmed+death+ligand+1+%28PD-L1%29&doi=10.18632%2Foncotarget.8730"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)</span></div><div class="casAuthors">Zak Krzysztof M; Zieba Bartosz J; Dubin Grzegorz; Holak Tad A; Zak Krzysztof M; Grudnik Przemyslaw; Dubin Grzegorz; Guzik Katarzyna; Zieba Bartosz J; Musielak Bogdan; Holak Tad A; Domling Alexander; Holak Tad A</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">30323-35</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Targeting the PD-1/PD-L1 immunologic checkpoint with monoclonal antibodies has provided unprecedented results in cancer treatment in the recent years.  Development of chemical inhibitors for this pathway lags the antibody development because of insufficient structural information.  The first nonpeptidic chemical inhibitors that target the PD-1/PD-L1 interaction have only been recently disclosed by Bristol-Myers Squibb.  Here, we show that these small-molecule compounds bind directly to PD-L1 and that they potently block PD-1 binding.  Structural studies reveal a dimeric protein complex with a single small molecule which stabilizes the dimer thus occluding the PD-1 interaction surface of PD-L1s.  The small-molecule interaction "hot spots" on PD-L1 surfaces suggest approaches for the PD-1/PD-L1 antagonist drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSANcdv1BQm-QvupmecNw_lfW6udTcc2eZbvSW7-L2H5Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28bgt1egtg%253D%253D&md5=f96c24c78de0139c4e3c269e45d42559</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.8730&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.8730%26sid%3Dliteratum%253Aachs%26aulast%3DZak%26aufirst%3DK.%2BM.%26aulast%3DGrudnik%26aufirst%3DP.%26aulast%3DGuzik%26aufirst%3DK.%26aulast%3DZieba%26aufirst%3DB.%2BJ.%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DDomling%26aufirst%3DA.%26aulast%3DDubin%26aufirst%3DG.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26atitle%3DStructural%2520basis%2520for%2520small%2520molecule%2520targeting%2520of%2520the%2520programmed%2520death%2520ligand%25201%2520%2528PD-L1%2529%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D30323%26epage%3D30335%26doi%3D10.18632%2Foncotarget.8730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zak, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grudnik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span> <span> </span><span class="NLM_article-title">Structural biology of the immune checkpoint receptor PD-1 and its ligands PD-L1/PD-L2</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1163</span>– <span class="NLM_lpage">1174</span>, <span class="refDoi"> DOI: 10.1016/j.str.2017.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1016%2Fj.str.2017.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=28768162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1OiurvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=1163-1174&author=K.+M.+Zakauthor=P.+Grudnikauthor=K.+Magieraauthor=A.+Domlingauthor=G.+Dubinauthor=T.+A.+Holak&title=Structural+biology+of+the+immune+checkpoint+receptor+PD-1+and+its+ligands+PD-L1%2FPD-L2&doi=10.1016%2Fj.str.2017.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2</span></div><div class="casAuthors">Zak, Krzysztof M.; Grudnik, Przemyslaw; Magiera, Katarzyna; Domling, Alexander; Dubin, Grzegorz; Holak, Tad A.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1163-1174</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cancer cells can avoid and suppress immune responses through activation of inhibitory immune checkpoint proteins, such as PD-1, PD-L1, and CTLA-4.  Blocking the activities of these proteins with monoclonal antibodies, and thus restoring T cell function, has delivered breakthrough therapies against cancer.  In this review, we describe the latest work on structural characterization of the checkpoint proteins, their interactions with cognate ligands and with therapeutic antibodies.  Structures of the extracellular portions of these proteins reveal that they all have a similar modular structure, composed of small domains similar in topol. to the domains found in antibodies.  Structural basis for blocking the PD-1/PD-L1 interaction by small mols. is illustrated with the compd. BMS-202 that binds to and induces dimerization of PD-L1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4k4n4b209p7Vg90H21EOLACvtfcHk0lhZXU5YGVupjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1OiurvE&md5=473642ccce8c757f6ef2708ece9d295e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2017.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2017.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DZak%26aufirst%3DK.%2BM.%26aulast%3DGrudnik%26aufirst%3DP.%26aulast%3DMagiera%26aufirst%3DK.%26aulast%3DDomling%26aufirst%3DA.%26aulast%3DDubin%26aufirst%3DG.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26atitle%3DStructural%2520biology%2520of%2520the%2520immune%2520checkpoint%2520receptor%2520PD-1%2520and%2520its%2520ligands%2520PD-L1%252FPD-L2%26jtitle%3DStructure%26date%3D2017%26volume%3D25%26spage%3D1163%26epage%3D1174%26doi%3D10.1016%2Fj.str.2017.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Naremaddepalli, S. S. S.</span></span> <span> </span><span class="NLM_article-title">1,3,4-Oxadiazole and 1,3,4-Thiadiazole Derivatives as Immunomodulators</span>. <span class="NLM_patent">WO2015033301</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=S.+S.+S.+Naremaddepalli&title=1%2C3%2C4-Oxadiazole+and+1%2C3%2C4-Thiadiazole+Derivatives+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3D1%252C3%252C4-Oxadiazole%2520and%25201%252C3%252C4-Thiadiazole%2520Derivatives%2520as%2520Immunomodulators%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Naremaddepalli, S. S. S.</span></span> <span> </span><span class="NLM_article-title">1,2,4-Oxadiazole Derivatives as Immunomodulators</span>. <span class="NLM_patent">US201414478759</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=S.+S.+S.+Naremaddepalli&title=1%2C2%2C4-Oxadiazole+Derivatives+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3D1%252C2%252C4-Oxadiazole%2520Derivatives%2520as%2520Immunomodulators%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.</span>; <span class="NLM_string-name">Chen, X.</span>; <span class="NLM_string-name">Zhang, L.</span>; <span class="NLM_string-name">Yang, Y.</span>; <span class="NLM_string-name">Lai, F.</span>; <span class="NLM_string-name">Ji, M.</span>; <span class="NLM_string-name">Zhou, C.</span>; <span class="NLM_string-name">Zhen, Y.</span>; <span class="NLM_string-name">Xue, N.</span>; <span class="NLM_string-name">Li, L.</span></span> <span> </span><span class="NLM_article-title">Bromo Benzyl Ether Derivative, Preparation Method Therefor, and Pharmaceutical Composition and Uses Thereof</span>. <span class="NLM_patent">WO2017202275 A1</span>, <span class="NLM_year">2017</span>; Institute of Materia Medica, Chinese Academy of Medical Sciences.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Z.+Feng&author=X.+Chen&author=L.+Zhang&author=Y.+Yang&author=F.+Lai&author=M.+Ji&author=C.+Zhou&author=Y.+Zhen&author=N.+Xue&author=L.+Li&title=Bromo+Benzyl+Ether+Derivative%2C+Preparation+Method+Therefor%2C+and+Pharmaceutical+Composition+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DZ.%26atitle%3DBromo%2520Benzyl%2520Ether%2520Derivative%252C%2520Preparation%2520Method%2520Therefor%252C%2520and%2520Pharmaceutical%2520Composition%2520and%2520Uses%2520Thereof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span></span> <span> </span><span class="NLM_article-title">Immunomodulating Peptidomimetic Derivatives</span>. <span class="NLM_patent">WO2015036927</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&title=Immunomodulating+Peptidomimetic+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DImmunomodulating%2520Peptidomimetic%2520Derivatives%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Immunomodulating Compounds</span>. <span class="NLM_patent">WO2015044900</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&title=Therapeutic+Immunomodulating+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DTherapeutic%2520Immunomodulating%2520Compounds%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span></span> <span> </span><span class="NLM_article-title">Immunomodulating Cyclic Compounds from the BC Loop of Human PD1</span>. <span class="NLM_patent">WO2013144704</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&title=Immunomodulating+Cyclic+Compounds+from+the+BC+Loop+of+Human+PD1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DImmunomodulating%2520Cyclic%2520Compounds%2520from%2520the%2520BC%2520Loop%2520of%2520Human%2520PD1%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span></span> <span> </span><span class="NLM_article-title">Peptidomimetic Compounds as Immunomdulators</span>. <span class="NLM_patent">US20130237580</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&title=Peptidomimetic+Compounds+as+Immunomdulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DPeptidomimetic%2520Compounds%2520as%2520Immunomdulators%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Vadlamani, S. K.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Compounds for Immunomodulation</span>. <span class="NLM_patent">WO2012168944</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=S.+K.+Vadlamani&title=Therapeutic+Compounds+for+Immunomodulation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DTherapeutic%2520Compounds%2520for%2520Immunomodulation%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Vadlamani, S. K.</span></span> <span> </span><span class="NLM_article-title">Immunosuppression Modulating Compounds</span>. <span class="NLM_patent">US20110318373</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=S.+K.+Vadlamani&title=Immunosuppression+Modulating+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DImmunosuppression%2520Modulating%2520Compounds%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Webber, S. E.</span>; <span class="NLM_string-name">Almassy, R. J.</span></span> <span> </span><span class="NLM_article-title">Immune Checkpoint Inhibitors, Compositions And Methods There For</span>. <span class="NLM_patent">WO2018045142 A1</span>, <span class="NLM_year">2018</span>; Polaris Pharmaceuticals, Inc.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=S.+E.+Webber&author=R.+J.+Almassy&title=Immune+Checkpoint+Inhibitors%2C+Compositions+And+Methods+There+For"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWebber%26aufirst%3DS.%2BE.%26atitle%3DImmune%2520Checkpoint%2520Inhibitors%252C%2520Compositions%2520And%2520Methods%2520There%2520For%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lajkiewicz, N.</span>; <span class="NLM_string-name">Wu, L.</span>; <span class="NLM_string-name">Yao, W.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic Compounds As Immunomodulators</span>. <span class="NLM_patent">US20170174679</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=N.+Lajkiewicz&author=L.+Wu&author=W.+Yao&title=Heterocyclic+Compounds+As+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLajkiewicz%26aufirst%3DN.%26atitle%3DHeterocyclic%2520Compounds%2520As%2520Immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. M.</span>; <span class="NLM_string-name">Mapelli, C.</span>; <span class="NLM_string-name">Allen, M. P.</span></span>; <span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Macrocyclic Inhibtors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 Protein/Protein Interactions</span>. <span class="NLM_patent">WO2014151634</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=M.+M.+Miller&author=C.+Mapelli&author=M.+P.+Allen&title=Macrocyclic+Inhibtors+of+the+PD-1%2FPD-L1+and+CD80%28B7-1%29%2FPD-L1+Protein%2FProtein+Interactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DM.%2BM.%26atitle%3DMacrocyclic%2520Inhibtors%2520of%2520the%2520PD-1%252FPD-L1%2520and%2520CD80%2528B7-1%2529%252FPD-L1%2520Protein%252FProtein%2520Interactions%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, A. H.</span>; <span class="NLM_string-name">Butte, M. J.</span>; <span class="NLM_string-name">Oyama, S.</span></span> <span> </span><span class="NLM_article-title">Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof</span>. <span class="NLM_patent">US2011020046</span> <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=A.+H.+Sharpe&author=M.+J.+Butte&author=S.+Oyama&title=Modulators+of+Immunoinhibitory+Receptor+PD-1%2C+and+Methods+of+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26atitle%3DModulators%2520of%2520Immunoinhibitory%2520Receptor%2520PD-1%252C%2520and%2520Methods%2520of%2520Use%2520Thereof%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span> </span><span class="NLM_article-title">Heterocyclic Compounds
as Immunomodulators</span>. <span class="NLM_patent">US2017/0174679A1</span>, <span class="NLM_year">2017</span>; Incyte Corporation.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Heterocyclic+Compounds%0Aas+Immunomodulators.+US2017%2F0174679A1%2C+2017%3B+Incyte+Corporation."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26atitle%3DHeterocyclic%2520Compounds%250Aas%2520Immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span> </span><span class="NLM_article-title">Heterocyclic
Compounds as Immunomodulators</span>. <span class="NLM_patent">WO2017/070089A1</span>, <span class="NLM_year">2017</span>; Incyte Corporation.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Heterocyclic%0ACompounds+as+Immunomodulators.+WO2017%2F070089A1%2C+2017%3B+Incyte+Corporation."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26atitle%3DHeterocyclic%250ACompounds%2520as%2520Immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span> </span><span class="NLM_article-title">Heterocyclic
Compounds as Immunomodulators</span>. <span class="NLM_patent">US2017/0107216
A1</span>, <span class="NLM_year">2017</span>; Incyte Corporation.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Heterocyclic%0ACompounds+as+Immunomodulators.+US2017%2F0107216%0AA1%2C+2017%3B+Incyte+Corporation."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26atitle%3DHeterocyclic%250ACompounds%2520as%2520Immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span> </span><span class="NLM_article-title">Heterocyclic Compounds as Immunomodulators</span>. <span class="NLM_patent">WO2017/205464
A1</span>, <span class="NLM_year">2017</span>; Incyte Corporation.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Heterocyclic+Compounds+as+Immunomodulators.+WO2017%2F205464%0AA1%2C+2017%3B+Incyte+Corporation."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26atitle%3DHeterocyclic%2520Compounds%2520as%2520Immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chupak, L. S.</span>; <span class="NLM_string-name">Zheng, X.</span></span> <span> </span><span class="NLM_article-title">Compounds Useful as Immunomodulators</span>. <span class="NLM_patent">WO2015034820</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=L.+S.+Chupak&author=X.+Zheng&title=Compounds+Useful+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChupak%26aufirst%3DL.%2BS.%26atitle%3DCompounds%2520Useful%2520as%2520Immunomodulators%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span> </span><span class="NLM_article-title">Immunomodulator Compounds</span>. <span class="NLM_patent">WO2018/005374
A1</span>, <span class="NLM_year">2018</span>; Chemocentryx, Inc.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Immunomodulator+Compounds.+WO2018%2F005374%0AA1%2C+2018%3B+Chemocentryx%2C+Inc."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26atitle%3DImmunomodulator%2520Compounds%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span> </span><span class="NLM_article-title">Biaryl Compounds Useful as Immunomodulators</span>. <span class="NLM_patent">WO2018/044963
A1</span>, <span class="NLM_year">2018</span>; Bristol-Myers Squibb Company.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Biaryl+Compounds+Useful+as+Immunomodulators.+WO2018%2F044963%0AA1%2C+2018%3B+Bristol-Myers+Squibb+Company."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26atitle%3DBiaryl%2520Compounds%2520Useful%2520as%2520Immunomodulators%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span> </span><span class="NLM_article-title">1,3-Dihydroxy-Phenyl Derivatives Useful as Immunomodulators</span>. <span class="NLM_patent">WO2018/009505
A1</span>, <span class="NLM_year">2018</span>; Bristol-Myers Squibb Company.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=1%2C3-Dihydroxy-Phenyl+Derivatives+Useful+as+Immunomodulators.+WO2018%2F009505%0AA1%2C+2018%3B+Bristol-Myers+Squibb+Company."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26atitle%3D1%252C3-Dihydroxy-Phenyl%2520Derivatives%2520Useful%2520as%2520Immunomodulators%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span> </span><span class="NLM_article-title">Compounds Useful as Immunomodulators</span>. <span class="NLM_patent">WO2017/066227
A1</span>, <span class="NLM_year">2017</span>; Bristol-Myers Squibb Company.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Compounds+Useful+as+Immunomodulators.+WO2017%2F066227%0AA1%2C+2017%3B+Bristol-Myers+Squibb+Company."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26atitle%3DCompounds%2520Useful%2520as%2520Immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel resorcinol dibenzyl ethers targeting the programmed cell death-1/programmed cell death-ligand 1 interaction as potential anticancer agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">8338</span>– <span class="NLM_lpage">8358</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00574</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00574" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtl2rsrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=8338-8358&author=B.+Chengauthor=Y.+Renauthor=X.+Niuauthor=W.+Wangauthor=S.+Wangauthor=Y.+Tuauthor=S.+Liuauthor=J.+Wangauthor=D.+Yangauthor=G.+Liaoauthor=J.+Chen&title=Discovery+of+novel+resorcinol+dibenzyl+ethers+targeting+the+programmed+cell+death-1%2Fprogrammed+cell+death-ligand+1+interaction+as+potential+anticancer+agents&doi=10.1021%2Facs.jmedchem.0c00574"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction as Potential Anticancer Agents</span></div><div class="casAuthors">Cheng, Binbin; Ren, Yichang; Niu, Xiaoge; Wang, Wei; Wang, Shuanghu; Tu, Yingfeng; Liu, Shuwen; Wang, Jin; Yang, Deying; Liao, Guochao; Chen, Jianjun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">8338-8358</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel small mol. compds. based on various scaffolds including chalcone, flavonoid, and resorcinol dibenzyl ether were designed and tested for their inhibitory activity against the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 (PD-1/PD-L1) pathway.  Among them, compd. NP19(I) inhibited the human PD-1/PD-L1 interaction with IC50 values of 12.5 nM in homogeneous time-resolved fluorescence (HTRF) binding assays.  In addn., NP19 dose-dependently elevated IFN-γ prodn. in a coculture model of Hep3B/OS-8/hPD-L1 and CD3 T cells.  Furthermore, NP19 displayed significant in vivo antitumor efficacy in two different mouse models of cancer (a melanoma B16-F10 tumor model and an H22 hepatoma tumor model).  Moreover, H&E staining and flow cytometry data suggested that NP19 activated the immune microenvironment in the tumor, which may contribute to its antitumor effects.  This work shows NP19 is a promising lead compd. for further development as a new generation of small mol. inhibitors targeting the PD-1/PD-L1 pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruD5Zp9HM0jrVg90H21EOLACvtfcHk0lgiLttGQc4ccQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtl2rsrfL&md5=a1f6b3b4c440a7152ed8194ad842370f</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00574%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DB.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DNiu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DTu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DLiao%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520novel%2520resorcinol%2520dibenzyl%2520ethers%2520targeting%2520the%2520programmed%2520cell%2520death-1%252Fprogrammed%2520cell%2520death-ligand%25201%2520interaction%2520as%2520potential%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D8338%26epage%3D8358%26doi%3D10.1021%2Facs.jmedchem.0c00574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Domling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span> <span> </span><span class="NLM_article-title">Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2286</span>– <span class="NLM_lpage">2288</span>, <span class="refDoi"> DOI: 10.1002/anie.201307906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1002%2Fanie.201307906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A280%3ADC%252BC2czpvVOhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=2286-2288&author=A.+Domlingauthor=T.+A.+Holak&title=Programmed+death-1%3A+therapeutic+success+after+more+than+100+years+of+cancer+immunotherapy&doi=10.1002%2Fanie.201307906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy</span></div><div class="casAuthors">Domling Alexander; Holak Tad A</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie (International ed. in English)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2286-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">No other cancer therapy target class caused more excitement than the programmed death-1 (PD-1) pathway related.  Antibodies against PD-1 and PD-1 ligands represent a therapeutic breakthrough and are the first examples of broadly efficacious and durable cancer immunotherapies.  Cancer for the first time seems to have transformed from an often incurable to a "clinically manageable" disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT8kC5nL6VwzPcsfMJQC1ZdfW6udTcc2eZ8pdBbkhAbQrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2czpvVOhuw%253D%253D&md5=907c71bc856c102a3d93600aac71a2ea</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1002%2Fanie.201307906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201307906%26sid%3Dliteratum%253Aachs%26aulast%3DDomling%26aufirst%3DA.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26atitle%3DProgrammed%2520death-1%253A%2520therapeutic%2520success%2520after%2520more%2520than%2520100%2520years%2520of%2520cancer%2520immunotherapy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D2286%26epage%3D2288%26doi%3D10.1002%2Fanie.201307906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burr, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparbier, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beavis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, E. Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolzenburg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilan, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgens, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassik, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neeson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behren, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcy, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voskoboinik, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapani, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cebon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehner, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, M. A.</span></span> <span> </span><span class="NLM_article-title">CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>549</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1038/nature23643</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1038%2Fnature23643" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=28813417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlGktrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=549&publication_year=2017&pages=101-105&author=M.+L.+Burrauthor=C.+E.+Sparbierauthor=Y.+C.+Chanauthor=J.+C.+Williamsonauthor=K.+Woodsauthor=P.+A.+Beavisauthor=E.+Y.+N.+Lamauthor=M.+A.+Hendersonauthor=C.+C.+Bellauthor=S.+Stolzenburgauthor=O.+Gilanauthor=S.+Bloorauthor=T.+Nooriauthor=D.+W.+Morgensauthor=M.+C.+Bassikauthor=P.+J.+Neesonauthor=A.+Behrenauthor=P.+K.+Darcyauthor=S.+J.+Dawsonauthor=I.+Voskoboinikauthor=J.+A.+Trapaniauthor=J.+Cebonauthor=P.+J.+Lehnerauthor=M.+A.+Dawson&title=CMTM6+maintains+the+expression+of+PD-L1+and+regulates+anti-tumour+immunity&doi=10.1038%2Fnature23643"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity</span></div><div class="casAuthors">Burr, Marian L.; Sparbier, Christina E.; Chan, Yih-Chih; Williamson, James C.; Woods, Katherine; Beavis, Paul A.; Lam, Enid Y. N.; Henderson, Melissa A.; Bell, Charles C.; Stolzenburg, Sabine; Gilan, Omer; Bloor, Stuart; Noori, Tahereh; Morgens, David W.; Bassik, Michael C.; Neeson, Paul J.; Behren, Andreas; Darcy, Phillip K.; Dawson, Sarah-Jane; Voskoboinik, Ilia; Trapani, Joseph A.; Cebon, Jonathan; Lehner, Paul J.; Dawson, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">549</span>
        (<span class="NLM_cas:issue">7670</span>),
    <span class="NLM_cas:pages">101-105</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancer cells exploit the expression of the programmed death-1 (PD-1) ligand 1 (PD-L1) to subvert T-cell-mediated immunosurveillance.  The success of therapies that disrupt PD-L1-mediated tumor tolerance has highlighted the need to understand the mol. regulation of PD-L1 expression.  Here we identify the uncharacterized protein CMTM6 as a crit. regulator of PD-L1 in a broad range of cancer cells, by using a genome-wide CRISPR-Cas9 screen.  CMTM6 is a ubiquitously expressed protein that binds PD-L1 and maintains its cell surface expression.  CMTM6 is not required for PD-L1 maturation but co-localizes with PD-L1 at the plasma membrane and in recycling endosomes, where it prevents PD-L1 from being targeted for lysosome-mediated degrdn.  Using a quant. approach to profile the entire plasma membrane proteome, we find that CMTM6 displays specificity for PD-L1.  Notably, CMTM6 depletion decreases PD-L1 without compromising cell surface expression of MHC class I.  CMTM6 depletion, via the redn. of PD-L1, significantly alleviates the suppression of tumor-specific T cell activity in vitro and in vivo.  These findings provide insights into the biol. of PD-L1 regulation, identify a previously unrecognized master regulator of this crit. immune checkpoint and highlight a potential therapeutic target to overcome immune evasion by tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOaE7qlrP04LVg90H21EOLACvtfcHk0ljK31LhB8-TLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlGktrvK&md5=c37c58dcfa75b3057fe4e9635789281d</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fnature23643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature23643%26sid%3Dliteratum%253Aachs%26aulast%3DBurr%26aufirst%3DM.%2BL.%26aulast%3DSparbier%26aufirst%3DC.%2BE.%26aulast%3DChan%26aufirst%3DY.%2BC.%26aulast%3DWilliamson%26aufirst%3DJ.%2BC.%26aulast%3DWoods%26aufirst%3DK.%26aulast%3DBeavis%26aufirst%3DP.%2BA.%26aulast%3DLam%26aufirst%3DE.%2BY.%2BN.%26aulast%3DHenderson%26aufirst%3DM.%2BA.%26aulast%3DBell%26aufirst%3DC.%2BC.%26aulast%3DStolzenburg%26aufirst%3DS.%26aulast%3DGilan%26aufirst%3DO.%26aulast%3DBloor%26aufirst%3DS.%26aulast%3DNoori%26aufirst%3DT.%26aulast%3DMorgens%26aufirst%3DD.%2BW.%26aulast%3DBassik%26aufirst%3DM.%2BC.%26aulast%3DNeeson%26aufirst%3DP.%2BJ.%26aulast%3DBehren%26aufirst%3DA.%26aulast%3DDarcy%26aufirst%3DP.%2BK.%26aulast%3DDawson%26aufirst%3DS.%2BJ.%26aulast%3DVoskoboinik%26aufirst%3DI.%26aulast%3DTrapani%26aufirst%3DJ.%2BA.%26aulast%3DCebon%26aufirst%3DJ.%26aulast%3DLehner%26aufirst%3DP.%2BJ.%26aulast%3DDawson%26aufirst%3DM.%2BA.%26atitle%3DCMTM6%2520maintains%2520the%2520expression%2520of%2520PD-L1%2520and%2520regulates%2520anti-tumour%2520immunity%26jtitle%3DNature%26date%3D2017%26volume%3D549%26spage%3D101%26epage%3D105%26doi%3D10.1038%2Fnature23643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imamovic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vranic, S.</span></span> <span> </span><span class="NLM_article-title">Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors</span>. <i>Ann. Transl Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">470</span>, <span class="refDoi"> DOI: 10.21037/atm.2017.09.32</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.21037%2Fatm.2017.09.32" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=29285500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtlKiu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=467-470&author=D.+Imamovicauthor=S.+Vranic&title=Novel+regulators+of+PD-L1+expression+in+cancer%3A+CMTM6+and+CMTM4-a+new+avenue+to+enhance+the+therapeutic+benefits+of+immune+checkpoint+inhibitors&doi=10.21037%2Fatm.2017.09.32"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors</span></div><div class="casAuthors">Imamovic, Denira; Vranic, Semir</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Translational Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">467/1-467/3</span>CODEN:
                <span class="NLM_cas:coden">ATMNDX</span>;
        ISSN:<span class="NLM_cas:issn">2305-5847</span>.
    
            (<span class="NLM_cas:orgname">AME Publishing Co.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_PSMq-F9ay7Vg90H21EOLACvtfcHk0ljbMSNS97gRZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtlKiu7w%253D&md5=7ca2a61bf8bf9a2b914c494e8a8ac8b2</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.21037%2Fatm.2017.09.32&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21037%252Fatm.2017.09.32%26sid%3Dliteratum%253Aachs%26aulast%3DImamovic%26aufirst%3DD.%26aulast%3DVranic%26aufirst%3DS.%26atitle%3DNovel%2520regulators%2520of%2520PD-L1%2520expression%2520in%2520cancer%253A%2520CMTM6%2520and%2520CMTM4-a%2520new%2520avenue%2520to%2520enhance%2520the%2520therapeutic%2520benefits%2520of%2520immune%2520checkpoint%2520inhibitors%26jtitle%3DAnn.%2520Transl%2520Med.%26date%3D2017%26volume%3D5%26spage%3D467%26epage%3D470%26doi%3D10.21037%2Fatm.2017.09.32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mamessier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birnbaum, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birnbaum, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertucci, F.</span></span> <span> </span><span class="NLM_article-title">CMTM6 stabilizes PD-L1 expression and refines its prognostic value in tumors</span>. <i>Ann. Transl Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.21037/atm.2017.11.26</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.21037%2Fatm.2017.11.26" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=29610746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlsVCkt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=54-60&author=E.+Mamessierauthor=D.+J.+Birnbaumauthor=P.+Finettiauthor=D.+Birnbaumauthor=F.+Bertucci&title=CMTM6+stabilizes+PD-L1+expression+and+refines+its+prognostic+value+in+tumors&doi=10.21037%2Fatm.2017.11.26"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">CMTM6 stabilizes PD-L1 expression and refines its prognostic value in tumors</span></div><div class="casAuthors">Mamessier, Emilie; Birnbaum, David J.; Finetti, Pascal; Birnbaum, Daniel; Bertucci, Francois</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Translational Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">54/1-54/6</span>CODEN:
                <span class="NLM_cas:coden">ATMNDX</span>;
        ISSN:<span class="NLM_cas:issn">2305-5847</span>.
    
            (<span class="NLM_cas:orgname">AME Publishing Co.</span>)
        </div><div class="casAbstract">The PD-1 protein turned out to be a receptor delivering a co-inhibitory signal, playing a decisive role in maintaining peripheral tolerance and impeding autoimmunity, but with no effect on cell apoptosis.  PD-L1 expression is mostly regulated at the transcriptional level, and involves fixation of transcription factors or HIFα to the PD-L1 promoter.  CMTM6 enhanced both constitutive and induced PD-L1 expression at the cell membrane, without compromising antigen presentation by reducing cell surface MHC class I expression levels.  Exogenous expression of CMTM6 in CMTM6-knockout cells restored PD-L1 expression in a dose-dependent manner.  The PD-1/PD-L1 immune checkpoint, which could provide a new therapeutic target to block this crit. pathway and to help overcoming immune evasion by tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprJM3bQ4sUZLVg90H21EOLACvtfcHk0ljbMSNS97gRZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlsVCkt70%253D&md5=ea339646b60b781aa85af777b611fb3e</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.21037%2Fatm.2017.11.26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21037%252Fatm.2017.11.26%26sid%3Dliteratum%253Aachs%26aulast%3DMamessier%26aufirst%3DE.%26aulast%3DBirnbaum%26aufirst%3DD.%2BJ.%26aulast%3DFinetti%26aufirst%3DP.%26aulast%3DBirnbaum%26aufirst%3DD.%26aulast%3DBertucci%26aufirst%3DF.%26atitle%3DCMTM6%2520stabilizes%2520PD-L1%2520expression%2520and%2520refines%2520its%2520prognostic%2520value%2520in%2520tumors%26jtitle%3DAnn.%2520Transl%2520Med.%26date%3D2018%26volume%3D6%26spage%3D54%26epage%3D60%26doi%3D10.21037%2Fatm.2017.11.26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Melaiu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chierici, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boldrini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romania, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Alicandro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furlanello, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locatelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruci, D.</span></span> <span> </span><span class="NLM_article-title">PD-L1 is a therapeutic target of the bromodomain inhibitor JQ1 and, combined with HLA class I, a promising prognostic biomarker in neuroblastoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">4462</span>– <span class="NLM_lpage">4472</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-2601</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1158%2F1078-0432.CCR-16-2601" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=28270499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Ghu7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=4462-4472&author=O.+Melaiuauthor=M.+Minaauthor=M.+Chiericiauthor=R.+Boldriniauthor=G.+Jurmanauthor=P.+Romaniaauthor=V.+D%E2%80%99Alicandroauthor=M.+C.+Benedettiauthor=A.+Castellanoauthor=T.+Liuauthor=C.+Furlanelloauthor=F.+Locatelliauthor=D.+Fruci&title=PD-L1+is+a+therapeutic+target+of+the+bromodomain+inhibitor+JQ1+and%2C+combined+with+HLA+class+I%2C+a+promising+prognostic+biomarker+in+neuroblastoma&doi=10.1158%2F1078-0432.CCR-16-2601"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma</span></div><div class="casAuthors">Melaiu, Ombretta; Mina, Marco; Chierici, Marco; Boldrini, Renata; Jurman, Giuseppe; Romania, Paolo; D'Alicandro, Valerio; Benedetti, Maria C.; Castellano, Aurora; Liu, Tao; Furlanello, Cesare; Locatelli, Franco; Fruci, Doriana</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4462-4472</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: This study sought to evaluate the expression of programmed cell death-ligand-1 (PD-L1) and HLA class I on neuroblastoma cells and programmed cell death-1 (PD-1) and lymphocyte activation gene 3 (LAG3) on tumor-infiltrating lymphocytes to better define patient risk stratification and understand whether this tumor may benefit from therapies targeting immune checkpoint mols.  Exptl. Design: In situ IHC staining for PD-L1, HLA class I, PD-1, and LAG3 was assessed in 77 neuroblastoma specimens, previously characterized for tumor-infiltrating T-cell d. and correlated with clin. outcome.  Surface expression of PD-L1 was evaluated by flow cytometry and IHC in neuroblastoma cell lines and tumors genetically and/or pharmacol. inhibited for MYC and MYCN.  A dataset of 477 human primary neuroblastomas from GEO and ArrayExpress databases was explored for PD-L1, MYC, and MYCN correlation.  Results: Multivariate Cox regression anal. demonstrated that the combination of PD-L1 and HLA class I tumor cell d. is a prognostic biomarker for predicting overall survival in neuroblastoma patients (P = 0.0448).  MYC and MYCN control the expression of PD-L1 in neuroblastoma cells both in vitro and in vivo.  Consistently, abundance of PD-L1 transcript correlates with MYC expression in primary neuroblastoma.  Conclusions: The combination of PD-L1 and HLA class I represents a novel prognostic biomarker for neuroblastoma.  Pharmacol. inhibition of MYCN and MYC may be exploited to target PD-L1 and restore an efficient antitumor immunity in high-risk neuroblastoma.  Clin Cancer Res; 23(15); 4462-72. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo66-oQkiUsO7Vg90H21EOLACvtfcHk0lh8NAZSjuN9Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Ghu7jN&md5=1907d6d7b9238d22e71a6e56f9ceab46</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-2601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-2601%26sid%3Dliteratum%253Aachs%26aulast%3DMelaiu%26aufirst%3DO.%26aulast%3DMina%26aufirst%3DM.%26aulast%3DChierici%26aufirst%3DM.%26aulast%3DBoldrini%26aufirst%3DR.%26aulast%3DJurman%26aufirst%3DG.%26aulast%3DRomania%26aufirst%3DP.%26aulast%3DD%25E2%2580%2599Alicandro%26aufirst%3DV.%26aulast%3DBenedetti%26aufirst%3DM.%2BC.%26aulast%3DCastellano%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DFurlanello%26aufirst%3DC.%26aulast%3DLocatelli%26aufirst%3DF.%26aulast%3DFruci%26aufirst%3DD.%26atitle%3DPD-L1%2520is%2520a%2520therapeutic%2520target%2520of%2520the%2520bromodomain%2520inhibitor%2520JQ1%2520and%252C%2520combined%2520with%2520HLA%2520class%2520I%252C%2520a%2520promising%2520prognostic%2520biomarker%2520in%2520neuroblastoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D4462%26epage%3D4472%26doi%3D10.1158%2F1078-0432.CCR-16-2601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Visan, I.</span></span> <span> </span><span class="NLM_article-title">CMTM6 controls PD-L1</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1067</span>, <span class="refDoi"> DOI: 10.1038/ni.3844</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1038%2Fni.3844" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFWiu7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1067&author=I.+Visan&title=CMTM6+controls+PD-L1&doi=10.1038%2Fni.3844"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">CMTM6 controls PD-L1</span></div><div class="casAuthors">Visan, Ioana</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1067</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">CMTM6 assocs. with both constitutive PD-L1 and interferon-γ-induced PD-L1 at the plasma membrane and in recycling endosomes.  Depletion of CMTM6 does not affect transcription of the gene encoding PD-L1 or trafficking of PD-L1 from the endoplasmic reticulum to the cell surface but stabilizes cell-surface PD-L1 by preventing its lysosome-mediated degrdn., possibly by preventing its ubiquitination.  Depletion of CMTM6 enhances T cell activation and the anti-tumor response in vitro and in mouse melanoma models.  In this article, transmembrane protein CMTM6 as crit. regulator of cell-surface expression of PD-L1 in cancer cells and myeloid cells in mice and humans were discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcI7U1mwSxFLVg90H21EOLACvtfcHk0lh8NAZSjuN9Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFWiu7fM&md5=1650c394e9fbc70c163a296daabf25bb</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fni.3844&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.3844%26sid%3Dliteratum%253Aachs%26aulast%3DVisan%26aufirst%3DI.%26atitle%3DCMTM6%2520controls%2520PD-L1%26jtitle%3DNat.%2520Immunol.%26date%3D2017%26volume%3D18%26spage%3D1067%26doi%3D10.1038%2Fni.3844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera-Mularz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skalniak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kholodovych, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, evaluation, and structural studies of C2-symmetric small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 protein-protein interaction</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7250</span>– <span class="NLM_lpage">7263</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00795</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00795" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlOhu7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7250-7263&author=S.+Basuauthor=J.+Yangauthor=B.+Xuauthor=K.+Magiera-Mularzauthor=L.+Skalniakauthor=B.+Musielakauthor=V.+Kholodovychauthor=T.+A.+Holakauthor=L.+Hu&title=Design%2C+synthesis%2C+evaluation%2C+and+structural+studies+of+C2-symmetric+small+molecule+inhibitors+of+programmed+cell+death-1%2Fprogrammed+death-ligand+1+protein-protein+interaction&doi=10.1021%2Facs.jmedchem.9b00795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, Evaluation, and Structural Studies of C2-Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein Interaction</span></div><div class="casAuthors">Basu, Subhadwip; Yang, Jeffrey; Xu, Bin; Magiera-Mularz, Katarzyna; Skalniak, Lukasz; Musielak, Bogdan; Kholodovych, Vladyslav; Holak, Tad A.; Hu, Longqin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7250-7263</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of C2-sym. inhibitors was designed and evaluated for inhibitory activity against the programmed cell death-1/programmed death-ligand 1(PD-1/PD-L1) protein-protein interaction (PPI) in a homogeneous time-resolved fluorescence (HTRF) assay and PD-1 signaling in cell-based coculture assays.  C2-sym. inhibitors 2a (LH1306) and 2b (LH1307) exhibited IC50 values of 25 and 3.0 nM, resp., in the HTRF assay.  While 2a was ∼3.8-fold more potent than previously reported inhibitor 1a, 2b could not be differentiated from 1b due to their high potency and the limit of our HTRF assay conditions.  In one cell-based coculture PD-1 signaling assay, 2a and 2b were 8.2- and 2.8-fold more potent in inhibiting PD-1 signaling than 1a and 1b, resp.  NMR and X-ray cocrystal structural studies provided more structural insights into the interaction between 2b and PD-L1; 2b binds to PD-L1 at the PD-1 binding site and induces the formation of a more sym. arranged PD-L1 homodimer than that previously reported for other inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS9fdh7FbNLLVg90H21EOLACvtfcHk0lh8NAZSjuN9Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlOhu7zJ&md5=0dae949116a4157a281802aea6d21b6c</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00795%26sid%3Dliteratum%253Aachs%26aulast%3DBasu%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DMagiera-Mularz%26aufirst%3DK.%26aulast%3DSkalniak%26aufirst%3DL.%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DKholodovych%26aufirst%3DV.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26aulast%3DHu%26aufirst%3DL.%26atitle%3DDesign%252C%2520synthesis%252C%2520evaluation%252C%2520and%2520structural%2520studies%2520of%2520C2-symmetric%2520small%2520molecule%2520inhibitors%2520of%2520programmed%2520cell%2520death-1%252Fprogrammed%2520death-ligand%25201%2520protein-protein%2520interaction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7250%26epage%3D7263%26doi%3D10.1021%2Facs.jmedchem.9b00795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellerschmied, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salami, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaime-Figueroa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Modular PROTAC design for the degradation of oncogenic BCR-ABL</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">807</span>– <span class="NLM_lpage">810</span>, <span class="refDoi"> DOI: 10.1002/anie.201507634</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1002%2Fanie.201507634" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVOlt7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=807-810&author=A.+C.+Laiauthor=M.+Toureauthor=D.+Hellerschmiedauthor=J.+Salamiauthor=S.+Jaime-Figueroaauthor=E.+Koauthor=J.+Hinesauthor=C.+M.+Crews&title=Modular+PROTAC+design+for+the+degradation+of+oncogenic+BCR-ABL&doi=10.1002%2Fanie.201507634"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL</span></div><div class="casAuthors">Lai, Ashton C.; Toure, Momar; Hellerschmied, Doris; Salami, Jemilat; Jaime-Figueroa, Saul; Ko, Eunhwa; Hines, John; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">807-810</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Proteolysis Targeting Chimera (PROTAC) technol. is a rapidly emerging alternative therapeutic strategy with the potential to address many of the challenges currently faced in modern drug development programs.  PROTAC technol. employs small mols. that recruit target proteins for ubiquitination and removal by the proteasome.  The synthesis of PROTAC compds. that mediate the degrdn. of c-ABL and BCR-ABL by recruiting either Cereblon or Von Hippel Lindau E3 ligases is reported.  During the course of their development, the authors discovered that the capacity of a PROTAC to induce degrdn. involves more than just target binding: the identity of the inhibitor warhead and the recruited E3 ligase largely det. the degrdn. profiles of the compds.; thus, as a starting point for PROTAC development, both the target ligand and the recruited E3 ligase should be varied to rapidly generate a PROTAC with the desired degrdn. profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdcSTHt5WfILVg90H21EOLACvtfcHk0lh-PvAj1TupzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVOlt7rN&md5=58a5d78f32bc8a21fd1a6e0c38b8979c</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2Fanie.201507634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201507634%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%2BC.%26aulast%3DToure%26aufirst%3DM.%26aulast%3DHellerschmied%26aufirst%3DD.%26aulast%3DSalami%26aufirst%3DJ.%26aulast%3DJaime-Figueroa%26aufirst%3DS.%26aulast%3DKo%26aufirst%3DE.%26aulast%3DHines%26aufirst%3DJ.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DModular%2520PROTAC%2520design%2520for%2520the%2520degradation%2520of%2520oncogenic%2520BCR-ABL%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D807%26epage%3D810%26doi%3D10.1002%2Fanie.201507634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>186</i></span>,  <span class="NLM_fpage">111856</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111856</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1016%2Fj.ejmech.2019.111856" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=31734021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFOmu7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2020&pages=111856&author=M.+Qinauthor=Q.+Caoauthor=X.+Wuauthor=C.+Liuauthor=S.+Zhengauthor=H.+Xieauthor=Y.+Tianauthor=J.+Xieauthor=Y.+Zhaoauthor=Y.+Houauthor=X.+Zhangauthor=B.+Xuauthor=H.+Zhangauthor=X.+Wang&title=Discovery+of+the+programmed+cell+death-1%2Fprogrammed+cell+death-ligand+1+interaction+inhibitors+bearing+an+indoline+scaffold&doi=10.1016%2Fj.ejmech.2019.111856"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold</span></div><div class="casAuthors">Qin, Mingze; Cao, Qi; Wu, Xia; Liu, Chunyang; Zheng, Shuaishuai; Xie, Hongbo; Tian, Ye; Xie, Jun; Zhao, Yanfang; Hou, Yunlei; Zhang, Xian; Xu, Boxuan; Zhang, Haotian; Wang, Xiaobo</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">186</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111856</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Inhibiting the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway is an attractive strategy for tumor immunotherapy.  Here, a novel series of indoline-contg. compds. were developed, among which, A13 was identified as the most promising PD-1/PD-L1 pathway inhibitor.  At the biochem. level, A13 demonstrated strong inhibition of the PD-1/PD-L1 interaction, with an IC50 of 132.8 nM.  Notably, it exhibited outstanding immunoregulatory activity, and significantly elevated interferon-γ secretion in a Hep3B/OS-8/hPD-L1 and CD3 T cell co-culture model, without significant toxic effect.  Therefore, A13 could be employed as a suitable lead compd. for further design of non-peptide inhibitors targeting the PD-1/PD-L1 interaction.  In addn., the preliminary structure-activity relationships of these new indoline compds. were investigated in this study, providing valuable information for future drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7nYUI852jyLVg90H21EOLACvtfcHk0lh-PvAj1TupzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFOmu7zN&md5=b757929dd24437bb5af585e73a884a51</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111856&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111856%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DHou%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520the%2520programmed%2520cell%2520death-1%252Fprogrammed%2520cell%2520death-ligand%25201%2520interaction%2520inhibitors%2520bearing%2520an%2520indoline%2520scaffold%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D186%26spage%3D111856%26doi%3D10.1016%2Fj.ejmech.2019.111856" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shekarian, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valsesia-Wittmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marabelle, A.</span></span> <span> </span><span class="NLM_article-title">Paradigm shift in oncology: targeting the immune system rather than cancer cells</span>. <i>Mutagenesis</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">211</span>, <span class="refDoi"> DOI: 10.1093/mutage/geu073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1093%2Fmutage%2Fgeu073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=25688113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlaqs73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2015&pages=205-211&author=T.+Shekarianauthor=S.+Valsesia-Wittmannauthor=C.+Cauxauthor=A.+Marabelle&title=Paradigm+shift+in+oncology%3A+targeting+the+immune+system+rather+than+cancer+cells&doi=10.1093%2Fmutage%2Fgeu073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Paradigm shift in oncology: targeting the immune system rather than cancer cells</span></div><div class="casAuthors">Shekarian, Tala; Valsesia-Wittmann, Sandrine; Caux, Christophe; Marabelle, Aurelien</div><div class="citationInfo"><span class="NLM_cas:title">Mutagenesis</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">205-211</span>CODEN:
                <span class="NLM_cas:coden">MUTAEX</span>;
        ISSN:<span class="NLM_cas:issn">0267-8357</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The clin. benefits obtained with rituximab in the treatment of CD20+ B-cell malignancies and of imatinib in the treatment of Phi+ leukemias have opened a new era in oncol., transforming the concepts of tumor-targeted therapies and personalised medicine into reality.  Since then, many tumor-targeted monoclonal antibodies and tyrosine kinase inhibitors have been approved for the treatment of cancers.  Compared to conventional chemotherapies, these new drugs have more specificity against cancer cells and less systemic toxicities.  However, like conventional chemotherapies, they often provide limited therapeutic benefits with short-lasting tumor responses as the vast majority of cancers become resistant to these drugs over time.  Therefore, tumor-targeted therapies are an incremental innovation as compared to historical chemotherapies.  Recently, a paradigm shift has been brought to the clinic with drugs targeting immune cells rather than cancer cells with the aim of stimulating the anti-tumor immune response of patients against their own cancer.  Immunomodulatory drugs such as anti-CTLA4 and anti-PD-1 have generated long-lasting tumor responses when used as single agent in patients with refractory/relapsing cancers such as metastatic melanomas, renal cell carcinoma or non-small-cell lung carcinoma.  These new immune-targeted therapies are therefore a disruptive innovation in cancer treatment: they demonstrate that long-lasting clin. benefits could be obtained by targeting mols. involved in the immune tolerance of cancer cells rather than by targeting oncogenic drivers or antigens expressed by cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIgftDslSuLbVg90H21EOLACvtfcHk0lh2pCWg_bpQnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlaqs73L&md5=ca56e09fd20963569e1829a8c91d7759</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1093%2Fmutage%2Fgeu073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fmutage%252Fgeu073%26sid%3Dliteratum%253Aachs%26aulast%3DShekarian%26aufirst%3DT.%26aulast%3DValsesia-Wittmann%26aufirst%3DS.%26aulast%3DCaux%26aufirst%3DC.%26aulast%3DMarabelle%26aufirst%3DA.%26atitle%3DParadigm%2520shift%2520in%2520oncology%253A%2520targeting%2520the%2520immune%2520system%2520rather%2520than%2520cancer%2520cells%26jtitle%3DMutagenesis%26date%3D2015%26volume%3D30%26spage%3D205%26epage%3D211%26doi%3D10.1093%2Fmutage%2Fgeu073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Screening of kinase inhibitors downregulating PD-L1 expression via on/in cell quantitative immunoblots</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">105088</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2019.105088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1016%2Fj.ejps.2019.105088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=31626963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFCjsL%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2020&pages=105088&author=Y.+Xieauthor=J.+Dingauthor=X.+Cuiauthor=M.+Wuauthor=C.+Huangauthor=R.+Zhangauthor=J.+Wangauthor=X.+Liauthor=S.+Cenauthor=J.+Zhou&title=Screening+of+kinase+inhibitors+downregulating+PD-L1+expression+via+on%2Fin+cell+quantitative+immunoblots&doi=10.1016%2Fj.ejps.2019.105088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Screening of kinase inhibitors down-regulating PD-L1 expression via on/in cell quantitative immunoblots.</span></div><div class="casAuthors">Xie, Yongli; Ding, Jiwei; Cui, Xiangling; Wu, Meng; Huang, Chenchao; Zhang, Rongyu; Wang, Jing; Li, Xiaoyu; Cen, Shan; Zhou, Jinming</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">105088</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The interaction of programmed death-1 (PD-1) and its ligands (PD-L1) is an important immune checkpoint and blockade of PD-1/PD-L1 axis with antibodies against PD-L1 showed promising anti-tumor activity in clin. practice.  However, only a small percentage of patients can benefit from PD-L1 mAbs.  Small mol. kinase inhibitors have been widely used as antitumor drugs for many years, and several kinase inhibitors were recently reported to inhibit the expression of PD-L1.  However, the connections between PD-L1 expression and kinase inhibitors were not thoroughly elucidated.  Herein, we set up a novel and robust screening system to identify small mol. compds. which down-regulate the PD-L1 level of tumor cell based on Odyssey on/in cell quant. immunoblots technol.  A collected kinase inhibitor library was screened and 14 hits were further confirmed by western blot and flow cytometry.  System biol. anal. and further bio-assay identified a synergy combination between KU-60019 and Vacquinol-1 in down-regulation of PD-L1.  Taken together, the work established a novel method to screen the PD-L1 down-regulators using kinase inhibitors library, thus providing new clues for the application of kinase inhibitors in cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqspW2LcYpa7bVg90H21EOLACvtfcHk0lh2pCWg_bpQnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFCjsL%252FI&md5=42a12c5e2c1f84670b47d9211debd279</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2019.105088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2019.105088%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DCen%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DScreening%2520of%2520kinase%2520inhibitors%2520downregulating%2520PD-L1%2520expression%2520via%2520on%252Fin%2520cell%2520quantitative%2520immunoblots%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2020%26volume%3D142%26spage%3D105088%26doi%3D10.1016%2Fj.ejps.2019.105088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span> <span> </span><span class="NLM_article-title">In vitro assay for the development of small molecule inhibitors targeting PD-1/PD-L1</span>. <i>Methods Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>629</i></span>,  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">381</span>, <span class="refDoi"> DOI: 10.1016/bs.mie.2019.05.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1016%2Fbs.mie.2019.05.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=31727249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisVyrt7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=629&publication_year=2019&pages=361-381&author=W.+Zhaiauthor=X.+Zhouauthor=J.+Duauthor=Y.+Gao&title=In+vitro+assay+for+the+development+of+small+molecule+inhibitors+targeting+PD-1%2FPD-L1&doi=10.1016%2Fbs.mie.2019.05.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro assay for the development of small molecule inhibitors targeting PD-1/PD-L1</span></div><div class="casAuthors">Zhai, Wenjie; Zhou, Xiuman; Du, Jiangfeng; Gao, Yanfeng</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">629</span>
        (<span class="NLM_cas:issue">Tumor Immunology and Immunotherapy: Molecular Methods</span>),
    <span class="NLM_cas:pages">361-381</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Cancer immunotherapy has recently emerged as one of the hot research field since clin. successes achieved by antibody drugs of immune checkpoints, among which PD-1 and its ligand PD-L1 are the well established mols.  PD-1/PD-L1 pathway induces immune tolerance and immune evasion, esp. in tumor microenvironment, cancer cell is capable to escape the immune surveillance by up-regulating the expression level of PD-1 or PD-L1.  Blockade of PD-1/PD-L1 can unleash the anti-tumor activity, and the strategy shows great successes in the treatment of various cancer types in the late stage.  Beside antibody drugs, many other mols. such as peptides, high affinity PD(L)-1 mutants, chem. compds., and DNA aptamers are designed for inhibitors of PD-1/PD-L1 pathway.  Each modulators show their pros and cons based on their own physiochem. properties.  Here we introduced the methods for identifying low mol. wt. inhibitors of PD-1/PD-L1 and mainly discussed the cell-based blocking test.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpciI296XaTR7Vg90H21EOLACvtfcHk0lh2pCWg_bpQnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisVyrt7fM&md5=29aae0a76aecb165f5a5a28835f68845</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fbs.mie.2019.05.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.mie.2019.05.051%26sid%3Dliteratum%253Aachs%26aulast%3DZhai%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DY.%26atitle%3DIn%2520vitro%2520assay%2520for%2520the%2520development%2520of%2520small%2520molecule%2520inhibitors%2520targeting%2520PD-1%252FPD-L1%26jtitle%3DMethods%2520Enzymol.%26date%3D2019%26volume%3D629%26spage%3D361%26epage%3D381%26doi%3D10.1016%2Fbs.mie.2019.05.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, D.</span></span> <span> </span><span class="NLM_article-title">SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1</span>. <i>EBioMedicine</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1016/j.ebiom.2019.01.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1016%2Fj.ebiom.2019.01.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=30711516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A280%3ADC%252BB3cjot1Khtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2019&pages=151-162&author=N.+Zhangauthor=Y.+Douauthor=L.+Liuauthor=X.+Zhangauthor=X.+Liuauthor=Q.+Zengauthor=Y.+Liuauthor=M.+Yinauthor=X.+Liuauthor=H.+Dengauthor=D.+Song&title=SA-49%2C+a+novel+aloperine+derivative%2C+induces+MITF-dependent+lysosomal+degradation+of+PD-L1&doi=10.1016%2Fj.ebiom.2019.01.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1</span></div><div class="casAuthors">Zhang Na; Zhang Xin; Liu Xiaojia; Zeng Qingxuan; Liu Yang; Yin Mingxiao; Liu Xiujun; Dou Yueying; Liu Lu; Deng Hongbin; Song Danqing</div><div class="citationInfo"><span class="NLM_cas:title">EBioMedicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">151-162</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Programmed death-ligand 1 (PD-L1) is a T-cell inhibitory checkpoint molecule that suppresses antitumor immunity.  Anti-PD-L1 antibodies have shown remarkable promise in treating tumors, but the patient response rate is low.  Therefore, small-molecule checkpoint inhibitors blocking PD-L1 function are urgently needed.  METHODS:  Changes of protein expression and phosphorylation levels were determined by immunoblotting.  The level of Membrane PD-L1 was examined by flow cytometer.  Cytotoxicity of T cells and NK cells toward tumor cells were detected using LDH and cell index assays.  Lysosome function was investigated by NAG assay.  Changes in lysosomal-related genes were measured by RT-PCR.  In vivo anti-NSCLC cancer effects were assessed using C57BL/6 mice bearing Lewis tumor xenografts.  FINDINGS:  We identified SA-49 as a new regulator of PD-L1 expression from a series of novel aloperine derivatives.  SA-49 decreased the expression of PD-L1 in NSCLC cells and enhanced the cytotoxicity of co-cultured T and NK cells toward tumor cells.  Importantly, lysosomal pathway contributed to SA-49-mediated down-regulation of PD-L1.  SA-49 increased the biogenesis of lysosome and promoted translocation of PD-L1 to lysosome for proteolysis, which was associated with nuclear translocation of MITF.  SA-49-induced MITF translocation acted through activation of PKCα and subsequently suppression of GSK3β activity.  Furthermore, SA-49 suppressed Lewis tumor xenograft growth by activating immune microenvironment in C57BL/6 mice.  INTERPRETATION:  Our data demonstrate that SA-49 can be used to regulate PD-L1 in cancer cells and trigger its degradation by activating lysosome function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ6YPF3oXZ1MVm8bhe6roZYfW6udTcc2ebodSKTKMEKQLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjot1Khtg%253D%253D&md5=cc0b3398c65bdd729dde73f45492af6e</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.ebiom.2019.01.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ebiom.2019.01.054%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DDou%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYin%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DDeng%26aufirst%3DH.%26aulast%3DSong%26aufirst%3DD.%26atitle%3DSA-49%252C%2520a%2520novel%2520aloperine%2520derivative%252C%2520induces%2520MITF-dependent%2520lysosomal%2520degradation%2520of%2520PD-L1%26jtitle%3DEBioMedicine%26date%3D2019%26volume%3D40%26spage%3D151%26epage%3D162%26doi%3D10.1016%2Fj.ebiom.2019.01.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>199</i></span>,  <span class="NLM_fpage">112377</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112377</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1016%2Fj.ejmech.2020.112377" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=32388281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptFGisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=199&publication_year=2020&pages=112377&author=B.+Chengauthor=Y.+Renauthor=H.+Caoauthor=J.+Chen&title=Discovery+of+novel+resorcinol+diphenyl+ether-based+PROTAC-like+molecules+as+dual+inhibitors+and+degraders+of+PD-L1&doi=10.1016%2Fj.ejmech.2020.112377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1</span></div><div class="casAuthors">Cheng, Binbin; Ren, Yichang; Cao, Hao; Chen, Jianjun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">199</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112377</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Novel resorcinol di-Ph ether-based PROTACs (PROteolysis TArgeting Chimeras) were designed and evaluated for their inhibitory activity against the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) pathway and their ability to degrade PD-L1 protein.  Most of the compds. displayed excellent inhibitory activities against PD-1/PD-L1, as assessed by the homogeneous time-resolved fluorescence (HTRF) binding assay, with IC50 values ranging from 25 nM to 200 nM.  Among them, compd. P22 (I) is one of the best with an IC50 value of 39.2 nM.  In addn. to inhibiting PD-1/PD-L1 interaction, P22 also significantly restored the immunity repressed in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells.  Furthermore, flow cytometry (FCM) and western-blot data demonstrated that P22 could moderately reduce the protein levels of PD-L1 in a lysosome-dependent manner, which may contribute to its immune effects.  Preliminary FCM and western-blot data suggest that it is possible to build PD-L1-targeting PROTAC-like mols. based on PD-1/PD-L1 small mol. inhibitors, though these compds. showed only modest degrdn. efficiencies.  Collectively, this work suggests that P22 may serve as a starting point for exploring the degrdn. of PD-L1 by PROTAC-like strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiG4nI2klh77Vg90H21EOLACvtfcHk0lhXwVtMupxebQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptFGisLk%253D&md5=ec722d2e118668f601c0f9648e6f893b</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112377%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DB.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DCao%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520novel%2520resorcinol%2520diphenyl%2520ether-based%2520PROTAC-like%2520molecules%2520as%2520dual%2520inhibitors%2520and%2520degraders%2520of%2520PD-L1%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D199%26spage%3D112377%26doi%3D10.1016%2Fj.ejmech.2020.112377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">D’Andrea, A. D.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of PARP inhibitor sensitivity and resistance</span>. <i>DNA Repair</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">172</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1016/j.dnarep.2018.08.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1016%2Fj.dnarep.2018.08.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=30177437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Cgs7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2018&pages=172-176&author=A.+D.+D%E2%80%99Andrea&title=Mechanisms+of+PARP+inhibitor+sensitivity+and+resistance&doi=10.1016%2Fj.dnarep.2018.08.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of PARP inhibitor sensitivity and resistance</span></div><div class="casAuthors">D'Andrea, Alan D.</div><div class="citationInfo"><span class="NLM_cas:title">DNA Repair</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">172-176</span>CODEN:
                <span class="NLM_cas:coden">DRNEAR</span>;
        ISSN:<span class="NLM_cas:issn">1568-7864</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">BRCA1 and BRCA2 deficient tumor cells are sensitive to inhibitors of Poly ADP Ribose Polymerase (PARP1) through the mechanism of synthetic lethality.  Several PARP inhibitors, which are oral drugs and generally well tolerated, have now received FDA approval for various ovarian cancer and breast cancer indications.  Despite their use in the clinic, PARP inhibitor resistance is common and develops through multiple mechanisms.  Broadly speaking, BRCA1/2-deficient tumor cells can become resistant to PARP inhibitors by restoring homologous recombination (HR) repair and/or by stabilizing their replication forks.  Here, we review the mechanism of PARP inhibitor resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvIBaDAbajp7Vg90H21EOLACvtfcHk0lhXwVtMupxebQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Cgs7jI&md5=892ee46fb9b85c7eb00193584b5557b9</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.dnarep.2018.08.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.dnarep.2018.08.021%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DA.%2BD.%26atitle%3DMechanisms%2520of%2520PARP%2520inhibitor%2520sensitivity%2520and%2520resistance%26jtitle%3DDNA%2520Repair%26date%3D2018%26volume%3D71%26spage%3D172%26epage%3D176%26doi%3D10.1016%2Fj.dnarep.2018.08.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drean, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span> <span> </span><span class="NLM_article-title">PARP inhibitor combination therapy</span>. <i>Crit Rev. Oncol Hematol</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1016/j.critrevonc.2016.10.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1016%2Fj.critrevonc.2016.10.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=27931843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A280%3ADC%252BC2sjkvFCgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2016&pages=73-85&author=A.+Dreanauthor=C.+J.+Lordauthor=A.+Ashworth&title=PARP+inhibitor+combination+therapy&doi=10.1016%2Fj.critrevonc.2016.10.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">PARP inhibitor combination therapy</span></div><div class="casAuthors">Drean Amy; Lord Christopher J; Ashworth Alan</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">73-85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In 2014, olaparib (Lynparza) became the first PARP (Poly(ADP-ribose) polymerase) inhibitor to be approved for the treatment of cancer.  When used as single agents, PARP inhibitors can selectively target tumour cells with BRCA1 or BRCA2 tumour suppressor gene mutations through synthetic lethality.  However, PARP inhibition also shows considerable promise when used together with other therapeutic agents.  Here, we summarise both the pre-clinical and clinical evidence for the utility of such combinations and discuss the future prospects and challenges for PARP inhibitor combinatorial therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRrc1DGTVYh3rBItaL1WaVAfW6udTcc2eYy8GvhyL0_Lbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjkvFCgtA%253D%253D&md5=77ba6fe10daf60936688cf320259e996</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2016.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2016.10.010%26sid%3Dliteratum%253Aachs%26aulast%3DDrean%26aufirst%3DA.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DPARP%2520inhibitor%2520combination%2520therapy%26jtitle%3DCrit%2520Rev.%2520Oncol%2520Hematol%26date%3D2016%26volume%3D108%26spage%3D73%26epage%3D85%26doi%3D10.1016%2Fj.critrevonc.2016.10.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Washington, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, K. N.</span></span> <span> </span><span class="NLM_article-title">Olaparib in the treatment of ovarian cancer</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3435</span>– <span class="NLM_lpage">3449</span>, <span class="refDoi"> DOI: 10.2217/fon-2019-0271</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.2217%2Ffon-2019-0271" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=31478762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVemsLbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=3435-3449&author=C.+R.+Washingtonauthor=D.+L.+Richardsonauthor=K.+N.+Moore&title=Olaparib+in+the+treatment+of+ovarian+cancer&doi=10.2217%2Ffon-2019-0271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Olaparib in the treatment of ovarian cancer</span></div><div class="casAuthors">Washington, Christina R.; Richardson, Debra L.; Moore, Kathleen N.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">3435-3449</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1744-8301</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  The poly ADP ribose polymerase olaparib is currently approved in front line BRCA-assocd. epithelial ovarian cancer (EOC), platinum-sensitive recurrence agnostic to BRCA status and for gBRCA as treatment in the fourth line and beyond.  Women who are diagnosed with advanced stage EOC face a formidable challenge in overcoming their disease and achieving long-term, disease-free survival.  The qualifier here is disease free.  EOC is largely exquisitely chemosensitive, esp. in the treatment naive (first line) setting and the expectation is that the vast majority of women will complete front line platinum-based chemotherapy with a response.  When unselected (not selected by BRCA) women are enrolled on clin. trials, the response rate among those who have measurable disease at the time of chemotherapy initiation is 48% for carboplatin/paclitaxel and 67% for carboplatin/paclitaxel plus bevacizumab.  When one considers the addn. of women who start chemotherapy without measurable disease, they will likely also end chemotherapy without measurable disease and the overall rate of no evidence of disease at conclusion of chemotherapy approaches 80%.  Despite this, the majority of women will suffer relapse of their disease, typically within the first 3 years following completion of therapy.  Once recurrent, the disease is highly treatable for many years but no longer considered curable.  This review will cover indications for olaparib in ovarian cancer as well as ongoing combination trials and rationale for these combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWQxXw7FIWK7Vg90H21EOLACvtfcHk0ljWlOY82X15pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVemsLbL&md5=564943e170c6c5cc0e085a4e38b1f7a8</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.2217%2Ffon-2019-0271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon-2019-0271%26sid%3Dliteratum%253Aachs%26aulast%3DWashington%26aufirst%3DC.%2BR.%26aulast%3DRichardson%26aufirst%3DD.%2BL.%26aulast%3DMoore%26aufirst%3DK.%2BN.%26atitle%3DOlaparib%2520in%2520the%2520treatment%2520of%2520ovarian%2520cancer%26jtitle%3DFuture%2520Oncol.%26date%3D2019%26volume%3D15%26spage%3D3435%26epage%3D3449%26doi%3D10.2217%2Ffon-2019-0271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilie, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span> <span> </span><span class="NLM_article-title">Development of PARP and immune-checkpoint inhibitor combinations</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">6717</span>– <span class="NLM_lpage">6725</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-18-2652</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1158%2F0008-5472.CAN-18-2652" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=30498083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnsVKnt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=6717-6725&author=R.+A.+Stewartauthor=P.+G.+Pilieauthor=T.+A.+Yap&title=Development+of+PARP+and+immune-checkpoint+inhibitor+combinations&doi=10.1158%2F0008-5472.CAN-18-2652"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Development of PARP and immune-checkpoint inhibitor combinations</span></div><div class="casAuthors">Stewart, Ross A.; Pilie, Patrick G.; Yap, Timothy A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6717-6725</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PARP inhibitors drive increased DNA damage, particularly in tumors with existing defects in DNA repair.  This damage not only promotes immune priming through a range of mol. mechanisms, but also leads to adaptive upregulation of programmed death ligand 1 (PD-L1) expression.  In this context, PARP inhibition and programmed cell death 1(PD-1)/PD-L1-targeting antibodies represent a rationale combination.  In this review, we detail the basic and translational science underpinning this promising new combination, summarize available clin. data, and discuss the key questions that remain to be addressed during future development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUomq4ben3XbVg90H21EOLACvtfcHk0ljWlOY82X15pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnsVKnt7o%253D&md5=5f24d1a52ea99f8269b4b6a5aebcdf31</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-18-2652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-18-2652%26sid%3Dliteratum%253Aachs%26aulast%3DStewart%26aufirst%3DR.%2BA.%26aulast%3DPilie%26aufirst%3DP.%2BG.%26aulast%3DYap%26aufirst%3DT.%2BA.%26atitle%3DDevelopment%2520of%2520PARP%2520and%2520immune-checkpoint%2520inhibitor%2520combinations%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26spage%3D6717%26epage%3D6725%26doi%3D10.1158%2F0008-5472.CAN-18-2652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ofori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awuah, S. G.</span></span> <span> </span><span class="NLM_article-title">Small-molecule poly(ADP-ribose) polymerase and PD-L1 inhibitor conjugates as dual-action anticancer agents</span>. <i>ACS Omega</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">12584</span>– <span class="NLM_lpage">12597</span>, <span class="refDoi"> DOI: 10.1021/acsomega.9b01106</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsomega.9b01106" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVWrsLzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&pages=12584-12597&author=S.+Oforiauthor=S.+G.+Awuah&title=Small-molecule+poly%28ADP-ribose%29+polymerase+and+PD-L1+inhibitor+conjugates+as+dual-action+anticancer+agents&doi=10.1021%2Facsomega.9b01106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Poly(ADP-ribose) Polymerase and PD-L1 Inhibitor Conjugates as Dual-Action Anticancer Agents</span></div><div class="casAuthors">Ofori, Samuel; Awuah, Samuel G.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Omega</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">12584-12597</span>CODEN:
                <span class="NLM_cas:coden">ACSODF</span>;
        ISSN:<span class="NLM_cas:issn">2470-1343</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Immune checkpoint blockades have revolutionized the treatment landscape for several cancer indications, yet they have not gained traction in a range of other tumors such as triple-neg. breast cancer.  Despite durable disease control by many patients, a third of cancer patients relapse due to acquired resistance.  Combined immunotherapy has shown significant promise to overcome these grand challenges.  In this report, we describe the synthesis and characterization of dual-action small-mol. PARP1/PD-L1 inhibitor conjugates as potential targeted anticancer agents.  These conjugates display significant apoptosis and cytotoxic efficacy to approx. 2-20-fold better than their individual agents in a panel of cancer cell lines.  This was underscored by derived combination indexes, which was consistent with strong synergy when cells were treated with the individual agents, olaparib and BMS-001 using the Chou-Talalay method.  Furthermore, we sought to unravel the mechanistic behavior of the conjugates and their implications on the PARP/PD-L1 axis.  We used apoptosis, cell cycle, immunoblotting, and T-cell proliferation assays to establish the synergy imparted by these conjugates.  These multifunctional compds. enable the discovery of small-mol. immunochemotherapeutic agents and chem. probes to elucidate the cross-talk between DNA repair and PD-L1 pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0QoqQg4ov77Vg90H21EOLACvtfcHk0lj95RA9aEDnfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVWrsLzO&md5=761d4be91f27085012db8e76a9247c38</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Facsomega.9b01106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsomega.9b01106%26sid%3Dliteratum%253Aachs%26aulast%3DOfori%26aufirst%3DS.%26aulast%3DAwuah%26aufirst%3DS.%2BG.%26atitle%3DSmall-molecule%2520poly%2528ADP-ribose%2529%2520polymerase%2520and%2520PD-L1%2520inhibitor%2520conjugates%2520as%2520dual-action%2520anticancer%2520agents%26jtitle%3DACS%2520Omega%26date%3D2019%26volume%3D4%26spage%3D12584%26epage%3D12597%26doi%3D10.1021%2Facsomega.9b01106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">42</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1038/s41589-018-0161-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1038%2Fs41589-018-0161-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=30397328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2qtbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=42-50&author=H.+Wangauthor=H.+Yaoauthor=C.+Liauthor=H.+Shiauthor=J.+Lanauthor=Z.+Liauthor=Y.+Zhangauthor=L.+Liangauthor=J.+Y.+Fangauthor=J.+Xu&title=HIP1R+targets+PD-L1+to+lysosomal+degradation+to+alter+T+cell-mediated+cytotoxicity&doi=10.1038%2Fs41589-018-0161-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity</span></div><div class="casAuthors">Wang, Huanbin; Yao, Han; Li, Chushu; Shi, Hubing; Lan, Jiang; Li, Zhaoli; Zhang, Yao; Liang, Lunxi; Fang, Jing-Yuan; Xu, Jie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">42-50</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Expression of programmed cell death 1 (PD-1) ligand 1 (PD-L1) protects tumor cells from T cell-mediated immune surveillance, and immune checkpoint blockade (ICB) therapies targeting PD-1 and PD-L1 have exhibited significant clin. benefits.  However, the relatively low response rate and obsd. ICB resistance highlight the need to understand the mol. regulation of PD-L1.  Here we show that HIP1R targets PD-L1 to lysosomal degrdn. to alter T cell-mediated cytotoxicity.  HIP1R phys. interacts with PD-L1 and delivers PD-L1 to the lysosome through a lysosomal targeting signal.  Depletion of HIP1R in tumor cells caused PD-L1 accumulation and suppressed T cell-mediated cytotoxicity.  A rationally designed peptide (PD-LYSO) incorporating the lysosome-sorting signal and the PD-L1-binding sequence of HIP1R successfully depleted PD-L1 expression in tumor cells.  Our results identify the mol. machineries governing the lysosomal degrdn. of PD-L1 and exemplify the development of a chimeric peptide for targeted degrdn. of PD-L1 as a crucial anticancer target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreVHjIVSWPmLVg90H21EOLACvtfcHk0lj95RA9aEDnfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2qtbbN&md5=eac9da24ac6ff6e17cf10cfc6ee2c08a</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1038%2Fs41589-018-0161-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41589-018-0161-x%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DLan%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DFang%26aufirst%3DJ.%2BY.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DHIP1R%2520targets%2520PD-L1%2520to%2520lysosomal%2520degradation%2520to%2520alter%2520T%2520cell-mediated%2520cytotoxicity%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2019%26volume%3D15%26spage%3D42%26epage%3D50%26doi%3D10.1038%2Fs41589-018-0161-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bu, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Z. J.</span></span> <span> </span><span class="NLM_article-title">STAT3 induces immunosuppression by upregulating PD-1/PD-L1 in HNSCC</span>. <i>J. Dent. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">1027</span>– <span class="NLM_lpage">1034</span>, <span class="refDoi"> DOI: 10.1177/0022034517712435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1177%2F0022034517712435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=28605599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltV2qug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2017&pages=1027-1034&author=L.+L.+Buauthor=G.+T.+Yuauthor=L.+Wuauthor=L.+Maoauthor=W.+W.+Dengauthor=J.+F.+Liuauthor=A.+B.+Kulkarniauthor=W.+F.+Zhangauthor=L.+Zhangauthor=Z.+J.+Sun&title=STAT3+induces+immunosuppression+by+upregulating+PD-1%2FPD-L1+in+HNSCC&doi=10.1177%2F0022034517712435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC</span></div><div class="casAuthors">Bu, L. L.; Yu, G. T.; Wu, L.; Mao, L.; Deng, W. W.; Liu, J. F.; Kulkarni, A. B.; Zhang, W. F.; Zhang, L.; Sun, Z. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Dental Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1027-1034</span>CODEN:
                <span class="NLM_cas:coden">JDREAF</span>;
        ISSN:<span class="NLM_cas:issn">0022-0345</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Head and neck cancer is one of the most prevalent cancers around the world.  Head and neck squamous cell carcinoma (HNSCC) accounts for nearly 90% of head and neck cancer.  In recent years, significant advances have been made in immunotherapy for HNSCC.  Although some clin. trials targeting immune checkpoints have shown success, the mol. mechanism for regulation of programmed death 1 (PD-1) and its ligand (PD-L1) is partially understood.  In an effort to explore the effect of activation of signal transducers and activators of transcriptions (STAT3) on PD-1/PD-L1, the expression and correlation between phosphorylation of STAT3 and PD-1/PD-L1 were detd. with immunostaining of human and mouse HNSCC tissue sections.  PD-1/PD-L1 overexpression was found to be significantly assocd. with p-STAT3 in human and mouse HNSCC.  Targeting STAT3 by a small mol. effectively inhibited the expression of PD-L1 in the CAL27 cell line.  Furthermore, we found that blockade of STAT3 signaling downregulated PD-1/PD-L1 in a Tgfbr1/Pten 2cKO HNSCC mouse model.  These findings suggest that STAT3 signaling plays an important role in PD-1/PD-L1 regulation and the antitumor immune response of HNSCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_CXJ7Mr4wubVg90H21EOLACvtfcHk0lj95RA9aEDnfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltV2qug%253D%253D&md5=e16c8a4c14a1d7c1d4da626cc6c3a62c</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1177%2F0022034517712435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0022034517712435%26sid%3Dliteratum%253Aachs%26aulast%3DBu%26aufirst%3DL.%2BL.%26aulast%3DYu%26aufirst%3DG.%2BT.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DMao%26aufirst%3DL.%26aulast%3DDeng%26aufirst%3DW.%2BW.%26aulast%3DLiu%26aufirst%3DJ.%2BF.%26aulast%3DKulkarni%26aufirst%3DA.%2BB.%26aulast%3DZhang%26aufirst%3DW.%2BF.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DZ.%2BJ.%26atitle%3DSTAT3%2520induces%2520immunosuppression%2520by%2520upregulating%2520PD-1%252FPD-L1%2520in%2520HNSCC%26jtitle%3DJ.%2520Dent.%2520Res.%26date%3D2017%26volume%3D96%26spage%3D1027%26epage%3D1034%26doi%3D10.1177%2F0022034517712435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">Regulation of PD-L1: emerging routes for targeting tumor immune evasion</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">536</span>, <span class="refDoi"> DOI: 10.3389/fphar.2018.00536</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.3389%2Ffphar.2018.00536" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=29910728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFyrsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=536&author=Y.+Wangauthor=H.+Wangauthor=H.+Yaoauthor=C.+Liauthor=J.+Y.+Fangauthor=J.+Xu&title=Regulation+of+PD-L1%3A+emerging+routes+for+targeting+tumor+immune+evasion&doi=10.3389%2Ffphar.2018.00536"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of PD-L1: emerging routes for targeting tumor immune evasion</span></div><div class="casAuthors">Wang, Yiting; Wang, Huanbin; Yao, Han; Li, Chushu; Fang, Jing-Yuan; Xu, Jie</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">536/1-536/13</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Immune checkpoint blockade therapies (ICBTs) targeting programmed cell death 1 (PD-1) and its ligand programmed death ligand-1 (PD-L1/B7-H1/CD274) have exhibited momentous clin. benefits and durable responses in multiple tumor types.  However, primary resistance is found in considerable no. of cancer patients, and most responders eventually develop acquired resistance to ICBT.  To tackle these challenges, it is essential to understand how PD-L1 is controlled by cancer cells to evade immune surveillance.  Recent research has shed new light into the mechanisms of PD-L1 regulation at genetic, epigenetic, transcriptional, translational, and posttranslational levels.  In this work, we systematically discuss the mechanisms that control the gene amplification, epigenetic alteration, transcription, subcellular transportation and posttranscriptional modification of PD-L1 in cancer cells.  We further categorize posttranscriptional PD-L1 regulations by the mol. modification of PD-L1, including glycosylation, phosphorylation, ubiquitination, deubiquitination, and lysosomal degrdn.  These findings may provide new routes for targeting tumor immune escape and catalyze the development of small mol. inhibitors of PD-L1 in addn. to existing antibody drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcgJr7PjbSvbVg90H21EOLACvtfcHk0lgIyFOYTfh4FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFyrsLg%253D&md5=96815e00642aaec4309c3cccf90ed22e</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.00536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.00536%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DFang%26aufirst%3DJ.%2BY.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DRegulation%2520of%2520PD-L1%253A%2520emerging%2520routes%2520for%2520targeting%2520tumor%2520immune%2520evasion%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26spage%3D536%26doi%3D10.3389%2Ffphar.2018.00536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M. C.</span></span> <span> </span><span class="NLM_article-title">Posttranslational modifications of PD-L1 and their applications in cancer therapy</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">6349</span>– <span class="NLM_lpage">6353</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-18-1892</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1158%2F0008-5472.CAN-18-1892" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=30442814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmt1Wmtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=6349-6353&author=J.+M.+Hsuauthor=C.+W.+Liauthor=Y.+J.+Laiauthor=M.+C.+Hung&title=Posttranslational+modifications+of+PD-L1+and+their+applications+in+cancer+therapy&doi=10.1158%2F0008-5472.CAN-18-1892"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Posttranslational modifications of PD-L1 and their applications in cancer therapy</span></div><div class="casAuthors">Hsu, Jung-Mao; Li, Chia-Wei; Lai, Yun-Ju; Hung, Mien-Chie</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6349-6353</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Posttranslational modifications (PTM) of PD-L1 have emerged as important regulatory mechanisms that modulate immunosuppression in patients with cancer.  In exposure to inflammatory cytokines, cancer cells and antigen-presenting cells, such as macrophages and dendritic cells, express PD-L1 to inhibit the activity of effector T cells through PD-1 engagement.  Recent studies suggested that glycosylation, phosphorylation, ubiquitination, sumoylation, and acetylation play important roles in the regulation of PD-L1 protein stability and translocation and protein-protein interactions.  Aberrant alterations of PTMs directly influence PD-L1-mediated immune resistance.  On the basis of the newly identified regulatory signaling pathways of PD-L1 PTMs, researchers have investigated the cancer therapeutic potential of natural food compds., small-mol. inhibitors, and mAbs by targeting PD-L1 PTMs.  Results of these preclin. studies demonstrated that targeting PTMs of PD-L1 yields promising antitumor effects and that clin. translation of these therapeutic strategies is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooUYw8JTFgb7Vg90H21EOLACvtfcHk0lgIyFOYTfh4FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmt1Wmtbg%253D&md5=4b13bcee212f423f825f33c38cbe427a</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-18-1892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-18-1892%26sid%3Dliteratum%253Aachs%26aulast%3DHsu%26aufirst%3DJ.%2BM.%26aulast%3DLi%26aufirst%3DC.%2BW.%26aulast%3DLai%26aufirst%3DY.%2BJ.%26aulast%3DHung%26aufirst%3DM.%2BC.%26atitle%3DPosttranslational%2520modifications%2520of%2520PD-L1%2520and%2520their%2520applications%2520in%2520cancer%2520therapy%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26spage%3D6349%26epage%3D6353%26doi%3D10.1158%2F0008-5472.CAN-18-1892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bengsch, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svoronos, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkowski, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitler, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allegrezza, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kossenkov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conejo-Garcia, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span> <span> </span><span class="NLM_article-title">BET bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2829</span>– <span class="NLM_lpage">2837</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2016.08.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1016%2Fj.celrep.2016.08.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=27626654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWht7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=2829-2837&author=H.+Zhuauthor=F.+Bengschauthor=N.+Svoronosauthor=M.+R.+Rutkowskiauthor=B.+G.+Bitlerauthor=M.+J.+Allegrezzaauthor=Y.+Yokoyamaauthor=A.+V.+Kossenkovauthor=J.+E.+Bradnerauthor=J.+R.+Conejo-Garciaauthor=R.+Zhang&title=BET+bromodomain+inhibition+promotes+anti-tumor+immunity+by+suppressing+PD-L1+expression&doi=10.1016%2Fj.celrep.2016.08.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression</span></div><div class="casAuthors">Zhu, Hengrui; Bengsch, Fee; Svoronos, Nikolaos; Rutkowski, Melanie R.; Bitler, Benjamin G.; Allegrezza, Michael J.; Yokoyama, Yuhki; Kossenkov, Andrew V.; Bradner, James E.; Conejo-Garcia, Jose R.; Zhang, Rugang</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2829-2837</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Restoration of anti-tumor immunity by blocking PD-L1 signaling through the use of antibodies has proven to be beneficial in cancer therapy.  Here, we show that BET bromodomain inhibition suppresses PD-L1 expression and limits tumor progression in ovarian cancer.  CD274 (encoding PD-L1) is a direct target of BRD4-mediated gene transcription.  In mouse models, treatment with the BET inhibitor JQ1 significantly reduced PD-L1 expression on tumor cells and tumor-assocd. dendritic cells and macrophages, which correlated with an increase in the activity of anti-tumor cytotoxic T cells.  The BET inhibitor limited tumor progression in a cytotoxic T-cell-dependent manner.  Together, these data demonstrate a small-mol. approach to block PD-L1 signaling.  Given the fact that BET inhibitors have been proven to be safe with manageable reversible toxicity in clin. trials, our findings indicate that pharmacol. BET inhibitors represent a treatment strategy for targeting PD-L1 expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp--rKN-Dcm3bVg90H21EOLACvtfcHk0lh4Ue1p0XhppA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWht7jJ&md5=e84024537ea9ca83be4e5b7ad7043616</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2016.08.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2016.08.032%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DBengsch%26aufirst%3DF.%26aulast%3DSvoronos%26aufirst%3DN.%26aulast%3DRutkowski%26aufirst%3DM.%2BR.%26aulast%3DBitler%26aufirst%3DB.%2BG.%26aulast%3DAllegrezza%26aufirst%3DM.%2BJ.%26aulast%3DYokoyama%26aufirst%3DY.%26aulast%3DKossenkov%26aufirst%3DA.%2BV.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DConejo-Garcia%26aufirst%3DJ.%2BR.%26aulast%3DZhang%26aufirst%3DR.%26atitle%3DBET%2520bromodomain%2520inhibition%2520promotes%2520anti-tumor%2520immunity%2520by%2520suppressing%2520PD-L1%2520expression%26jtitle%3DCell%2520Rep.%26date%3D2016%26volume%3D16%26spage%3D2829%26epage%3D2837%26doi%3D10.1016%2Fj.celrep.2016.08.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, M. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, F. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span> <span> </span><span class="NLM_article-title">C-Myc regulates PD-L1 expression in esophageal squamous cell carcinoma</span>. <i>Am. J. Transl. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">379</span>– <span class="NLM_lpage">388</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=32194890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVent7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=379-388&author=M.+Q.+Liangauthor=F.+Q.+Yuauthor=C.+Chen&title=C-Myc+regulates+PD-L1+expression+in+esophageal+squamous+cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">C-Myc regulates PD-L1 expressionin esophageal squamous cell carcinoma</span></div><div class="casAuthors">Liang, Ming-Qiang; Yu, Feng-Qiang; Chen, Chun</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Translational Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">379-388</span>CODEN:
                <span class="NLM_cas:coden">AJTRA7</span>;
        ISSN:<span class="NLM_cas:issn">1943-8141</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">Immunotherapy using antibodies blocking the programmed cell death 1 (PD-1)/programmed cell deathligand 1 (PD-L1) pathway has achieved great success in preclin. models and the clin. treatment of esophageal squamous cell carcinoma (ESCC).  The c-Myc proto-oncogene helps prevent immune cells from attacking tumor cells by inducing PD-L1 expression.  However, the underlying mechanisms of c-Myc and PD-L1 in ESCC remain unclear, and a thorough understanding of this regulation would allow the development of new approaches to enhance antitumor immunity.  In the present study, the pos. relationship between c-Myc and PD-L1 was explored in the Cancer Genome Atlas dataset using the bioinformatics tool GEPIA, and was confirmed in 105 ESCC tissues by immunostaining (r=0.516, P<0.001).  The patients pos. for both proteins had a poorer overall survival (P=0.032).  Furthermore, in ESCC cell lines, c-Myc overexpression, depletion, and inhibition was able to regulate the expression of PD-L1.  Also, the ChIP assays showed that the increase in PD-L1 expression was likely due to the binding of c-Myc to the PD-L1 promoter.  Taken together, c-Myc and PD-L1 levels were significantly correlated, and c-Myc expression regulated the expression of PD-L1 in ESCC cells.  In addn., a small mol. inhibitor of c-Myc effectively regulated PD-L1 expression.  This indicates that synergistic therapy combining a c-Myc inhibitor with PD-L1 immunotherapy might be a promising new treatment strategy for ESCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjOgN3IOR7OLVg90H21EOLACvtfcHk0lh4Ue1p0XhppA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVent7%252FN&md5=262ac13061fbd2c68e2f6fec126acf39</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DM.%2BQ.%26aulast%3DYu%26aufirst%3DF.%2BQ.%26aulast%3DChen%26aufirst%3DC.%26atitle%3DC-Myc%2520regulates%2520PD-L1%2520expression%2520in%2520esophageal%2520squamous%2520cell%2520carcinoma%26jtitle%3DAm.%2520J.%2520Transl.%2520Res.%26date%3D2020%26volume%3D12%26spage%3D379%26epage%3D388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer</span>. <i>Gut</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">1764</span>– <span class="NLM_lpage">1773</span>, <span class="refDoi"> DOI: 10.1136/gutjnl-2018-316324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1136%2Fgutjnl-2018-316324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=30661053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BB3cXms1WhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2019&pages=1764-1773&author=C.+Linauthor=H.+Heauthor=H.+Liuauthor=R.+Liauthor=Y.+Chenauthor=Y.+Qiauthor=Q.+Jiangauthor=L.+Chenauthor=P.+Zhangauthor=H.+Zhangauthor=H.+Liauthor=W.+Zhangauthor=Y.+Sunauthor=J.+Xu&title=Tumour-associated+macrophages-derived+CXCL8+determines+immune+evasion+through+autonomous+PD-L1+expression+in+gastric+cancer&doi=10.1136%2Fgutjnl-2018-316324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer</span></div><div class="casAuthors">Lin, Chao; He, Hongyong; Liu, Hao; Li, Ruochen; Chen, Yifan; Qi, Yangyang; Jiang, Qi; Chen, Lingli; Zhang, Peipei; Zhang, Heng; Li, He; Zhang, Weijuan; Sun, Yihong; Xu, Jiejie</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1764-1773</span>CODEN:
                <span class="NLM_cas:coden">GUTTAK</span>;
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    
            (<span class="NLM_cas:orgname">BMJ</span>)
        </div><div class="casAbstract">Objective Our previous studies have identified CXCL8 as the crucial chemokine responsible for gastric cancer metastasis mediated by loss of RACK1.  However, the regulatory effect of CXCL8 on immune surveillance in gastric cancer remains obscure.  Design Flow cytometry analyses were performed to examine major source of CXCL8 and phenotypes of immune cells in fresh tumor tissues from 76 patients with gastric cancer.  Real-time PCR was performed to analyze CXCL8 mRNA level in gastric cancer tissues.  For immunohistochem. analyses, a total of 420 patients with gastric cancer undergoing curative resection were enrolled.  In vitro culture of fresh tumor tissue was performed to evaluate the potential therapeutic effect of blocking CXCL8 pathway in gastric cancer.  Results Increased level of CXCL8 indicates poor clin. outcome and tumor progression in patients with gastric cancer.  In gastric cancer tissues, CXCL8 is predominantly secreted by macrophages and colony stimulating factor 2 (CSF-2) facilitates macrophage-derived CXCL8 secretion.  High level of CXCL8 is assocd. with decreased CD8+ T cells infiltration and Ki67+ CD8+ T cells proportion.  Moreover, CXCL8 also inhibits CD8+ T cells function by inducing the expression of PD-L1 on macrophages.  Finally, we show that a small-mol. CXCR2 inhibitor, reparixin, drives the decreased programmed death-ligand 1 (PD-L1+) macrophages and promotes antitumor immunity.  Accordingly, high levels of CXCL8+ macrophages are pos. correlated with poor prognosis in patients with gastric cancer.  Conclusions CXCL8 is predominantly secreted by macrophages and contributes to the immunosuppressive microenvironment by inducing PD-L1+ macrophages in gastric cancer.  CXCL8 inhibitors may drive antitumor response, providing potential therapeutic effects for patients with gastric cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNL3D2anGOpbVg90H21EOLACvtfcHk0ljI0FGLNnxHpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXms1WhtA%253D%253D&md5=6555a4ad5cef67eb5da53cee75788492</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1136%2Fgutjnl-2018-316324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgutjnl-2018-316324%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DQi%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DTumour-associated%2520macrophages-derived%2520CXCL8%2520determines%2520immune%2520evasion%2520through%2520autonomous%2520PD-L1%2520expression%2520in%2520gastric%2520cancer%26jtitle%3DGut%26date%3D2019%26volume%3D68%26spage%3D1764%26epage%3D1773%26doi%3D10.1136%2Fgutjnl-2018-316324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maher, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longen, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyer, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, F. J.</span></span> <span> </span><span class="NLM_article-title">Small-molecule sigma1 modulator induces autophagic degradation of PD-L1</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-17-0166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1158%2F1541-7786.MCR-17-0166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=29117944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVeiurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2018&pages=243-255&author=C.+M.+Maherauthor=J.+D.+Thomasauthor=D.+A.+Haasauthor=C.+G.+Longenauthor=H.+M.+Oyerauthor=J.+Y.+Tongauthor=F.+J.+Kim&title=Small-molecule+sigma1+modulator+induces+autophagic+degradation+of+PD-L1&doi=10.1158%2F1541-7786.MCR-17-0166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Sigma1 Modulator Induces Autophagic Degradation of PD-L1</span></div><div class="casAuthors">Maher, Christina M.; Thomas, Jeffrey D.; Haas, Derick A.; Longen, Charles G.; Oyer, Halley M.; Tong, Jane Y.; Kim, Felix J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">243-255</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Emerging evidence suggests that Sigma1 (SIGMAR1, also known as sigma-1 receptor) is a unique ligand-regulated integral membrane scaffolding protein that contributes to cellular protein and lipid homeostasis.  Previously, we demonstrated that some small-mol. modulators of Sigma1 alter endoplasmic reticulum (ER)-assocd. protein homeostasis pathways in cancer cells, including the unfolded protein response and autophagy.  Programmed death-ligand 1 (PD-L1) is a type I integral membrane glycoprotein that is cotranslationally inserted into the ER and is processed and transported through the secretory pathway.  Once at the surface of cancer cells, PD-L1 acts as a T-cell inhibitory checkpoint mol. and suppresses antitumor immunity.  Here, we demonstrate that in Sigma1-expressing triple-neg. breast and androgen-independent prostate cancer cells, PD-L1 protein levels were suppressed by RNAi knockdown of Sigma1 and by small-mol. inhibition of Sigma1.  Sigma1-mediated action was confirmed by pharmacol. competition between Sigma1-selective inhibitor and activator ligands.  When administered alone, the Sigma1 inhibitor decreased cell surface PD-L1 expression and suppressed functional interaction of PD-1 and PD-L1 in a coculture of T cells and cancer cells.  Conversely, the Sigma1 activator increased PD-L1 cell surface expression, demonstrating the ability to pos. and neg. modulate Sigma1 assocd. PD-L1 processing.  We discovered that the Sigma1 inhibitor induced degrdn. of PD-L1 via autophagy, by a mechanism distinct from bulk macroautophagy or general ER stress-assocd. autophagy.  Finally, the Sigma1 inhibitor suppressed IFNγ-induced PD-L1.  Our data demonstrate that small-mol. Sigma1 modulators can be used to regulate PD-L1 in cancer cells and trigger its degrdn. by selective autophagy.  Implications: Sigma1 modulators sequester and eliminate PD-L1 by autophagy, thus preventing functional PD-L1 expression at the cell surface.  This posits Sigma1 modulators as novel therapeutic agents in PD-L1/PD-1 blockade strategies that regulate the tumor immune microenvironment.  Visual Overview: http//mcr.accrjournals.org/content/molcanres/16/02/243/F1.large.jpg.  Mol Cancer Res; 16(2); 243-55. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPoBdyWoswA7Vg90H21EOLACvtfcHk0ljI0FGLNnxHpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVeiurc%253D&md5=84f9aee84ada0bb2b7ce13f2d210b52b</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-17-0166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-17-0166%26sid%3Dliteratum%253Aachs%26aulast%3DMaher%26aufirst%3DC.%2BM.%26aulast%3DThomas%26aufirst%3DJ.%2BD.%26aulast%3DHaas%26aufirst%3DD.%2BA.%26aulast%3DLongen%26aufirst%3DC.%2BG.%26aulast%3DOyer%26aufirst%3DH.%2BM.%26aulast%3DTong%26aufirst%3DJ.%2BY.%26aulast%3DKim%26aufirst%3DF.%2BJ.%26atitle%3DSmall-molecule%2520sigma1%2520modulator%2520induces%2520autophagic%2520degradation%2520of%2520PD-L1%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2018%26volume%3D16%26spage%3D243%26epage%3D255%26doi%3D10.1158%2F1541-7786.MCR-17-0166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murase, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oshima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, H.</span></span> <span> </span><span class="NLM_article-title">Downregulation of PD-L1 via amide analogues of brefelamide: alternatives to antibody-based cancer immunotherapy</span>. <i>Exp. Ther. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">3150</span>– <span class="NLM_lpage">3158</span>, <span class="refDoi"> DOI: 10.3892/etm.2020.8553</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.3892%2Fetm.2020.8553" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=32256803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVakt73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2020&pages=3150-3158&author=J.+Zhangauthor=O.+Yamadaauthor=S.+Kidaauthor=S.+Muraseauthor=T.+Hattoriauthor=Y.+Oshimaauthor=H.+Kikuchi&title=Downregulation+of+PD-L1+via+amide+analogues+of+brefelamide%3A+alternatives+to+antibody-based+cancer+immunotherapy&doi=10.3892%2Fetm.2020.8553"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Downregulation of PD-L1 via amide analogues of brefelamide: Alternatives to antibody-based cancer immunotherapy</span></div><div class="casAuthors">Zhang, Jing; Yamada, Osamu; Kida, Shinya; Murase, Shinya; Hattori, Toshio; Oshima, Yoshiteru; Kikuchi, Haruhisa</div><div class="citationInfo"><span class="NLM_cas:title">Experimental and Therapeutic Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">3150-3158</span>CODEN:
                <span class="NLM_cas:coden">ETMXA2</span>;
        ISSN:<span class="NLM_cas:issn">1792-1015</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">The therapeutic blockade of immune checkpoint has emerged as an effective treatment option for a broad range of tumors.  However, the objective tumor response is still limited to a small no. of cases and tumor types.  The full utility of monoclonal antibody (mAb)-based treatment is hindered by several inherent limitations.  Thus, there is an urgent requirement to explore alternative modalities targeting the same pathways.  In the present study, two amide analogs of brefelamide, TPFS-201 and TPFS-202, were identified as small mol. immune checkpoint inhibitors, as they downregulated PD-L1 expression in tumor cells.  PD-L1 was suppressed in cancer cells treated with TPFD compds. at both mRNA and protein levels, as detected by reverse transcription quant. PCR and flow cytometric anal., resp.  Reporter assays using a PD-L1 promoter luciferase construct confirmed the transcriptional inhibition of PD L1 by TPFS compds.  TPFS compd.-mediated PD-L1 downregulation in cancer cells consequently restored T cell activity, as identified by the redn. of apoptosis and an increase in interleukin-2 promoter activity in Jurkat T cells, which were co-cultured with TPFS compd.-treated A549 cells.  TPFS compd.-mediated PD-L1 inhibition was partially abolished by the disruption of the putative transcriptional co-activator with PDZ (TAZ)/TEA domain (TEAD)-binding motif in the PD-L1 promoter.  The inhibitory effect of TPFS compds. on PD-L1 was markedly inhibited in mouse cell lines, which is consistent with previous research demonstrating that PD-L1 regulation by TAZ is not conserved in mice due to distinct promoter sequences flanking the TAZ/TEAD-binding motif.  Together, the data of the current study indicated the potential utility of the brefelamide amide analogs as small mol. immune checkpoint inhibitors, thereby providing therapeutic alternatives, which could be used as monotherapy or in combination with mAbs-based treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7QEcMIY6OH7Vg90H21EOLACvtfcHk0ljI0FGLNnxHpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVakt73M&md5=cab56791f5df9627282c648e5c9539f3</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.3892%2Fetm.2020.8553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fetm.2020.8553%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYamada%26aufirst%3DO.%26aulast%3DKida%26aufirst%3DS.%26aulast%3DMurase%26aufirst%3DS.%26aulast%3DHattori%26aufirst%3DT.%26aulast%3DOshima%26aufirst%3DY.%26aulast%3DKikuchi%26aufirst%3DH.%26atitle%3DDownregulation%2520of%2520PD-L1%2520via%2520amide%2520analogues%2520of%2520brefelamide%253A%2520alternatives%2520to%2520antibody-based%2520cancer%2520immunotherapy%26jtitle%3DExp.%2520Ther.%2520Med.%26date%3D2020%26volume%3D19%26spage%3D3150%26epage%3D3158%26doi%3D10.3892%2Fetm.2020.8553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marisetty, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassab, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claret, F. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimberger, A. B.</span></span> <span> </span><span class="NLM_article-title">Verteporfin inhibits PD-L1 through autophagy and the STAT1-IRF1-TRIM28 signaling axis, exerting antitumor efficacy</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">952</span>– <span class="NLM_lpage">965</span>, <span class="refDoi"> DOI: 10.1158/2326-6066.CIR-19-0159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1158%2F2326-6066.CIR-19-0159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=32265228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit12qu7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=952-965&author=J.+Liangauthor=L.+Wangauthor=C.+Wangauthor=J.+Shenauthor=B.+Suauthor=A.+L.+Marisettyauthor=D.+Fangauthor=C.+Kassabauthor=K.+J.+Jeongauthor=W.+Zhaoauthor=Y.+Luauthor=A.+K.+Jainauthor=Z.+Zhouauthor=H.+Liangauthor=S.+C.+Sunauthor=C.+Luauthor=Z.+X.+Xuauthor=Q.+Yuauthor=S.+Shaoauthor=X.+Chenauthor=M.+Gaoauthor=F.+X.+Claretauthor=Z.+Dingauthor=J.+Chenauthor=P.+Chenauthor=M.+C.+Bartonauthor=G.+Pengauthor=G.+B.+Millsauthor=A.+B.+Heimberger&title=Verteporfin+inhibits+PD-L1+through+autophagy+and+the+STAT1-IRF1-TRIM28+signaling+axis%2C+exerting+antitumor+efficacy&doi=10.1158%2F2326-6066.CIR-19-0159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Verteporfin inhibits PD-L1 through autophagy and the STAT1-IRF1-TRIM28 signaling axis, exerting antitumor efficacy</span></div><div class="casAuthors">Liang, Jiyong; Wang, Lulu; Wang, Chao; Shen, Jianfeng; Su, Bojin; Marisetty, Anantha L.; Fang, Dexing; Kassab, Cynthia; Jeong, Kang Jin; Zhao, Wei; Lu, Yiling; Jain, Abhinav K.; Zhou, Zhicheng; Liang, Han; Sun, Shao-Cong; Lu, Changming; Xu, Zhi-Xiang; Yu, Qinghua; Shao, Shan; Chen, Xiaohua; Gao, Meng; Claret, Francois X.; Ding, Zhiyong; Chen, Jian; Chen, Pingsheng; Barton, Michelle C.; Peng, Guang; Mills, Gordon B.; Heimberger, Amy B.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">952-965</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Programmed cell death 1 ligand 1 (PD-L1) is a key driver of tumor-mediated immune suppression, and targeting it with antibodies can induce therapeutic responses.  Given the costs and assocd. toxicity of PD-L1 blockade, alternative therapeutic strategies arc needed.  Using reverse phase protein arrays to assess drugs in use or likely to enter trials, we performed a candidate drug screen for inhibitors of PD-L1 expression and identified verteporfin as a possible small-mol. inhibitor.  Vertcporfin suppressed basal and IFN-induced PD-L1 expression in vitro and in vivo through Golgi related autophagy and disruption of the STAT1-IRF -TRIM28 signaling cascade, but did not affect the proinflammatory CIITA-MHC 11 cascade.  Within the tumor microenvironment, verteporfin inhibited PD-L1 expression, which assocd. with enhanced T-Iymphocyte infiltration.  Inhibition of chromatin-assocd. enzyme PARPl induced PD-L1 expression in high endothelial venules (HLV) in tumors and, when combined with verteporfin, enhanced therapeutic efficacy.  Thus, verteporfin effectively targets PD-L1 through transcription al and posttranslational mechanisms, representing an alternative therapeutic strategy for targeting PD-L1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHe21tJ-eYT7Vg90H21EOLACvtfcHk0liElG3LrLWFxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit12qu7nO&md5=6645f85efc3ad89437333a6b303e9a85</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.CIR-19-0159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.CIR-19-0159%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DB.%26aulast%3DMarisetty%26aufirst%3DA.%2BL.%26aulast%3DFang%26aufirst%3DD.%26aulast%3DKassab%26aufirst%3DC.%26aulast%3DJeong%26aufirst%3DK.%2BJ.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DJain%26aufirst%3DA.%2BK.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DLiang%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DS.%2BC.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DZ.%2BX.%26aulast%3DYu%26aufirst%3DQ.%26aulast%3DShao%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DClaret%26aufirst%3DF.%2BX.%26aulast%3DDing%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DBarton%26aufirst%3DM.%2BC.%26aulast%3DPeng%26aufirst%3DG.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DHeimberger%26aufirst%3DA.%2BB.%26atitle%3DVerteporfin%2520inhibits%2520PD-L1%2520through%2520autophagy%2520and%2520the%2520STAT1-IRF1-TRIM28%2520signaling%2520axis%252C%2520exerting%2520antitumor%2520efficacy%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2020%26volume%3D8%26spage%3D952%26epage%3D965%26doi%3D10.1158%2F2326-6066.CIR-19-0159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, M. H.</span></span> <span> </span><span class="NLM_article-title">FDA-approved small-molecule kinase inhibitors</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">422</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2015.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1016%2Fj.tips.2015.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=25975227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1KisLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=422-439&author=P.+Wuauthor=T.+E.+Nielsenauthor=M.+H.+Clausen&title=FDA-approved+small-molecule+kinase+inhibitors&doi=10.1016%2Fj.tips.2015.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">FDA-approved small-molecule kinase inhibitors</span></div><div class="casAuthors">Wu, Peng; Nielsen, Thomas E.; Clausen, Mads H.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">422-439</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Kinases have emerged as one of the most intensively pursued targets in current pharmacol. research, esp. for cancer, due to their crit. roles in cellular signaling.  To date, the US FDA has approved 28 small-mol. kinase inhibitors, half of which were approved in the past 3 years.  While the clin. data of these approved mols. are widely presented and structure-activity relationship (SAR) has been reported for individual mols., an updated review that analyzes all approved mols. and summarizes current achievements and trends in the field has yet to be found.  Here we present all approved small-mol. kinase inhibitors with an emphasis on binding mechanism and structural features, summarize current challenges, and discuss future directions in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrudyvM3eO09bVg90H21EOLACvtfcHk0liElG3LrLWFxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1KisLg%253D&md5=a6aa3dbb11e6fe3001fa5fa03a4c950a</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2015.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2015.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DP.%26aulast%3DNielsen%26aufirst%3DT.%2BE.%26aulast%3DClausen%26aufirst%3DM.%2BH.%26atitle%3DFDA-approved%2520small-molecule%2520kinase%2520inhibitors%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D36%26spage%3D422%26epage%3D439%26doi%3D10.1016%2Fj.tips.2015.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Azuma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ota, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawahara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takayama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takamori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kage, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoshino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakanishi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, I.</span></span> <span> </span><span class="NLM_article-title">Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer</span>. <i>Ann. Oncol</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1935</span>– <span class="NLM_lpage">1940</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdu242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1093%2Fannonc%2Fmdu242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=25009014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A280%3ADC%252BC2cbhtVChsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=1935-1940&author=K.+Azumaauthor=K.+Otaauthor=A.+Kawaharaauthor=S.+Hattoriauthor=E.+Iwamaauthor=T.+Haradaauthor=K.+Matsumotoauthor=K.+Takayamaauthor=S.+Takamoriauthor=M.+Kageauthor=T.+Hoshinoauthor=Y.+Nakanishiauthor=I.+Okamoto&title=Association+of+PD-L1+overexpression+with+activating+EGFR+mutations+in+surgically+resected+nonsmall-cell+lung+cancer&doi=10.1093%2Fannonc%2Fmdu242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer</span></div><div class="casAuthors">Azuma K; Hoshino T; Ota K; Iwama E; Harada T; Matsumoto K; Takayama K; Kawahara A; Kage M; Hattori S; Takamori S; Nakanishi Y; Okamoto I</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1935-1940</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Recent clinical trials have shown that immune-checkpoint blockade yields a clinical response in a subset of individuals with advanced nonsmall-cell lung cancer (NSCLC).  We examined whether the expression of programmed death-ligand 1 (PD-L1) is related to clinicopathologic or prognostic factors in patients with surgically resected NSCLC.  PATIENTS AND METHODS:  The expression of PD-L1 was evaluated by immunohistochemical analysis in 164 specimens of surgically resected NSCLC.  Cell surface expression of PD-L1 in NSCLC cell lines was quantified by flow cytometry.  RESULTS:  Expression of PD-L1 in tumor specimens was significantly higher for women than for men, for never smokers than for smokers, and for patients with adenocarcinoma than for those with squamous cell carcinoma.  Multivariate analysis revealed that the presence of epidermal growth factor receptor gene (EGFR) mutations and adenocarcinoma histology were significantly associated with increased PD-L1 expression in a manner independent of other factors.  Cell surface expression of PD-L1 was also significantly higher in NSCLC cell lines positive for activating EGFR mutations than in those with wild-type EGFR.  The EGFR inhibitor erlotinib downregulated PD-L1 expression in the former cell lines but not in the latter, suggesting that PD-L1 expression is increased by EGFR signaling conferred by activating EGFR mutations.  A high level of PD-L1 expression in resected tumor tissue was associated with a significantly shorter overall survival for NSCLC patients.  CONCLUSIONS:  High expression of PD-L1 was associated with the presence of EGFR mutations in surgically resected NSCLC and was an independent negative prognostic factor for this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRp6teAQsaYtwyMywPm6HgQfW6udTcc2eZgR7ObtIGMULntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbhtVChsQ%253D%253D&md5=e5a8e9cf6fbd85ca2ed7a13b049ba81d</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdu242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdu242%26sid%3Dliteratum%253Aachs%26aulast%3DAzuma%26aufirst%3DK.%26aulast%3DOta%26aufirst%3DK.%26aulast%3DKawahara%26aufirst%3DA.%26aulast%3DHattori%26aufirst%3DS.%26aulast%3DIwama%26aufirst%3DE.%26aulast%3DHarada%26aufirst%3DT.%26aulast%3DMatsumoto%26aufirst%3DK.%26aulast%3DTakayama%26aufirst%3DK.%26aulast%3DTakamori%26aufirst%3DS.%26aulast%3DKage%26aufirst%3DM.%26aulast%3DHoshino%26aufirst%3DT.%26aulast%3DNakanishi%26aufirst%3DY.%26aulast%3DOkamoto%26aufirst%3DI.%26atitle%3DAssociation%2520of%2520PD-L1%2520overexpression%2520with%2520activating%2520EGFR%2520mutations%2520in%2520surgically%2520resected%2520nonsmall-cell%2520lung%2520cancer%26jtitle%3DAnn.%2520Oncol%26date%3D2014%26volume%3D25%26spage%3D1935%26epage%3D1940%26doi%3D10.1093%2Fannonc%2Fmdu242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dorand, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nthale, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barkauskas, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avril, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirieleison, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pareek, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbott, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stearns, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letterio, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrosiute, A.</span></span> <span> </span><span class="NLM_article-title">Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>353</i></span>,  <span class="NLM_fpage">399</span>– <span class="NLM_lpage">403</span>, <span class="refDoi"> DOI: 10.1126/science.aae0477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1126%2Fscience.aae0477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=27463676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFyit7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2016&pages=399-403&author=R.+D.+Dorandauthor=J.+Nthaleauthor=J.+T.+Myersauthor=D.+S.+Barkauskasauthor=S.+Avrilauthor=S.+M.+Chirieleisonauthor=T.+K.+Pareekauthor=D.+W.+Abbottauthor=D.+S.+Stearnsauthor=J.+J.+Letterioauthor=A.+Y.+Huangauthor=A.+Petrosiute&title=Cdk5+disruption+attenuates+tumor+PD-L1+expression+and+promotes+antitumor+immunity&doi=10.1126%2Fscience.aae0477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity</span></div><div class="casAuthors">Dorand, R. Dixon; Nthale, Joseph; Myers, Jay T.; Barkauskas, Deborah S.; Avril, Stefanie; Chirieleison, Steven M.; Pareek, Tej K.; Abbott, Derek W.; Stearns, Duncan S.; Letterio, John J.; Huang, Alex Y.; Petrosiute, Agne</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">6297</span>),
    <span class="NLM_cas:pages">399-403</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Cancers often evade immune surveillance by adopting peripheral tissue- tolerance mechanisms, such as the expression of programmed cell death ligand 1 (PD-L1), the inhibition of which results in potent antitumor immunity.  Here, we show that cyclin-dependent kinase 5 (Cdk5), a serine-threonine kinase that is highly active in postmitotic neurons and in many cancers, allows medulloblastoma (MB) to evade immune elimination.  Interferon-γ (IFN-γ)-induced PD-L1 up-regulation on MB requires Cdk5, and disruption of Cdk5 expression in a mouse model of MB results in potent CD4+ T cell-mediated tumor rejection.  Loss of Cdk5 results in persistent expression of the PD-L1 transcriptional repressors, the interferon regulatory factors IRF2 and IRF2BP2, which likely leads to reduced PD-L1 expression on tumors.  Our finding highlights a central role for Cdk5 in immune checkpoint regulation by tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKYHJiyEhE0rVg90H21EOLACvtfcHk0lhBdGhcPY1z7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFyit7bF&md5=d91dc0f4e5290960f3407bf96e886bb1</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1126%2Fscience.aae0477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aae0477%26sid%3Dliteratum%253Aachs%26aulast%3DDorand%26aufirst%3DR.%2BD.%26aulast%3DNthale%26aufirst%3DJ.%26aulast%3DMyers%26aufirst%3DJ.%2BT.%26aulast%3DBarkauskas%26aufirst%3DD.%2BS.%26aulast%3DAvril%26aufirst%3DS.%26aulast%3DChirieleison%26aufirst%3DS.%2BM.%26aulast%3DPareek%26aufirst%3DT.%2BK.%26aulast%3DAbbott%26aufirst%3DD.%2BW.%26aulast%3DStearns%26aufirst%3DD.%2BS.%26aulast%3DLetterio%26aufirst%3DJ.%2BJ.%26aulast%3DHuang%26aufirst%3DA.%2BY.%26aulast%3DPetrosiute%26aufirst%3DA.%26atitle%3DCdk5%2520disruption%2520attenuates%2520tumor%2520PD-L1%2520expression%2520and%2520promotes%2520antitumor%2520immunity%26jtitle%3DScience%26date%3D2016%26volume%3D353%26spage%3D399%26epage%3D403%26doi%3D10.1126%2Fscience.aae0477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Go, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, D. H.</span></span> <span> </span><span class="NLM_article-title">EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1alpha and STAT3</span>. <i>Oncoimmunology</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e1108514</span>, <span class="refDoi"> DOI: 10.1080/2162402X.2015.1108514</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1080%2F2162402X.2015.1108514" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=27141364" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=e1108514&author=J.+Kohauthor=J.+Y.+Jangauthor=B.+Keamauthor=S.+Kimauthor=M.+Y.+Kimauthor=H.+Goauthor=T.+M.+Kimauthor=D.+W.+Kimauthor=C.+W.+Kimauthor=Y.+K.+Jeonauthor=D.+H.+Chung&title=EML4-ALK+enhances+programmed+cell+death-ligand+1+expression+in+pulmonary+adenocarcinoma+via+hypoxia-inducible+factor+%28HIF%29-1alpha+and+STAT3&doi=10.1080%2F2162402X.2015.1108514"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1080%2F2162402X.2015.1108514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F2162402X.2015.1108514%26sid%3Dliteratum%253Aachs%26aulast%3DKoh%26aufirst%3DJ.%26aulast%3DJang%26aufirst%3DJ.%2BY.%26aulast%3DKeam%26aufirst%3DB.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DM.%2BY.%26aulast%3DGo%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DT.%2BM.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DKim%26aufirst%3DC.%2BW.%26aulast%3DJeon%26aufirst%3DY.%2BK.%26aulast%3DChung%26aufirst%3DD.%2BH.%26atitle%3DEML4-ALK%2520enhances%2520programmed%2520cell%2520death-ligand%25201%2520expression%2520in%2520pulmonary%2520adenocarcinoma%2520via%2520hypoxia-inducible%2520factor%2520%2528HIF%2529-1alpha%2520and%2520STAT3%26jtitle%3DOncoimmunology%26date%3D2015%26volume%3D5%26spage%3De1108514%26doi%3D10.1080%2F2162402X.2015.1108514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banik, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedram, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisnovsky, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertozzi, C. R.</span></span> <span> </span><span class="NLM_article-title">Lysosome-targeting chimaeras for degradation of extracellular proteins</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>584</i></span>,  <span class="NLM_fpage">291</span>– <span class="NLM_lpage">297</span>, <span class="refDoi"> DOI: 10.1038/s41586-020-2545-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1038%2Fs41586-020-2545-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=32728216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVygtLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=584&publication_year=2020&pages=291-297&author=S.+M.+Banikauthor=K.+Pedramauthor=S.+Wisnovskyauthor=G.+Ahnauthor=N.+M.+Rileyauthor=C.+R.+Bertozzi&title=Lysosome-targeting+chimaeras+for+degradation+of+extracellular+proteins&doi=10.1038%2Fs41586-020-2545-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Lysosome-targeting chimaeras for degradation of extracellular proteins</span></div><div class="casAuthors">Banik, Steven M.; Pedram, Kayvon; Wisnovsky, Simon; Ahn, Green; Riley, Nicholas M.; Bertozzi, Carolyn R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">584</span>
        (<span class="NLM_cas:issue">7820</span>),
    <span class="NLM_cas:pages">291-297</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: The majority of therapies that target individual proteins rely on specific activity-modulating interactions with the target protein-for example, enzyme inhibition or ligand blocking.  However, several major classes of therapeutically relevant proteins have unknown or inaccessible activity profiles and so cannot be targeted by such strategies.  Protein-degrdn. platforms such as proteolysis-targeting chimaeras (PROTACs)1,2 and others (for example, dTAGs3, Trim-Away4, chaperone-mediated autophagy targeting5 and SNIPERs6) have been developed for proteins that are typically difficult to target; however, these methods involve the manipulation of intracellular protein degrdn. machinery and are therefore fundamentally limited to proteins that contain cytosolic domains to which ligands can bind and recruit the requisite cellular components.  Extracellular and membrane-assocd. proteins-the products of 40% of all protein-encoding genes7-are key agents in cancer, ageing-related diseases and autoimmune disorders8, and so a general strategy to selectively degrade these proteins has the potential to improve human health.  Here we establish the targeted degrdn. of extracellular and membrane-assocd. proteins using conjugates that bind both a cell-surface lysosome-shuttling receptor and the extracellular domain of a target protein.  These initial lysosome-targeting chimaeras, which we term LYTACs, consist of a small mol. or antibody fused to chem. synthesized glycopeptide ligands that are agonists of the cation-independent mannose-6-phosphate receptor (CI-M6PR).  We use LYTACs to develop a CRISPR interference screen that reveals the biochem. pathway for CI-M6PR-mediated cargo internalization in cell lines, and uncover the exocyst complex as a previously unidentified-but essential-component of this pathway.  We demonstrate the scope of this platform through the degrdn. of therapeutically relevant proteins, including apolipoprotein E4, epidermal growth factor receptor, CD71 and programmed death-ligand 1.  Our results establish a modular strategy for directing secreted and membrane proteins for lysosomal degrdn., with broad implications for biochem. research and for therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmZfj1oJhbx7Vg90H21EOLACvtfcHk0lhBdGhcPY1z7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVygtLrP&md5=1109c68b56a3ee93427ae89f194c0a16</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1038%2Fs41586-020-2545-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-020-2545-9%26sid%3Dliteratum%253Aachs%26aulast%3DBanik%26aufirst%3DS.%2BM.%26aulast%3DPedram%26aufirst%3DK.%26aulast%3DWisnovsky%26aufirst%3DS.%26aulast%3DAhn%26aufirst%3DG.%26aulast%3DRiley%26aufirst%3DN.%2BM.%26aulast%3DBertozzi%26aufirst%3DC.%2BR.%26atitle%3DLysosome-targeting%2520chimaeras%2520for%2520degradation%2520of%2520extracellular%2520proteins%26jtitle%3DNature%26date%3D2020%26volume%3D584%26spage%3D291%26epage%3D297%26doi%3D10.1038%2Fs41586-020-2545-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klauser, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span> <span> </span><span class="NLM_article-title">Developing covalent protein drugs via proximity-enabled reactive therapeutics</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>182</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">97</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2020.05.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1016%2Fj.cell.2020.05.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=32579975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1KjurfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2020&pages=85-97&author=Q.+Liauthor=Q.+Chenauthor=P.+C.+Klauserauthor=M.+Liauthor=F.+Zhengauthor=N.+Wangauthor=X.+Liauthor=Q.+Zhangauthor=X.+Fuauthor=Q.+Wangauthor=Y.+Xuauthor=L.+Wang&title=Developing+covalent+protein+drugs+via+proximity-enabled+reactive+therapeutics&doi=10.1016%2Fj.cell.2020.05.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Developing Covalent Protein Drugs via Proximity-Enabled Reactive Therapeutics</span></div><div class="casAuthors">Li, Qingke; Chen, Qu; Klauser, Paul C.; Li, Mengyuan; Zheng, Feng; Wang, Nanxi; Li, Xiaoying; Zhang, Qianbing; Fu, Xuemei; Wang, Qian; Xu, Yang; Wang, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-97.e16</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Small mol. covalent drugs provide desirable therapeutic properties over noncovalent ones for treating challenging diseases.  The potential of covalent protein drugs, however, remains unexplored due to protein's inability to bind targets covalently.  We report a proximity-enabled reactive therapeutics (PERx) approach to generate covalent protein drugs.  Through genetic code expansion, a latent bioreactive amino acid fluorosulfate-L-tyrosine (FSY) was incorporated into human programmed cell death protein-1 (PD-1).  Only when PD-1 interacts with PD-L1 did the FSY react with a proximal histidine of PD-L1 selectively, enabling irreversible binding of PD-1 to only PD-L1 in vitro and in vivo.  When administrated in immune-humanized mice, the covalent PD-1(FSY) exhibited strikingly more potent antitumor effect over the noncovalent wild-type PD-1, attaining therapeutic efficacy equiv. or superior to anti-PD-L1 antibody.  PERx should provide a general platform technol. for converting various interacting proteins into covalent binders, achieving specific covalent protein targeting for biol. studies and therapeutic capability unattainable with conventional noncovalent protein drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcj64Nv4lYwrVg90H21EOLACvtfcHk0lhKzrVcmZF8iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1KjurfK&md5=85e16c071ccbb4e5249e359e956a590d</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2020.05.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2020.05.028%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DKlauser%26aufirst%3DP.%2BC.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DZheng%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DFu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26atitle%3DDeveloping%2520covalent%2520protein%2520drugs%2520via%2520proximity-enabled%2520reactive%2520therapeutics%26jtitle%3DCell%26date%3D2020%26volume%3D182%26spage%3D85%26epage%3D97%26doi%3D10.1016%2Fj.cell.2020.05.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 3 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yiqiang OuYang, Jian Gao, Lei Zhao, Junfeng Lu, Haiqing Zhong, Hua Tang, Shuanglong Jin, Lu Yue, Yuezhen Li, Wenjie Guo, Qiang Xu, <span class="NLM_string-name hlFld-ContribAuthor">Yisheng Lai</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Evaluation of o-(Biphenyl-3-ylmethoxy)nitrophenyl Derivatives as PD-1/PD-L1 Inhibitors with Potent Anticancer Efficacy In Vivo. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (11)
                                     , 7646-7666. <a href="https://doi.org/10.1021/acs.jmedchem.1c00370" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00370</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00370&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00370%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BEvaluation%252Bof%252Bo-%252528Biphenyl-3-ylmethoxy%252529nitrophenyl%252BDerivatives%252Bas%252BPD-1%25252FPD-L1%252BInhibitors%252Bwith%252BPotent%252BAnticancer%252BEfficacy%252BIn%252BVivo%26aulast%3DOuYang%26aufirst%3DYiqiang%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D01032021%26date%3D26052021%26volume%3D64%26issue%3D11%26spage%3D7646%26epage%3D7666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christian  Bailly</span>, <span class="hlFld-ContribAuthor ">Xavier  Thuru</span>, <span class="hlFld-ContribAuthor ">Bruno  Quesnel</span>. </span><span class="cited-content_cbyCitation_article-title">Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (12)
                                     , 3034. <a href="https://doi.org/10.3390/cancers13123034" title="DOI URL">https://doi.org/10.3390/cancers13123034</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13123034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13123034%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DSoluble%252BProgrammed%252BDeath%252BLigand-1%252B%252528sPD-L1%252529%25253A%252BA%252BPool%252Bof%252BCirculating%252BProteins%252BImplicated%252Bin%252BHealth%252Band%252BDiseases%26aulast%3DBailly%26aufirst%3DChristian%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D12%26spage%3D3034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Chen</span>, <span class="hlFld-ContribAuthor ">Ke  Wang</span>, <span class="hlFld-ContribAuthor ">Yang  Yang</span>, <span class="hlFld-ContribAuthor ">Xupeng  Huang</span>, <span class="hlFld-ContribAuthor ">Xinyan  Dai</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  Feng</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and structure-activity relationship of programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing a benzo[d]isothiazole scaffold. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>217 </em>, 113377. <a href="https://doi.org/10.1016/j.ejmech.2021.113377" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113377</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113377%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bstructure-activity%252Brelationship%252Bof%252Bprogrammed%252Bcell%252Bdeath-1%25252Fprogrammed%252Bcell%252Bdeath-ligand%252B1%252Binteraction%252Binhibitors%252Bbearing%252Ba%252Bbenzo%25255Bd%25255Disothiazole%252Bscaffold%26aulast%3DChen%26aufirst%3DHao%26date%3D2021%26volume%3D217%26spage%3D113377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/medium/jm0c01362_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01362&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/medium/jm0c01362_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic diagram of the mechanism for the inhibition of human PD-1/PD-L1 pathway in cancer immunotherapy. Activating signals (e.g., IFN-γ) can enable the upregulation of PD-L1 by cancer cells, and PD-1 (expressed in activated tumor-specific T cells) binding to PD-L1 results in immune escape and tumor growth, while inhibitory molecules (e.g., PD-1 or PD-L1 inhibitory mAbs) are able to interfere with the binding interactions of PD-L1 and PD-1, consequently enhancing antitumor immune effects.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01362&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/medium/jm0c01362_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Views of the human PD-1 and human PD-L1 interface. (A) Human PD-1 and human PD-L1 are colored in blue and pink, respectively. (B) Important amino acid residues for the hPD-1/PD-L1 binding interaction are highlighted as sticks: PD-1 (LEU128, Val64, ILE126, ILE134, THR76, GLN75) and PD-L1 (ILE54, TYR56, MET115, TYR123, ARG125).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01362&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/medium/jm0c01362_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical structures of small molecule PD-1/PD-L1 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01362&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/medium/jm0c01362_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Crystal structure of human PD-L1 in complex with compound <b>2</b>.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25,26)</a> (A) Compound <b>2</b> induced the formation of PD-L1 homodimer, as indicated by blue and pink space-filling models. (B) Detailed interactions of ligand (compound <b>2</b>) with the binding cleft of human PD-L1 homodimer. Compound <b>2</b> binds to the hydrophobic binding interface formed at the interface of PD-L1 dimer. All important amino acid residues for the compound <b>2</b>/hPD-L1 interaction are highlighted as sticks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01362&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/medium/jm0c01362_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Rationale for the design of PD-L1 degraders based on pomalidomide and BMS-8. The PROTAC-like molecule consists of a PD-L1 inhibitor (e.g., BMS-8, BMS1233, BMS1198) and a ligand of pomalidomide. Adapted with permission from   <cite><i>European
Journal of Medicinal Chemistry</i></cite> (<a href="https://www.sciencedirect.com/journal/european-journal-of-medicinal-chemistry" class="extLink">https://www.sciencedirect.com/journal/european-journal-of-medicinal-chemistry</a>) <span class="NLM_year">2020</span>, <em>199</em>, 112377;<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Copyright 2020 Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01362&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/medium/jm0c01362_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Design of bifunctional/dual-acting small-molecule PARP1/PD-L1 inhibitors. PARP inhibitors were combined with PD-L1 inhibitors to provide enhanced antitumor activities.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01362&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/medium/jm0c01362_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. HIP1R and the rationalized design of chimeric PD-LYSO peptide targeting PD-L1 for degradation in lysosomes. In the left diagram, the degradation route of PD-L1 is shown, wherein HIP1R targets PD-L1 for lysosomal degradation. PD-L1 distribution in subcellular compartments is also shown. The diagram on the right is a magnified view that shows the molecular roles of PD-LYSO. Briefly, PD-LYSO binds to the intracellular region of PD-L1 by its C-terminal domain, and then the intrinsic sorting signal of lysosomal degradation of PD-L1 was activated by adaptor protein (AP) complexes. Finally, PD-L1 can be internalized to the lysosome by interacting with the ALIX and ESCRT machinery. Adapted with permission from   <cite><i>Nature
Chemical Biology</i></cite> <span class="NLM_year">2019</span>, <em>15</em>, 42–50;<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Copyright 2019 Springer Nature Limited.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01362&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/medium/jm0c01362_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Proposed mechanism for compound <b>13</b> (SA-49)-mediated degradation of PD-L1 by modulating the PKCα-GSK3β cascade to boost lysosomal function. Adapted with permission from   <cite><i>EBioMedicine</i></cite> (<a href="https://www.sciencedirect.com/journal/ebiomedicine" class="extLink">https://www.sciencedirect.com/journal/ebiomedicine</a>) <span class="NLM_year">2019</span>, <em>40</em>, 151–162,<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> published by Elsevier B.V. under license CC BY-NC-ND 4.0 (<a href="http://creativecommons.org/licenses/by-nc-nd/4.0/" class="extLink">http://creativecommons.org/licenses/by-nc-nd/4.0/</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01362&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/medium/jm0c01362_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Mode of action for compound <b>14</b> [(+)-JQ-1]-mediated downregulation of PD-L1. By binding to BRD4, compound <b>14</b> affects the acetylation of CD274 gene and ultimately reduces the PD-L1 expression in cancer cells. Adapted with permission from   <cite><i>Cell Reports</i></cite> <span class="NLM_year">2016</span>, <em>16</em>, 2829–2837,<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> published under license CC BY-NC-ND 4.0 (<a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="extLink">https://creativecommons.org/licenses/by-nc-nd/4.0/</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01362&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/medium/jm0c01362_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Representative small molecule downregulators/degraders of PD-L1 that can reduce PD-L1 expression through affecting the PD-L1 pathway as well as regulatory mechanisms.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01362&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/medium/jm0c01362_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Representative kinase inhibitor-based downregulators of PD-L1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01362&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/medium/jm0c01362_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Mechanism of extracellular and membrane protein degradation by LYTACs. LYTACs act by inducing clathrin-dependent endocytosis via the M6PR (also called IGF2R) and subsequent degradation of the target proteins in lysosomes. CI-M6PR is a cation-independent mannose 6-phosphate receptor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01362&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/medium/jm0c01362_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. PERx strategy to develop covalent protein drugs of PD-1. First, PD-1 protein drugs are modified with a latent bioreactive unnatural amino acid (Uaa, e.g., fluorosulfate-<span class="smallcaps smallerCapital">l</span>-tyrosine). Then, the electrophilic fluorosulfate-<span class="smallcaps smallerCapital">l</span>-tyrosine selectively reacts with a nucleophilic residue (e.g., histidine) in the PD-L1 target. The result is a covalent linkage between the modified PD-1 protein and the target residue. SuFEx, sulfur(VI)-fluoride exchange reaction; PBMCs, peripheral blood mononuclear cells. Adapted with permission from   <cite><i>Cell</i></cite> (<a href="https://www.sciencedirect.com/journal/cell" class="extLink">https://www.sciencedirect.com/journal/cell</a>) <span class="NLM_year">2020</span>, <em>182</em>, 85–97,<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Copyright 2020 Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01362/20201218/images/large/jm0c01362_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01362&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i19">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24240" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24240" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 84 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gittis, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikami, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garboczi, D. N.</span></span> <span> </span><span class="NLM_article-title">The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">3011</span>– <span class="NLM_lpage">3016</span>, <span class="refDoi"> DOI: 10.1073/pnas.0712278105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1073%2Fpnas.0712278105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=18287011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtVSitr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=3011-3016&author=D.+Y.+Linauthor=Y.+Tanakaauthor=M.+Iwasakiauthor=A.+G.+Gittisauthor=H.+P.+Suauthor=B.+Mikamiauthor=T.+Okazakiauthor=T.+Honjoauthor=N.+Minatoauthor=D.+N.+Garboczi&title=The+PD-1%2FPD-L1+complex+resembles+the+antigen-binding+Fv+domains+of+antibodies+and+T+cell+receptors&doi=10.1073%2Fpnas.0712278105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors</span></div><div class="casAuthors">Lin, David Yin-Wei; Tanaka, Yoshimasa; Iwasaki, Masashi; Gittis, Apostolos G.; Su, Hua-Poo; Mikami, Bunzo; Okazaki, Taku; Honjo, Tasuku; Minato, Nagahiro; Garboczi, David N.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3011-3016</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Signaling via the programmed death 1 (PD-1) inhibitory receptor upon binding its ligand, PD-L1, suppresses immune responses against autoantigens and tumors and plays an important role in the maintenance of peripheral immune tolerance.  Release from PD-1 inhibitory signaling revives "exhausted" virus-specific T cells in chronic viral infections.  Here the authors present the crystal structure of murine PD-1 in complex with human PD-L1.  PD-1 and PD-L1 interact through the conserved front and side of their Ig variable (IgV) domains, as do the IgV domains of antibodies and T cell receptors.  This places the loops at the ends of the IgV domains on the same side of the PD-1/PD-L1 complex, forming a surface that is similar to the antigen-binding surface of antibodies and T cell receptors.  Mapping conserved residues allowed the identification of residues that are important in forming the PD-1/PD-L1 interface.  Based on the structure, the authors show that some reported loss-of-binding mutations involve the PD-1/PD-L1 interaction but that others compromise protein folding.  The PD-1/PD-L1 interaction described here may be blocked by antibodies or by designed small-mol. drugs to lower inhibitory signaling that results in a stronger immune response.  The immune receptor-like loops offer a new surface for further study and potentially the design of mols. that would affect PD-1/PD-L1 complex formation and thereby modulate the immune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqbP0BPGxxELVg90H21EOLACvtfcHk0ljmPBhHxQqJAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtVSitr4%253D&md5=5ea708a1fdb0b926d109ec515c9b81cc</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0712278105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0712278105%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DD.%2BY.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DIwasaki%26aufirst%3DM.%26aulast%3DGittis%26aufirst%3DA.%2BG.%26aulast%3DSu%26aufirst%3DH.%2BP.%26aulast%3DMikami%26aufirst%3DB.%26aulast%3DOkazaki%26aufirst%3DT.%26aulast%3DHonjo%26aufirst%3DT.%26aulast%3DMinato%26aufirst%3DN.%26aulast%3DGarboczi%26aufirst%3DD.%2BN.%26atitle%3DThe%2520PD-1%252FPD-L1%2520complex%2520resembles%2520the%2520antigen-binding%2520Fv%2520domains%2520of%2520antibodies%2520and%2520T%2520cell%2520receptors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D3011%26epage%3D3016%26doi%3D10.1073%2Fpnas.0712278105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, Y.</span></span> <span> </span><span class="NLM_article-title">The IFN-gamma/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy</span>. <i>J. Neuroinflammation</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">290</span>, <span class="refDoi"> DOI: 10.1186/s12974-018-1330-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1186%2Fs12974-018-1330-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=30333036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFaisLbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=290&author=J.+Qianauthor=C.+Wangauthor=B.+Wangauthor=J.+Yangauthor=Y.+Wangauthor=F.+Luoauthor=J.+Xuauthor=C.+Zhaoauthor=R.+Liuauthor=Y.+Chu&title=The+IFN-gamma%2FPD-L1+axis+between+T+cells+and+tumor+microenvironment%3A+hints+for+glioma+anti-PD-1%2FPD-L1+therapy&doi=10.1186%2Fs12974-018-1330-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy</span></div><div class="casAuthors">Qian, Jiawen; Wang, Chen; Wang, Bo; Yang, Jiao; Wang, Yuedi; Luo, Feifei; Xu, Junying; Zhao, Chujun; Liu, Ronghua; Chu, Yiwei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroinflammation</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">290</span>CODEN:
                <span class="NLM_cas:coden">JNOEB3</span>;
        ISSN:<span class="NLM_cas:issn">1742-2094</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">PD-L1 is an immune inhibitory receptor ligand that leads to T cell dysfunction and apoptosis by binding to its receptor PD-1, which works in braking inflammatory response and conspiring tumor immune evasion.  However, in gliomas, the cause of PD-L1 expression in the tumor microenvironment is not yet clear.  Besides, auxiliary biomarkers are urgently needed for screening possible responsive glioma patients for anti-PD-1/PD-L1 therapies.  The distribution of tumor-infiltrating T cells and PD-L1 expression was analyzed via immunofluorescence in orthotopic murine glioma model.  The expression of PD-L1 in immune cell populations was detected by flow cytometry.  Data excavated from TCGA LGG/GBM datasets and the Ivy Glioblastoma Atlas Project was used for in silico anal. of the correlation among genes and survival.  The distribution of tumor-infiltrating T cells and PD-L1 expression, which parallels in murine orthotopic glioma model and human glioma microdissections, was interrelated.  The IFN-γ level was pos. correlated with PD-L1 expression in murine glioma.  Further, IFN-γ induces PD-L1 expression on primary cultured microglia, bone marrow-derived macrophages, and GL261 glioma cells in vitro.  Seven IFN-γ-induced genes, namely GBP5, ICAM1, CAMK2D, IRF1, SOCS3, CD44, and CCL2, were selected to calc. as substitute indicator for IFN-γ level.  By combining the relative expression of the listed IFN-γ-induced genes, IFN-γ score was pos. correlated with PD-L1 expression in different anat. structures of human glioma and in glioma of different malignancies.  Our study identified the distribution of tumor-infiltrating T cells and PD-L1 expression in murine glioma model and human glioma samples.  And we found that IFN-γ is an important cause of PD-L1 expression in the glioma microenvironment.  Further, we proposed IFN-γ score aggregated from the expressions of the listed IFN-γ-induced genes as a complementary prognostic indicator for anti-PD-1/PD-L1 therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8rUADz5qf7rVg90H21EOLACvtfcHk0ljmPBhHxQqJAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFaisLbI&md5=1585ebade3417a6f95360f6e4d001cea</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1186%2Fs12974-018-1330-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12974-018-1330-2%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DChu%26aufirst%3DY.%26atitle%3DThe%2520IFN-gamma%252FPD-L1%2520axis%2520between%2520T%2520cells%2520and%2520tumor%2520microenvironment%253A%2520hints%2520for%2520glioma%2520anti-PD-1%252FPD-L1%2520therapy%26jtitle%3DJ.%2520Neuroinflammation%26date%3D2018%26volume%3D15%26spage%3D290%26doi%3D10.1186%2Fs12974-018-1330-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horner, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troncoso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zebala, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DePinho, R. A.</span></span> <span> </span><span class="NLM_article-title">Effective combinatorial immunotherapy for castration-resistant prostate cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>543</i></span>,  <span class="NLM_fpage">728</span>– <span class="NLM_lpage">732</span>, <span class="refDoi"> DOI: 10.1038/nature21676</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1038%2Fnature21676" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=28321130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltVWntbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=543&publication_year=2017&pages=728-732&author=X.+Luauthor=J.+W.+Hornerauthor=E.+Paulauthor=X.+Shangauthor=P.+Troncosoauthor=P.+Dengauthor=S.+Jiangauthor=Q.+Changauthor=D.+J.+Springauthor=P.+Sharmaauthor=J.+A.+Zebalaauthor=D.+Y.+Maedaauthor=Y.+A.+Wangauthor=R.+A.+DePinho&title=Effective+combinatorial+immunotherapy+for+castration-resistant+prostate+cancer&doi=10.1038%2Fnature21676"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Effective combinatorial immunotherapy for castration-resistant prostate cancer</span></div><div class="casAuthors">Lu, Xin; Horner, James W.; Paul, Erin; Shang, Xiaoying; Troncoso, Patricia; Deng, Pingna; Jiang, Shan; Chang, Qing; Spring, Denise J.; Sharma, Padmanee; Zebala, John A.; Maeda, Dean Y.; Wang, Y. Alan; DePinho, Ronald A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">543</span>
        (<span class="NLM_cas:issue">7647</span>),
    <span class="NLM_cas:pages">728-732</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A significant fraction of patients with advanced prostate cancer treated with androgen deprivation therapy experience relapse with relentless progression to lethal metastatic castration-resistant prostate cancer (mCRPC).  Immune checkpoint blockade using antibodies against cytotoxic-T-lymphocyte-assocd. protein 4 (CTLA4) or programmed cell death 1/programmed cell death 1 ligand 1 (PD1/PD-L1) generates durable therapeutic responses in a significant subset of patients across a variety of cancer types.  However, mCRPC showed overwhelming de novo resistance to immune checkpoint blockade, motivating a search for targeted therapies that overcome this resistance.  Myeloid-derived suppressor cells (MDSCs) are known to play important roles in tumor immune evasion.  The abundance of circulating MDSCs correlates with prostate-specific antigen levels and metastasis in patients with prostate cancer.  Mouse models of prostate cancer show that MDSCs (CD11b+Gr1+) promote tumor initiation and progression.  These observations prompted the authors to hypothesize that robust immunotherapy responses in mCRPC may be elicited by the combined actions of immune checkpoint blockade agents together with targeted agents that neutralize MDSCs yet preserve T-cell function.  Here the authors develop a novel chimeric mouse model of mCRPC to efficiently test combination therapies in an autochthonous setting.  Combination of anti-CTLA4 and anti-PD1 engendered only modest efficacy.  Targeted therapy against mCRPC-infiltrating MDSCs, using multi-kinase inhibitors such as cabozantinib and BEZ235, also showed minimal anti-tumor activities.  Strikingly, primary and metastatic CRPC showed robust synergistic responses when immune checkpoint blockade was combined with MDSC-targeted therapy.  Mechanistically, combination therapy efficacy stemmed from the up-regulation of interleukin-1 receptor antagonist and suppression of MDSC-promoting cytokines secreted by prostate cancer cells.  These observations illuminate a clin. path hypothesis for combining immune checkpoint blockade with MDSC-targeted therapies in the treatment of mCRPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh7-q_yEgcWrVg90H21EOLACvtfcHk0lgSMEpLR4eHAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltVWntbg%253D&md5=66daee4919d9beaeb083b73a7e686fe7</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnature21676&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature21676%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DHorner%26aufirst%3DJ.%2BW.%26aulast%3DPaul%26aufirst%3DE.%26aulast%3DShang%26aufirst%3DX.%26aulast%3DTroncoso%26aufirst%3DP.%26aulast%3DDeng%26aufirst%3DP.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DQ.%26aulast%3DSpring%26aufirst%3DD.%2BJ.%26aulast%3DSharma%26aufirst%3DP.%26aulast%3DZebala%26aufirst%3DJ.%2BA.%26aulast%3DMaeda%26aufirst%3DD.%2BY.%26aulast%3DWang%26aufirst%3DY.%2BA.%26aulast%3DDePinho%26aufirst%3DR.%2BA.%26atitle%3DEffective%2520combinatorial%2520immunotherapy%2520for%2520castration-resistant%2520prostate%2520cancer%26jtitle%3DNature%26date%3D2017%26volume%3D543%26spage%3D728%26epage%3D732%26doi%3D10.1038%2Fnature21676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, J.</span></span> <span> </span><span class="NLM_article-title">The systemic activation of programmed death 1-PD-L1 axis protects systemic lupus erythematosus model from nephritis</span>. <i>Am. J. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">379</span>, <span class="refDoi"> DOI: 10.1159/000480641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1159%2F000480641" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=29069649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvV2gsbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2017&pages=371-379&author=W.+Liaoauthor=H.+Zhengauthor=S.+Wuauthor=Y.+Zhangauthor=W.+Wangauthor=Z.+Zhangauthor=C.+Zhouauthor=H.+Wuauthor=J.+Min&title=The+systemic+activation+of+programmed+death+1-PD-L1+axis+protects+systemic+lupus+erythematosus+model+from+nephritis&doi=10.1159%2F000480641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The Systemic Activation of Programmed Death 1-PD-L1 Axis Protects Systemic Lupus Erythematosus Model from Nephritis</span></div><div class="casAuthors">Liao, Wenjun; Zheng, Hua; Wu, Sha; Zhang, Yanmei; Wang, Wei; Zhang, Zili; Zhou, Chenfei; Wu, Hongjun; Min, Jie</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Nephrology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">371-379</span>CODEN:
                <span class="NLM_cas:coden">AJNED9</span>;
        ISSN:<span class="NLM_cas:issn">0250-8095</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Background: Systemic lupus erythematosus (SLE) is characterized by abnormal activated T cells, autoreactive B cells, and massive cytokines.  The CD4+ T cells detd. B-cells differentiation and cytokines prodn.  The programmed death 1 (PD-1) is the checkpoint immunoinhibitory receptor of activated T cells, and its engagement could exhaust T cells.  In this study, we investigated the role of PD-1 systemic engagement with PD-L1-Ig in lupus-like nephritis in SLE mice.  Methods: The murine PD-L1-Ig was injected into SLE-prone mice.  The proteinuria and survival ratio were monitored.  The prodn. of anti-dsDNA autoantibodies and cytokines in serum were measured by ELISA.  The cytokine-producing T cells (interferon-γ, IFN-γ and IL-17α) in kidney and spleen were detected with flowcytometry.  The pathol. evaluation of the Ig deposition in the glomeruliand was detd. with immunofluorescence.  Lymphocytes in 24-h urine were detected with flowcytometry.  Results: The systemic administration of PD-L1-Ig activated PD-1-PD-L1 axis of CD4+ T lymphocytes, suppressed Th17 formation in many organs, including the spleen and the kidney, demolished abnormal prodn. of cytokines (IFN-γ, IL-17, and IL-10) and anti-dsDNA autoantibodies in serum, inhibited IgG deposition in the glomeruli with the decrease of proteinuria, and activated T cells in urine.  Accordingly, the systemic conjugation of PD-L1-PD-1 impaired renal autoimmune injure and prolonged survival time.  Conclusion: Our research demonstrated that the protective function of systemic activation of PD-1-PD-L1 axis with PD-L1-Ig attenuates the nephritis in SLE-prone mice, which facilitates us to understand the suppressive function of PD-1-PD-L1 axis in the pathogenesis and progress of the lupus nephritis, and to explore a possible effective therapeutic strategy to SLE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow--p2nB5yobVg90H21EOLACvtfcHk0lgSMEpLR4eHAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvV2gsbvO&md5=c555ef6c1df4bfdf86d582877e357d98</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1159%2F000480641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000480641%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DW.%26aulast%3DZheng%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DMin%26aufirst%3DJ.%26atitle%3DThe%2520systemic%2520activation%2520of%2520programmed%2520death%25201-PD-L1%2520axis%2520protects%2520systemic%2520lupus%2520erythematosus%2520model%2520from%2520nephritis%26jtitle%3DAm.%2520J.%2520Nephrol.%26date%3D2017%26volume%3D46%26spage%3D371%26epage%3D379%26doi%3D10.1159%2F000480641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, H.</span></span> <span> </span><span class="NLM_article-title">Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy</span>. <i>J. Drug Targeting</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">244</span>, <span class="refDoi"> DOI: 10.1080/1061186X.2018.1440400</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1080%2F1061186X.2018.1440400" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=29448849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtVagsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=244&author=K.+Liauthor=H.+Tian&title=Development+of+small-molecule+immune+checkpoint+inhibitors+of+PD-1%2FPD-L1+as+a+new+therapeutic+strategy+for+tumour+immunotherapy&doi=10.1080%2F1061186X.2018.1440400"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy</span></div><div class="casAuthors">Li, Kui; Tian, Hongqi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Drug Targeting</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">244-256</span>CODEN:
                <span class="NLM_cas:coden">JDTAEH</span>;
        ISSN:<span class="NLM_cas:issn">1026-7158</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Cancer immunotherapy has been increasingly utilized to treat advanced malignancies.  The signalling network of immune checkpoints has attracted considerable attention.  Immune checkpoint inhibitors are revolutionising the treatment options and expectations for patients with cancer.  The reported clin. success of targeting the T-cell immune checkpoint receptors PD-1/PD-L1 has demonstrated the importance of immune modulation.  Indeed, antibodies binding to PD-1 or PD-L1 have shown remarkable efficacy.  However, antibody drugs have many disadvantages, such as their prodn. cost, stability, and immunogenicity and, therefore, small-mol. inhibitors of PD-1 and its ligand PD-L1 are being introduced.  Small-mol. inhibitors could offer inherent advantages in terms of pharmacokinetics and druggability, thereby providing addnl. methods for cancer treatment and achieving better therapeutic effects.  In this review, we first discuss how PD-1/PD-L1-targeting inhibitors modulate the relationship between immune cells and tumor cells in tumor immunotherapy.  Second, we discuss how the immunomodulatory potential of these inhibitors can be exploited via rational combinations with immunotherapy and targeted therapy.  Third, this review is the first to summarise the current clin. and preclin. evidence regarding small-mol. inhibitors of the PD-1/PD-L1 immune checkpoint, considering features and responses related to the tumors and to the host immune system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFV2nDZO10ObVg90H21EOLACvtfcHk0lgSMEpLR4eHAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtVagsLs%253D&md5=faee5edc1f4cc14203c023066e802384</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1080%2F1061186X.2018.1440400&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1061186X.2018.1440400%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DK.%26aulast%3DTian%26aufirst%3DH.%26atitle%3DDevelopment%2520of%2520small-molecule%2520immune%2520checkpoint%2520inhibitors%2520of%2520PD-1%252FPD-L1%2520as%2520a%2520new%2520therapeutic%2520strategy%2520for%2520tumour%2520immunotherapy%26jtitle%3DJ.%2520Drug%2520Targeting%26date%3D2019%26volume%3D27%26spage%3D244%26doi%3D10.1080%2F1061186X.2018.1440400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keir, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butte, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, A. H.</span></span> <span> </span><span class="NLM_article-title">PD-1 and its ligands in tolerance and immunity</span>. <i>Annu. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">677</span>– <span class="NLM_lpage">704</span>, <span class="refDoi"> DOI: 10.1146/annurev.immunol.26.021607.090331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1146%2Fannurev.immunol.26.021607.090331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=18173375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltlWktrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=677-704&author=M.+E.+Keirauthor=M.+J.+Butteauthor=G.+J.+Freemanauthor=A.+H.+Sharpe&title=PD-1+and+its+ligands+in+tolerance+and+immunity&doi=10.1146%2Fannurev.immunol.26.021607.090331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">PD-1 and its ligands in tolerance and immunity</span></div><div class="casAuthors">Keir, Mary E.; Butte, Manish J.; Freeman, Gordon J.; Sharpe, Arlene H.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">677-704</span>CODEN:
                <span class="NLM_cas:coden">ARIMDU</span>;
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Programmed death 1 (PD-1) and its ligands, PD-L1 and PD-L2, deliver inhibitory signals that regulate the balance between T cell activation, tolerance, and immunopathol.  Immune responses to foreign and self-antigens require specific and balanced responses to clear pathogens and tumors and yet maintain tolerance.  Induction and maintenance of T cell tolerance requires PD-1, and its ligand PD-L1 on nonhematopoietic cells can limit effector T cell responses and protect tissues from immune-mediated tissue damage.  The PD-1:PD-L pathway also has been usurped by microorganisms and tumors to attenuate antimicrobial or tumor immunity and facilitate chronic infection and tumor survival.  The identification of B7-1 as an addnl. binding partner for PD-L1, together with the discovery of an inhibitory bidirectional interaction between PD-L1 and B7-1, reveals new ways the B7:CD28 family regulates T cell activation and tolerance.  In this review, we discuss current understanding of the immunoregulatory functions of PD-1 and its ligands and their therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTbTIs2Ruos7Vg90H21EOLACvtfcHk0lj9ru2EGS6BtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltlWktrY%253D&md5=4b9b36a8716b8b1b47b7953f134448cf</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1146%2Fannurev.immunol.26.021607.090331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.immunol.26.021607.090331%26sid%3Dliteratum%253Aachs%26aulast%3DKeir%26aufirst%3DM.%2BE.%26aulast%3DButte%26aufirst%3DM.%2BJ.%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26atitle%3DPD-1%2520and%2520its%2520ligands%2520in%2520tolerance%2520and%2520immunity%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D2008%26volume%3D26%26spage%3D677%26epage%3D704%26doi%3D10.1146%2Fannurev.immunol.26.021607.090331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoos, A.</span></span> <span> </span><span class="NLM_article-title">Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.1038/nrd.2015.35</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1038%2Fnrd.2015.35" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=26965203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVCgsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=235-247&author=A.+Hoos&title=Development+of+immuno-oncology+drugs+-+from+CTLA4+to+PD1+to+the+next+generations&doi=10.1038%2Fnrd.2015.35"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations</span></div><div class="casAuthors">Hoos, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">235-247</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Since the regulatory approval of ipilimumab in 2011, the field of cancer immunotherapy has been experiencing a renaissance.  This success is based on progress in both preclin. and clin. science, including the development of new methods of investigation.  Immuno-oncol. has become a sub-specialty within oncol. owing to its unique science and its potential for substantial and long-term clin. benefit.  Immunotherapy agents do not directly attack the tumor but instead mobilize the immune system - this can be achieved through various approaches that utilize adaptive or innate immunity.  Therefore, immuno-oncol. drug development encompasses a broad range of agents, including antibodies, peptides, proteins, small mols., adjuvants, cytokines, oncolytic viruses, bi-specific mols. and cellular therapies.  This Perspective summarizes the recent history of cancer immunotherapy, including the factors that led to its success, provides an overview of novel drug-development considerations, summarizes three generations of immunotherapies that have been developed since 2011 and, thus, illustrates the breadth of opportunities these new generations of immunotherapies represent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8GBkFRW-5VLVg90H21EOLACvtfcHk0lj9ru2EGS6BtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVCgsLo%253D&md5=547a5ef71cf6e494ea3abeb8b2c2e463</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2015.35&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2015.35%26sid%3Dliteratum%253Aachs%26aulast%3DHoos%26aufirst%3DA.%26atitle%3DDevelopment%2520of%2520immuno-oncology%2520drugs%2520-%2520from%2520CTLA4%2520to%2520PD1%2520to%2520the%2520next%2520generations%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26spage%3D235%26epage%3D247%26doi%3D10.1038%2Fnrd.2015.35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Callahan, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postow, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span> <span> </span><span class="NLM_article-title">Targeting T cell co-receptors for cancer therapy</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">1069</span>– <span class="NLM_lpage">1078</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2016.04.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1016%2Fj.immuni.2016.04.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=27192570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC28XotFarsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=1069-1078&author=M.+K.+Callahanauthor=M.+A.+Postowauthor=J.+D.+Wolchok&title=Targeting+T+cell+co-receptors+for+cancer+therapy&doi=10.1016%2Fj.immuni.2016.04.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting T Cell Co-receptors for Cancer Therapy</span></div><div class="casAuthors">Callahan, Margaret K.; Postow, Michael A.; Wolchok, Jedd D.</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1069-1078</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Checkpoint-blocking antibodies can generate potent anti-tumor responses by encouraging the immune system to seek and destroy cancer cells.  At this time, the United States Food and Drug Administration has approved three checkpoint-blocking antibodies in three disease indications, and addnl. approvals are expected to broaden the clin. scope of immunotherapy.  Herein, we review the clin. development of CTLA-4-, PD-1-, and PD-L1-blocking antibodies across tumor types and briefly discuss areas of active investigation of potential biomarkers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9tM_RjJV5G7Vg90H21EOLACvtfcHk0liZpTlw4lsp1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XotFarsLs%253D&md5=e5e3e3df43520118b3670b514b94e466</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2016.04.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2016.04.023%26sid%3Dliteratum%253Aachs%26aulast%3DCallahan%26aufirst%3DM.%2BK.%26aulast%3DPostow%26aufirst%3DM.%2BA.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26atitle%3DTargeting%2520T%2520cell%2520co-receptors%2520for%2520cancer%2520therapy%26jtitle%3DImmunity%26date%3D2016%26volume%3D44%26spage%3D1069%26epage%3D1078%26doi%3D10.1016%2Fj.immuni.2016.04.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span> <span> </span><span class="NLM_article-title">Immunotherapy: anti-PD-1 therapies-a new first-line option in advanced melanoma</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">625</span>– <span class="NLM_lpage">626</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2015.170</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1038%2Fnrclinonc.2015.170" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=26416151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A280%3ADC%252BC283ms1Wmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=625-626&author=R.+J.+Sullivanauthor=K.+T.+Flaherty&title=Immunotherapy%3A+anti-PD-1+therapies-a+new+first-line+option+in+advanced+melanoma&doi=10.1038%2Fnrclinonc.2015.170"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Immunotherapy: Anti-PD-1 therapies-a new first-line option in advanced melanoma</span></div><div class="casAuthors">Sullivan Ryan J; Flaherty Keith T</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Clinical oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">625-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQkbwjUIJOh8YUSrryheKE6fW6udTcc2ebBO05qj-q6O7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283ms1Wmsg%253D%253D&md5=015a1194cf584003c341b1315faa8669</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2015.170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2015.170%26sid%3Dliteratum%253Aachs%26aulast%3DSullivan%26aufirst%3DR.%2BJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26atitle%3DImmunotherapy%253A%2520anti-PD-1%2520therapies-a%2520new%2520first-line%2520option%2520in%2520advanced%2520melanoma%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D12%26spage%3D625%26epage%3D626%26doi%3D10.1038%2Fnrclinonc.2015.170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimeno, A.</span></span> <span> </span><span class="NLM_article-title">Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1358/dot.2015.51.1.2250387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1358%2Fdot.2015.51.1.2250387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A280%3ADC%252BC2MrmsVyntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=7-20&author=J.+McDermottauthor=A.+Jimeno&title=Pembrolizumab%3A+PD-1+inhibition+as+a+therapeutic+strategy+in+cancer&doi=10.1358%2Fdot.2015.51.1.2250387"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer</span></div><div class="casAuthors">McDermott J; Jimeno A</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-20</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Programmed cell death protein 1 (PD-1) and its ligands, programmed cell death 1 ligand 1 (PD-L1) and 2 (PD-L2) play an important role in regulating immune response through various mechanisms.  This inhibitory action is thought to assist in immune evasion by cancer cells as PD-1, PD-L1 and PD-L2 have been found to be abnormally expressed by tumor cells and lymphocytes in the tumor microenvironment.  Preclinical studies described PD-1 blockade resulting in tumor growth suppression and even decreased metastasis.  This has led to the development of pembrolizumab (MK-3475), a highly selective, humanized monoclonal IgG4-kappa isotype antibody against PD-1.  Early clinical trials have shown high tumor response rates and long duration of effect in previously treated advanced melanoma resulting in accelerated FDA approval for the drug in this situation.  Pembrolizumab has also had success in non-small cell lung cancer and is being tested in multiple other tumor types.  This review will discuss the development, preclinical data, pharmacokinetics and clinical efficacy to date of pembrolizumab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTBBryFJmsYVMuCWE5mhx1RfW6udTcc2ebUmtQdoxuenrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MrmsVyntQ%253D%253D&md5=27520a64818c171071d2dd5b6dfae53d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1358%2Fdot.2015.51.1.2250387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2015.51.1.2250387%26sid%3Dliteratum%253Aachs%26aulast%3DMcDermott%26aufirst%3DJ.%26aulast%3DJimeno%26aufirst%3DA.%26atitle%3DPembrolizumab%253A%2520PD-1%2520inhibition%2520as%2520a%2520therapeutic%2520strategy%2520in%2520cancer%26jtitle%3DDrugs%2520Today%26date%3D2015%26volume%3D51%26spage%3D7%26epage%3D20%26doi%3D10.1358%2Fdot.2015.51.1.2250387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Atezolizumab: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1227</span>– <span class="NLM_lpage">1232</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0618-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1007%2Fs40265-016-0618-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=27412122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOlsbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=1227-1232&author=A.+Markham&title=Atezolizumab%3A+first+global+approval&doi=10.1007%2Fs40265-016-0618-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Atezolizumab: First Global Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1227-1232</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Atezolizumab (Tecentriq)-a monoclonal antibody targeting programmed death ligand 1 (PD-L1 or CD274 antigen)-is being developed by Genentech as treatment for a variety of haematol. malignancies and solid tumors.  It been approved in the US as a second-line therapy for urothelial carcinoma and is awaiting approval as a second-line therapy for non-small cell lung cancer.  This article summarizes the milestones in the development of atezolizumab leading to this first approval for urothelial carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3WAd7EcBi37Vg90H21EOLACvtfcHk0li4cyopOKB56w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOlsbnI&md5=e9c8e579945779e24c9fc74fab967843</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0618-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0618-8%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DAtezolizumab%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D1227%26epage%3D1232%26doi%3D10.1007%2Fs40265-016-0618-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zobniw, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trinh, V. A.</span></span> <span> </span><span class="NLM_article-title">Avelumab: a review of its application in metastatic merkel cell carcinoma</span>. <i>Ann. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">928</span>– <span class="NLM_lpage">935</span>, <span class="refDoi"> DOI: 10.1177/1060028018768809</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1177%2F1060028018768809" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=29616562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVClsL7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2018&pages=928-935&author=J.+Josephauthor=C.+Zobniwauthor=J.+Davisauthor=J.+Andersonauthor=V.+A.+Trinh&title=Avelumab%3A+a+review+of+its+application+in+metastatic+merkel+cell+carcinoma&doi=10.1177%2F1060028018768809"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Avelumab: A Review of Its Application in Metastatic Merkel Cell Carcinoma</span></div><div class="casAuthors">Joseph, Jocelyn; Zobniw, Chrystia; Davis, Jennifer; Anderson, Jaime; Trinh, Van Anh</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Pharmacotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">928-935</span>CODEN:
                <span class="NLM_cas:coden">APHRER</span>;
        ISSN:<span class="NLM_cas:issn">1542-6270</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Objective: To summarize the clin. development of avelumab and its clin. relevance in metastatic Merkel cell carcinoma (MCC).  Data Sources: An English-language literature search using PubMed was performed using the terms avelumab, anti-PD-1, anti-PD-L1, and MCC from Jan. of 1950 to March 2018.  Data were also obtained from package inserts, meeting abstrs., and clin. registries.  Study Selection/Data Extn.: All relevant published articles of avelumab were reviewed.  Clin. trial registries and meeting abstrs. were used for information about ongoing trials.  Data Synthesis: Avelumab is a fully human monoclonal antibody that inhibits programmed death ligand-1, which reverses T-cell exhaustion and induces antitumor responses.  Avelumab is safe and effective in previously treated metastatic MCC based on a phase II trial of previously treated patients with objective response rates in 28 of 88 patients, including 10 complete responses and 19 partial responses.  Median overall survival (OS) was 12.9 mo, and 1-yr progression-free survival and OS were 30% and 52%, resp.  Grade 3 treatment-related side effects included lymphopenia (2 patients), serum creatine phosphokinase increase (1 patient), aminotransferase elevation (1 patient), and serum cholesterol increase (1 patient).  Relevance to Patient Care and Clin. Practice: This review outlines the pharmacol. and clin. trial data for avelumab in metastatic MCC and guides clinicians on avelumab's place in therapy.  Conclusions: Avelumab is the first Food and Drug Administration-approved medication for metastatic MCC and provides an advantage of durable responses and possibly improved tolerability compared with traditional platinum-based chemotherapy.  Clin. trials are under way to expand its utility into the adjuvant and frontline settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokwvc4wyjOSrVg90H21EOLACvtfcHk0liz3K2vNJJSXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVClsL7O&md5=9ffbd68f67e2b4c77c8b440ee4c2a6b4</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1177%2F1060028018768809&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1060028018768809%26sid%3Dliteratum%253Aachs%26aulast%3DJoseph%26aufirst%3DJ.%26aulast%3DZobniw%26aufirst%3DC.%26aulast%3DDavis%26aufirst%3DJ.%26aulast%3DAnderson%26aufirst%3DJ.%26aulast%3DTrinh%26aufirst%3DV.%2BA.%26atitle%3DAvelumab%253A%2520a%2520review%2520of%2520its%2520application%2520in%2520metastatic%2520merkel%2520cell%2520carcinoma%26jtitle%3DAnn.%2520Pharmacother.%26date%3D2018%26volume%3D52%26spage%3D928%26epage%3D935%26doi%3D10.1177%2F1060028018768809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Camacho, L. H.</span></span> <span> </span><span class="NLM_article-title">CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations</span>. <i>Cancer Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">661</span>– <span class="NLM_lpage">672</span>, <span class="refDoi"> DOI: 10.1002/cam4.371</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1002%2Fcam4.371" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=25619164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlCitL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=661-672&author=L.+H.+Camacho&title=CTLA-4+blockade+with+ipilimumab%3A+biology%2C+safety%2C+efficacy%2C+and+future+considerations&doi=10.1002%2Fcam4.371"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations</span></div><div class="casAuthors">Camacho, Luis H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">661-672</span>CODEN:
                <span class="NLM_cas:coden">CMAEDL</span>;
        ISSN:<span class="NLM_cas:issn">2045-7634</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  Melanoma remains a crit. public health problem worldwide.  Patients with stage IV disease have very poor prognosis and their 1-yr survival rate is only 25%.  Until recently, systemic treatments with a pos. impact on overall survival (OS) had remained elusive.  In recent years, the United States Food and Drug Administration (FDA) - approved several novel agents targeting the RAS/RAF/MEK/ERK pathway (vemurafenib, dabrafenib, and trametinib) - crit. in cell division and proliferation of melanoma, and an immune checkpoint inhibitor (ipilimumab) directed against the cytotoxic T lymphocyte Antigen - (CTLA-4).  Moreover, recent reports of clin. trials studying other immune checkpoint modulating agents will most likely result in their FDA approval within the next months.  This review focuses on ipilimumab, its safety and efficacy, and future considerations.  Ipilimumab has demonstrated a pos. OS impact after a several-year follow-up.  It is also recognized that due to its mechanism of action, the response patterns to ipilimumab can differ from those obsd. in patients following treatment with conventional cytotoxic agents and even the most recently approved BRAF inhibitors.  Most patients (84.8%) experience drug-related adverse events (AEs) of any grade; most of these are mild to moderate and immune mediated.  However, a minority of patients may also experience severe and life-threatening AEs.  In clin. studies, AEs were managed according to guidelines that emphasized close clin. monitoring and early use of corticosteroids when appropriate.  Preliminary results have taught us the potential greater toxicity when in combination with vemurafenib, and the greater antitumor efficacy when combined with nivolumab, a monoclonal antibody directed against programmed death receptor-1 (PD-1), another immune checkpoint inhibitor.  Future challenges include the optimization of dosing and toxicities when used as a single agent, and studying the safety and efficacy of combinations with targeted small mols. and other monoclonal antibodies to treat patients with melanoma and other malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqgKhI5zDfRrVg90H21EOLACvtfcHk0liz3K2vNJJSXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlCitL8%253D&md5=c228a867827d6778907e3ee39f4db25c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fcam4.371&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcam4.371%26sid%3Dliteratum%253Aachs%26aulast%3DCamacho%26aufirst%3DL.%2BH.%26atitle%3DCTLA-4%2520blockade%2520with%2520ipilimumab%253A%2520biology%252C%2520safety%252C%2520efficacy%252C%2520and%2520future%2520considerations%26jtitle%3DCancer%2520Med.%26date%3D2015%26volume%3D4%26spage%3D661%26epage%3D672%26doi%3D10.1002%2Fcam4.371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellmann, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoRusso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emens, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodi, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieu, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eder, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleary, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jelovac, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuhako, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrissey, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahrus, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirzkall, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, L. S.</span></span> <span> </span><span class="NLM_article-title">A Phase 1b dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-1 (atezolizumab) in patients with locally advanced or metastatic solid tumors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.35.15_suppl.105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1200%2FJCO.2017.35.15_suppl.105" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=105-105&author=H.+A.+Burrisauthor=M.+Gordonauthor=M.+D.+Hellmannauthor=P.+LoRussoauthor=L.+A.+Emensauthor=F.+S.+Hodiauthor=H.+C.+Lieuauthor=J.+R.+Infanteauthor=Y.+F.+Tsaiauthor=J.+P.+Ederauthor=J.+M.+Clearyauthor=D.+Jelovacauthor=A.+L.+Tsuhakoauthor=L.+Muellerauthor=R.+Linauthor=K.+Morrisseyauthor=S.+Mahrusauthor=R.+Morleyauthor=A.+Pirzkallauthor=L.+S.+Davis&title=A+Phase+1b+dose+escalation+study+of+combined+inhibition+of+IDO1+%28GDC-0919%29+and+PD-1+%28atezolizumab%29+in+patients+with+locally+advanced+or+metastatic+solid+tumors&doi=10.1200%2FJCO.2017.35.15_suppl.105"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.35.15_suppl.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.35.15_suppl.105%26sid%3Dliteratum%253Aachs%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DGordon%26aufirst%3DM.%26aulast%3DHellmann%26aufirst%3DM.%2BD.%26aulast%3DLoRusso%26aufirst%3DP.%26aulast%3DEmens%26aufirst%3DL.%2BA.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26aulast%3DLieu%26aufirst%3DH.%2BC.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DTsai%26aufirst%3DY.%2BF.%26aulast%3DEder%26aufirst%3DJ.%2BP.%26aulast%3DCleary%26aufirst%3DJ.%2BM.%26aulast%3DJelovac%26aufirst%3DD.%26aulast%3DTsuhako%26aufirst%3DA.%2BL.%26aulast%3DMueller%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DR.%26aulast%3DMorrissey%26aufirst%3DK.%26aulast%3DMahrus%26aufirst%3DS.%26aulast%3DMorley%26aufirst%3DR.%26aulast%3DPirzkall%26aufirst%3DA.%26aulast%3DDavis%26aufirst%3DL.%2BS.%26atitle%3DA%2520Phase%25201b%2520dose%2520escalation%2520study%2520of%2520combined%2520inhibition%2520of%2520IDO1%2520%2528GDC-0919%2529%2520and%2520PD-1%2520%2528atezolizumab%2529%2520in%2520patients%2520with%2520locally%2520advanced%2520or%2520metastatic%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26spage%3D105%26epage%3D105%26doi%3D10.1200%2FJCO.2017.35.15_suppl.105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brahmer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammers, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipson, E. J.</span></span> <span> </span><span class="NLM_article-title">Nivolumab: targeting PD-1 to bolster antitumor immunity</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1307</span>– <span class="NLM_lpage">1326</span>, <span class="refDoi"> DOI: 10.2217/fon.15.52</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.2217%2Ffon.15.52" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=25798726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotFait7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=1307-1326&author=J.+R.+Brahmerauthor=H.+Hammersauthor=E.+J.+Lipson&title=Nivolumab%3A+targeting+PD-1+to+bolster+antitumor+immunity&doi=10.2217%2Ffon.15.52"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Nivolumab: targeting PD-1 to bolster antitumor immunity</span></div><div class="casAuthors">Brahmer, Julie R.; Hammers, Hans; Lipson, Evan J.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1307-1326</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">Nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, blocks PD-1 and can restore anticancer immune responses by abrogating PD-1 pathway-mediated T-cell inhibition.  Nivolumab is approved in Japan and the USA for the treatment of patients with advanced melanoma.  A Phase I trial reported overall objective response rates of 17, 32 and 29% in patients with advanced non-small-cell lung cancer, melanoma and renal cell carcinoma, resp., which included many heavily pretreated patients. 1-/2-yr overall survival rates were 42%/24%, 63%/48% and 70%/50% for non-small-cell lung cancer, melanoma and renal cell carcinoma, resp.  Nivolumab significantly improved survival vs. dacarbazine in previously untreated patients with metastatic melanoma in a Phase III trial.  Nivolumab is assocd. with a manageable adverse event profile.  Numerous clin. trials are investigating nivolumab alone or in combination with other therapies in multiple cancer settings.  This article summarizes the development of nivolumab as of Nov. 2014.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxyOwDIZFMy7Vg90H21EOLACvtfcHk0lj1sc8DSKWBzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotFait7g%253D&md5=674728e6f32246799ce0c8738405ace6</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.2217%2Ffon.15.52&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.15.52%26sid%3Dliteratum%253Aachs%26aulast%3DBrahmer%26aufirst%3DJ.%2BR.%26aulast%3DHammers%26aufirst%3DH.%26aulast%3DLipson%26aufirst%3DE.%2BJ.%26atitle%3DNivolumab%253A%2520targeting%2520PD-1%2520to%2520bolster%2520antitumor%2520immunity%26jtitle%3DFuture%2520Oncol.%26date%3D2015%26volume%3D11%26spage%3D1307%26epage%3D1326%26doi%3D10.2217%2Ffon.15.52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonia, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villegas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicente, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiappori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Wit, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourhaba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quantin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mekhail, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karapetis, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiret, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostoros, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubota, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz-Ares, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Castro Carpeno, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadsworth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melillo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozguroglu, M.</span></span> <span> </span><span class="NLM_article-title">Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">1919</span>– <span class="NLM_lpage">1929</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1709937</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1056%2FNEJMoa1709937" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=28885881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktVOr" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=1919-1929&author=S.+J.+Antoniaauthor=A.+Villegasauthor=D.+Danielauthor=D.+Vicenteauthor=S.+Murakamiauthor=R.+Huiauthor=T.+Yokoiauthor=A.+Chiapporiauthor=K.+H.+Leeauthor=M.+de+Witauthor=B.+C.+Choauthor=M.+Bourhabaauthor=X.+Quantinauthor=T.+Tokitoauthor=T.+Mekhailauthor=D.+Planchardauthor=Y.+C.+Kimauthor=C.+S.+Karapetisauthor=S.+Hiretauthor=G.+Ostorosauthor=K.+Kubotaauthor=J.+E.+Grayauthor=L.+Paz-Aresauthor=J.+de+Castro+Carpenoauthor=C.+Wadsworthauthor=G.+Melilloauthor=H.+Jiangauthor=Y.+Huangauthor=P.+A.+Dennisauthor=M.+Ozguroglu&title=Durvalumab+after+chemoradiotherapy+in+stage+III+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa1709937"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer</span></div><div class="casAuthors">Antonia, S. J.; Villegas, A.; Daniel, D.; Vicente, D.; Murakami, S.; Hui, R.; Yokoi, T.; Chiappori, A.; Lee, K. H.; de Wit, M.; Cho, B. C.; Bourhaba, M.; Quantin, X.; Tokito, T.; Mekhail, T.; Planchard, D.; Kim, Y.-C.; Karapetis, C. S.; Hiret, S.; Ostoros, G.; Kubota, K.; Gray, J. E.; Paz-Ares, L.; de Castro Carpeno, J.; Wadsworth, C.; Melillo, G.; Jiang, H.; Huang, Y.; Dennis, P. A.; Ozguroglu, M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1919-1929</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Most patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy).  This phase 3 study compared the anti-programmed death ligand 1 antibody durvalumab as consolidation therapy with placebo in patients with stage III NSCLC who did not have disease progression after two or more cycles of platinum-based chemoradiotherapy.  Methods: We randomly assigned patients, in a 2:1 ratio, to receive durvalumab (at a dose of 10 mg per kg of body wt. i.v.) or placebo every 2 wk for up to 12 mo.  The study drug was administered 1 to 42 days after the patients had received chemoradiotherapy.  The coprimary end points were progression-free survival (as assessed by means of blinded independent central review) and overall survival (unplanned for the interim anal.).  Secondary end points included 12-mo and 18-mo progression-free survival rates, the objective response rate, the duration of response, the time to death or distant metastasis, and safety.  Results: Of 713 patients who underwent randomization, 709 received consolidation therapy (473 received durvalumab and 236 received placebo).  The median progression-free survival from randomization was 16.8 mo (95% confidence interval [CI], 13.0 to 18.1) with durvalumab vs. 5.6 mo (95% CI, 4.6 to 7.8) with placebo (stratified hazard ratio for disease progression or death, 0.52; 95% CI, 0.42 to 0.65; P<0.001); the 12-mo progression-free survival rate was 55.9% vs. 35.3%, and the 18-mo progression-free survival rate was 44.2% vs. 27.0%.  The response rate was higher with durvalumab than with placebo (28.4% vs. 16.0%; P<0.001), and the median duration of response was longer (72.8% vs. 46.8% of the patients had an ongoing response at 18 mo).  The median time to death or distant metastasis was longer with durvalumab than with placebo (23.2 mo vs. 14.6 mo; P<0.001).  Grade 3 or 4 adverse events occurred in 29.9% of the patients who received durvalumab and 26.1% of those who received placebo; the most common adverse event of grade 3 or 4 was pneumonia (4.4% and 3.8%, resp.).  A total of 15.4% of patients in the durvalumab group and 9.8% of those in the placebo group discontinued the study drug because of adverse events.  Conclusions: Progression-free survival was significantly longer with durvalumab than with placebo.  The secondary end points also favored durvalumab, and safety was similar between the groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLr5-R3gHtVbVg90H21EOLACvtfcHk0lhv2g4zF8D84g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktVOr&md5=95be11a1c165acdc826c4ee049a5f010</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1709937&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1709937%26sid%3Dliteratum%253Aachs%26aulast%3DAntonia%26aufirst%3DS.%2BJ.%26aulast%3DVillegas%26aufirst%3DA.%26aulast%3DDaniel%26aufirst%3DD.%26aulast%3DVicente%26aufirst%3DD.%26aulast%3DMurakami%26aufirst%3DS.%26aulast%3DHui%26aufirst%3DR.%26aulast%3DYokoi%26aufirst%3DT.%26aulast%3DChiappori%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3Dde%2BWit%26aufirst%3DM.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DBourhaba%26aufirst%3DM.%26aulast%3DQuantin%26aufirst%3DX.%26aulast%3DTokito%26aufirst%3DT.%26aulast%3DMekhail%26aufirst%3DT.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DY.%2BC.%26aulast%3DKarapetis%26aufirst%3DC.%2BS.%26aulast%3DHiret%26aufirst%3DS.%26aulast%3DOstoros%26aufirst%3DG.%26aulast%3DKubota%26aufirst%3DK.%26aulast%3DGray%26aufirst%3DJ.%2BE.%26aulast%3DPaz-Ares%26aufirst%3DL.%26aulast%3Dde%2BCastro%2BCarpeno%26aufirst%3DJ.%26aulast%3DWadsworth%26aufirst%3DC.%26aulast%3DMelillo%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DDennis%26aufirst%3DP.%2BA.%26aulast%3DOzguroglu%26aufirst%3DM.%26atitle%3DDurvalumab%2520after%2520chemoradiotherapy%2520in%2520stage%2520III%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26spage%3D1919%26epage%3D1929%26doi%3D10.1056%2FNEJMoa1709937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wargo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuben, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, R. J.</span></span> <span> </span><span class="NLM_article-title">Immune effects of chemotherapy, radiation, and targeted therapy and opportunities for combination with immunotherapy</span>. <i>Semin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">601</span>– <span class="NLM_lpage">616</span>, <span class="refDoi"> DOI: 10.1053/j.seminoncol.2015.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1053%2Fj.seminoncol.2015.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=26320064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2mur3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2015&pages=601-616&author=J.+A.+Wargoauthor=A.+Reubenauthor=Z.+A.+Cooperauthor=K.+S.+Ohauthor=R.+J.+Sullivan&title=Immune+effects+of+chemotherapy%2C+radiation%2C+and+targeted+therapy+and+opportunities+for+combination+with+immunotherapy&doi=10.1053%2Fj.seminoncol.2015.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy</span></div><div class="casAuthors">Wargo, Jennifer A.; Reuben, Alexandre; Cooper, Zachary A.; Oh, Kevin S.; Sullivan, Ryan J.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">601-616</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">There have been significant advances in cancer treatment over the past several years through the use of chemotherapy, radiation therapy, molecularly targeted therapy, and immunotherapy.  Despite these advances, treatments such as monotherapy or monomodality have significant limitations.  There is increasing interest in using these strategies in combination; however, it is not completely clear how best to incorporate molecularly targeted and immune-targeted therapies into combination regimens.  This is particularly pertinent when considering combinations with immunotherapy, as other types of therapy may have significant impact on host immunity, the tumor microenvironment, or both.  Thus, the influence of chemotherapy, radiation therapy, and molecularly targeted therapy on the host anti-tumor immune response and the host anti-host response (ie, autoimmune toxicity) must be taken into consideration when designing immunotherapy-based combination regimens.  We present data related to many of these combination approaches in the context of investigations in patients with melanoma and discuss their potential relationship to management of patients with other tumor types.  Importantly, we also highlight challenges of these approaches and emphasize the need for continued translational research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeTH_CMJTqsLVg90H21EOLACvtfcHk0lhv2g4zF8D84g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2mur3K&md5=5c1e42a15655f8d796e35d54b7412c5f</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1053%2Fj.seminoncol.2015.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.seminoncol.2015.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DWargo%26aufirst%3DJ.%2BA.%26aulast%3DReuben%26aufirst%3DA.%26aulast%3DCooper%26aufirst%3DZ.%2BA.%26aulast%3DOh%26aufirst%3DK.%2BS.%26aulast%3DSullivan%26aufirst%3DR.%2BJ.%26atitle%3DImmune%2520effects%2520of%2520chemotherapy%252C%2520radiation%252C%2520and%2520targeted%2520therapy%2520and%2520opportunities%2520for%2520combination%2520with%2520immunotherapy%26jtitle%3DSemin.%2520Oncol.%26date%3D2015%26volume%3D42%26spage%3D601%26epage%3D616%26doi%3D10.1053%2Fj.seminoncol.2015.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vladimer, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snijder, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krall, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigenzahn, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, K. V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lardeau, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanjiv, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berglund, U. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Fuente, O. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knobl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubicek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helleday, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jager, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Superti-Furga, G.</span></span> <span> </span><span class="NLM_article-title">Global survey of the immunomodulatory potential of common drugs</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">681</span>– <span class="NLM_lpage">690</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1038%2Fnchembio.2360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=28437395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvVCltbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=681-690&author=G.+I.+Vladimerauthor=B.+Snijderauthor=N.+Krallauthor=J.+W.+Bigenzahnauthor=K.+V.+M.+Huberauthor=C.+H.+Lardeauauthor=K.+Sanjivauthor=A.+Ringlerauthor=U.+W.+Berglundauthor=M.+Sablerauthor=O.+L.+de+la+Fuenteauthor=P.+Knoblauthor=S.+Kubicekauthor=T.+Helledayauthor=U.+Jagerauthor=G.+Superti-Furga&title=Global+survey+of+the+immunomodulatory+potential+of+common+drugs&doi=10.1038%2Fnchembio.2360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Global survey of the immunomodulatory potential of common drugs</span></div><div class="casAuthors">Vladimer, Gregory I.; Snijder, Berend; Krall, Nikolaus; Bigenzahn, Johannes W.; Huber, Kilian V. M.; Lardeau, Charles-Hugues; Sanjiv, Kumar; Ringler, Anna; Berglund, Ulrika Warpman; Sabler, Monika; de la Fuente, Oscar Lopez; Knoebl, Paul; Kubicek, Stefan; Helleday, Thomas; Jaeger, Ulrich; Superti-Furga, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">681-690</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. drugs may complement antibody-based therapies in an immune-oncol. setting, yet systematic methods for the identification and characterization of the immunomodulatory properties of these entities are lacking.  We surveyed the immumomodulatory potential of 1,402 small chem. mols., as defined by their ability to alter the cell-cell interactions among peripheral mononuclear leukocytes ex vivo, using automated microscopy and population-wide single-cell image anal.  Unexpectedly, ∼10% of the agents tested affected these cell-cell interactions differentially.  The results accurately recapitulated known immunomodulatory drug classes and revealed several clin. approved drugs that unexpectedly harbor the ability to modulate the immune system, which could potentially contribute to their physiol. mechanism of action.  For instance, the kinase inhibitor crizotinib promoted T cell interactions with monocytes, as well as with cancer cells, through inhibition of the receptor tyrosine kinase MSTR1 and subsequent upregulation of the expression of major histocompatibility complex mols.  The approach offers an attractive platform for the personalized identification and characterization of immunomodulatory therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXf0_7KFGbY7Vg90H21EOLACvtfcHk0lhv2g4zF8D84g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvVCltbg%253D&md5=c177974d4daf99d7a40b5c2a73c6504a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2360%26sid%3Dliteratum%253Aachs%26aulast%3DVladimer%26aufirst%3DG.%2BI.%26aulast%3DSnijder%26aufirst%3DB.%26aulast%3DKrall%26aufirst%3DN.%26aulast%3DBigenzahn%26aufirst%3DJ.%2BW.%26aulast%3DHuber%26aufirst%3DK.%2BV.%2BM.%26aulast%3DLardeau%26aufirst%3DC.%2BH.%26aulast%3DSanjiv%26aufirst%3DK.%26aulast%3DRingler%26aufirst%3DA.%26aulast%3DBerglund%26aufirst%3DU.%2BW.%26aulast%3DSabler%26aufirst%3DM.%26aulast%3Dde%2Bla%2BFuente%26aufirst%3DO.%2BL.%26aulast%3DKnobl%26aufirst%3DP.%26aulast%3DKubicek%26aufirst%3DS.%26aulast%3DHelleday%26aufirst%3DT.%26aulast%3DJager%26aufirst%3DU.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26atitle%3DGlobal%2520survey%2520of%2520the%2520immunomodulatory%2520potential%2520of%2520common%2520drugs%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D13%26spage%3D681%26epage%3D690%26doi%3D10.1038%2Fnchembio.2360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span> <span> </span><span class="NLM_article-title">Cancer immunotherapy using checkpoint blockade</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>359</i></span>,  <span class="NLM_fpage">1350</span>– <span class="NLM_lpage">1355</span>, <span class="refDoi"> DOI: 10.1126/science.aar4060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1126%2Fscience.aar4060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=29567705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltFehtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=2018&pages=1350-1355&author=A.+Ribasauthor=J.+D.+Wolchok&title=Cancer+immunotherapy+using+checkpoint+blockade&doi=10.1126%2Fscience.aar4060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer immunotherapy using checkpoint blockade</span></div><div class="casAuthors">Ribas, Antoni; Wolchok, Jedd D.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">359</span>
        (<span class="NLM_cas:issue">6382</span>),
    <span class="NLM_cas:pages">1350-1355</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  The release of neg. regulators of immune activation (immune checkpoints) that limit antitumor responses has resulted in unprecedented rates of long-lasting tumor responses in patients with a variety of cancers.  This can be achieved by antibodies blocking the cytotoxic T lymphocyte-assocd. protein 4 (CTLA-4) or the programmed cell death 1 (PD-1) pathway, either alone or in combination.  The main premise for inducing an immune response is the preexistence of antitumor T cells that were limited by specific immune checkpoints.  Most patients who have tumor responses maintain long-lasting disease control, yet one-third of patients relapse.  Mechanisms of acquired resistance are currently poorly understood, but evidence points to alterations that converge on the antigen presentation and interferon-γ signaling pathways.  New-generation combinatorial therapies may overcome resistance mechanisms to immune checkpoint therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHaFGKqeFnWLVg90H21EOLACvtfcHk0liOKdb7lBsEtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltFehtb8%253D&md5=65120662af8a2c63425212b07e423939</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1126%2Fscience.aar4060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aar4060%26sid%3Dliteratum%253Aachs%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26atitle%3DCancer%2520immunotherapy%2520using%2520checkpoint%2520blockade%26jtitle%3DScience%26date%3D2018%26volume%3D359%26spage%3D1350%26epage%3D1355%26doi%3D10.1126%2Fscience.aar4060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patchett, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darby, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tovar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, G. M.</span></span> <span> </span><span class="NLM_article-title">The immunomodulatory small molecule imiquimod induces apoptosis in devil facial tumour cell lines</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e0168068</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0168068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1371%2Fjournal.pone.0168068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=27936237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktFaju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0168068&author=A.+L.+Patchettauthor=J.+M.+Darbyauthor=C.+Tovarauthor=A.+B.+Lyonsauthor=G.+M.+Woods&title=The+immunomodulatory+small+molecule+imiquimod+induces+apoptosis+in+devil+facial+tumour+cell+lines&doi=10.1371%2Fjournal.pone.0168068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The immunomodulatory small molecule imiquimod induces apoptosis in devil facial tumour cell lines</span></div><div class="casAuthors">Patchett, Amanda L.; Darby, Jocelyn M.; Tovar, Cesar; Lyons, A. Bruce; Woods, Gregory M.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e0168068/1-e0168068/17</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The survival of the Tasmanian devil (Sarcophilus harrisii) is threatened by devil facial tumor disease (DFTD).  This transmissible cancer is usually fatal, and no successful treatments have been developed.  In human studies, the small immunomodulatory mol. imiquimod is a successful immunotherapy, activating anti-tumor immunity via stimulation of toll-like receptor-7 (TLR7) signaling pathways.  In addn., imiquimod is a potent inducer of apoptosis in human tumor cell lines via TLR7 independent mechanisms.  Here we investigate the potential of imiquimod as a DFTD therapy through anal. of treated DFTD cell lines and Tasmanian devil fibroblasts.  WST-8 proliferation assays and annexin V apoptosis assays were performed to monitor apoptosis, and changes to the expression of pro- and anti-apoptotic genes were analyzed using qRT-PCR.  Our results show that DFTD cell lines, but not Tasmanian devil fibroblasts, are sensitive to imiquimod-induced apoptosis in a time and concn. dependent manner.  Induction of apoptosis was accompanied by down-regulation of the anti-apoptotic BCL2 and BCLXL genes, and up-regulation of the pro-apoptotic BIM gene.  Continuous imiquimod treatment was required for these effects to occur.  These results demonstrate that imiquimod can deregulate DFTD cell growth and survival in direct and targeted manner.  In vivo, this may increase DFTD vulnerability to imiquimod-induced TLR7-mediated immune responses.  Our findings have improved the current knowledge of imiquimod action in tumor cells for application to both DFTD and human cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh6ZLveszvALVg90H21EOLACvtfcHk0liOKdb7lBsEtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktFaju7g%253D&md5=7b8680a2ae9eb801ac44b73e874eb218</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0168068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0168068%26sid%3Dliteratum%253Aachs%26aulast%3DPatchett%26aufirst%3DA.%2BL.%26aulast%3DDarby%26aufirst%3DJ.%2BM.%26aulast%3DTovar%26aufirst%3DC.%26aulast%3DLyons%26aufirst%3DA.%2BB.%26aulast%3DWoods%26aufirst%3DG.%2BM.%26atitle%3DThe%2520immunomodulatory%2520small%2520molecule%2520imiquimod%2520induces%2520apoptosis%2520in%2520devil%2520facial%2520tumour%2520cell%2520lines%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0168068%26doi%3D10.1371%2Fjournal.pone.0168068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ni, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassady, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, D.</span></span> <span> </span><span class="NLM_article-title">PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">1960</span>– <span class="NLM_lpage">1977</span>, <span class="refDoi"> DOI: 10.1172/JCI91138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1172%2FJCI91138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=28414296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A280%3ADC%252BC1cvotlShtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2017&pages=1960-1977&author=X.+Niauthor=Q.+Songauthor=K.+Cassadyauthor=R.+Dengauthor=H.+Jinauthor=M.+Zhangauthor=H.+Dongauthor=S.+Formanauthor=P.+J.+Martinauthor=Y.+Z.+Chenauthor=J.+Wangauthor=D.+Zeng&title=PD-L1+interacts+with+CD80+to+regulate+graft-versus-leukemia+activity+of+donor+CD8%2B+T+cells&doi=10.1172%2FJCI91138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells</span></div><div class="casAuthors">Ni Xiong; Song Qingxiao; Cassady Kaniel; Deng Ruishu; Jin Hua; Zhang Mingfeng; Dong Haidong; Forman Stephen; Martin Paul J; Chen Yuan-Zhong; Wang Jianmin; Zeng Defu</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1960-1977</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Programmed death ligand-1 (PD-L1) interacts with programmed death-1 (PD-1) and the immunostimulatory molecule CD80 and functions as a checkpoint to regulate immune responses.  The interaction of PD-L1 with CD80 alone has been shown to exacerbate the severity of graft-versus-host disease (GVHD), whereas costimulation of CD80 and PD-1 ameliorates GVHD.  Here we have demonstrated that temporary depletion of donor CD4+ T cells early after hematopoietic cell transplantation effectively prevents GVHD while preserving strong graft-versus-leukemia (GVL) effects in allogeneic and xenogeneic murine GVHD models.  Depletion of donor CD4+ T cells increased serum IFN-γ but reduced IL-2 concentrations, leading to upregulation of PD-L1 expression by recipient tissues and donor CD8+ T cells.  In GVHD target tissues, the interactions of PD-L1 with PD-1 on donor CD8+ T cells cause anergy, exhaustion, and apoptosis, thereby preventing GVHD.  In lymphoid tissues, the interactions of PD-L1 with CD80 augment CD8+ T cell expansion without increasing anergy, exhaustion, or apoptosis, resulting in strong GVL effects.  These results indicate that the outcome of PD-L1-mediated signaling in CD8+ T cells depends on the presence or absence of CD4+ T cells, the nature of the interacting receptor expressed by CD8+ T cells, and the tissue environment in which the signaling occurs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRj4Yk771GSWjDnmmyUf5qOfW6udTcc2ebysoXGObjVnrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvotlShtQ%253D%253D&md5=39c5a3f1375dafd766a0ad4952f27dca</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1172%2FJCI91138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI91138%26sid%3Dliteratum%253Aachs%26aulast%3DNi%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DQ.%26aulast%3DCassady%26aufirst%3DK.%26aulast%3DDeng%26aufirst%3DR.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DForman%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DP.%2BJ.%26aulast%3DChen%26aufirst%3DY.%2BZ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DD.%26atitle%3DPD-L1%2520interacts%2520with%2520CD80%2520to%2520regulate%2520graft-versus-leukemia%2520activity%2520of%2520donor%2520CD8%252B%2520T%2520cells%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2017%26volume%3D127%26spage%3D1960%26epage%3D1977%26doi%3D10.1172%2FJCI91138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krupka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kufer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kischel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zugmaier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtenegger, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohnke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vick, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeremias, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metzeler, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiegl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiekermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauerle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiddemann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riethmuller, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subklewe, M.</span></span> <span> </span><span class="NLM_article-title">Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">484</span>– <span class="NLM_lpage">491</span>, <span class="refDoi"> DOI: 10.1038/leu.2015.214</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1038%2Fleu.2015.214" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=26239198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVWgtr%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=484-491&author=C.+Krupkaauthor=P.+Kuferauthor=R.+Kischelauthor=G.+Zugmaierauthor=F.+S.+Lichteneggerauthor=T.+Kohnkeauthor=B.+Vickauthor=I.+Jeremiasauthor=K.+H.+Metzelerauthor=T.+Altmannauthor=S.+Schneiderauthor=M.+Fieglauthor=K.+Spiekermannauthor=P.+A.+Bauerleauthor=W.+Hiddemannauthor=G.+Riethmullerauthor=M.+Subklewe&title=Blockade+of+the+PD-1%2FPD-L1+axis+augments+lysis+of+AML+cells+by+the+CD33%2FCD3+BiTE+antibody+construct+AMG+330%3A+reversing+a+T-cell-induced+immune+escape+mechanism&doi=10.1038%2Fleu.2015.214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism</span></div><div class="casAuthors">Krupka, C.; Kufer, P.; Kischel, R.; Zugmaier, G.; Lichtenegger, F. S.; Koehnke, T.; Vick, B.; Jeremias, I.; Metzeler, K. H.; Altmann, T.; Schneider, S.; Fiegl, M.; Spiekermann, K.; Bauerle, P. A.; Hiddemann, W.; Riethmueller, G.; Subklewe, M.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">484-491</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bispecific T-cell engagers (BiTEs) are very effective in recruiting and activating T cells.  We tested the cytotoxicity of the CD33/CD3 BiTE antibody construct AMG 330 on primary acute myeloid leukemia (AML) cells ex vivo and characterized parameters contributing to antileukemic cytolytic activity.  The E:T ratio and the CD33 expression level significantly influenced lysis kinetics in long-term cultures of primary AML cells (n=38).  AMG 330 induced T-cell-mediated proinflammatory conditions, favoring the upregulation of immune checkpoints on target and effector cells.  Although not constitutively expressed at the time of primary diagnosis (n=123), PD-L1 was strongly upregulated on primary AML cells upon AMG 330 addn. to ex vivo cultures (n=27, P<0.0001).  This phenomenon was cytokine-driven as the sole addn. of interferon (IFN)-γ and tumor necrosis factor-α also induced expression.  Through blockade of the PD-1/PD-L1 interaction, AMG 330-mediated lysis (n=9, P=0.03), T-cell proliferation (n=9, P=0.01) and IFN-γ secretion (n=8, P=0.008) were significantly enhanced.  The combinatorial approach was most beneficial in settings of protracted AML cell lysis.  Taken together, we have characterized a crit. resistance mechanism employed by primary AML cells under AMG 330-mediated proinflammatory conditions.  Our results support the evaluation of checkpoint mols. in upcoming clin. trials with AMG 330 to enhance BiTE antibody construct-mediated cytotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY6o4l8H8hXbVg90H21EOLACvtfcHk0lhMzLmYIlf13w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVWgtr%252FF&md5=c7cdddb37f2e034cdfde250a0aaf6ed0</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fleu.2015.214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2015.214%26sid%3Dliteratum%253Aachs%26aulast%3DKrupka%26aufirst%3DC.%26aulast%3DKufer%26aufirst%3DP.%26aulast%3DKischel%26aufirst%3DR.%26aulast%3DZugmaier%26aufirst%3DG.%26aulast%3DLichtenegger%26aufirst%3DF.%2BS.%26aulast%3DKohnke%26aufirst%3DT.%26aulast%3DVick%26aufirst%3DB.%26aulast%3DJeremias%26aufirst%3DI.%26aulast%3DMetzeler%26aufirst%3DK.%2BH.%26aulast%3DAltmann%26aufirst%3DT.%26aulast%3DSchneider%26aufirst%3DS.%26aulast%3DFiegl%26aufirst%3DM.%26aulast%3DSpiekermann%26aufirst%3DK.%26aulast%3DBauerle%26aufirst%3DP.%2BA.%26aulast%3DHiddemann%26aufirst%3DW.%26aulast%3DRiethmuller%26aufirst%3DG.%26aulast%3DSubklewe%26aufirst%3DM.%26atitle%3DBlockade%2520of%2520the%2520PD-1%252FPD-L1%2520axis%2520augments%2520lysis%2520of%2520AML%2520cells%2520by%2520the%2520CD33%252FCD3%2520BiTE%2520antibody%2520construct%2520AMG%2520330%253A%2520reversing%2520a%2520T-cell-induced%2520immune%2520escape%2520mechanism%26jtitle%3DLeukemia%26date%3D2016%26volume%3D30%26spage%3D484%26epage%3D491%26doi%3D10.1038%2Fleu.2015.214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span> <span> </span><span class="NLM_article-title">Small-molecule targets in tumor immunotherapy</span>. <i>Nat. Prod. Bioprospect.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">297</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1007/s13659-018-0177-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1007%2Fs13659-018-0177-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=29974338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht12lsrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=297-301&author=H.+F.+Zhuauthor=Y.+Li&title=Small-molecule+targets+in+tumor+immunotherapy&doi=10.1007%2Fs13659-018-0177-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Targets in Tumor Immunotherapy</span></div><div class="casAuthors">Zhu, Hui-Fang; Li, Yan</div><div class="citationInfo"><span class="NLM_cas:title">Natural Products and Bioprospecting</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">297-301</span>CODEN:
                <span class="NLM_cas:coden">NPBAAH</span>;
        ISSN:<span class="NLM_cas:issn">2192-2209</span>.
    
            (<span class="NLM_cas:orgname">Kunming Institute of Botany, Chinese Academy of Sciences</span>)
        </div><div class="casAbstract">A review.  Cancer immunotherapy has been widely recognized as a powerful approach to fight cancers.  To date, over 50 phase III trials in cancer immunotherapy are in progress.  Among the many immunotherapy approaches, immune checkpoint therapy has attracted considerable attention.  The reported clin. success of targeting the T cell immune checkpoint receptors PD-1 or CTLA4 by antibodies blockade in advanced stages of cancers has demonstrated the importance of immune modulation.  But antibodies-based immunotherapy confronted with some disadvantages, such as immunogenicity, stability, membrane permeability, and prodn. cost.  Therefore, alternative approaches including small-mol.-regulated immune response are being introduced.  In this review, we focused on some of the key intracellular pathways where small-mol. therapeutic is potential and attractive, which highlights the great potential of natural products in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrit8YB3mZAwLVg90H21EOLACvtfcHk0lhMzLmYIlf13w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht12lsrvI&md5=1ce40d184a3dea755c98c949e851e929</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1007%2Fs13659-018-0177-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13659-018-0177-7%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DH.%2BF.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DSmall-molecule%2520targets%2520in%2520tumor%2520immunotherapy%26jtitle%3DNat.%2520Prod.%2520Bioprospect.%26date%3D2018%26volume%3D8%26spage%3D297%26epage%3D301%26doi%3D10.1007%2Fs13659-018-0177-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leishman, A. J.</span></span> <span> </span><span class="NLM_article-title">Further advances in cancer immunotherapy: going beyond checkpoint blockade</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1082</span>– <span class="NLM_lpage">1086</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2018.01082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.3389%2Ffimmu.2018.01082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=29910800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1KrsrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1082-1086&author=R.+W.+Wilkinsonauthor=A.+J.+Leishman&title=Further+advances+in+cancer+immunotherapy%3A+going+beyond+checkpoint+blockade&doi=10.3389%2Ffimmu.2018.01082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Further advances in cancer immunotherapy: going beyond checkpoint blockade</span></div><div class="casAuthors">Wilkinson, Robert W.; Leishman, Andrew J.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1082/1-1082/4</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Significant advances have been made to identify effective therapies that either restore or generate de novo a patient's immune response to cancer, so-called immunotherapy or immuno-oncol. (IO) therapies.  Some tumors overcome immune surveillance by promoting mechanisms to evade or suppress the immune system.  This conference report highlights the clin. promise and current challenges of IO therapy, including the use of immune-checkpoint antagonist monoclonal antibodies.  Furthermore, this report investigates advances in preclin. modeling of cancer immunobiol. and how this is helping our understanding of which patients will receive clin. benefits from current immune-checkpoint treatment.  Looking to the future, the report looks at emerging IO approaches, which aim to specifically target the tumor microenvironment.  This includes the use of toll-like receptors (TLRs) agonists that link the activation of innate immune, cells to the priming of T cells and an adaptive memory anti-tumor immune response through to the reversal of local immunosuppression using adenosinergic and indoleamine 2,3-dioxygenase (IDO) inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxni7uIIb3obVg90H21EOLACvtfcHk0lhMzLmYIlf13w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1KrsrvJ&md5=c245216e13c7f402e4a4eb438aefb512</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2018.01082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2018.01082%26sid%3Dliteratum%253Aachs%26aulast%3DWilkinson%26aufirst%3DR.%2BW.%26aulast%3DLeishman%26aufirst%3DA.%2BJ.%26atitle%3DFurther%2520advances%2520in%2520cancer%2520immunotherapy%253A%2520going%2520beyond%2520checkpoint%2520blockade%26jtitle%3DFront.%2520Immunol.%26date%3D2018%26volume%3D9%26spage%3D1082%26epage%3D1086%26doi%3D10.3389%2Ffimmu.2018.01082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zak, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grudnik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzik, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zieba, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span> <span> </span><span class="NLM_article-title">Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">30323</span>– <span class="NLM_lpage">30335</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.8730</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.18632%2Foncotarget.8730" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=27083005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A280%3ADC%252BC28bgt1egtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=30323-30335&author=K.+M.+Zakauthor=P.+Grudnikauthor=K.+Guzikauthor=B.+J.+Ziebaauthor=B.+Musielakauthor=A.+Domlingauthor=G.+Dubinauthor=T.+A.+Holak&title=Structural+basis+for+small+molecule+targeting+of+the+programmed+death+ligand+1+%28PD-L1%29&doi=10.18632%2Foncotarget.8730"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)</span></div><div class="casAuthors">Zak Krzysztof M; Zieba Bartosz J; Dubin Grzegorz; Holak Tad A; Zak Krzysztof M; Grudnik Przemyslaw; Dubin Grzegorz; Guzik Katarzyna; Zieba Bartosz J; Musielak Bogdan; Holak Tad A; Domling Alexander; Holak Tad A</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">30323-35</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Targeting the PD-1/PD-L1 immunologic checkpoint with monoclonal antibodies has provided unprecedented results in cancer treatment in the recent years.  Development of chemical inhibitors for this pathway lags the antibody development because of insufficient structural information.  The first nonpeptidic chemical inhibitors that target the PD-1/PD-L1 interaction have only been recently disclosed by Bristol-Myers Squibb.  Here, we show that these small-molecule compounds bind directly to PD-L1 and that they potently block PD-1 binding.  Structural studies reveal a dimeric protein complex with a single small molecule which stabilizes the dimer thus occluding the PD-1 interaction surface of PD-L1s.  The small-molecule interaction "hot spots" on PD-L1 surfaces suggest approaches for the PD-1/PD-L1 antagonist drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSANcdv1BQm-QvupmecNw_lfW6udTcc2eYIBLKRceeP5rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28bgt1egtg%253D%253D&md5=f96c24c78de0139c4e3c269e45d42559</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.8730&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.8730%26sid%3Dliteratum%253Aachs%26aulast%3DZak%26aufirst%3DK.%2BM.%26aulast%3DGrudnik%26aufirst%3DP.%26aulast%3DGuzik%26aufirst%3DK.%26aulast%3DZieba%26aufirst%3DB.%2BJ.%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DDomling%26aufirst%3DA.%26aulast%3DDubin%26aufirst%3DG.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26atitle%3DStructural%2520basis%2520for%2520small%2520molecule%2520targeting%2520of%2520the%2520programmed%2520death%2520ligand%25201%2520%2528PD-L1%2529%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D30323%26epage%3D30335%26doi%3D10.18632%2Foncotarget.8730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zak, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grudnik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span> <span> </span><span class="NLM_article-title">Structural biology of the immune checkpoint receptor PD-1 and its ligands PD-L1/PD-L2</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1163</span>– <span class="NLM_lpage">1174</span>, <span class="refDoi"> DOI: 10.1016/j.str.2017.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1016%2Fj.str.2017.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=28768162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1OiurvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=1163-1174&author=K.+M.+Zakauthor=P.+Grudnikauthor=K.+Magieraauthor=A.+Domlingauthor=G.+Dubinauthor=T.+A.+Holak&title=Structural+biology+of+the+immune+checkpoint+receptor+PD-1+and+its+ligands+PD-L1%2FPD-L2&doi=10.1016%2Fj.str.2017.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2</span></div><div class="casAuthors">Zak, Krzysztof M.; Grudnik, Przemyslaw; Magiera, Katarzyna; Domling, Alexander; Dubin, Grzegorz; Holak, Tad A.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1163-1174</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cancer cells can avoid and suppress immune responses through activation of inhibitory immune checkpoint proteins, such as PD-1, PD-L1, and CTLA-4.  Blocking the activities of these proteins with monoclonal antibodies, and thus restoring T cell function, has delivered breakthrough therapies against cancer.  In this review, we describe the latest work on structural characterization of the checkpoint proteins, their interactions with cognate ligands and with therapeutic antibodies.  Structures of the extracellular portions of these proteins reveal that they all have a similar modular structure, composed of small domains similar in topol. to the domains found in antibodies.  Structural basis for blocking the PD-1/PD-L1 interaction by small mols. is illustrated with the compd. BMS-202 that binds to and induces dimerization of PD-L1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4k4n4b209p7Vg90H21EOLACvtfcHk0liXKCrRPqElJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1OiurvE&md5=473642ccce8c757f6ef2708ece9d295e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2017.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2017.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DZak%26aufirst%3DK.%2BM.%26aulast%3DGrudnik%26aufirst%3DP.%26aulast%3DMagiera%26aufirst%3DK.%26aulast%3DDomling%26aufirst%3DA.%26aulast%3DDubin%26aufirst%3DG.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26atitle%3DStructural%2520biology%2520of%2520the%2520immune%2520checkpoint%2520receptor%2520PD-1%2520and%2520its%2520ligands%2520PD-L1%252FPD-L2%26jtitle%3DStructure%26date%3D2017%26volume%3D25%26spage%3D1163%26epage%3D1174%26doi%3D10.1016%2Fj.str.2017.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Naremaddepalli, S. S. S.</span></span> <span> </span><span class="NLM_article-title">1,3,4-Oxadiazole and 1,3,4-Thiadiazole Derivatives as Immunomodulators</span>. <span class="NLM_patent">WO2015033301</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=S.+S.+S.+Naremaddepalli&title=1%2C3%2C4-Oxadiazole+and+1%2C3%2C4-Thiadiazole+Derivatives+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3D1%252C3%252C4-Oxadiazole%2520and%25201%252C3%252C4-Thiadiazole%2520Derivatives%2520as%2520Immunomodulators%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Naremaddepalli, S. S. S.</span></span> <span> </span><span class="NLM_article-title">1,2,4-Oxadiazole Derivatives as Immunomodulators</span>. <span class="NLM_patent">US201414478759</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=S.+S.+S.+Naremaddepalli&title=1%2C2%2C4-Oxadiazole+Derivatives+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3D1%252C2%252C4-Oxadiazole%2520Derivatives%2520as%2520Immunomodulators%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.</span>; <span class="NLM_string-name">Chen, X.</span>; <span class="NLM_string-name">Zhang, L.</span>; <span class="NLM_string-name">Yang, Y.</span>; <span class="NLM_string-name">Lai, F.</span>; <span class="NLM_string-name">Ji, M.</span>; <span class="NLM_string-name">Zhou, C.</span>; <span class="NLM_string-name">Zhen, Y.</span>; <span class="NLM_string-name">Xue, N.</span>; <span class="NLM_string-name">Li, L.</span></span> <span> </span><span class="NLM_article-title">Bromo Benzyl Ether Derivative, Preparation Method Therefor, and Pharmaceutical Composition and Uses Thereof</span>. <span class="NLM_patent">WO2017202275 A1</span>, <span class="NLM_year">2017</span>; Institute of Materia Medica, Chinese Academy of Medical Sciences.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Z.+Feng&author=X.+Chen&author=L.+Zhang&author=Y.+Yang&author=F.+Lai&author=M.+Ji&author=C.+Zhou&author=Y.+Zhen&author=N.+Xue&author=L.+Li&title=Bromo+Benzyl+Ether+Derivative%2C+Preparation+Method+Therefor%2C+and+Pharmaceutical+Composition+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DZ.%26atitle%3DBromo%2520Benzyl%2520Ether%2520Derivative%252C%2520Preparation%2520Method%2520Therefor%252C%2520and%2520Pharmaceutical%2520Composition%2520and%2520Uses%2520Thereof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span></span> <span> </span><span class="NLM_article-title">Immunomodulating Peptidomimetic Derivatives</span>. <span class="NLM_patent">WO2015036927</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&title=Immunomodulating+Peptidomimetic+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DImmunomodulating%2520Peptidomimetic%2520Derivatives%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Immunomodulating Compounds</span>. <span class="NLM_patent">WO2015044900</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&title=Therapeutic+Immunomodulating+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DTherapeutic%2520Immunomodulating%2520Compounds%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span></span> <span> </span><span class="NLM_article-title">Immunomodulating Cyclic Compounds from the BC Loop of Human PD1</span>. <span class="NLM_patent">WO2013144704</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&title=Immunomodulating+Cyclic+Compounds+from+the+BC+Loop+of+Human+PD1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DImmunomodulating%2520Cyclic%2520Compounds%2520from%2520the%2520BC%2520Loop%2520of%2520Human%2520PD1%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span></span> <span> </span><span class="NLM_article-title">Peptidomimetic Compounds as Immunomdulators</span>. <span class="NLM_patent">US20130237580</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&title=Peptidomimetic+Compounds+as+Immunomdulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DPeptidomimetic%2520Compounds%2520as%2520Immunomdulators%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Vadlamani, S. K.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Compounds for Immunomodulation</span>. <span class="NLM_patent">WO2012168944</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=S.+K.+Vadlamani&title=Therapeutic+Compounds+for+Immunomodulation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DTherapeutic%2520Compounds%2520for%2520Immunomodulation%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Vadlamani, S. K.</span></span> <span> </span><span class="NLM_article-title">Immunosuppression Modulating Compounds</span>. <span class="NLM_patent">US20110318373</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=S.+K.+Vadlamani&title=Immunosuppression+Modulating+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DImmunosuppression%2520Modulating%2520Compounds%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Webber, S. E.</span>; <span class="NLM_string-name">Almassy, R. J.</span></span> <span> </span><span class="NLM_article-title">Immune Checkpoint Inhibitors, Compositions And Methods There For</span>. <span class="NLM_patent">WO2018045142 A1</span>, <span class="NLM_year">2018</span>; Polaris Pharmaceuticals, Inc.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=S.+E.+Webber&author=R.+J.+Almassy&title=Immune+Checkpoint+Inhibitors%2C+Compositions+And+Methods+There+For"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWebber%26aufirst%3DS.%2BE.%26atitle%3DImmune%2520Checkpoint%2520Inhibitors%252C%2520Compositions%2520And%2520Methods%2520There%2520For%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lajkiewicz, N.</span>; <span class="NLM_string-name">Wu, L.</span>; <span class="NLM_string-name">Yao, W.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic Compounds As Immunomodulators</span>. <span class="NLM_patent">US20170174679</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=N.+Lajkiewicz&author=L.+Wu&author=W.+Yao&title=Heterocyclic+Compounds+As+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLajkiewicz%26aufirst%3DN.%26atitle%3DHeterocyclic%2520Compounds%2520As%2520Immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. M.</span>; <span class="NLM_string-name">Mapelli, C.</span>; <span class="NLM_string-name">Allen, M. P.</span></span>; <span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Macrocyclic Inhibtors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 Protein/Protein Interactions</span>. <span class="NLM_patent">WO2014151634</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=M.+M.+Miller&author=C.+Mapelli&author=M.+P.+Allen&title=Macrocyclic+Inhibtors+of+the+PD-1%2FPD-L1+and+CD80%28B7-1%29%2FPD-L1+Protein%2FProtein+Interactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DM.%2BM.%26atitle%3DMacrocyclic%2520Inhibtors%2520of%2520the%2520PD-1%252FPD-L1%2520and%2520CD80%2528B7-1%2529%252FPD-L1%2520Protein%252FProtein%2520Interactions%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, A. H.</span>; <span class="NLM_string-name">Butte, M. J.</span>; <span class="NLM_string-name">Oyama, S.</span></span> <span> </span><span class="NLM_article-title">Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof</span>. <span class="NLM_patent">US2011020046</span> <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=A.+H.+Sharpe&author=M.+J.+Butte&author=S.+Oyama&title=Modulators+of+Immunoinhibitory+Receptor+PD-1%2C+and+Methods+of+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26atitle%3DModulators%2520of%2520Immunoinhibitory%2520Receptor%2520PD-1%252C%2520and%2520Methods%2520of%2520Use%2520Thereof%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span> </span><span class="NLM_article-title">Heterocyclic Compounds
as Immunomodulators</span>. <span class="NLM_patent">US2017/0174679A1</span>, <span class="NLM_year">2017</span>; Incyte Corporation.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Heterocyclic+Compounds%0Aas+Immunomodulators.+US2017%2F0174679A1%2C+2017%3B+Incyte+Corporation."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26atitle%3DHeterocyclic%2520Compounds%250Aas%2520Immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span> </span><span class="NLM_article-title">Heterocyclic
Compounds as Immunomodulators</span>. <span class="NLM_patent">WO2017/070089A1</span>, <span class="NLM_year">2017</span>; Incyte Corporation.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Heterocyclic%0ACompounds+as+Immunomodulators.+WO2017%2F070089A1%2C+2017%3B+Incyte+Corporation."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26atitle%3DHeterocyclic%250ACompounds%2520as%2520Immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span> </span><span class="NLM_article-title">Heterocyclic
Compounds as Immunomodulators</span>. <span class="NLM_patent">US2017/0107216
A1</span>, <span class="NLM_year">2017</span>; Incyte Corporation.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Heterocyclic%0ACompounds+as+Immunomodulators.+US2017%2F0107216%0AA1%2C+2017%3B+Incyte+Corporation."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26atitle%3DHeterocyclic%250ACompounds%2520as%2520Immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span> </span><span class="NLM_article-title">Heterocyclic Compounds as Immunomodulators</span>. <span class="NLM_patent">WO2017/205464
A1</span>, <span class="NLM_year">2017</span>; Incyte Corporation.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Heterocyclic+Compounds+as+Immunomodulators.+WO2017%2F205464%0AA1%2C+2017%3B+Incyte+Corporation."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26atitle%3DHeterocyclic%2520Compounds%2520as%2520Immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chupak, L. S.</span>; <span class="NLM_string-name">Zheng, X.</span></span> <span> </span><span class="NLM_article-title">Compounds Useful as Immunomodulators</span>. <span class="NLM_patent">WO2015034820</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=L.+S.+Chupak&author=X.+Zheng&title=Compounds+Useful+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChupak%26aufirst%3DL.%2BS.%26atitle%3DCompounds%2520Useful%2520as%2520Immunomodulators%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span> </span><span class="NLM_article-title">Immunomodulator Compounds</span>. <span class="NLM_patent">WO2018/005374
A1</span>, <span class="NLM_year">2018</span>; Chemocentryx, Inc.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Immunomodulator+Compounds.+WO2018%2F005374%0AA1%2C+2018%3B+Chemocentryx%2C+Inc."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26atitle%3DImmunomodulator%2520Compounds%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span> </span><span class="NLM_article-title">Biaryl Compounds Useful as Immunomodulators</span>. <span class="NLM_patent">WO2018/044963
A1</span>, <span class="NLM_year">2018</span>; Bristol-Myers Squibb Company.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Biaryl+Compounds+Useful+as+Immunomodulators.+WO2018%2F044963%0AA1%2C+2018%3B+Bristol-Myers+Squibb+Company."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26atitle%3DBiaryl%2520Compounds%2520Useful%2520as%2520Immunomodulators%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span> </span><span class="NLM_article-title">1,3-Dihydroxy-Phenyl Derivatives Useful as Immunomodulators</span>. <span class="NLM_patent">WO2018/009505
A1</span>, <span class="NLM_year">2018</span>; Bristol-Myers Squibb Company.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=1%2C3-Dihydroxy-Phenyl+Derivatives+Useful+as+Immunomodulators.+WO2018%2F009505%0AA1%2C+2018%3B+Bristol-Myers+Squibb+Company."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26atitle%3D1%252C3-Dihydroxy-Phenyl%2520Derivatives%2520Useful%2520as%2520Immunomodulators%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span> </span><span class="NLM_article-title">Compounds Useful as Immunomodulators</span>. <span class="NLM_patent">WO2017/066227
A1</span>, <span class="NLM_year">2017</span>; Bristol-Myers Squibb Company.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Compounds+Useful+as+Immunomodulators.+WO2017%2F066227%0AA1%2C+2017%3B+Bristol-Myers+Squibb+Company."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26atitle%3DCompounds%2520Useful%2520as%2520Immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel resorcinol dibenzyl ethers targeting the programmed cell death-1/programmed cell death-ligand 1 interaction as potential anticancer agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">8338</span>– <span class="NLM_lpage">8358</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00574</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00574" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtl2rsrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=8338-8358&author=B.+Chengauthor=Y.+Renauthor=X.+Niuauthor=W.+Wangauthor=S.+Wangauthor=Y.+Tuauthor=S.+Liuauthor=J.+Wangauthor=D.+Yangauthor=G.+Liaoauthor=J.+Chen&title=Discovery+of+novel+resorcinol+dibenzyl+ethers+targeting+the+programmed+cell+death-1%2Fprogrammed+cell+death-ligand+1+interaction+as+potential+anticancer+agents&doi=10.1021%2Facs.jmedchem.0c00574"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction as Potential Anticancer Agents</span></div><div class="casAuthors">Cheng, Binbin; Ren, Yichang; Niu, Xiaoge; Wang, Wei; Wang, Shuanghu; Tu, Yingfeng; Liu, Shuwen; Wang, Jin; Yang, Deying; Liao, Guochao; Chen, Jianjun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">8338-8358</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel small mol. compds. based on various scaffolds including chalcone, flavonoid, and resorcinol dibenzyl ether were designed and tested for their inhibitory activity against the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 (PD-1/PD-L1) pathway.  Among them, compd. NP19(I) inhibited the human PD-1/PD-L1 interaction with IC50 values of 12.5 nM in homogeneous time-resolved fluorescence (HTRF) binding assays.  In addn., NP19 dose-dependently elevated IFN-γ prodn. in a coculture model of Hep3B/OS-8/hPD-L1 and CD3 T cells.  Furthermore, NP19 displayed significant in vivo antitumor efficacy in two different mouse models of cancer (a melanoma B16-F10 tumor model and an H22 hepatoma tumor model).  Moreover, H&E staining and flow cytometry data suggested that NP19 activated the immune microenvironment in the tumor, which may contribute to its antitumor effects.  This work shows NP19 is a promising lead compd. for further development as a new generation of small mol. inhibitors targeting the PD-1/PD-L1 pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruD5Zp9HM0jrVg90H21EOLACvtfcHk0liKAk6and5qOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtl2rsrfL&md5=a1f6b3b4c440a7152ed8194ad842370f</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00574%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DB.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DNiu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DTu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DLiao%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520novel%2520resorcinol%2520dibenzyl%2520ethers%2520targeting%2520the%2520programmed%2520cell%2520death-1%252Fprogrammed%2520cell%2520death-ligand%25201%2520interaction%2520as%2520potential%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D8338%26epage%3D8358%26doi%3D10.1021%2Facs.jmedchem.0c00574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Domling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span> <span> </span><span class="NLM_article-title">Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2286</span>– <span class="NLM_lpage">2288</span>, <span class="refDoi"> DOI: 10.1002/anie.201307906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1002%2Fanie.201307906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A280%3ADC%252BC2czpvVOhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=2286-2288&author=A.+Domlingauthor=T.+A.+Holak&title=Programmed+death-1%3A+therapeutic+success+after+more+than+100+years+of+cancer+immunotherapy&doi=10.1002%2Fanie.201307906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy</span></div><div class="casAuthors">Domling Alexander; Holak Tad A</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie (International ed. in English)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2286-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">No other cancer therapy target class caused more excitement than the programmed death-1 (PD-1) pathway related.  Antibodies against PD-1 and PD-1 ligands represent a therapeutic breakthrough and are the first examples of broadly efficacious and durable cancer immunotherapies.  Cancer for the first time seems to have transformed from an often incurable to a "clinically manageable" disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT8kC5nL6VwzPcsfMJQC1ZdfW6udTcc2eaS-o3abDzgLbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2czpvVOhuw%253D%253D&md5=907c71bc856c102a3d93600aac71a2ea</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1002%2Fanie.201307906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201307906%26sid%3Dliteratum%253Aachs%26aulast%3DDomling%26aufirst%3DA.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26atitle%3DProgrammed%2520death-1%253A%2520therapeutic%2520success%2520after%2520more%2520than%2520100%2520years%2520of%2520cancer%2520immunotherapy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D2286%26epage%3D2288%26doi%3D10.1002%2Fanie.201307906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burr, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparbier, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beavis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, E. Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolzenburg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilan, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgens, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassik, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neeson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behren, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcy, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voskoboinik, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapani, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cebon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehner, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, M. A.</span></span> <span> </span><span class="NLM_article-title">CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>549</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1038/nature23643</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1038%2Fnature23643" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=28813417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlGktrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=549&publication_year=2017&pages=101-105&author=M.+L.+Burrauthor=C.+E.+Sparbierauthor=Y.+C.+Chanauthor=J.+C.+Williamsonauthor=K.+Woodsauthor=P.+A.+Beavisauthor=E.+Y.+N.+Lamauthor=M.+A.+Hendersonauthor=C.+C.+Bellauthor=S.+Stolzenburgauthor=O.+Gilanauthor=S.+Bloorauthor=T.+Nooriauthor=D.+W.+Morgensauthor=M.+C.+Bassikauthor=P.+J.+Neesonauthor=A.+Behrenauthor=P.+K.+Darcyauthor=S.+J.+Dawsonauthor=I.+Voskoboinikauthor=J.+A.+Trapaniauthor=J.+Cebonauthor=P.+J.+Lehnerauthor=M.+A.+Dawson&title=CMTM6+maintains+the+expression+of+PD-L1+and+regulates+anti-tumour+immunity&doi=10.1038%2Fnature23643"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity</span></div><div class="casAuthors">Burr, Marian L.; Sparbier, Christina E.; Chan, Yih-Chih; Williamson, James C.; Woods, Katherine; Beavis, Paul A.; Lam, Enid Y. N.; Henderson, Melissa A.; Bell, Charles C.; Stolzenburg, Sabine; Gilan, Omer; Bloor, Stuart; Noori, Tahereh; Morgens, David W.; Bassik, Michael C.; Neeson, Paul J.; Behren, Andreas; Darcy, Phillip K.; Dawson, Sarah-Jane; Voskoboinik, Ilia; Trapani, Joseph A.; Cebon, Jonathan; Lehner, Paul J.; Dawson, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">549</span>
        (<span class="NLM_cas:issue">7670</span>),
    <span class="NLM_cas:pages">101-105</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancer cells exploit the expression of the programmed death-1 (PD-1) ligand 1 (PD-L1) to subvert T-cell-mediated immunosurveillance.  The success of therapies that disrupt PD-L1-mediated tumor tolerance has highlighted the need to understand the mol. regulation of PD-L1 expression.  Here we identify the uncharacterized protein CMTM6 as a crit. regulator of PD-L1 in a broad range of cancer cells, by using a genome-wide CRISPR-Cas9 screen.  CMTM6 is a ubiquitously expressed protein that binds PD-L1 and maintains its cell surface expression.  CMTM6 is not required for PD-L1 maturation but co-localizes with PD-L1 at the plasma membrane and in recycling endosomes, where it prevents PD-L1 from being targeted for lysosome-mediated degrdn.  Using a quant. approach to profile the entire plasma membrane proteome, we find that CMTM6 displays specificity for PD-L1.  Notably, CMTM6 depletion decreases PD-L1 without compromising cell surface expression of MHC class I.  CMTM6 depletion, via the redn. of PD-L1, significantly alleviates the suppression of tumor-specific T cell activity in vitro and in vivo.  These findings provide insights into the biol. of PD-L1 regulation, identify a previously unrecognized master regulator of this crit. immune checkpoint and highlight a potential therapeutic target to overcome immune evasion by tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOaE7qlrP04LVg90H21EOLACvtfcHk0lgC7Zallb1I9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlGktrvK&md5=c37c58dcfa75b3057fe4e9635789281d</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fnature23643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature23643%26sid%3Dliteratum%253Aachs%26aulast%3DBurr%26aufirst%3DM.%2BL.%26aulast%3DSparbier%26aufirst%3DC.%2BE.%26aulast%3DChan%26aufirst%3DY.%2BC.%26aulast%3DWilliamson%26aufirst%3DJ.%2BC.%26aulast%3DWoods%26aufirst%3DK.%26aulast%3DBeavis%26aufirst%3DP.%2BA.%26aulast%3DLam%26aufirst%3DE.%2BY.%2BN.%26aulast%3DHenderson%26aufirst%3DM.%2BA.%26aulast%3DBell%26aufirst%3DC.%2BC.%26aulast%3DStolzenburg%26aufirst%3DS.%26aulast%3DGilan%26aufirst%3DO.%26aulast%3DBloor%26aufirst%3DS.%26aulast%3DNoori%26aufirst%3DT.%26aulast%3DMorgens%26aufirst%3DD.%2BW.%26aulast%3DBassik%26aufirst%3DM.%2BC.%26aulast%3DNeeson%26aufirst%3DP.%2BJ.%26aulast%3DBehren%26aufirst%3DA.%26aulast%3DDarcy%26aufirst%3DP.%2BK.%26aulast%3DDawson%26aufirst%3DS.%2BJ.%26aulast%3DVoskoboinik%26aufirst%3DI.%26aulast%3DTrapani%26aufirst%3DJ.%2BA.%26aulast%3DCebon%26aufirst%3DJ.%26aulast%3DLehner%26aufirst%3DP.%2BJ.%26aulast%3DDawson%26aufirst%3DM.%2BA.%26atitle%3DCMTM6%2520maintains%2520the%2520expression%2520of%2520PD-L1%2520and%2520regulates%2520anti-tumour%2520immunity%26jtitle%3DNature%26date%3D2017%26volume%3D549%26spage%3D101%26epage%3D105%26doi%3D10.1038%2Fnature23643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imamovic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vranic, S.</span></span> <span> </span><span class="NLM_article-title">Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors</span>. <i>Ann. Transl Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">470</span>, <span class="refDoi"> DOI: 10.21037/atm.2017.09.32</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.21037%2Fatm.2017.09.32" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=29285500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtlKiu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=467-470&author=D.+Imamovicauthor=S.+Vranic&title=Novel+regulators+of+PD-L1+expression+in+cancer%3A+CMTM6+and+CMTM4-a+new+avenue+to+enhance+the+therapeutic+benefits+of+immune+checkpoint+inhibitors&doi=10.21037%2Fatm.2017.09.32"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors</span></div><div class="casAuthors">Imamovic, Denira; Vranic, Semir</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Translational Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">467/1-467/3</span>CODEN:
                <span class="NLM_cas:coden">ATMNDX</span>;
        ISSN:<span class="NLM_cas:issn">2305-5847</span>.
    
            (<span class="NLM_cas:orgname">AME Publishing Co.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_PSMq-F9ay7Vg90H21EOLACvtfcHk0ljYpTGsrSl1UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtlKiu7w%253D&md5=7ca2a61bf8bf9a2b914c494e8a8ac8b2</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.21037%2Fatm.2017.09.32&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21037%252Fatm.2017.09.32%26sid%3Dliteratum%253Aachs%26aulast%3DImamovic%26aufirst%3DD.%26aulast%3DVranic%26aufirst%3DS.%26atitle%3DNovel%2520regulators%2520of%2520PD-L1%2520expression%2520in%2520cancer%253A%2520CMTM6%2520and%2520CMTM4-a%2520new%2520avenue%2520to%2520enhance%2520the%2520therapeutic%2520benefits%2520of%2520immune%2520checkpoint%2520inhibitors%26jtitle%3DAnn.%2520Transl%2520Med.%26date%3D2017%26volume%3D5%26spage%3D467%26epage%3D470%26doi%3D10.21037%2Fatm.2017.09.32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mamessier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birnbaum, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birnbaum, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertucci, F.</span></span> <span> </span><span class="NLM_article-title">CMTM6 stabilizes PD-L1 expression and refines its prognostic value in tumors</span>. <i>Ann. Transl Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.21037/atm.2017.11.26</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.21037%2Fatm.2017.11.26" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=29610746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlsVCkt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=54-60&author=E.+Mamessierauthor=D.+J.+Birnbaumauthor=P.+Finettiauthor=D.+Birnbaumauthor=F.+Bertucci&title=CMTM6+stabilizes+PD-L1+expression+and+refines+its+prognostic+value+in+tumors&doi=10.21037%2Fatm.2017.11.26"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">CMTM6 stabilizes PD-L1 expression and refines its prognostic value in tumors</span></div><div class="casAuthors">Mamessier, Emilie; Birnbaum, David J.; Finetti, Pascal; Birnbaum, Daniel; Bertucci, Francois</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Translational Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">54/1-54/6</span>CODEN:
                <span class="NLM_cas:coden">ATMNDX</span>;
        ISSN:<span class="NLM_cas:issn">2305-5847</span>.
    
            (<span class="NLM_cas:orgname">AME Publishing Co.</span>)
        </div><div class="casAbstract">The PD-1 protein turned out to be a receptor delivering a co-inhibitory signal, playing a decisive role in maintaining peripheral tolerance and impeding autoimmunity, but with no effect on cell apoptosis.  PD-L1 expression is mostly regulated at the transcriptional level, and involves fixation of transcription factors or HIFα to the PD-L1 promoter.  CMTM6 enhanced both constitutive and induced PD-L1 expression at the cell membrane, without compromising antigen presentation by reducing cell surface MHC class I expression levels.  Exogenous expression of CMTM6 in CMTM6-knockout cells restored PD-L1 expression in a dose-dependent manner.  The PD-1/PD-L1 immune checkpoint, which could provide a new therapeutic target to block this crit. pathway and to help overcoming immune evasion by tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprJM3bQ4sUZLVg90H21EOLACvtfcHk0ljYpTGsrSl1UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlsVCkt70%253D&md5=ea339646b60b781aa85af777b611fb3e</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.21037%2Fatm.2017.11.26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21037%252Fatm.2017.11.26%26sid%3Dliteratum%253Aachs%26aulast%3DMamessier%26aufirst%3DE.%26aulast%3DBirnbaum%26aufirst%3DD.%2BJ.%26aulast%3DFinetti%26aufirst%3DP.%26aulast%3DBirnbaum%26aufirst%3DD.%26aulast%3DBertucci%26aufirst%3DF.%26atitle%3DCMTM6%2520stabilizes%2520PD-L1%2520expression%2520and%2520refines%2520its%2520prognostic%2520value%2520in%2520tumors%26jtitle%3DAnn.%2520Transl%2520Med.%26date%3D2018%26volume%3D6%26spage%3D54%26epage%3D60%26doi%3D10.21037%2Fatm.2017.11.26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Melaiu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chierici, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boldrini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romania, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Alicandro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furlanello, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locatelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruci, D.</span></span> <span> </span><span class="NLM_article-title">PD-L1 is a therapeutic target of the bromodomain inhibitor JQ1 and, combined with HLA class I, a promising prognostic biomarker in neuroblastoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">4462</span>– <span class="NLM_lpage">4472</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-2601</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1158%2F1078-0432.CCR-16-2601" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=28270499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Ghu7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=4462-4472&author=O.+Melaiuauthor=M.+Minaauthor=M.+Chiericiauthor=R.+Boldriniauthor=G.+Jurmanauthor=P.+Romaniaauthor=V.+D%E2%80%99Alicandroauthor=M.+C.+Benedettiauthor=A.+Castellanoauthor=T.+Liuauthor=C.+Furlanelloauthor=F.+Locatelliauthor=D.+Fruci&title=PD-L1+is+a+therapeutic+target+of+the+bromodomain+inhibitor+JQ1+and%2C+combined+with+HLA+class+I%2C+a+promising+prognostic+biomarker+in+neuroblastoma&doi=10.1158%2F1078-0432.CCR-16-2601"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma</span></div><div class="casAuthors">Melaiu, Ombretta; Mina, Marco; Chierici, Marco; Boldrini, Renata; Jurman, Giuseppe; Romania, Paolo; D'Alicandro, Valerio; Benedetti, Maria C.; Castellano, Aurora; Liu, Tao; Furlanello, Cesare; Locatelli, Franco; Fruci, Doriana</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4462-4472</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: This study sought to evaluate the expression of programmed cell death-ligand-1 (PD-L1) and HLA class I on neuroblastoma cells and programmed cell death-1 (PD-1) and lymphocyte activation gene 3 (LAG3) on tumor-infiltrating lymphocytes to better define patient risk stratification and understand whether this tumor may benefit from therapies targeting immune checkpoint mols.  Exptl. Design: In situ IHC staining for PD-L1, HLA class I, PD-1, and LAG3 was assessed in 77 neuroblastoma specimens, previously characterized for tumor-infiltrating T-cell d. and correlated with clin. outcome.  Surface expression of PD-L1 was evaluated by flow cytometry and IHC in neuroblastoma cell lines and tumors genetically and/or pharmacol. inhibited for MYC and MYCN.  A dataset of 477 human primary neuroblastomas from GEO and ArrayExpress databases was explored for PD-L1, MYC, and MYCN correlation.  Results: Multivariate Cox regression anal. demonstrated that the combination of PD-L1 and HLA class I tumor cell d. is a prognostic biomarker for predicting overall survival in neuroblastoma patients (P = 0.0448).  MYC and MYCN control the expression of PD-L1 in neuroblastoma cells both in vitro and in vivo.  Consistently, abundance of PD-L1 transcript correlates with MYC expression in primary neuroblastoma.  Conclusions: The combination of PD-L1 and HLA class I represents a novel prognostic biomarker for neuroblastoma.  Pharmacol. inhibition of MYCN and MYC may be exploited to target PD-L1 and restore an efficient antitumor immunity in high-risk neuroblastoma.  Clin Cancer Res; 23(15); 4462-72. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo66-oQkiUsO7Vg90H21EOLACvtfcHk0liepwog6_QFnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Ghu7jN&md5=1907d6d7b9238d22e71a6e56f9ceab46</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-2601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-2601%26sid%3Dliteratum%253Aachs%26aulast%3DMelaiu%26aufirst%3DO.%26aulast%3DMina%26aufirst%3DM.%26aulast%3DChierici%26aufirst%3DM.%26aulast%3DBoldrini%26aufirst%3DR.%26aulast%3DJurman%26aufirst%3DG.%26aulast%3DRomania%26aufirst%3DP.%26aulast%3DD%25E2%2580%2599Alicandro%26aufirst%3DV.%26aulast%3DBenedetti%26aufirst%3DM.%2BC.%26aulast%3DCastellano%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DFurlanello%26aufirst%3DC.%26aulast%3DLocatelli%26aufirst%3DF.%26aulast%3DFruci%26aufirst%3DD.%26atitle%3DPD-L1%2520is%2520a%2520therapeutic%2520target%2520of%2520the%2520bromodomain%2520inhibitor%2520JQ1%2520and%252C%2520combined%2520with%2520HLA%2520class%2520I%252C%2520a%2520promising%2520prognostic%2520biomarker%2520in%2520neuroblastoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D4462%26epage%3D4472%26doi%3D10.1158%2F1078-0432.CCR-16-2601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Visan, I.</span></span> <span> </span><span class="NLM_article-title">CMTM6 controls PD-L1</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1067</span>, <span class="refDoi"> DOI: 10.1038/ni.3844</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1038%2Fni.3844" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFWiu7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1067&author=I.+Visan&title=CMTM6+controls+PD-L1&doi=10.1038%2Fni.3844"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">CMTM6 controls PD-L1</span></div><div class="casAuthors">Visan, Ioana</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1067</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">CMTM6 assocs. with both constitutive PD-L1 and interferon-γ-induced PD-L1 at the plasma membrane and in recycling endosomes.  Depletion of CMTM6 does not affect transcription of the gene encoding PD-L1 or trafficking of PD-L1 from the endoplasmic reticulum to the cell surface but stabilizes cell-surface PD-L1 by preventing its lysosome-mediated degrdn., possibly by preventing its ubiquitination.  Depletion of CMTM6 enhances T cell activation and the anti-tumor response in vitro and in mouse melanoma models.  In this article, transmembrane protein CMTM6 as crit. regulator of cell-surface expression of PD-L1 in cancer cells and myeloid cells in mice and humans were discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcI7U1mwSxFLVg90H21EOLACvtfcHk0liepwog6_QFnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFWiu7fM&md5=1650c394e9fbc70c163a296daabf25bb</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fni.3844&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.3844%26sid%3Dliteratum%253Aachs%26aulast%3DVisan%26aufirst%3DI.%26atitle%3DCMTM6%2520controls%2520PD-L1%26jtitle%3DNat.%2520Immunol.%26date%3D2017%26volume%3D18%26spage%3D1067%26doi%3D10.1038%2Fni.3844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera-Mularz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skalniak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kholodovych, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, evaluation, and structural studies of C2-symmetric small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 protein-protein interaction</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7250</span>– <span class="NLM_lpage">7263</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00795</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00795" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlOhu7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7250-7263&author=S.+Basuauthor=J.+Yangauthor=B.+Xuauthor=K.+Magiera-Mularzauthor=L.+Skalniakauthor=B.+Musielakauthor=V.+Kholodovychauthor=T.+A.+Holakauthor=L.+Hu&title=Design%2C+synthesis%2C+evaluation%2C+and+structural+studies+of+C2-symmetric+small+molecule+inhibitors+of+programmed+cell+death-1%2Fprogrammed+death-ligand+1+protein-protein+interaction&doi=10.1021%2Facs.jmedchem.9b00795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, Evaluation, and Structural Studies of C2-Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein Interaction</span></div><div class="casAuthors">Basu, Subhadwip; Yang, Jeffrey; Xu, Bin; Magiera-Mularz, Katarzyna; Skalniak, Lukasz; Musielak, Bogdan; Kholodovych, Vladyslav; Holak, Tad A.; Hu, Longqin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7250-7263</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of C2-sym. inhibitors was designed and evaluated for inhibitory activity against the programmed cell death-1/programmed death-ligand 1(PD-1/PD-L1) protein-protein interaction (PPI) in a homogeneous time-resolved fluorescence (HTRF) assay and PD-1 signaling in cell-based coculture assays.  C2-sym. inhibitors 2a (LH1306) and 2b (LH1307) exhibited IC50 values of 25 and 3.0 nM, resp., in the HTRF assay.  While 2a was ∼3.8-fold more potent than previously reported inhibitor 1a, 2b could not be differentiated from 1b due to their high potency and the limit of our HTRF assay conditions.  In one cell-based coculture PD-1 signaling assay, 2a and 2b were 8.2- and 2.8-fold more potent in inhibiting PD-1 signaling than 1a and 1b, resp.  NMR and X-ray cocrystal structural studies provided more structural insights into the interaction between 2b and PD-L1; 2b binds to PD-L1 at the PD-1 binding site and induces the formation of a more sym. arranged PD-L1 homodimer than that previously reported for other inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS9fdh7FbNLLVg90H21EOLACvtfcHk0livb8g-mKNFzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlOhu7zJ&md5=0dae949116a4157a281802aea6d21b6c</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00795%26sid%3Dliteratum%253Aachs%26aulast%3DBasu%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DMagiera-Mularz%26aufirst%3DK.%26aulast%3DSkalniak%26aufirst%3DL.%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DKholodovych%26aufirst%3DV.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26aulast%3DHu%26aufirst%3DL.%26atitle%3DDesign%252C%2520synthesis%252C%2520evaluation%252C%2520and%2520structural%2520studies%2520of%2520C2-symmetric%2520small%2520molecule%2520inhibitors%2520of%2520programmed%2520cell%2520death-1%252Fprogrammed%2520death-ligand%25201%2520protein-protein%2520interaction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7250%26epage%3D7263%26doi%3D10.1021%2Facs.jmedchem.9b00795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellerschmied, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salami, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaime-Figueroa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Modular PROTAC design for the degradation of oncogenic BCR-ABL</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">807</span>– <span class="NLM_lpage">810</span>, <span class="refDoi"> DOI: 10.1002/anie.201507634</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1002%2Fanie.201507634" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVOlt7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=807-810&author=A.+C.+Laiauthor=M.+Toureauthor=D.+Hellerschmiedauthor=J.+Salamiauthor=S.+Jaime-Figueroaauthor=E.+Koauthor=J.+Hinesauthor=C.+M.+Crews&title=Modular+PROTAC+design+for+the+degradation+of+oncogenic+BCR-ABL&doi=10.1002%2Fanie.201507634"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL</span></div><div class="casAuthors">Lai, Ashton C.; Toure, Momar; Hellerschmied, Doris; Salami, Jemilat; Jaime-Figueroa, Saul; Ko, Eunhwa; Hines, John; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">807-810</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Proteolysis Targeting Chimera (PROTAC) technol. is a rapidly emerging alternative therapeutic strategy with the potential to address many of the challenges currently faced in modern drug development programs.  PROTAC technol. employs small mols. that recruit target proteins for ubiquitination and removal by the proteasome.  The synthesis of PROTAC compds. that mediate the degrdn. of c-ABL and BCR-ABL by recruiting either Cereblon or Von Hippel Lindau E3 ligases is reported.  During the course of their development, the authors discovered that the capacity of a PROTAC to induce degrdn. involves more than just target binding: the identity of the inhibitor warhead and the recruited E3 ligase largely det. the degrdn. profiles of the compds.; thus, as a starting point for PROTAC development, both the target ligand and the recruited E3 ligase should be varied to rapidly generate a PROTAC with the desired degrdn. profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdcSTHt5WfILVg90H21EOLACvtfcHk0livb8g-mKNFzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVOlt7rN&md5=58a5d78f32bc8a21fd1a6e0c38b8979c</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2Fanie.201507634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201507634%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%2BC.%26aulast%3DToure%26aufirst%3DM.%26aulast%3DHellerschmied%26aufirst%3DD.%26aulast%3DSalami%26aufirst%3DJ.%26aulast%3DJaime-Figueroa%26aufirst%3DS.%26aulast%3DKo%26aufirst%3DE.%26aulast%3DHines%26aufirst%3DJ.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DModular%2520PROTAC%2520design%2520for%2520the%2520degradation%2520of%2520oncogenic%2520BCR-ABL%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D807%26epage%3D810%26doi%3D10.1002%2Fanie.201507634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>186</i></span>,  <span class="NLM_fpage">111856</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111856</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1016%2Fj.ejmech.2019.111856" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=31734021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFOmu7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2020&pages=111856&author=M.+Qinauthor=Q.+Caoauthor=X.+Wuauthor=C.+Liuauthor=S.+Zhengauthor=H.+Xieauthor=Y.+Tianauthor=J.+Xieauthor=Y.+Zhaoauthor=Y.+Houauthor=X.+Zhangauthor=B.+Xuauthor=H.+Zhangauthor=X.+Wang&title=Discovery+of+the+programmed+cell+death-1%2Fprogrammed+cell+death-ligand+1+interaction+inhibitors+bearing+an+indoline+scaffold&doi=10.1016%2Fj.ejmech.2019.111856"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold</span></div><div class="casAuthors">Qin, Mingze; Cao, Qi; Wu, Xia; Liu, Chunyang; Zheng, Shuaishuai; Xie, Hongbo; Tian, Ye; Xie, Jun; Zhao, Yanfang; Hou, Yunlei; Zhang, Xian; Xu, Boxuan; Zhang, Haotian; Wang, Xiaobo</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">186</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111856</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Inhibiting the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway is an attractive strategy for tumor immunotherapy.  Here, a novel series of indoline-contg. compds. were developed, among which, A13 was identified as the most promising PD-1/PD-L1 pathway inhibitor.  At the biochem. level, A13 demonstrated strong inhibition of the PD-1/PD-L1 interaction, with an IC50 of 132.8 nM.  Notably, it exhibited outstanding immunoregulatory activity, and significantly elevated interferon-γ secretion in a Hep3B/OS-8/hPD-L1 and CD3 T cell co-culture model, without significant toxic effect.  Therefore, A13 could be employed as a suitable lead compd. for further design of non-peptide inhibitors targeting the PD-1/PD-L1 interaction.  In addn., the preliminary structure-activity relationships of these new indoline compds. were investigated in this study, providing valuable information for future drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7nYUI852jyLVg90H21EOLACvtfcHk0ljBFRtos0_Ijw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFOmu7zN&md5=b757929dd24437bb5af585e73a884a51</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111856&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111856%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DHou%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520the%2520programmed%2520cell%2520death-1%252Fprogrammed%2520cell%2520death-ligand%25201%2520interaction%2520inhibitors%2520bearing%2520an%2520indoline%2520scaffold%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D186%26spage%3D111856%26doi%3D10.1016%2Fj.ejmech.2019.111856" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shekarian, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valsesia-Wittmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marabelle, A.</span></span> <span> </span><span class="NLM_article-title">Paradigm shift in oncology: targeting the immune system rather than cancer cells</span>. <i>Mutagenesis</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">211</span>, <span class="refDoi"> DOI: 10.1093/mutage/geu073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1093%2Fmutage%2Fgeu073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=25688113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlaqs73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2015&pages=205-211&author=T.+Shekarianauthor=S.+Valsesia-Wittmannauthor=C.+Cauxauthor=A.+Marabelle&title=Paradigm+shift+in+oncology%3A+targeting+the+immune+system+rather+than+cancer+cells&doi=10.1093%2Fmutage%2Fgeu073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Paradigm shift in oncology: targeting the immune system rather than cancer cells</span></div><div class="casAuthors">Shekarian, Tala; Valsesia-Wittmann, Sandrine; Caux, Christophe; Marabelle, Aurelien</div><div class="citationInfo"><span class="NLM_cas:title">Mutagenesis</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">205-211</span>CODEN:
                <span class="NLM_cas:coden">MUTAEX</span>;
        ISSN:<span class="NLM_cas:issn">0267-8357</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The clin. benefits obtained with rituximab in the treatment of CD20+ B-cell malignancies and of imatinib in the treatment of Phi+ leukemias have opened a new era in oncol., transforming the concepts of tumor-targeted therapies and personalised medicine into reality.  Since then, many tumor-targeted monoclonal antibodies and tyrosine kinase inhibitors have been approved for the treatment of cancers.  Compared to conventional chemotherapies, these new drugs have more specificity against cancer cells and less systemic toxicities.  However, like conventional chemotherapies, they often provide limited therapeutic benefits with short-lasting tumor responses as the vast majority of cancers become resistant to these drugs over time.  Therefore, tumor-targeted therapies are an incremental innovation as compared to historical chemotherapies.  Recently, a paradigm shift has been brought to the clinic with drugs targeting immune cells rather than cancer cells with the aim of stimulating the anti-tumor immune response of patients against their own cancer.  Immunomodulatory drugs such as anti-CTLA4 and anti-PD-1 have generated long-lasting tumor responses when used as single agent in patients with refractory/relapsing cancers such as metastatic melanomas, renal cell carcinoma or non-small-cell lung carcinoma.  These new immune-targeted therapies are therefore a disruptive innovation in cancer treatment: they demonstrate that long-lasting clin. benefits could be obtained by targeting mols. involved in the immune tolerance of cancer cells rather than by targeting oncogenic drivers or antigens expressed by cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIgftDslSuLbVg90H21EOLACvtfcHk0ljBFRtos0_Ijw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlaqs73L&md5=ca56e09fd20963569e1829a8c91d7759</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1093%2Fmutage%2Fgeu073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fmutage%252Fgeu073%26sid%3Dliteratum%253Aachs%26aulast%3DShekarian%26aufirst%3DT.%26aulast%3DValsesia-Wittmann%26aufirst%3DS.%26aulast%3DCaux%26aufirst%3DC.%26aulast%3DMarabelle%26aufirst%3DA.%26atitle%3DParadigm%2520shift%2520in%2520oncology%253A%2520targeting%2520the%2520immune%2520system%2520rather%2520than%2520cancer%2520cells%26jtitle%3DMutagenesis%26date%3D2015%26volume%3D30%26spage%3D205%26epage%3D211%26doi%3D10.1093%2Fmutage%2Fgeu073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Screening of kinase inhibitors downregulating PD-L1 expression via on/in cell quantitative immunoblots</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">105088</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2019.105088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1016%2Fj.ejps.2019.105088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=31626963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFCjsL%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2020&pages=105088&author=Y.+Xieauthor=J.+Dingauthor=X.+Cuiauthor=M.+Wuauthor=C.+Huangauthor=R.+Zhangauthor=J.+Wangauthor=X.+Liauthor=S.+Cenauthor=J.+Zhou&title=Screening+of+kinase+inhibitors+downregulating+PD-L1+expression+via+on%2Fin+cell+quantitative+immunoblots&doi=10.1016%2Fj.ejps.2019.105088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Screening of kinase inhibitors down-regulating PD-L1 expression via on/in cell quantitative immunoblots.</span></div><div class="casAuthors">Xie, Yongli; Ding, Jiwei; Cui, Xiangling; Wu, Meng; Huang, Chenchao; Zhang, Rongyu; Wang, Jing; Li, Xiaoyu; Cen, Shan; Zhou, Jinming</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">105088</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The interaction of programmed death-1 (PD-1) and its ligands (PD-L1) is an important immune checkpoint and blockade of PD-1/PD-L1 axis with antibodies against PD-L1 showed promising anti-tumor activity in clin. practice.  However, only a small percentage of patients can benefit from PD-L1 mAbs.  Small mol. kinase inhibitors have been widely used as antitumor drugs for many years, and several kinase inhibitors were recently reported to inhibit the expression of PD-L1.  However, the connections between PD-L1 expression and kinase inhibitors were not thoroughly elucidated.  Herein, we set up a novel and robust screening system to identify small mol. compds. which down-regulate the PD-L1 level of tumor cell based on Odyssey on/in cell quant. immunoblots technol.  A collected kinase inhibitor library was screened and 14 hits were further confirmed by western blot and flow cytometry.  System biol. anal. and further bio-assay identified a synergy combination between KU-60019 and Vacquinol-1 in down-regulation of PD-L1.  Taken together, the work established a novel method to screen the PD-L1 down-regulators using kinase inhibitors library, thus providing new clues for the application of kinase inhibitors in cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqspW2LcYpa7bVg90H21EOLACvtfcHk0ljOnOvdn73LPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFCjsL%252FI&md5=42a12c5e2c1f84670b47d9211debd279</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2019.105088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2019.105088%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DCen%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DScreening%2520of%2520kinase%2520inhibitors%2520downregulating%2520PD-L1%2520expression%2520via%2520on%252Fin%2520cell%2520quantitative%2520immunoblots%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2020%26volume%3D142%26spage%3D105088%26doi%3D10.1016%2Fj.ejps.2019.105088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span> <span> </span><span class="NLM_article-title">In vitro assay for the development of small molecule inhibitors targeting PD-1/PD-L1</span>. <i>Methods Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>629</i></span>,  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">381</span>, <span class="refDoi"> DOI: 10.1016/bs.mie.2019.05.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1016%2Fbs.mie.2019.05.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=31727249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisVyrt7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=629&publication_year=2019&pages=361-381&author=W.+Zhaiauthor=X.+Zhouauthor=J.+Duauthor=Y.+Gao&title=In+vitro+assay+for+the+development+of+small+molecule+inhibitors+targeting+PD-1%2FPD-L1&doi=10.1016%2Fbs.mie.2019.05.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro assay for the development of small molecule inhibitors targeting PD-1/PD-L1</span></div><div class="casAuthors">Zhai, Wenjie; Zhou, Xiuman; Du, Jiangfeng; Gao, Yanfeng</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">629</span>
        (<span class="NLM_cas:issue">Tumor Immunology and Immunotherapy: Molecular Methods</span>),
    <span class="NLM_cas:pages">361-381</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Cancer immunotherapy has recently emerged as one of the hot research field since clin. successes achieved by antibody drugs of immune checkpoints, among which PD-1 and its ligand PD-L1 are the well established mols.  PD-1/PD-L1 pathway induces immune tolerance and immune evasion, esp. in tumor microenvironment, cancer cell is capable to escape the immune surveillance by up-regulating the expression level of PD-1 or PD-L1.  Blockade of PD-1/PD-L1 can unleash the anti-tumor activity, and the strategy shows great successes in the treatment of various cancer types in the late stage.  Beside antibody drugs, many other mols. such as peptides, high affinity PD(L)-1 mutants, chem. compds., and DNA aptamers are designed for inhibitors of PD-1/PD-L1 pathway.  Each modulators show their pros and cons based on their own physiochem. properties.  Here we introduced the methods for identifying low mol. wt. inhibitors of PD-1/PD-L1 and mainly discussed the cell-based blocking test.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpciI296XaTR7Vg90H21EOLACvtfcHk0ljOnOvdn73LPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisVyrt7fM&md5=29aae0a76aecb165f5a5a28835f68845</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fbs.mie.2019.05.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.mie.2019.05.051%26sid%3Dliteratum%253Aachs%26aulast%3DZhai%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DY.%26atitle%3DIn%2520vitro%2520assay%2520for%2520the%2520development%2520of%2520small%2520molecule%2520inhibitors%2520targeting%2520PD-1%252FPD-L1%26jtitle%3DMethods%2520Enzymol.%26date%3D2019%26volume%3D629%26spage%3D361%26epage%3D381%26doi%3D10.1016%2Fbs.mie.2019.05.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, D.</span></span> <span> </span><span class="NLM_article-title">SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1</span>. <i>EBioMedicine</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1016/j.ebiom.2019.01.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1016%2Fj.ebiom.2019.01.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=30711516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A280%3ADC%252BB3cjot1Khtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2019&pages=151-162&author=N.+Zhangauthor=Y.+Douauthor=L.+Liuauthor=X.+Zhangauthor=X.+Liuauthor=Q.+Zengauthor=Y.+Liuauthor=M.+Yinauthor=X.+Liuauthor=H.+Dengauthor=D.+Song&title=SA-49%2C+a+novel+aloperine+derivative%2C+induces+MITF-dependent+lysosomal+degradation+of+PD-L1&doi=10.1016%2Fj.ebiom.2019.01.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1</span></div><div class="casAuthors">Zhang Na; Zhang Xin; Liu Xiaojia; Zeng Qingxuan; Liu Yang; Yin Mingxiao; Liu Xiujun; Dou Yueying; Liu Lu; Deng Hongbin; Song Danqing</div><div class="citationInfo"><span class="NLM_cas:title">EBioMedicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">151-162</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Programmed death-ligand 1 (PD-L1) is a T-cell inhibitory checkpoint molecule that suppresses antitumor immunity.  Anti-PD-L1 antibodies have shown remarkable promise in treating tumors, but the patient response rate is low.  Therefore, small-molecule checkpoint inhibitors blocking PD-L1 function are urgently needed.  METHODS:  Changes of protein expression and phosphorylation levels were determined by immunoblotting.  The level of Membrane PD-L1 was examined by flow cytometer.  Cytotoxicity of T cells and NK cells toward tumor cells were detected using LDH and cell index assays.  Lysosome function was investigated by NAG assay.  Changes in lysosomal-related genes were measured by RT-PCR.  In vivo anti-NSCLC cancer effects were assessed using C57BL/6 mice bearing Lewis tumor xenografts.  FINDINGS:  We identified SA-49 as a new regulator of PD-L1 expression from a series of novel aloperine derivatives.  SA-49 decreased the expression of PD-L1 in NSCLC cells and enhanced the cytotoxicity of co-cultured T and NK cells toward tumor cells.  Importantly, lysosomal pathway contributed to SA-49-mediated down-regulation of PD-L1.  SA-49 increased the biogenesis of lysosome and promoted translocation of PD-L1 to lysosome for proteolysis, which was associated with nuclear translocation of MITF.  SA-49-induced MITF translocation acted through activation of PKCα and subsequently suppression of GSK3β activity.  Furthermore, SA-49 suppressed Lewis tumor xenograft growth by activating immune microenvironment in C57BL/6 mice.  INTERPRETATION:  Our data demonstrate that SA-49 can be used to regulate PD-L1 in cancer cells and trigger its degradation by activating lysosome function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ6YPF3oXZ1MVm8bhe6roZYfW6udTcc2eaw3yaQl0zjF7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjot1Khtg%253D%253D&md5=cc0b3398c65bdd729dde73f45492af6e</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.ebiom.2019.01.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ebiom.2019.01.054%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DDou%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYin%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DDeng%26aufirst%3DH.%26aulast%3DSong%26aufirst%3DD.%26atitle%3DSA-49%252C%2520a%2520novel%2520aloperine%2520derivative%252C%2520induces%2520MITF-dependent%2520lysosomal%2520degradation%2520of%2520PD-L1%26jtitle%3DEBioMedicine%26date%3D2019%26volume%3D40%26spage%3D151%26epage%3D162%26doi%3D10.1016%2Fj.ebiom.2019.01.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>199</i></span>,  <span class="NLM_fpage">112377</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112377</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1016%2Fj.ejmech.2020.112377" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=32388281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptFGisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=199&publication_year=2020&pages=112377&author=B.+Chengauthor=Y.+Renauthor=H.+Caoauthor=J.+Chen&title=Discovery+of+novel+resorcinol+diphenyl+ether-based+PROTAC-like+molecules+as+dual+inhibitors+and+degraders+of+PD-L1&doi=10.1016%2Fj.ejmech.2020.112377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1</span></div><div class="casAuthors">Cheng, Binbin; Ren, Yichang; Cao, Hao; Chen, Jianjun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">199</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112377</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Novel resorcinol di-Ph ether-based PROTACs (PROteolysis TArgeting Chimeras) were designed and evaluated for their inhibitory activity against the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) pathway and their ability to degrade PD-L1 protein.  Most of the compds. displayed excellent inhibitory activities against PD-1/PD-L1, as assessed by the homogeneous time-resolved fluorescence (HTRF) binding assay, with IC50 values ranging from 25 nM to 200 nM.  Among them, compd. P22 (I) is one of the best with an IC50 value of 39.2 nM.  In addn. to inhibiting PD-1/PD-L1 interaction, P22 also significantly restored the immunity repressed in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells.  Furthermore, flow cytometry (FCM) and western-blot data demonstrated that P22 could moderately reduce the protein levels of PD-L1 in a lysosome-dependent manner, which may contribute to its immune effects.  Preliminary FCM and western-blot data suggest that it is possible to build PD-L1-targeting PROTAC-like mols. based on PD-1/PD-L1 small mol. inhibitors, though these compds. showed only modest degrdn. efficiencies.  Collectively, this work suggests that P22 may serve as a starting point for exploring the degrdn. of PD-L1 by PROTAC-like strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiG4nI2klh77Vg90H21EOLACvtfcHk0ljlTTAo4R65ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptFGisLk%253D&md5=ec722d2e118668f601c0f9648e6f893b</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112377%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DB.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DCao%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520novel%2520resorcinol%2520diphenyl%2520ether-based%2520PROTAC-like%2520molecules%2520as%2520dual%2520inhibitors%2520and%2520degraders%2520of%2520PD-L1%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D199%26spage%3D112377%26doi%3D10.1016%2Fj.ejmech.2020.112377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">D’Andrea, A. D.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of PARP inhibitor sensitivity and resistance</span>. <i>DNA Repair</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">172</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1016/j.dnarep.2018.08.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1016%2Fj.dnarep.2018.08.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=30177437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Cgs7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2018&pages=172-176&author=A.+D.+D%E2%80%99Andrea&title=Mechanisms+of+PARP+inhibitor+sensitivity+and+resistance&doi=10.1016%2Fj.dnarep.2018.08.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of PARP inhibitor sensitivity and resistance</span></div><div class="casAuthors">D'Andrea, Alan D.</div><div class="citationInfo"><span class="NLM_cas:title">DNA Repair</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">172-176</span>CODEN:
                <span class="NLM_cas:coden">DRNEAR</span>;
        ISSN:<span class="NLM_cas:issn">1568-7864</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">BRCA1 and BRCA2 deficient tumor cells are sensitive to inhibitors of Poly ADP Ribose Polymerase (PARP1) through the mechanism of synthetic lethality.  Several PARP inhibitors, which are oral drugs and generally well tolerated, have now received FDA approval for various ovarian cancer and breast cancer indications.  Despite their use in the clinic, PARP inhibitor resistance is common and develops through multiple mechanisms.  Broadly speaking, BRCA1/2-deficient tumor cells can become resistant to PARP inhibitors by restoring homologous recombination (HR) repair and/or by stabilizing their replication forks.  Here, we review the mechanism of PARP inhibitor resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvIBaDAbajp7Vg90H21EOLACvtfcHk0ljlTTAo4R65ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Cgs7jI&md5=892ee46fb9b85c7eb00193584b5557b9</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.dnarep.2018.08.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.dnarep.2018.08.021%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DA.%2BD.%26atitle%3DMechanisms%2520of%2520PARP%2520inhibitor%2520sensitivity%2520and%2520resistance%26jtitle%3DDNA%2520Repair%26date%3D2018%26volume%3D71%26spage%3D172%26epage%3D176%26doi%3D10.1016%2Fj.dnarep.2018.08.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drean, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lord, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span> <span> </span><span class="NLM_article-title">PARP inhibitor combination therapy</span>. <i>Crit Rev. Oncol Hematol</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1016/j.critrevonc.2016.10.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1016%2Fj.critrevonc.2016.10.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=27931843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A280%3ADC%252BC2sjkvFCgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2016&pages=73-85&author=A.+Dreanauthor=C.+J.+Lordauthor=A.+Ashworth&title=PARP+inhibitor+combination+therapy&doi=10.1016%2Fj.critrevonc.2016.10.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">PARP inhibitor combination therapy</span></div><div class="casAuthors">Drean Amy; Lord Christopher J; Ashworth Alan</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">73-85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In 2014, olaparib (Lynparza) became the first PARP (Poly(ADP-ribose) polymerase) inhibitor to be approved for the treatment of cancer.  When used as single agents, PARP inhibitors can selectively target tumour cells with BRCA1 or BRCA2 tumour suppressor gene mutations through synthetic lethality.  However, PARP inhibition also shows considerable promise when used together with other therapeutic agents.  Here, we summarise both the pre-clinical and clinical evidence for the utility of such combinations and discuss the future prospects and challenges for PARP inhibitor combinatorial therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRrc1DGTVYh3rBItaL1WaVAfW6udTcc2eYNY4xmppPibbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjkvFCgtA%253D%253D&md5=77ba6fe10daf60936688cf320259e996</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2016.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2016.10.010%26sid%3Dliteratum%253Aachs%26aulast%3DDrean%26aufirst%3DA.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DPARP%2520inhibitor%2520combination%2520therapy%26jtitle%3DCrit%2520Rev.%2520Oncol%2520Hematol%26date%3D2016%26volume%3D108%26spage%3D73%26epage%3D85%26doi%3D10.1016%2Fj.critrevonc.2016.10.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Washington, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, K. N.</span></span> <span> </span><span class="NLM_article-title">Olaparib in the treatment of ovarian cancer</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3435</span>– <span class="NLM_lpage">3449</span>, <span class="refDoi"> DOI: 10.2217/fon-2019-0271</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.2217%2Ffon-2019-0271" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=31478762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVemsLbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=3435-3449&author=C.+R.+Washingtonauthor=D.+L.+Richardsonauthor=K.+N.+Moore&title=Olaparib+in+the+treatment+of+ovarian+cancer&doi=10.2217%2Ffon-2019-0271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Olaparib in the treatment of ovarian cancer</span></div><div class="casAuthors">Washington, Christina R.; Richardson, Debra L.; Moore, Kathleen N.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">3435-3449</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1744-8301</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  The poly ADP ribose polymerase olaparib is currently approved in front line BRCA-assocd. epithelial ovarian cancer (EOC), platinum-sensitive recurrence agnostic to BRCA status and for gBRCA as treatment in the fourth line and beyond.  Women who are diagnosed with advanced stage EOC face a formidable challenge in overcoming their disease and achieving long-term, disease-free survival.  The qualifier here is disease free.  EOC is largely exquisitely chemosensitive, esp. in the treatment naive (first line) setting and the expectation is that the vast majority of women will complete front line platinum-based chemotherapy with a response.  When unselected (not selected by BRCA) women are enrolled on clin. trials, the response rate among those who have measurable disease at the time of chemotherapy initiation is 48% for carboplatin/paclitaxel and 67% for carboplatin/paclitaxel plus bevacizumab.  When one considers the addn. of women who start chemotherapy without measurable disease, they will likely also end chemotherapy without measurable disease and the overall rate of no evidence of disease at conclusion of chemotherapy approaches 80%.  Despite this, the majority of women will suffer relapse of their disease, typically within the first 3 years following completion of therapy.  Once recurrent, the disease is highly treatable for many years but no longer considered curable.  This review will cover indications for olaparib in ovarian cancer as well as ongoing combination trials and rationale for these combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWQxXw7FIWK7Vg90H21EOLACvtfcHk0ljlTTAo4R65ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVemsLbL&md5=564943e170c6c5cc0e085a4e38b1f7a8</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.2217%2Ffon-2019-0271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon-2019-0271%26sid%3Dliteratum%253Aachs%26aulast%3DWashington%26aufirst%3DC.%2BR.%26aulast%3DRichardson%26aufirst%3DD.%2BL.%26aulast%3DMoore%26aufirst%3DK.%2BN.%26atitle%3DOlaparib%2520in%2520the%2520treatment%2520of%2520ovarian%2520cancer%26jtitle%3DFuture%2520Oncol.%26date%3D2019%26volume%3D15%26spage%3D3435%26epage%3D3449%26doi%3D10.2217%2Ffon-2019-0271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilie, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span> <span> </span><span class="NLM_article-title">Development of PARP and immune-checkpoint inhibitor combinations</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">6717</span>– <span class="NLM_lpage">6725</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-18-2652</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1158%2F0008-5472.CAN-18-2652" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=30498083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnsVKnt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=6717-6725&author=R.+A.+Stewartauthor=P.+G.+Pilieauthor=T.+A.+Yap&title=Development+of+PARP+and+immune-checkpoint+inhibitor+combinations&doi=10.1158%2F0008-5472.CAN-18-2652"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Development of PARP and immune-checkpoint inhibitor combinations</span></div><div class="casAuthors">Stewart, Ross A.; Pilie, Patrick G.; Yap, Timothy A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6717-6725</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PARP inhibitors drive increased DNA damage, particularly in tumors with existing defects in DNA repair.  This damage not only promotes immune priming through a range of mol. mechanisms, but also leads to adaptive upregulation of programmed death ligand 1 (PD-L1) expression.  In this context, PARP inhibition and programmed cell death 1(PD-1)/PD-L1-targeting antibodies represent a rationale combination.  In this review, we detail the basic and translational science underpinning this promising new combination, summarize available clin. data, and discuss the key questions that remain to be addressed during future development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUomq4ben3XbVg90H21EOLACvtfcHk0lh0zxZXwi37Gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnsVKnt7o%253D&md5=5f24d1a52ea99f8269b4b6a5aebcdf31</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-18-2652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-18-2652%26sid%3Dliteratum%253Aachs%26aulast%3DStewart%26aufirst%3DR.%2BA.%26aulast%3DPilie%26aufirst%3DP.%2BG.%26aulast%3DYap%26aufirst%3DT.%2BA.%26atitle%3DDevelopment%2520of%2520PARP%2520and%2520immune-checkpoint%2520inhibitor%2520combinations%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26spage%3D6717%26epage%3D6725%26doi%3D10.1158%2F0008-5472.CAN-18-2652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ofori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awuah, S. G.</span></span> <span> </span><span class="NLM_article-title">Small-molecule poly(ADP-ribose) polymerase and PD-L1 inhibitor conjugates as dual-action anticancer agents</span>. <i>ACS Omega</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">12584</span>– <span class="NLM_lpage">12597</span>, <span class="refDoi"> DOI: 10.1021/acsomega.9b01106</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsomega.9b01106" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVWrsLzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&pages=12584-12597&author=S.+Oforiauthor=S.+G.+Awuah&title=Small-molecule+poly%28ADP-ribose%29+polymerase+and+PD-L1+inhibitor+conjugates+as+dual-action+anticancer+agents&doi=10.1021%2Facsomega.9b01106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Poly(ADP-ribose) Polymerase and PD-L1 Inhibitor Conjugates as Dual-Action Anticancer Agents</span></div><div class="casAuthors">Ofori, Samuel; Awuah, Samuel G.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Omega</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">12584-12597</span>CODEN:
                <span class="NLM_cas:coden">ACSODF</span>;
        ISSN:<span class="NLM_cas:issn">2470-1343</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Immune checkpoint blockades have revolutionized the treatment landscape for several cancer indications, yet they have not gained traction in a range of other tumors such as triple-neg. breast cancer.  Despite durable disease control by many patients, a third of cancer patients relapse due to acquired resistance.  Combined immunotherapy has shown significant promise to overcome these grand challenges.  In this report, we describe the synthesis and characterization of dual-action small-mol. PARP1/PD-L1 inhibitor conjugates as potential targeted anticancer agents.  These conjugates display significant apoptosis and cytotoxic efficacy to approx. 2-20-fold better than their individual agents in a panel of cancer cell lines.  This was underscored by derived combination indexes, which was consistent with strong synergy when cells were treated with the individual agents, olaparib and BMS-001 using the Chou-Talalay method.  Furthermore, we sought to unravel the mechanistic behavior of the conjugates and their implications on the PARP/PD-L1 axis.  We used apoptosis, cell cycle, immunoblotting, and T-cell proliferation assays to establish the synergy imparted by these conjugates.  These multifunctional compds. enable the discovery of small-mol. immunochemotherapeutic agents and chem. probes to elucidate the cross-talk between DNA repair and PD-L1 pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0QoqQg4ov77Vg90H21EOLACvtfcHk0lh0zxZXwi37Gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVWrsLzO&md5=761d4be91f27085012db8e76a9247c38</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Facsomega.9b01106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsomega.9b01106%26sid%3Dliteratum%253Aachs%26aulast%3DOfori%26aufirst%3DS.%26aulast%3DAwuah%26aufirst%3DS.%2BG.%26atitle%3DSmall-molecule%2520poly%2528ADP-ribose%2529%2520polymerase%2520and%2520PD-L1%2520inhibitor%2520conjugates%2520as%2520dual-action%2520anticancer%2520agents%26jtitle%3DACS%2520Omega%26date%3D2019%26volume%3D4%26spage%3D12584%26epage%3D12597%26doi%3D10.1021%2Facsomega.9b01106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">42</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1038/s41589-018-0161-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1038%2Fs41589-018-0161-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=30397328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2qtbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=42-50&author=H.+Wangauthor=H.+Yaoauthor=C.+Liauthor=H.+Shiauthor=J.+Lanauthor=Z.+Liauthor=Y.+Zhangauthor=L.+Liangauthor=J.+Y.+Fangauthor=J.+Xu&title=HIP1R+targets+PD-L1+to+lysosomal+degradation+to+alter+T+cell-mediated+cytotoxicity&doi=10.1038%2Fs41589-018-0161-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity</span></div><div class="casAuthors">Wang, Huanbin; Yao, Han; Li, Chushu; Shi, Hubing; Lan, Jiang; Li, Zhaoli; Zhang, Yao; Liang, Lunxi; Fang, Jing-Yuan; Xu, Jie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">42-50</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Expression of programmed cell death 1 (PD-1) ligand 1 (PD-L1) protects tumor cells from T cell-mediated immune surveillance, and immune checkpoint blockade (ICB) therapies targeting PD-1 and PD-L1 have exhibited significant clin. benefits.  However, the relatively low response rate and obsd. ICB resistance highlight the need to understand the mol. regulation of PD-L1.  Here we show that HIP1R targets PD-L1 to lysosomal degrdn. to alter T cell-mediated cytotoxicity.  HIP1R phys. interacts with PD-L1 and delivers PD-L1 to the lysosome through a lysosomal targeting signal.  Depletion of HIP1R in tumor cells caused PD-L1 accumulation and suppressed T cell-mediated cytotoxicity.  A rationally designed peptide (PD-LYSO) incorporating the lysosome-sorting signal and the PD-L1-binding sequence of HIP1R successfully depleted PD-L1 expression in tumor cells.  Our results identify the mol. machineries governing the lysosomal degrdn. of PD-L1 and exemplify the development of a chimeric peptide for targeted degrdn. of PD-L1 as a crucial anticancer target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreVHjIVSWPmLVg90H21EOLACvtfcHk0lh0zxZXwi37Gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2qtbbN&md5=eac9da24ac6ff6e17cf10cfc6ee2c08a</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1038%2Fs41589-018-0161-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41589-018-0161-x%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DLan%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DFang%26aufirst%3DJ.%2BY.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DHIP1R%2520targets%2520PD-L1%2520to%2520lysosomal%2520degradation%2520to%2520alter%2520T%2520cell-mediated%2520cytotoxicity%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2019%26volume%3D15%26spage%3D42%26epage%3D50%26doi%3D10.1038%2Fs41589-018-0161-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bu, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Z. J.</span></span> <span> </span><span class="NLM_article-title">STAT3 induces immunosuppression by upregulating PD-1/PD-L1 in HNSCC</span>. <i>J. Dent. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">1027</span>– <span class="NLM_lpage">1034</span>, <span class="refDoi"> DOI: 10.1177/0022034517712435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1177%2F0022034517712435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=28605599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltV2qug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2017&pages=1027-1034&author=L.+L.+Buauthor=G.+T.+Yuauthor=L.+Wuauthor=L.+Maoauthor=W.+W.+Dengauthor=J.+F.+Liuauthor=A.+B.+Kulkarniauthor=W.+F.+Zhangauthor=L.+Zhangauthor=Z.+J.+Sun&title=STAT3+induces+immunosuppression+by+upregulating+PD-1%2FPD-L1+in+HNSCC&doi=10.1177%2F0022034517712435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC</span></div><div class="casAuthors">Bu, L. L.; Yu, G. T.; Wu, L.; Mao, L.; Deng, W. W.; Liu, J. F.; Kulkarni, A. B.; Zhang, W. F.; Zhang, L.; Sun, Z. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Dental Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1027-1034</span>CODEN:
                <span class="NLM_cas:coden">JDREAF</span>;
        ISSN:<span class="NLM_cas:issn">0022-0345</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Head and neck cancer is one of the most prevalent cancers around the world.  Head and neck squamous cell carcinoma (HNSCC) accounts for nearly 90% of head and neck cancer.  In recent years, significant advances have been made in immunotherapy for HNSCC.  Although some clin. trials targeting immune checkpoints have shown success, the mol. mechanism for regulation of programmed death 1 (PD-1) and its ligand (PD-L1) is partially understood.  In an effort to explore the effect of activation of signal transducers and activators of transcriptions (STAT3) on PD-1/PD-L1, the expression and correlation between phosphorylation of STAT3 and PD-1/PD-L1 were detd. with immunostaining of human and mouse HNSCC tissue sections.  PD-1/PD-L1 overexpression was found to be significantly assocd. with p-STAT3 in human and mouse HNSCC.  Targeting STAT3 by a small mol. effectively inhibited the expression of PD-L1 in the CAL27 cell line.  Furthermore, we found that blockade of STAT3 signaling downregulated PD-1/PD-L1 in a Tgfbr1/Pten 2cKO HNSCC mouse model.  These findings suggest that STAT3 signaling plays an important role in PD-1/PD-L1 regulation and the antitumor immune response of HNSCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_CXJ7Mr4wubVg90H21EOLACvtfcHk0lhZ3Bf4dYEsAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltV2qug%253D%253D&md5=e16c8a4c14a1d7c1d4da626cc6c3a62c</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1177%2F0022034517712435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0022034517712435%26sid%3Dliteratum%253Aachs%26aulast%3DBu%26aufirst%3DL.%2BL.%26aulast%3DYu%26aufirst%3DG.%2BT.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DMao%26aufirst%3DL.%26aulast%3DDeng%26aufirst%3DW.%2BW.%26aulast%3DLiu%26aufirst%3DJ.%2BF.%26aulast%3DKulkarni%26aufirst%3DA.%2BB.%26aulast%3DZhang%26aufirst%3DW.%2BF.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DZ.%2BJ.%26atitle%3DSTAT3%2520induces%2520immunosuppression%2520by%2520upregulating%2520PD-1%252FPD-L1%2520in%2520HNSCC%26jtitle%3DJ.%2520Dent.%2520Res.%26date%3D2017%26volume%3D96%26spage%3D1027%26epage%3D1034%26doi%3D10.1177%2F0022034517712435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">Regulation of PD-L1: emerging routes for targeting tumor immune evasion</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">536</span>, <span class="refDoi"> DOI: 10.3389/fphar.2018.00536</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.3389%2Ffphar.2018.00536" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=29910728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFyrsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=536&author=Y.+Wangauthor=H.+Wangauthor=H.+Yaoauthor=C.+Liauthor=J.+Y.+Fangauthor=J.+Xu&title=Regulation+of+PD-L1%3A+emerging+routes+for+targeting+tumor+immune+evasion&doi=10.3389%2Ffphar.2018.00536"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of PD-L1: emerging routes for targeting tumor immune evasion</span></div><div class="casAuthors">Wang, Yiting; Wang, Huanbin; Yao, Han; Li, Chushu; Fang, Jing-Yuan; Xu, Jie</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">536/1-536/13</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Immune checkpoint blockade therapies (ICBTs) targeting programmed cell death 1 (PD-1) and its ligand programmed death ligand-1 (PD-L1/B7-H1/CD274) have exhibited momentous clin. benefits and durable responses in multiple tumor types.  However, primary resistance is found in considerable no. of cancer patients, and most responders eventually develop acquired resistance to ICBT.  To tackle these challenges, it is essential to understand how PD-L1 is controlled by cancer cells to evade immune surveillance.  Recent research has shed new light into the mechanisms of PD-L1 regulation at genetic, epigenetic, transcriptional, translational, and posttranslational levels.  In this work, we systematically discuss the mechanisms that control the gene amplification, epigenetic alteration, transcription, subcellular transportation and posttranscriptional modification of PD-L1 in cancer cells.  We further categorize posttranscriptional PD-L1 regulations by the mol. modification of PD-L1, including glycosylation, phosphorylation, ubiquitination, deubiquitination, and lysosomal degrdn.  These findings may provide new routes for targeting tumor immune escape and catalyze the development of small mol. inhibitors of PD-L1 in addn. to existing antibody drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcgJr7PjbSvbVg90H21EOLACvtfcHk0lhZ3Bf4dYEsAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFyrsLg%253D&md5=96815e00642aaec4309c3cccf90ed22e</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.00536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.00536%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DFang%26aufirst%3DJ.%2BY.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DRegulation%2520of%2520PD-L1%253A%2520emerging%2520routes%2520for%2520targeting%2520tumor%2520immune%2520evasion%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26spage%3D536%26doi%3D10.3389%2Ffphar.2018.00536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M. C.</span></span> <span> </span><span class="NLM_article-title">Posttranslational modifications of PD-L1 and their applications in cancer therapy</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">6349</span>– <span class="NLM_lpage">6353</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-18-1892</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1158%2F0008-5472.CAN-18-1892" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=30442814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmt1Wmtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=6349-6353&author=J.+M.+Hsuauthor=C.+W.+Liauthor=Y.+J.+Laiauthor=M.+C.+Hung&title=Posttranslational+modifications+of+PD-L1+and+their+applications+in+cancer+therapy&doi=10.1158%2F0008-5472.CAN-18-1892"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Posttranslational modifications of PD-L1 and their applications in cancer therapy</span></div><div class="casAuthors">Hsu, Jung-Mao; Li, Chia-Wei; Lai, Yun-Ju; Hung, Mien-Chie</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6349-6353</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Posttranslational modifications (PTM) of PD-L1 have emerged as important regulatory mechanisms that modulate immunosuppression in patients with cancer.  In exposure to inflammatory cytokines, cancer cells and antigen-presenting cells, such as macrophages and dendritic cells, express PD-L1 to inhibit the activity of effector T cells through PD-1 engagement.  Recent studies suggested that glycosylation, phosphorylation, ubiquitination, sumoylation, and acetylation play important roles in the regulation of PD-L1 protein stability and translocation and protein-protein interactions.  Aberrant alterations of PTMs directly influence PD-L1-mediated immune resistance.  On the basis of the newly identified regulatory signaling pathways of PD-L1 PTMs, researchers have investigated the cancer therapeutic potential of natural food compds., small-mol. inhibitors, and mAbs by targeting PD-L1 PTMs.  Results of these preclin. studies demonstrated that targeting PTMs of PD-L1 yields promising antitumor effects and that clin. translation of these therapeutic strategies is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooUYw8JTFgb7Vg90H21EOLACvtfcHk0lhZ3Bf4dYEsAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmt1Wmtbg%253D&md5=4b13bcee212f423f825f33c38cbe427a</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-18-1892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-18-1892%26sid%3Dliteratum%253Aachs%26aulast%3DHsu%26aufirst%3DJ.%2BM.%26aulast%3DLi%26aufirst%3DC.%2BW.%26aulast%3DLai%26aufirst%3DY.%2BJ.%26aulast%3DHung%26aufirst%3DM.%2BC.%26atitle%3DPosttranslational%2520modifications%2520of%2520PD-L1%2520and%2520their%2520applications%2520in%2520cancer%2520therapy%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26spage%3D6349%26epage%3D6353%26doi%3D10.1158%2F0008-5472.CAN-18-1892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bengsch, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svoronos, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkowski, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitler, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allegrezza, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kossenkov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conejo-Garcia, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span> <span> </span><span class="NLM_article-title">BET bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2829</span>– <span class="NLM_lpage">2837</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2016.08.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1016%2Fj.celrep.2016.08.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=27626654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFWht7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=2829-2837&author=H.+Zhuauthor=F.+Bengschauthor=N.+Svoronosauthor=M.+R.+Rutkowskiauthor=B.+G.+Bitlerauthor=M.+J.+Allegrezzaauthor=Y.+Yokoyamaauthor=A.+V.+Kossenkovauthor=J.+E.+Bradnerauthor=J.+R.+Conejo-Garciaauthor=R.+Zhang&title=BET+bromodomain+inhibition+promotes+anti-tumor+immunity+by+suppressing+PD-L1+expression&doi=10.1016%2Fj.celrep.2016.08.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression</span></div><div class="casAuthors">Zhu, Hengrui; Bengsch, Fee; Svoronos, Nikolaos; Rutkowski, Melanie R.; Bitler, Benjamin G.; Allegrezza, Michael J.; Yokoyama, Yuhki; Kossenkov, Andrew V.; Bradner, James E.; Conejo-Garcia, Jose R.; Zhang, Rugang</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2829-2837</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Restoration of anti-tumor immunity by blocking PD-L1 signaling through the use of antibodies has proven to be beneficial in cancer therapy.  Here, we show that BET bromodomain inhibition suppresses PD-L1 expression and limits tumor progression in ovarian cancer.  CD274 (encoding PD-L1) is a direct target of BRD4-mediated gene transcription.  In mouse models, treatment with the BET inhibitor JQ1 significantly reduced PD-L1 expression on tumor cells and tumor-assocd. dendritic cells and macrophages, which correlated with an increase in the activity of anti-tumor cytotoxic T cells.  The BET inhibitor limited tumor progression in a cytotoxic T-cell-dependent manner.  Together, these data demonstrate a small-mol. approach to block PD-L1 signaling.  Given the fact that BET inhibitors have been proven to be safe with manageable reversible toxicity in clin. trials, our findings indicate that pharmacol. BET inhibitors represent a treatment strategy for targeting PD-L1 expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp--rKN-Dcm3bVg90H21EOLACvtfcHk0li-GI18CLwWZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFWht7jJ&md5=e84024537ea9ca83be4e5b7ad7043616</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2016.08.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2016.08.032%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DBengsch%26aufirst%3DF.%26aulast%3DSvoronos%26aufirst%3DN.%26aulast%3DRutkowski%26aufirst%3DM.%2BR.%26aulast%3DBitler%26aufirst%3DB.%2BG.%26aulast%3DAllegrezza%26aufirst%3DM.%2BJ.%26aulast%3DYokoyama%26aufirst%3DY.%26aulast%3DKossenkov%26aufirst%3DA.%2BV.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DConejo-Garcia%26aufirst%3DJ.%2BR.%26aulast%3DZhang%26aufirst%3DR.%26atitle%3DBET%2520bromodomain%2520inhibition%2520promotes%2520anti-tumor%2520immunity%2520by%2520suppressing%2520PD-L1%2520expression%26jtitle%3DCell%2520Rep.%26date%3D2016%26volume%3D16%26spage%3D2829%26epage%3D2837%26doi%3D10.1016%2Fj.celrep.2016.08.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, M. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, F. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span> <span> </span><span class="NLM_article-title">C-Myc regulates PD-L1 expression in esophageal squamous cell carcinoma</span>. <i>Am. J. Transl. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">379</span>– <span class="NLM_lpage">388</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=32194890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVent7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=379-388&author=M.+Q.+Liangauthor=F.+Q.+Yuauthor=C.+Chen&title=C-Myc+regulates+PD-L1+expression+in+esophageal+squamous+cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">C-Myc regulates PD-L1 expressionin esophageal squamous cell carcinoma</span></div><div class="casAuthors">Liang, Ming-Qiang; Yu, Feng-Qiang; Chen, Chun</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Translational Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">379-388</span>CODEN:
                <span class="NLM_cas:coden">AJTRA7</span>;
        ISSN:<span class="NLM_cas:issn">1943-8141</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">Immunotherapy using antibodies blocking the programmed cell death 1 (PD-1)/programmed cell deathligand 1 (PD-L1) pathway has achieved great success in preclin. models and the clin. treatment of esophageal squamous cell carcinoma (ESCC).  The c-Myc proto-oncogene helps prevent immune cells from attacking tumor cells by inducing PD-L1 expression.  However, the underlying mechanisms of c-Myc and PD-L1 in ESCC remain unclear, and a thorough understanding of this regulation would allow the development of new approaches to enhance antitumor immunity.  In the present study, the pos. relationship between c-Myc and PD-L1 was explored in the Cancer Genome Atlas dataset using the bioinformatics tool GEPIA, and was confirmed in 105 ESCC tissues by immunostaining (r=0.516, P<0.001).  The patients pos. for both proteins had a poorer overall survival (P=0.032).  Furthermore, in ESCC cell lines, c-Myc overexpression, depletion, and inhibition was able to regulate the expression of PD-L1.  Also, the ChIP assays showed that the increase in PD-L1 expression was likely due to the binding of c-Myc to the PD-L1 promoter.  Taken together, c-Myc and PD-L1 levels were significantly correlated, and c-Myc expression regulated the expression of PD-L1 in ESCC cells.  In addn., a small mol. inhibitor of c-Myc effectively regulated PD-L1 expression.  This indicates that synergistic therapy combining a c-Myc inhibitor with PD-L1 immunotherapy might be a promising new treatment strategy for ESCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjOgN3IOR7OLVg90H21EOLACvtfcHk0li-GI18CLwWZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVent7%252FN&md5=262ac13061fbd2c68e2f6fec126acf39</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DM.%2BQ.%26aulast%3DYu%26aufirst%3DF.%2BQ.%26aulast%3DChen%26aufirst%3DC.%26atitle%3DC-Myc%2520regulates%2520PD-L1%2520expression%2520in%2520esophageal%2520squamous%2520cell%2520carcinoma%26jtitle%3DAm.%2520J.%2520Transl.%2520Res.%26date%3D2020%26volume%3D12%26spage%3D379%26epage%3D388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer</span>. <i>Gut</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">1764</span>– <span class="NLM_lpage">1773</span>, <span class="refDoi"> DOI: 10.1136/gutjnl-2018-316324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1136%2Fgutjnl-2018-316324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=30661053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BB3cXms1WhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2019&pages=1764-1773&author=C.+Linauthor=H.+Heauthor=H.+Liuauthor=R.+Liauthor=Y.+Chenauthor=Y.+Qiauthor=Q.+Jiangauthor=L.+Chenauthor=P.+Zhangauthor=H.+Zhangauthor=H.+Liauthor=W.+Zhangauthor=Y.+Sunauthor=J.+Xu&title=Tumour-associated+macrophages-derived+CXCL8+determines+immune+evasion+through+autonomous+PD-L1+expression+in+gastric+cancer&doi=10.1136%2Fgutjnl-2018-316324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer</span></div><div class="casAuthors">Lin, Chao; He, Hongyong; Liu, Hao; Li, Ruochen; Chen, Yifan; Qi, Yangyang; Jiang, Qi; Chen, Lingli; Zhang, Peipei; Zhang, Heng; Li, He; Zhang, Weijuan; Sun, Yihong; Xu, Jiejie</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1764-1773</span>CODEN:
                <span class="NLM_cas:coden">GUTTAK</span>;
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    
            (<span class="NLM_cas:orgname">BMJ</span>)
        </div><div class="casAbstract">Objective Our previous studies have identified CXCL8 as the crucial chemokine responsible for gastric cancer metastasis mediated by loss of RACK1.  However, the regulatory effect of CXCL8 on immune surveillance in gastric cancer remains obscure.  Design Flow cytometry analyses were performed to examine major source of CXCL8 and phenotypes of immune cells in fresh tumor tissues from 76 patients with gastric cancer.  Real-time PCR was performed to analyze CXCL8 mRNA level in gastric cancer tissues.  For immunohistochem. analyses, a total of 420 patients with gastric cancer undergoing curative resection were enrolled.  In vitro culture of fresh tumor tissue was performed to evaluate the potential therapeutic effect of blocking CXCL8 pathway in gastric cancer.  Results Increased level of CXCL8 indicates poor clin. outcome and tumor progression in patients with gastric cancer.  In gastric cancer tissues, CXCL8 is predominantly secreted by macrophages and colony stimulating factor 2 (CSF-2) facilitates macrophage-derived CXCL8 secretion.  High level of CXCL8 is assocd. with decreased CD8+ T cells infiltration and Ki67+ CD8+ T cells proportion.  Moreover, CXCL8 also inhibits CD8+ T cells function by inducing the expression of PD-L1 on macrophages.  Finally, we show that a small-mol. CXCR2 inhibitor, reparixin, drives the decreased programmed death-ligand 1 (PD-L1+) macrophages and promotes antitumor immunity.  Accordingly, high levels of CXCL8+ macrophages are pos. correlated with poor prognosis in patients with gastric cancer.  Conclusions CXCL8 is predominantly secreted by macrophages and contributes to the immunosuppressive microenvironment by inducing PD-L1+ macrophages in gastric cancer.  CXCL8 inhibitors may drive antitumor response, providing potential therapeutic effects for patients with gastric cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNL3D2anGOpbVg90H21EOLACvtfcHk0li-GI18CLwWZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXms1WhtA%253D%253D&md5=6555a4ad5cef67eb5da53cee75788492</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1136%2Fgutjnl-2018-316324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgutjnl-2018-316324%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DQi%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DTumour-associated%2520macrophages-derived%2520CXCL8%2520determines%2520immune%2520evasion%2520through%2520autonomous%2520PD-L1%2520expression%2520in%2520gastric%2520cancer%26jtitle%3DGut%26date%3D2019%26volume%3D68%26spage%3D1764%26epage%3D1773%26doi%3D10.1136%2Fgutjnl-2018-316324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maher, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longen, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyer, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, F. J.</span></span> <span> </span><span class="NLM_article-title">Small-molecule sigma1 modulator induces autophagic degradation of PD-L1</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-17-0166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1158%2F1541-7786.MCR-17-0166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=29117944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVeiurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2018&pages=243-255&author=C.+M.+Maherauthor=J.+D.+Thomasauthor=D.+A.+Haasauthor=C.+G.+Longenauthor=H.+M.+Oyerauthor=J.+Y.+Tongauthor=F.+J.+Kim&title=Small-molecule+sigma1+modulator+induces+autophagic+degradation+of+PD-L1&doi=10.1158%2F1541-7786.MCR-17-0166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Sigma1 Modulator Induces Autophagic Degradation of PD-L1</span></div><div class="casAuthors">Maher, Christina M.; Thomas, Jeffrey D.; Haas, Derick A.; Longen, Charles G.; Oyer, Halley M.; Tong, Jane Y.; Kim, Felix J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">243-255</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Emerging evidence suggests that Sigma1 (SIGMAR1, also known as sigma-1 receptor) is a unique ligand-regulated integral membrane scaffolding protein that contributes to cellular protein and lipid homeostasis.  Previously, we demonstrated that some small-mol. modulators of Sigma1 alter endoplasmic reticulum (ER)-assocd. protein homeostasis pathways in cancer cells, including the unfolded protein response and autophagy.  Programmed death-ligand 1 (PD-L1) is a type I integral membrane glycoprotein that is cotranslationally inserted into the ER and is processed and transported through the secretory pathway.  Once at the surface of cancer cells, PD-L1 acts as a T-cell inhibitory checkpoint mol. and suppresses antitumor immunity.  Here, we demonstrate that in Sigma1-expressing triple-neg. breast and androgen-independent prostate cancer cells, PD-L1 protein levels were suppressed by RNAi knockdown of Sigma1 and by small-mol. inhibition of Sigma1.  Sigma1-mediated action was confirmed by pharmacol. competition between Sigma1-selective inhibitor and activator ligands.  When administered alone, the Sigma1 inhibitor decreased cell surface PD-L1 expression and suppressed functional interaction of PD-1 and PD-L1 in a coculture of T cells and cancer cells.  Conversely, the Sigma1 activator increased PD-L1 cell surface expression, demonstrating the ability to pos. and neg. modulate Sigma1 assocd. PD-L1 processing.  We discovered that the Sigma1 inhibitor induced degrdn. of PD-L1 via autophagy, by a mechanism distinct from bulk macroautophagy or general ER stress-assocd. autophagy.  Finally, the Sigma1 inhibitor suppressed IFNγ-induced PD-L1.  Our data demonstrate that small-mol. Sigma1 modulators can be used to regulate PD-L1 in cancer cells and trigger its degrdn. by selective autophagy.  Implications: Sigma1 modulators sequester and eliminate PD-L1 by autophagy, thus preventing functional PD-L1 expression at the cell surface.  This posits Sigma1 modulators as novel therapeutic agents in PD-L1/PD-1 blockade strategies that regulate the tumor immune microenvironment.  Visual Overview: http//mcr.accrjournals.org/content/molcanres/16/02/243/F1.large.jpg.  Mol Cancer Res; 16(2); 243-55. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPoBdyWoswA7Vg90H21EOLACvtfcHk0lgMkK9Uu9HdTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVeiurc%253D&md5=84f9aee84ada0bb2b7ce13f2d210b52b</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-17-0166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-17-0166%26sid%3Dliteratum%253Aachs%26aulast%3DMaher%26aufirst%3DC.%2BM.%26aulast%3DThomas%26aufirst%3DJ.%2BD.%26aulast%3DHaas%26aufirst%3DD.%2BA.%26aulast%3DLongen%26aufirst%3DC.%2BG.%26aulast%3DOyer%26aufirst%3DH.%2BM.%26aulast%3DTong%26aufirst%3DJ.%2BY.%26aulast%3DKim%26aufirst%3DF.%2BJ.%26atitle%3DSmall-molecule%2520sigma1%2520modulator%2520induces%2520autophagic%2520degradation%2520of%2520PD-L1%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2018%26volume%3D16%26spage%3D243%26epage%3D255%26doi%3D10.1158%2F1541-7786.MCR-17-0166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murase, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oshima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, H.</span></span> <span> </span><span class="NLM_article-title">Downregulation of PD-L1 via amide analogues of brefelamide: alternatives to antibody-based cancer immunotherapy</span>. <i>Exp. Ther. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">3150</span>– <span class="NLM_lpage">3158</span>, <span class="refDoi"> DOI: 10.3892/etm.2020.8553</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.3892%2Fetm.2020.8553" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=32256803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVakt73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2020&pages=3150-3158&author=J.+Zhangauthor=O.+Yamadaauthor=S.+Kidaauthor=S.+Muraseauthor=T.+Hattoriauthor=Y.+Oshimaauthor=H.+Kikuchi&title=Downregulation+of+PD-L1+via+amide+analogues+of+brefelamide%3A+alternatives+to+antibody-based+cancer+immunotherapy&doi=10.3892%2Fetm.2020.8553"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Downregulation of PD-L1 via amide analogues of brefelamide: Alternatives to antibody-based cancer immunotherapy</span></div><div class="casAuthors">Zhang, Jing; Yamada, Osamu; Kida, Shinya; Murase, Shinya; Hattori, Toshio; Oshima, Yoshiteru; Kikuchi, Haruhisa</div><div class="citationInfo"><span class="NLM_cas:title">Experimental and Therapeutic Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">3150-3158</span>CODEN:
                <span class="NLM_cas:coden">ETMXA2</span>;
        ISSN:<span class="NLM_cas:issn">1792-1015</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">The therapeutic blockade of immune checkpoint has emerged as an effective treatment option for a broad range of tumors.  However, the objective tumor response is still limited to a small no. of cases and tumor types.  The full utility of monoclonal antibody (mAb)-based treatment is hindered by several inherent limitations.  Thus, there is an urgent requirement to explore alternative modalities targeting the same pathways.  In the present study, two amide analogs of brefelamide, TPFS-201 and TPFS-202, were identified as small mol. immune checkpoint inhibitors, as they downregulated PD-L1 expression in tumor cells.  PD-L1 was suppressed in cancer cells treated with TPFD compds. at both mRNA and protein levels, as detected by reverse transcription quant. PCR and flow cytometric anal., resp.  Reporter assays using a PD-L1 promoter luciferase construct confirmed the transcriptional inhibition of PD L1 by TPFS compds.  TPFS compd.-mediated PD-L1 downregulation in cancer cells consequently restored T cell activity, as identified by the redn. of apoptosis and an increase in interleukin-2 promoter activity in Jurkat T cells, which were co-cultured with TPFS compd.-treated A549 cells.  TPFS compd.-mediated PD-L1 inhibition was partially abolished by the disruption of the putative transcriptional co-activator with PDZ (TAZ)/TEA domain (TEAD)-binding motif in the PD-L1 promoter.  The inhibitory effect of TPFS compds. on PD-L1 was markedly inhibited in mouse cell lines, which is consistent with previous research demonstrating that PD-L1 regulation by TAZ is not conserved in mice due to distinct promoter sequences flanking the TAZ/TEAD-binding motif.  Together, the data of the current study indicated the potential utility of the brefelamide amide analogs as small mol. immune checkpoint inhibitors, thereby providing therapeutic alternatives, which could be used as monotherapy or in combination with mAbs-based treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7QEcMIY6OH7Vg90H21EOLACvtfcHk0lgMkK9Uu9HdTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVakt73M&md5=cab56791f5df9627282c648e5c9539f3</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.3892%2Fetm.2020.8553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fetm.2020.8553%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYamada%26aufirst%3DO.%26aulast%3DKida%26aufirst%3DS.%26aulast%3DMurase%26aufirst%3DS.%26aulast%3DHattori%26aufirst%3DT.%26aulast%3DOshima%26aufirst%3DY.%26aulast%3DKikuchi%26aufirst%3DH.%26atitle%3DDownregulation%2520of%2520PD-L1%2520via%2520amide%2520analogues%2520of%2520brefelamide%253A%2520alternatives%2520to%2520antibody-based%2520cancer%2520immunotherapy%26jtitle%3DExp.%2520Ther.%2520Med.%26date%3D2020%26volume%3D19%26spage%3D3150%26epage%3D3158%26doi%3D10.3892%2Fetm.2020.8553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marisetty, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassab, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claret, F. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimberger, A. B.</span></span> <span> </span><span class="NLM_article-title">Verteporfin inhibits PD-L1 through autophagy and the STAT1-IRF1-TRIM28 signaling axis, exerting antitumor efficacy</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">952</span>– <span class="NLM_lpage">965</span>, <span class="refDoi"> DOI: 10.1158/2326-6066.CIR-19-0159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1158%2F2326-6066.CIR-19-0159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=32265228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit12qu7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=952-965&author=J.+Liangauthor=L.+Wangauthor=C.+Wangauthor=J.+Shenauthor=B.+Suauthor=A.+L.+Marisettyauthor=D.+Fangauthor=C.+Kassabauthor=K.+J.+Jeongauthor=W.+Zhaoauthor=Y.+Luauthor=A.+K.+Jainauthor=Z.+Zhouauthor=H.+Liangauthor=S.+C.+Sunauthor=C.+Luauthor=Z.+X.+Xuauthor=Q.+Yuauthor=S.+Shaoauthor=X.+Chenauthor=M.+Gaoauthor=F.+X.+Claretauthor=Z.+Dingauthor=J.+Chenauthor=P.+Chenauthor=M.+C.+Bartonauthor=G.+Pengauthor=G.+B.+Millsauthor=A.+B.+Heimberger&title=Verteporfin+inhibits+PD-L1+through+autophagy+and+the+STAT1-IRF1-TRIM28+signaling+axis%2C+exerting+antitumor+efficacy&doi=10.1158%2F2326-6066.CIR-19-0159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Verteporfin inhibits PD-L1 through autophagy and the STAT1-IRF1-TRIM28 signaling axis, exerting antitumor efficacy</span></div><div class="casAuthors">Liang, Jiyong; Wang, Lulu; Wang, Chao; Shen, Jianfeng; Su, Bojin; Marisetty, Anantha L.; Fang, Dexing; Kassab, Cynthia; Jeong, Kang Jin; Zhao, Wei; Lu, Yiling; Jain, Abhinav K.; Zhou, Zhicheng; Liang, Han; Sun, Shao-Cong; Lu, Changming; Xu, Zhi-Xiang; Yu, Qinghua; Shao, Shan; Chen, Xiaohua; Gao, Meng; Claret, Francois X.; Ding, Zhiyong; Chen, Jian; Chen, Pingsheng; Barton, Michelle C.; Peng, Guang; Mills, Gordon B.; Heimberger, Amy B.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">952-965</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Programmed cell death 1 ligand 1 (PD-L1) is a key driver of tumor-mediated immune suppression, and targeting it with antibodies can induce therapeutic responses.  Given the costs and assocd. toxicity of PD-L1 blockade, alternative therapeutic strategies arc needed.  Using reverse phase protein arrays to assess drugs in use or likely to enter trials, we performed a candidate drug screen for inhibitors of PD-L1 expression and identified verteporfin as a possible small-mol. inhibitor.  Vertcporfin suppressed basal and IFN-induced PD-L1 expression in vitro and in vivo through Golgi related autophagy and disruption of the STAT1-IRF -TRIM28 signaling cascade, but did not affect the proinflammatory CIITA-MHC 11 cascade.  Within the tumor microenvironment, verteporfin inhibited PD-L1 expression, which assocd. with enhanced T-Iymphocyte infiltration.  Inhibition of chromatin-assocd. enzyme PARPl induced PD-L1 expression in high endothelial venules (HLV) in tumors and, when combined with verteporfin, enhanced therapeutic efficacy.  Thus, verteporfin effectively targets PD-L1 through transcription al and posttranslational mechanisms, representing an alternative therapeutic strategy for targeting PD-L1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHe21tJ-eYT7Vg90H21EOLACvtfcHk0lgMkK9Uu9HdTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit12qu7nO&md5=6645f85efc3ad89437333a6b303e9a85</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.CIR-19-0159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.CIR-19-0159%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DB.%26aulast%3DMarisetty%26aufirst%3DA.%2BL.%26aulast%3DFang%26aufirst%3DD.%26aulast%3DKassab%26aufirst%3DC.%26aulast%3DJeong%26aufirst%3DK.%2BJ.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DJain%26aufirst%3DA.%2BK.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DLiang%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DS.%2BC.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DZ.%2BX.%26aulast%3DYu%26aufirst%3DQ.%26aulast%3DShao%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DClaret%26aufirst%3DF.%2BX.%26aulast%3DDing%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DBarton%26aufirst%3DM.%2BC.%26aulast%3DPeng%26aufirst%3DG.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DHeimberger%26aufirst%3DA.%2BB.%26atitle%3DVerteporfin%2520inhibits%2520PD-L1%2520through%2520autophagy%2520and%2520the%2520STAT1-IRF1-TRIM28%2520signaling%2520axis%252C%2520exerting%2520antitumor%2520efficacy%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2020%26volume%3D8%26spage%3D952%26epage%3D965%26doi%3D10.1158%2F2326-6066.CIR-19-0159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, M. H.</span></span> <span> </span><span class="NLM_article-title">FDA-approved small-molecule kinase inhibitors</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">422</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2015.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1016%2Fj.tips.2015.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=25975227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1KisLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=422-439&author=P.+Wuauthor=T.+E.+Nielsenauthor=M.+H.+Clausen&title=FDA-approved+small-molecule+kinase+inhibitors&doi=10.1016%2Fj.tips.2015.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">FDA-approved small-molecule kinase inhibitors</span></div><div class="casAuthors">Wu, Peng; Nielsen, Thomas E.; Clausen, Mads H.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">422-439</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Kinases have emerged as one of the most intensively pursued targets in current pharmacol. research, esp. for cancer, due to their crit. roles in cellular signaling.  To date, the US FDA has approved 28 small-mol. kinase inhibitors, half of which were approved in the past 3 years.  While the clin. data of these approved mols. are widely presented and structure-activity relationship (SAR) has been reported for individual mols., an updated review that analyzes all approved mols. and summarizes current achievements and trends in the field has yet to be found.  Here we present all approved small-mol. kinase inhibitors with an emphasis on binding mechanism and structural features, summarize current challenges, and discuss future directions in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrudyvM3eO09bVg90H21EOLACvtfcHk0lhIH37Dk84AIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1KisLg%253D&md5=a6aa3dbb11e6fe3001fa5fa03a4c950a</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2015.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2015.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DP.%26aulast%3DNielsen%26aufirst%3DT.%2BE.%26aulast%3DClausen%26aufirst%3DM.%2BH.%26atitle%3DFDA-approved%2520small-molecule%2520kinase%2520inhibitors%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D36%26spage%3D422%26epage%3D439%26doi%3D10.1016%2Fj.tips.2015.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Azuma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ota, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawahara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takayama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takamori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kage, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoshino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakanishi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, I.</span></span> <span> </span><span class="NLM_article-title">Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer</span>. <i>Ann. Oncol</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1935</span>– <span class="NLM_lpage">1940</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdu242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1093%2Fannonc%2Fmdu242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=25009014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A280%3ADC%252BC2cbhtVChsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=1935-1940&author=K.+Azumaauthor=K.+Otaauthor=A.+Kawaharaauthor=S.+Hattoriauthor=E.+Iwamaauthor=T.+Haradaauthor=K.+Matsumotoauthor=K.+Takayamaauthor=S.+Takamoriauthor=M.+Kageauthor=T.+Hoshinoauthor=Y.+Nakanishiauthor=I.+Okamoto&title=Association+of+PD-L1+overexpression+with+activating+EGFR+mutations+in+surgically+resected+nonsmall-cell+lung+cancer&doi=10.1093%2Fannonc%2Fmdu242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer</span></div><div class="casAuthors">Azuma K; Hoshino T; Ota K; Iwama E; Harada T; Matsumoto K; Takayama K; Kawahara A; Kage M; Hattori S; Takamori S; Nakanishi Y; Okamoto I</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1935-1940</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Recent clinical trials have shown that immune-checkpoint blockade yields a clinical response in a subset of individuals with advanced nonsmall-cell lung cancer (NSCLC).  We examined whether the expression of programmed death-ligand 1 (PD-L1) is related to clinicopathologic or prognostic factors in patients with surgically resected NSCLC.  PATIENTS AND METHODS:  The expression of PD-L1 was evaluated by immunohistochemical analysis in 164 specimens of surgically resected NSCLC.  Cell surface expression of PD-L1 in NSCLC cell lines was quantified by flow cytometry.  RESULTS:  Expression of PD-L1 in tumor specimens was significantly higher for women than for men, for never smokers than for smokers, and for patients with adenocarcinoma than for those with squamous cell carcinoma.  Multivariate analysis revealed that the presence of epidermal growth factor receptor gene (EGFR) mutations and adenocarcinoma histology were significantly associated with increased PD-L1 expression in a manner independent of other factors.  Cell surface expression of PD-L1 was also significantly higher in NSCLC cell lines positive for activating EGFR mutations than in those with wild-type EGFR.  The EGFR inhibitor erlotinib downregulated PD-L1 expression in the former cell lines but not in the latter, suggesting that PD-L1 expression is increased by EGFR signaling conferred by activating EGFR mutations.  A high level of PD-L1 expression in resected tumor tissue was associated with a significantly shorter overall survival for NSCLC patients.  CONCLUSIONS:  High expression of PD-L1 was associated with the presence of EGFR mutations in surgically resected NSCLC and was an independent negative prognostic factor for this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRp6teAQsaYtwyMywPm6HgQfW6udTcc2eaHOPFj_P67M7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbhtVChsQ%253D%253D&md5=e5a8e9cf6fbd85ca2ed7a13b049ba81d</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdu242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdu242%26sid%3Dliteratum%253Aachs%26aulast%3DAzuma%26aufirst%3DK.%26aulast%3DOta%26aufirst%3DK.%26aulast%3DKawahara%26aufirst%3DA.%26aulast%3DHattori%26aufirst%3DS.%26aulast%3DIwama%26aufirst%3DE.%26aulast%3DHarada%26aufirst%3DT.%26aulast%3DMatsumoto%26aufirst%3DK.%26aulast%3DTakayama%26aufirst%3DK.%26aulast%3DTakamori%26aufirst%3DS.%26aulast%3DKage%26aufirst%3DM.%26aulast%3DHoshino%26aufirst%3DT.%26aulast%3DNakanishi%26aufirst%3DY.%26aulast%3DOkamoto%26aufirst%3DI.%26atitle%3DAssociation%2520of%2520PD-L1%2520overexpression%2520with%2520activating%2520EGFR%2520mutations%2520in%2520surgically%2520resected%2520nonsmall-cell%2520lung%2520cancer%26jtitle%3DAnn.%2520Oncol%26date%3D2014%26volume%3D25%26spage%3D1935%26epage%3D1940%26doi%3D10.1093%2Fannonc%2Fmdu242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dorand, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nthale, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barkauskas, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avril, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirieleison, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pareek, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbott, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stearns, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letterio, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrosiute, A.</span></span> <span> </span><span class="NLM_article-title">Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>353</i></span>,  <span class="NLM_fpage">399</span>– <span class="NLM_lpage">403</span>, <span class="refDoi"> DOI: 10.1126/science.aae0477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1126%2Fscience.aae0477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=27463676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFyit7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2016&pages=399-403&author=R.+D.+Dorandauthor=J.+Nthaleauthor=J.+T.+Myersauthor=D.+S.+Barkauskasauthor=S.+Avrilauthor=S.+M.+Chirieleisonauthor=T.+K.+Pareekauthor=D.+W.+Abbottauthor=D.+S.+Stearnsauthor=J.+J.+Letterioauthor=A.+Y.+Huangauthor=A.+Petrosiute&title=Cdk5+disruption+attenuates+tumor+PD-L1+expression+and+promotes+antitumor+immunity&doi=10.1126%2Fscience.aae0477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity</span></div><div class="casAuthors">Dorand, R. Dixon; Nthale, Joseph; Myers, Jay T.; Barkauskas, Deborah S.; Avril, Stefanie; Chirieleison, Steven M.; Pareek, Tej K.; Abbott, Derek W.; Stearns, Duncan S.; Letterio, John J.; Huang, Alex Y.; Petrosiute, Agne</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">6297</span>),
    <span class="NLM_cas:pages">399-403</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Cancers often evade immune surveillance by adopting peripheral tissue- tolerance mechanisms, such as the expression of programmed cell death ligand 1 (PD-L1), the inhibition of which results in potent antitumor immunity.  Here, we show that cyclin-dependent kinase 5 (Cdk5), a serine-threonine kinase that is highly active in postmitotic neurons and in many cancers, allows medulloblastoma (MB) to evade immune elimination.  Interferon-γ (IFN-γ)-induced PD-L1 up-regulation on MB requires Cdk5, and disruption of Cdk5 expression in a mouse model of MB results in potent CD4+ T cell-mediated tumor rejection.  Loss of Cdk5 results in persistent expression of the PD-L1 transcriptional repressors, the interferon regulatory factors IRF2 and IRF2BP2, which likely leads to reduced PD-L1 expression on tumors.  Our finding highlights a central role for Cdk5 in immune checkpoint regulation by tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKYHJiyEhE0rVg90H21EOLACvtfcHk0liVKQPK5PfoFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFyit7bF&md5=d91dc0f4e5290960f3407bf96e886bb1</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1126%2Fscience.aae0477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aae0477%26sid%3Dliteratum%253Aachs%26aulast%3DDorand%26aufirst%3DR.%2BD.%26aulast%3DNthale%26aufirst%3DJ.%26aulast%3DMyers%26aufirst%3DJ.%2BT.%26aulast%3DBarkauskas%26aufirst%3DD.%2BS.%26aulast%3DAvril%26aufirst%3DS.%26aulast%3DChirieleison%26aufirst%3DS.%2BM.%26aulast%3DPareek%26aufirst%3DT.%2BK.%26aulast%3DAbbott%26aufirst%3DD.%2BW.%26aulast%3DStearns%26aufirst%3DD.%2BS.%26aulast%3DLetterio%26aufirst%3DJ.%2BJ.%26aulast%3DHuang%26aufirst%3DA.%2BY.%26aulast%3DPetrosiute%26aufirst%3DA.%26atitle%3DCdk5%2520disruption%2520attenuates%2520tumor%2520PD-L1%2520expression%2520and%2520promotes%2520antitumor%2520immunity%26jtitle%3DScience%26date%3D2016%26volume%3D353%26spage%3D399%26epage%3D403%26doi%3D10.1126%2Fscience.aae0477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Go, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, D. H.</span></span> <span> </span><span class="NLM_article-title">EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1alpha and STAT3</span>. <i>Oncoimmunology</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e1108514</span>, <span class="refDoi"> DOI: 10.1080/2162402X.2015.1108514</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1080%2F2162402X.2015.1108514" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=27141364" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=e1108514&author=J.+Kohauthor=J.+Y.+Jangauthor=B.+Keamauthor=S.+Kimauthor=M.+Y.+Kimauthor=H.+Goauthor=T.+M.+Kimauthor=D.+W.+Kimauthor=C.+W.+Kimauthor=Y.+K.+Jeonauthor=D.+H.+Chung&title=EML4-ALK+enhances+programmed+cell+death-ligand+1+expression+in+pulmonary+adenocarcinoma+via+hypoxia-inducible+factor+%28HIF%29-1alpha+and+STAT3&doi=10.1080%2F2162402X.2015.1108514"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1080%2F2162402X.2015.1108514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F2162402X.2015.1108514%26sid%3Dliteratum%253Aachs%26aulast%3DKoh%26aufirst%3DJ.%26aulast%3DJang%26aufirst%3DJ.%2BY.%26aulast%3DKeam%26aufirst%3DB.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DM.%2BY.%26aulast%3DGo%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DT.%2BM.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DKim%26aufirst%3DC.%2BW.%26aulast%3DJeon%26aufirst%3DY.%2BK.%26aulast%3DChung%26aufirst%3DD.%2BH.%26atitle%3DEML4-ALK%2520enhances%2520programmed%2520cell%2520death-ligand%25201%2520expression%2520in%2520pulmonary%2520adenocarcinoma%2520via%2520hypoxia-inducible%2520factor%2520%2528HIF%2529-1alpha%2520and%2520STAT3%26jtitle%3DOncoimmunology%26date%3D2015%26volume%3D5%26spage%3De1108514%26doi%3D10.1080%2F2162402X.2015.1108514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banik, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedram, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisnovsky, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertozzi, C. R.</span></span> <span> </span><span class="NLM_article-title">Lysosome-targeting chimaeras for degradation of extracellular proteins</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>584</i></span>,  <span class="NLM_fpage">291</span>– <span class="NLM_lpage">297</span>, <span class="refDoi"> DOI: 10.1038/s41586-020-2545-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1038%2Fs41586-020-2545-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=32728216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVygtLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=584&publication_year=2020&pages=291-297&author=S.+M.+Banikauthor=K.+Pedramauthor=S.+Wisnovskyauthor=G.+Ahnauthor=N.+M.+Rileyauthor=C.+R.+Bertozzi&title=Lysosome-targeting+chimaeras+for+degradation+of+extracellular+proteins&doi=10.1038%2Fs41586-020-2545-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Lysosome-targeting chimaeras for degradation of extracellular proteins</span></div><div class="casAuthors">Banik, Steven M.; Pedram, Kayvon; Wisnovsky, Simon; Ahn, Green; Riley, Nicholas M.; Bertozzi, Carolyn R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">584</span>
        (<span class="NLM_cas:issue">7820</span>),
    <span class="NLM_cas:pages">291-297</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: The majority of therapies that target individual proteins rely on specific activity-modulating interactions with the target protein-for example, enzyme inhibition or ligand blocking.  However, several major classes of therapeutically relevant proteins have unknown or inaccessible activity profiles and so cannot be targeted by such strategies.  Protein-degrdn. platforms such as proteolysis-targeting chimaeras (PROTACs)1,2 and others (for example, dTAGs3, Trim-Away4, chaperone-mediated autophagy targeting5 and SNIPERs6) have been developed for proteins that are typically difficult to target; however, these methods involve the manipulation of intracellular protein degrdn. machinery and are therefore fundamentally limited to proteins that contain cytosolic domains to which ligands can bind and recruit the requisite cellular components.  Extracellular and membrane-assocd. proteins-the products of 40% of all protein-encoding genes7-are key agents in cancer, ageing-related diseases and autoimmune disorders8, and so a general strategy to selectively degrade these proteins has the potential to improve human health.  Here we establish the targeted degrdn. of extracellular and membrane-assocd. proteins using conjugates that bind both a cell-surface lysosome-shuttling receptor and the extracellular domain of a target protein.  These initial lysosome-targeting chimaeras, which we term LYTACs, consist of a small mol. or antibody fused to chem. synthesized glycopeptide ligands that are agonists of the cation-independent mannose-6-phosphate receptor (CI-M6PR).  We use LYTACs to develop a CRISPR interference screen that reveals the biochem. pathway for CI-M6PR-mediated cargo internalization in cell lines, and uncover the exocyst complex as a previously unidentified-but essential-component of this pathway.  We demonstrate the scope of this platform through the degrdn. of therapeutically relevant proteins, including apolipoprotein E4, epidermal growth factor receptor, CD71 and programmed death-ligand 1.  Our results establish a modular strategy for directing secreted and membrane proteins for lysosomal degrdn., with broad implications for biochem. research and for therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmZfj1oJhbx7Vg90H21EOLACvtfcHk0liVKQPK5PfoFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVygtLrP&md5=1109c68b56a3ee93427ae89f194c0a16</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1038%2Fs41586-020-2545-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-020-2545-9%26sid%3Dliteratum%253Aachs%26aulast%3DBanik%26aufirst%3DS.%2BM.%26aulast%3DPedram%26aufirst%3DK.%26aulast%3DWisnovsky%26aufirst%3DS.%26aulast%3DAhn%26aufirst%3DG.%26aulast%3DRiley%26aufirst%3DN.%2BM.%26aulast%3DBertozzi%26aufirst%3DC.%2BR.%26atitle%3DLysosome-targeting%2520chimaeras%2520for%2520degradation%2520of%2520extracellular%2520proteins%26jtitle%3DNature%26date%3D2020%26volume%3D584%26spage%3D291%26epage%3D297%26doi%3D10.1038%2Fs41586-020-2545-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klauser, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span> <span> </span><span class="NLM_article-title">Developing covalent protein drugs via proximity-enabled reactive therapeutics</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>182</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">97</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2020.05.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=10.1016%2Fj.cell.2020.05.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=32579975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1KjurfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2020&pages=85-97&author=Q.+Liauthor=Q.+Chenauthor=P.+C.+Klauserauthor=M.+Liauthor=F.+Zhengauthor=N.+Wangauthor=X.+Liauthor=Q.+Zhangauthor=X.+Fuauthor=Q.+Wangauthor=Y.+Xuauthor=L.+Wang&title=Developing+covalent+protein+drugs+via+proximity-enabled+reactive+therapeutics&doi=10.1016%2Fj.cell.2020.05.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Developing Covalent Protein Drugs via Proximity-Enabled Reactive Therapeutics</span></div><div class="casAuthors">Li, Qingke; Chen, Qu; Klauser, Paul C.; Li, Mengyuan; Zheng, Feng; Wang, Nanxi; Li, Xiaoying; Zhang, Qianbing; Fu, Xuemei; Wang, Qian; Xu, Yang; Wang, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-97.e16</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Small mol. covalent drugs provide desirable therapeutic properties over noncovalent ones for treating challenging diseases.  The potential of covalent protein drugs, however, remains unexplored due to protein's inability to bind targets covalently.  We report a proximity-enabled reactive therapeutics (PERx) approach to generate covalent protein drugs.  Through genetic code expansion, a latent bioreactive amino acid fluorosulfate-L-tyrosine (FSY) was incorporated into human programmed cell death protein-1 (PD-1).  Only when PD-1 interacts with PD-L1 did the FSY react with a proximal histidine of PD-L1 selectively, enabling irreversible binding of PD-1 to only PD-L1 in vitro and in vivo.  When administrated in immune-humanized mice, the covalent PD-1(FSY) exhibited strikingly more potent antitumor effect over the noncovalent wild-type PD-1, attaining therapeutic efficacy equiv. or superior to anti-PD-L1 antibody.  PERx should provide a general platform technol. for converting various interacting proteins into covalent binders, achieving specific covalent protein targeting for biol. studies and therapeutic capability unattainable with conventional noncovalent protein drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcj64Nv4lYwrVg90H21EOLACvtfcHk0liVKQPK5PfoFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1KjurfK&md5=85e16c071ccbb4e5249e359e956a590d</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2020.05.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2020.05.028%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DKlauser%26aufirst%3DP.%2BC.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DZheng%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DFu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26atitle%3DDeveloping%2520covalent%2520protein%2520drugs%2520via%2520proximity-enabled%2520reactive%2520therapeutics%26jtitle%3DCell%26date%3D2020%26volume%3D182%26spage%3D85%26epage%3D97%26doi%3D10.1016%2Fj.cell.2020.05.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01362&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-24%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01362%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01362" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67993443f8773d76","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
